Transplantation Tolerance through the Modulation of Dendritic Cells by Fayad, Amira Ibrahim & Fayad, Amira Ibrahim
  
 Transplantation Tolerance through the 
Modulation of Dendritic Cells  
 
By Amira Ibrahim Fayad 
  
 
 
 
 
 
Thesis submitted in the fulfillment of the requirements for the Imperial College 
London Degree of Doctor of Philosophy 
 Principal Supervisor: Professor Andrew JT George 
Department of Immunology 
Division of Medicine, Faculty of Medicine 
Imperial College London 
 
 
September 2010 
 
 
2 
 
 
 
 
 
  
 
 
 
For The Almighty 
 
 
 
 
 
 
 
 
 
 
3 
 
 
 
 
 
 
 
 
For my late mother and my husband 
If not for you, I would not be in my place. 
For all their love, encouragement and patience 
 
 
 
 
 
 
 
 
 
 
4 
 
Acknowledgments 
I would, first and foremost, like to express my gratitude and thanks to Professor Andrew George, 
for giving me the opportunity to work in his laboratory. He is an exceptional supervisor who 
gave me great support from the first moment I visited his office, guiding me through my work 
over the last four years. He was always there whenever I needed his help. I have learned so much 
from him, not only at science, which he is very clever but also in life. He taught me how to 
approach problems and never to give up and that there will be always light at the end of the 
tunnel. Undertaking research under his guidance has allowed me to acquire a meticulous 
scientific training. Professor Andrew, your support has meant so much to me that I cannot thank 
you enough. 
I would also like to thank and acknowledge my Egyptian supervisor Prof Amina Hassab as she 
was the first to guide me to explore the outside world. I also owe an enormous debt to Dr. 
Amany Sorour, who guided me in my very early steps in the United Kingdom. Dr Sorour was 
always generous with her time, knowledge, advice and patience.  
So many people in the lab have helped me during my PhD, whom I should name but clearly I 
cannot do that, so to give my thanks to everyone who has helped me. 
I would like to thank my second supervisor Dr. Oliver Garden for his help, support and insightful 
feedbacks on my thesis. 
Thanks to my generous government represented by the Egyptian ministry of high education for 
funding my work and living. I hope I will be able to pay my country back and pass what I 
learned to my people when I will return back to my work, my friends and my patients. 
Finally, but he is always the first in my life, to my husband, Mamdouh. You held me up when I 
was down and you had confidence in me when I had none in myself. To my late Uncle, Prof 
Mohamed Ali who passed two years ago, and whom I think was waiting for this moment, 
THANK YOU. 
 
 
5 
 
Abstract 
Allogeneic T cell stimulation requires antigen recognition through the T cell receptor and 
costimulatory signals provided by antigen presenting cells (APCs). For naïve T cells stimulation, 
interaction between CD28 on T cells and CD80/86 on dendritic cells (DCs) provides an essential 
costimulatory signal. While, activated effector T cells or memory T cells stimulation is more 
dependent on costimulation via ICOS on T cells and ICOSL on APCs. Engagement of the T cell 
receptor without costimulation can lead to anergy and the subsequent induction of regulatory T 
cells (Tregs).  
With the aim of generating tolerogenic DCs for the induction of transplantation tolerance 
specifically to the indirect allorecognition pathway, a negative-vaccine approach composed of 
two strategies was developed. First: an intra-cellular approach that prevents T cells costimulation 
composed of a fusion protein – ICOS-KDEL was constructed. ICOS-KDEL is a fusion gene 
between the human extracellular domain of ICOS and the endoplasmic reticulum (ER) retention 
signal, KDEL. Mammalian cells transfected with the construct showed knocking down of surface 
ICOSL expression due to ER retention. Second: an approach to provide the antigen to be 
recognized by responding T cells in an indirect allorecognition pathway. This was achieved by 
constructing a fusion protein - invariant chain fusion gene (Ii-A2) - between the 
immunodominant MHC derived peptide HLA-A2103-120 and the invariant chain of MHC class II. 
Mammalian cells transfected with the Ii-A2 fusion gene expressed A2 peptide on their surface. 
The two fusion genes were cloned into one bicistronic vector so that transfection of a single 
plasmid resulted in the expression of both genes. Functional analysis of the developed bicistronic 
vector was not possible due to the unavailability of the antigen-specific T cell clones. 
The last part of this project studied the kinetics of ICOSL expression by human DCs and the role 
of activated T cells to regulate ICOSL surface expression. The study showed that ICOSL down 
regulation is a negative feedback loop that regulates the immune response. Activated T cells up-
regulate ICOS receptor that binds to ICOSL on APC. This was followed by down-regulation of 
ICOSL expression causing modulation of the immune response. The kinetic changes of ICOSL 
expression by DC were related to the maturation state of the DCs. It was shown that ICOS 
induced ICOSL down regulation could be a novel regulatory mechanism in human DC. 
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1.1 History of Transplantation  
A tremendous milestone in the history of transplantation took place more than 46 years 
ago. This first successful human kidney transplant between identical twins performed at the Peter 
Bent Brigham Hospital by Dr. Joseph Murray and his colleagues in 1954 (Murray et al. 2001). 
This clinical achievement was the herald of clinical organ transplantation contemplated as a 
successful form of treatment for hundreds of thousands of patients, who would otherwise have 
been destined to death from failure of a vital organ.  
The history of organ transplantation is an epic journey that goes back to antiquity, depicting the 
audacious effort of the medical community's mission to understand how the human body works. 
This effort to defy illness and death has made today's medical miracles possible. Transplantation 
evolved through two distinguished epochs, the first as myths depicting imaginary creatures 
formed of human and animals‟ body parts as the Chimera and the sphinx. The Chimera was a 
monster in Greek mythology that had a lion's head, goat's body and serpent's tail Figure 1a. This 
was assumed to be the virtual start of a field of research known as Chimeric technology. In the 
laboratory, chimeras are organisms with tissues derived from more than one zygote to generate 
hybrids that are either inter- or intra- species. The first murine embryonic chimeras were made 
by Kristoph Tartowski and Beatrice Mintz in the 1960s, following which several attempts have 
been carried out (Tam and Rossant 2003). Chimera production has since been widely applied in 
the biomedical sciences as it is a key tool to generate designer mice and aids in analyzing the 
biological consequences of genetic changes (Brustle et al. 1998; Behringer 2007). 
The second epoch of transplantation started when it was attempted as a treatment approach. In 
the 4
th
 Century BC (407-310 BC), Chinese texts described a surgeon named Tsin Yue-Jen, who 
switched the hearts of two soldiers to cure the “disequilibrium in their energies” and was 
recognised as the first known description of a body-to-body organ transfer. In the 3rd Century 
AD, Christian mythology described Saints Cosmos and Damian who carried out a surgery 
involving the transplantion of the lower extremity of a dead Ethiopian gladiator onto a custodian 
of a Roman basilica who had a gangrenous leg Figure 1b. This was the first description of a new 
concept: the body of a dead person can help a living person. 
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Figure 1. Evolution of transplant history from myth to reality 
 
 
 
(a) Chimera: a monster in Greek mythology that had a lion's head, goat's body, and serpent's tail. Graphics; 
the image is adopted from http://www.britannica.com/EBchecked/topic/111597/Chimera /24-9-2010 
(b)  The first description of transplanting the body parts of a dead person to a living person. Altarpiece by 
an anonymous painter about 1490 (Wurttenbergisches Landes Museum in Stuttgart). 
(c) Renal homo-transplantion in identical twin. The Brigham transplant team-from the left; Joseph E. 
Murray, surgeon for the recipient; John P. Merill, nephrologist and co-leader of the team; J. Hartwell 
Harrison, urological surgeon for the donor. Seated; The Herrick identical twins, recipient on the left and 
donor on the right (Murray et al. 2001) 
 
  
(a) 
(c) 
(b) 
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The success of transplantation was limited by surgical skills and lack of enough knowledge of 
human biology. However, the twentieth Century was a time when significant improvements in 
surgical approaches have laid the groundwork for the success of transplantation. A remarkable 
wide step in organ transplantation were achieved by the 20th century (from 1902-1908) when the 
French surgeon Dr. Alexis Carrel developed a technique for connecting blood vessels, which is 
still currently used in organ transplantation and other surgical procedures. On account of his 
development, Carrel received the 1912 Nobel Prize in medicine (Cooley 2002). He also shared in 
the development of the “perfusion pump” which allowed the manipulation of living organs 
outside of the body during surgery, which was considered as a crucial step in the development of 
open-heart surgery and organ transplants (Sade 2005). Furthermore, one of the substantial 
advances in medicine that shared in transplantation success history was in the field of blood 
transfusion. With the identification of blood types in the early 20th century by Dr. Karl 
Landsteiner, and the discovery of methods of separating and preserving blood and its 
components, the first successful mammalian blood transfusion was performed at New York by 
Reuben Ottenberg (Owen 2000). In the twentieth century, several attempts for organ 
transplantation have been set out, except for corneal transplantation demonstrated by Eduard 
Zirm in 1905, it was not until the mid 20
th
 century when prolonged survival of organ transplants 
was reported on 1954 by Dr Murray, before immunosuppressive procedures were developed 
(Murray et al. 2001) Figure 1c. Dr Murray was awarded 1990 Nobel Prize for work on organ 
and cell transplantation. Aided by the laborious work of scientists work, a body of knowledge is 
kept on building up which made successful organ transplantation possible. 
1.2 Transplantation Immunology 
Transplantation Immunology was spearheaded by Sir Peter Medawar and his colleagues who 
established this discipline as a multidisciplinary science. Inspired by the problems of skin 
grafting operations in extensively burned soldiers in the World War II, the reaction to 
transplanted foreign skin grafts was studied by Medawar‟s group. They reported that graft 
rejection had an immune basis, the body reacting against a foreign graft in a similar manner to 
invading bacteria and viruses (Gibson and Medawar 1943). Ten years later, two key observations 
by Billingham, Brent, and Medawar revealed vulnerability in this adaptive immune defence 
(Billingham et al. 1953; Billingham et al. 2003). This team reported a way of preventing graft 
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rejection by challenging the developing immune system in the embryo or neonate with the 
putative antigen in question. This was inspired by the observation by Owen and his collegues in 
non-identical cattle twins, which share their blood circulation in the placenta (Owen 1945). 
Medawar and his colleagues were able to repeat this phenomenon in planned experiments by 
injecting cells from donor mice of one inbred strain into foetal recipients of another inbred strain. 
The neonatally injected mice were tolerized to the cell donor and were subsequently able to 
accept skin grafts from the donor strain for long periods. This phenomenon, which is the inverse 
of „actively acquired immunity‟, was described as „actively acquired tolerance‟ (Billingham et al. 
1953). 
Efforts to transplant organs or tissues from genetically non-identical persons had been 
unsuccessful for many decades. However, the identification of human major histocompatibility 
complex (MHC) launched the field of clinical organ and tissue transplantation. In 1968, the 
World Health Organization Nomenclature Committee designated that the leukocyte antigens 
controlled by the closely linked genes of MHC to be named human leukocyte antigen (HLA).  
The fundamental perception of transplantation immunology congregates on the fact that the 
immune system develops sophisticated mechanisms to respond to foreign, non-self peptide. 
Immune defence response develops with the antigen-presenting cells (APCs) presenting the 
foreign peptide. T cells receiving the signal from such cells mount an effective immune response. 
In the centre of this APC-T cell dialogue are the genetically encoded polymorphic molecules 
HLA encoded by the MHC, which becomes one of the most intensely studied regions in 
vertebrate genomes in relation to infection, autoimmunity and transplantation. 
1.3 Transplant antigens- histocompatibility antigens 
Histocompatibility antigens are specific cell-surface antigens capable of inducing an immune 
response in a genetically dissimilar (allogeneic) recipient, resulting in the rejection of the tissue 
bearing those antigens. These antigens are referred to as MHC in human and H2-locus in mice 
(Snell 1948; Dausset et al. 1954).  
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1.3.1 Major Histocompatibility Complex (MHC) 
1.3.1.1 Discovery of MHC  
In 1936, Peter Gorer in the Lister Institute in London was the first to describe a 
histocompatibility system in mice from his observations of tumours (allograft) rejection after 
being transplanted between different mouse strains due to an immune response (Gorer 1937).  
Gorer et al. showed that tumor rejection between different murine strains occurred if the donor 
expressed an antigen that the recipient lacked. Ten years later, in 1948, George Snell established 
that graft rejection in mice was due to incompatibility at the level of certain antigens and named 
the genes encoding these antigens, histocompatibility genes (H2 locus) (Snell 1948).  
Human MHC was identified by Jean Dausset and his associates, when they suggested the 
existence of antigenic system in human leukocytes similar to that detected in murine erythrocytes 
(Dausset et al. 1954).  Dausset‟s study detected the presence of anti-leukocytes antibodies from 
the serum of a polytransfused patient. These antibodies were inactive on the patient‟s own 
leukocytes but agglutinated leukocytes from other patients. This was due to antigenic differences 
between individuals and named these antigens MAC (known later as HLA-A2). MHC broader 
role in the immune response was established later by Baruj Benacerraf who demonstrated that 
the MHC controlled the ability to mobilize an immune response against a particular antigen 
(Benacerraf 1981). 
Driven by the enormous effort to improve the survival rate of transplant patients and to tackle 
infectious and autoimmune disease, improved MHC gene maps were generated for various 
vertebrate species over several decades, with the description of the first sequence-based gene 
map of a human MHC published through the combined efforts of the MHC Sequencing 
Consortium (The.MHC.sequencing.consortium 1999).  
1.3.1.2 MHC molecular structure  
MHC molecules are glycoproteins that belong to the immunoglobulin superfamily. The genes 
that encode these antigens reside in the MHC region on the short arm of human chromosome 6; 
(6p21.3) and encoded by chromosome 17 in mice (The.MHC.sequencing.consortium 1999). The 
MHC gene locus contains more than 200 genes of which more than 40% have a function in the 
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immune system (The.MHC.sequencing.consortium 1999). These genes and their encoded cell-
surface and soluble protein products are divided into three classical regions (Figure 2) denoted 
class I and class II, and an intervening region between the centromeric MHC class II and the 
telomeric MHC class I region known as class III, or central MHC 
(The.MHC.sequencing.consortium 1999). The MHC class III region encodes components of the 
complement system such as C4, C2 and factor B; cytokines such as tumor necrosis factor (TNF); 
and heat shock proteins (Hauptmann and Bahram 2004). A number of genes putatively involved 
in inflammation have been identified at the telomeric end of the class III region called MHC-
class IV (Gruen and Weissman 1997; The.MHC.sequencing.consortium 1999). 
 
MHC is the most dense and polymorphic gene region in human genome, where at least 3,411 
HLA-class I alleles and 1,222 HLA class II alleles have been identified, with additional 110 
other non-HLA alleles; MICA, MICB, TAP1 and 2 as been published by international 
ImMunoGeneTics project (IMGT)/HLA database on April 2010,  
(http://www.ebi.ac.uk/imgt/hla/stats.html). Their extraordinary genetic polymorphism guarantees 
the broadest diversity of recognized antigens and therefore reactivity against a wide range of 
pathogens, hence conferring a selective protective advantage.  
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Figure 2. Schematic diagram of the human MHC gene 
The diagram shows the location of subregions of the human MHC as arranged from the 
centromere - class II, class III and class I- and the positions of the major genes within the 
corresponding region. Class IV is located between the dotted lines between class III and class I 
(Gruen and Weissman 1997). 
 
1.3.1.2.1 MHC class I 
MHC class I molecules - HLA-A, B and C in humans and H-2K, D and L in mice - handle 
intrinsic antigens, namely those derived pathogens that inhabit the cell or endogenously derived 
self-peptides created during normal cellular degradation (Procko and Gaudet 2009). MHC class I 
molecules are expressed on almost all nucleated cells. Antigens in the context of MHC class I 
molecule are presented to cytotoxic T lymphocytes (CTLs) responsible for controlling viral 
infections by lysis of the infected cells (Procko and Gaudet 2009).  
The MHC class I molecule, depicted in Figure 3, is composed of two polypeptide chains: an 
extracellular, glycosylated heavy α chain (H) (44 kDa) which spans the membrane bilayer, and a 
non-covalently attached light chain, β2 microglobulin (β2-m) (12 kDa), which is encoded outside 
the MHC on a different chromosome(Bjorkman et al. 1987). The heavy chain is further divided 
into three extracellular domains- α1 (N-terminal), α2 and α3- each comprising around 90 amino 
                                                                                                                                                        Introduction 
30 
 
acids (aa) and encoded on separate exons; a transmembrane region, comprising 25 aa residues; 
and a cytoplasmic tail of 30-40 aa residues (Bjorkman et al. 1987; Roth 2006). The α2 and α3 
domains are bound by intra-chain disulphide bonds (Bjorkman et al. 1987; Roth 2006). The α3 
and β2-m domains are relatively conserved and show aa sequence homology to immunoglobulin 
constant domains, while the polymorphic α1 and α2 domains show no significant sequence 
homology to immunoglobulin constant or variable domains, they show weak sequence homology 
to each other (Bjorkman et al. 1987). 
The α1 and α2 domains form the antigen-binding groove, which is 25 ångström (A0) long and 10 
A
0
 wide and the ends of the groove is closed (Bjorkman et al. 1987). This structure limits the 
optimal size of binding peptides to short fragments of 8-10 residues. The α3 domain contains a 
CD8
+
 binding site which is responsible for binding to the CD8
+
 T cells. β2–m is non-
polymorphic in humans and dimorphic in mice, and is stabilized within the MHC class I 
structure by an intra-chain disulphide bond. β2-m is crucial for proper class I molecules 
expression; mutant mice lacking β2-m do not express MHC class I molecules and are defective in 
presenting intrinsic antigens to T cells with defective CD8
+
 T cell functions (Zijlstra et al. 1990). 
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1.3.1.2.2 MHC class II 
In human, there are three pairs of polymorphic MHC II-A and B genes named HLA -DR, -DP 
and –DQ  (The.MHC.sequencing.consortium 1999; Roth 2006) and two pairs of non-classical 
MHC II genes, HLA-DM (Kelly et al. 1991) and -DO (Douek and Altmann 1997). In mice, there 
are two MHC class II genes - H-2A and –2E- as well as the non-classical genes H-2M and –2O. 
MHC class II molecules are expressed on the surface of epithelial cells in the thymus (Starr et al. 
2003), human activated T cells (Holling et al. 2004; Schooten et al. 2005) and on APCs in the 
periphery (Ting and Trowsdale 2002; LeibundGut-Landmann et al. 2004). 
Figure 3. Schematic representation of MHC class I and class II in humans 
MHC class I is composed of α chain formed of three α domains and β2 microglobulin (β2-m). 
The α chain interacts non-covalently with β2-m to form the complete MHC class I protein. 
MHC class II is composed of α chain formed of two α domains and β chain formed of two β 
domains. The α and β chains interact non-covalently to heterodimerise thus forming the 
complete MHC class II protein. 
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MHC class II molecules (depicted in Figure 3) consist of non-covalently associated glycoprotein 
chains- the heavy (α) (30-40 kDa) and the light (β) (26-29 kDa) (Brown et al. 1993; Roth 2006). 
In addition to their extracellular regions, both chains have a single transmembrane (TM) 
sequence of about 30 aa residues, and a short cytoplasmic tail of about 10 to 15 aa residues (Roth 
2006). The amino (N)-terminal of α1 and β1 regions of the chains combine to form a membrane-
distal peptide-binding groove, containing pockets into which anchoring peptide side chains can 
fit (Rudensky et al. 1991). The peptide-binding groove is opened at the ends allowing long 
peptide fragments of varying length to bind, with an optimal size of 13-17 residues (Rudensky et 
al. 1991). The remaining extracellular portions of the two chains each form a membrane-
proximal immunoglobulin-like domain (α2 and β2 regions), structurally similar to class I α3 and 
β2-microglobulin in having the immunoglobulin constant domain structural characteristics 
(Brown et al. 1993). The β2 domain contains a binding site to CD4+ T cell (Brown et al. 1993).  
1.3.2 Minor histocompatibility antigens (mHag) 
The mHag are immunogenic peptides derived from polymorphic self-proteins presented in the 
context of MHC (Goulmy 1996). Of importance are those proteins that are encoded by sex 
chromosomes, autosomes and mitochondrial DNA (Simpson 1998; Afzali et al. 2007). Among 
the best characterized of the mHag are those encoded by the murine Y chromosome, which are 
known collectively as H-Y (Simpson 1998). 
 
The mHag were originally recognized as the antigens causing graft rejection or graft-versus-host 
disease (GVHD) in HLA-matched allogeneic transplantation (Goulmy et al. 1996). Analysis of 
the post-transplant female patient peripheral blood revealed the presence of strong CTL 
responses that were specific for the male HLA-matched donor (Goulmy et al. 1977). In MHC 
matched allogenic hematopoietic cell transplantation, when mHag is presented by the recipient 
cells but not on the donor cells, CD8
+
 and CD4
+
 recognize these mHags as foreign antigens and 
induces graft versus host disease (GVHD) (Bleakley and Riddell 2004) 
 
In transplantation setting, even if donor and recipient are HLA identical siblings, their repertoire 
of HLA-presented peptides still differs (Akatsuka et al. 2007). This difference arise from allelic 
polymorphisms in the genome, which frequently results from single nucleotide polymorphisms 
(SNPs), giving rise to amino acid sequence differences with consequent variation in normal 
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cellular proteins expression (Akatsuka et al. 2007). These polymorphisms result in the processing 
of immunogenic peptides, mHags which can be presented by MHC molecules to be recognized 
via both direct and indirect allorecognition (Simpson 1998).  
 
Immune responses to these antigens are generally weaker than those directed against HLA 
antigens, but they can nevertheless provoke graft rejection (Goulmy 1996; Simpson 1998). 
Identifying mHags in the population and their position in immune-dominance can improve the 
tissue typing and hence graft survival (Goulmy 2006; Dierselhuis and Goulmy 2009). 
 
1.3.3 MHC molecules are specialised for antigen-presentation 
The MHC has a vital role in the complex immunological response occurring between T cells and 
APCs. For T cells to identify foreign antigens (except for super-antigens), the antigens must be 
presented in the context of a specialised antigen presenting molecule, the MHC.  A wide range of 
peptides derived from intracellular proteins can be expressed by MHC molecules, and the 
peptide-MHC complex are identified by the T cell receptors (TCRs) (Trowsdale 2006). Prior to 
antigen presentation to T cells, antigen processing takes place through its degradation into 
peptide fragments, the recognized determinate being only a small fragment of the original 
antigen (Bjorkman et al. 1987; Rudensky et al. 1991). Antigen presentation is crucial not only for 
the protection against pathogens, but is necessary for maintaining self-tolerance (Griesemer et al. 
2010).  
1.3.3.1 The MHC class I molecule associates with endogenous peptides 
The MHC class I molecules are expressed by nearly all nucleated cells of the body (Raghavan et 
al. 2008; Procko and Gaudet 2009). They primarily present endogenously synthesised peptides 
such as viral and bacterial peptides, tumor-related peptides and endogenously derived self 
peptides (Roth 2006). These peptides are then presented to CD8
+
 T cell (CTL), initiating anti-
viral or anti-tumor immune responses (Procko and Gaudet 2009). 
Nascent MHC class I H chains and β2-m are assembled in the endoplasmic reticulum (ER)  with 
assistance from the coordinated action of a variety of resident ER chaperones (Raghavan et al. 
2008) Figure 4. The newly synthesised H chain, containing the α1, α2 and α3 extracellular 
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domains, binds rapidly to the membrane-bound molecular chaperone calnexin (Cnx), which 
prevents the aggregation of unfolded proteins (Zhang et al. 1995). Cnx-associated disulphide-
isomerase, ERp57 (Hughes and Cresswell 1998), enhances the formation of disulphide bonds in 
the H chain, essential for the proper folding and assembly of MHC class I molecules (Raghavan 
et al. 2008). 
The H chain then associates with the β2m subunit, and Cnx is replaced by its soluble homologue, 
calreticulin (Crt), which functions as a quality-control component (Zhang and Williams 2006). 
Crt  facilitates class I biogenesis, minimizing premature release of incompletely assembled class 
I from the ER (Zhang and Williams 2006). The B cell receptor associated protein (Bap31) is a 
putative cargo that is recruited and associated with the class I molecule assembly at this stage 
(Ladasky et al. 2006).  
 
Once the H chain–β2m heterodimer is formed, it associates with the membrane- bound 
glycoprotein, tapasin, and indirectly with the peptide transporter, transporter associated with 
antigen processing (TAP) – a member of ATP-binding cassette (ABC) family of transporter 
localised in the ER – to form a multi-molecular complex called the peptide-loading complex 
(PLC) (Procko and Gaudet 2009). Cytosolically generated peptides derived by proteasomal 
degradation are translocated by TAP into the ER lumen and are then loaded onto MHC class I 
molecules (Procko and Gaudet 2009).  
 
Peptides longer than 8–11 aa are trimmed by the ER amino-peptidases ERAP1 (York et al. 2002) 
and ERAP2 (Saveanu et al. 2005) before binding to the empty H chain-β2m heterodimer. 
Binding of the high affinity peptide into the MHC class I binding groove triggers the 
disassembly of the PLC, causing shedding of the ER chaperones (Procko and Gaudet 2009). The 
resulting ternary H chain–β2m–peptide complex is then exported out of the ER via the Golgi 
apparatus to the cell surface through its association with Bap31 (Ladasky et al. 2006).  On the 
cell surface, the antigen will be presented in the context of the fully assembled MHC class I to 
CD8
+
 T cells (Procko and Gaudet 2009). 
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Figure 4. Assembly of MHC class I and Antigen presentation 
Cytoplasmic antigens are degraded by proteosomes into small peptides. Peptides associate with ABC 
transporter family member, the transporter associated with antigen processing (TAP), which carries them 
across the ER membrane. MHC class I is assembled in the ER with the help of ER chaperone proteins 
such as calnexin (Cnx) that prevents the assembly of unfolded protein. As MHC class I chains start 
assembling, the peptide loading complex (PLC) is formed with ER chaperones such as ER-p57, which 
enhances the formation of the disulphide bonds, and tapasin, which facilitates binding of MHC class I 
with TAP transporter. Binding of the high affinity peptide triggers the disassembly of the PLC, causing 
shedding of the ER chaperones. The loaded MHC class I molecule is then exported out of the ER to the 
Golgi apparatus, before expression on the cell surface to CD8
+
 T cells`. 
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1.3.3.2 The MHC class II molecule associates with exogenous peptides  
MHC class II is constitutively expressed by APCs such as the monocyte-macrophage lineage, 
dendritic cells (DCs), B lymphocytes and activated human T cells (Trowsdale 2006). Thymic 
epithelial cells (TECs) display MHC class II which is essential for CD4
+
 T cell generation and 
the development of the TCR repertoire (Starr et al. 2003). The expression of MHC class II can be 
induced on various tissues by IFN-γ including intestinal epithelial cells (Buning et al. 2008) and 
vascular endothelial cells (Muczynski et al. 2003).     
MHC class II α and β chains are synthesised in the ER, and associated with a polypeptide called 
the invariant chain (Ii) to form a nonameric polypeptide complex Figure 5. Ii is encoded outside 
the MHC, in a region located on human chromosome 5 (q32). Murine Ii was first identified in 
1979 by Jones et al but it was not until 1983 that human Ii was described (Jones et al. 1979; 
Claesson et al. 1983; Long et al. 1983). Ii is a chaperone protein that is important at several 
stages of MHC II biogenesis and function (Romagnoli and Germain 1994; Wolf and Ploegh 
1995; Dixon et al. 2006).  
 
Ii is a type II TM glycoprotein (N-terminal in cytosol and C-terminal in lumen), that exists in 
human as four different isoforms defined by primary aa sequence - p33, p35, p41 and p43 
(Strubin et al. 1986; O'Sullivan et al. 1987). Only the p33 and p41 isoforms are found in mice, 
the former as p31. The main human isoform is p33, which consists of 216 aa including an N-
terminal cytosolic tail of 30 aa; a TM domain of 26 aa; and a C-terminal 160 residue luminal 
domain (Claesson et al. 1983). 
In the ER, newly synthesised MHC class II α and β chains associate with trimers of the Ii chain 
to form a nonameric complex [(αβIi)3] that itself is incapable of binding peptides. This complex 
is composed of three Ii chains, arranged as a core, surrounded by three class II αβ heterodimer 
(Cresswell 1996). Association with Ii has been proposed to contribute in a number of different 
ways to the function of class II molecules including: ensuring proper assembly and correct 
folding of the synthesised MHC class II proteins: facilitating its efficient egress from the ER and 
transport through the Golgi and trans-Golgi network to endosomes: preventing MHC class II 
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molecule from loading endogenous peptides in the ER intended for MHC class I molecules, or 
unfolded peptides (Bikoff et al. 1993; Elliott et al. 1994).  
The αβIi complex is then transported through the Golgi complex to the endosomal–lysosomal 
pathway, directed by targeting signals in the cytoplasmic domain of the Ii chain (Odorizzi et al. 
1994). Once in this pathway, the Ii chain is proteolytically degraded, leaving a small fragment, 
class II–associated Ii chain peptide (CLIP) bound to the released αβ dimers (Riberdy et al. 1992; 
Romagnoli and Germain 1994). αβCLIP represents a natural intermediate complex in MHC class 
II maturation (Morkowski et al. 1995).  
The αβCLIP complex interacts with another class II–related molecule, called HLA-DM in the 
human system (termed H2-M in mice) (Kelly et al. 1991) in multi-vesicular and multi-lamellar 
late endosomal compartments, known as the class II containing vesicles (CIIV) or MHC class II 
compartments (MIIC) respectively (Amigorena et al. 1994; Neefjes 1999). HLA-DM is a 
glycoprotein that consists of an α and a β chain, both of which are encoded in the MHC class II 
region. DM has a closed groove, which is incapable of peptide binding. It stabilises empty MHC 
class II molecules so that when CLIP is released, MHC class II can bind lysosomally generated 
peptides (Weenink et al. 1997). The peptide-loaded class II molecules then leave the MIIC to be 
expressed on the cell surface to CD4
+
 T lymphocytes.  
Mature class II MHC molecules are constitutively endocytosed and recycled, interacting with 
new peptides in the MIIC. This route may enhance MHC class II capacity to bind and present 
peptides that do not require processing (Reid and Watts 1992). 
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1.3.4 Cross Presentation  
Presenting endogenously derived antigens in the context of MHC class I is not a strict rule. The 
converse scenario can also occur namely, exogenously-derived peptides can be presented in the 
context of MHC class I by phenomena known as cross-presentation (Rock 1996; Heath and 
Carbone 2001). Also, endogenously derived peptide can be presented in the context of MHC 
Figure 5. Assembly of MHC class II and antigen presentation 
MHC class II associates with the invariant chain (Ii) in the endoplasmic reticulum (ER) to form a 
nonmeric complex (αβIi)3. Ii prevents the loading of MHC class II with peptide and contains a 
sorting signal that helps in MHC class II egress from the ER.  MHC class II complex is transported 
through the Golgi complex to the endosomal–lysosomal pathway. The Ii chain is then 
proteolytically degraded, leaving a small fragment (CLIP) to occupy the MHC class II peptide 
binding groove. In MHC class II compartment (MIIC) vesicles, MHC class II is stabilised by HLA-
DM and the CLIP is replaced by peptide derived from exogenous antigens. MHC class II is loaded 
with the appropriate antigen and then expressed on the cell surface to present antigens to CD4
+
 T 
cells. 
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class II by the same phenomena (Malnati et al. 1993). DCs are the principal cell type responsible 
for cross-presentation in vivo, while multiple cell types including macrophages (Shortman and 
Liu 2002), B cells (Tobian et al. 2005), neutrophils (Tvinnereim et al. 2004) and endothelial cells 
(Bagai et al. 2005) can cross present antigens in vitro, but with lower efficiency. 
Presentation of exogenously-derived antigens in the context of MHC class I is thought to be 
critical for initiating CD8
+
 T cell responses to antigens that would not otherwise gain access to 
the MHC class I presentation pathway in DCs (Groothuis and Neefjes 2005; Bevan 2006; Shen 
and Rock 2006). DCs acquire exogenous antigens derived from intracellular source such as 
infected cells and tumours and migrate to draining lymph nodes, where they present antigens in 
the context of MHC class I and initiate CTL immune response (Groothuis and Neefjes 2005). 
Two physical forms of antigen that is transferred to DCs for cross-presentation has been the 
postulated: a peptide bound to heat shock proteins (Heike et al. 1996; Baker-LePain et al. 2003) 
or intact protein or fragments thereof (Shen and Rock 2004).  
 
Several pieces of evidence suggested two major pathways for antigen cross-presentation 
including TAP-dependent, or canonical, and TAP-independent, or vacuolar pathways (Sigal and 
Rock 2000; Shen and Rock 2006). The canonical pathway is thought to involve the transfer of 
precursor antigens from the phagosomes to the cytoplasm, where they are degraded into peptides 
by proteosomes, then transported by TAP to enter the MHC class I presentation pathway 
(Kovacsovics-Bankowski and Rock 1995); by comparison, the vacuolar pathway involves the 
processing of endocytosed material via lysosomal proteases such as cathepsin S reaching MHC 
class I molecules via a TAP-independent route (Shen and Rock 2006) .  
 
Several alternative models for cross-presentation have been postulated including ER- phagosome 
pathway, in which a phagosome containing the exogenous antigen fuses with the ER to form ER-
phagosome, which is then degraded with the release of the phagosomal protein to the cytosol, to 
be expressed in the context of MHC class I (Groothuis and Neefjes 2005); and a gap junction 
pathway which involves direct transfer of peptides from virally infected cells to professional 
APCs through a gap-junction (Neijssen et al. 2005). 
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1.4 Allorecognition: T cell-peptide/MHC interactions 
In organ transplantation, donor-derived polymorphic HLA molecules are recognized as foreign 
by the recipient, in a phenomenon called allorecognition. Alloreactivity refers to the ability of T 
cell to recognise peptide–allogeneic MHC complexes that were not encountered during thymic 
development. Allorecognition manifests itself clinically, as GVHD in bone marrow 
transplantation, or graft rejection in solid organ transplantation. The study of alloreactivity has 
contributed to many key areas of immunological endeavor, such as the discovery of the MHC 
molecule (Gorer 1937), immune tolerance (Billingham et al. 1953), and resolution of the TCR– 
peptide–MHC complex co-crystal structure (Garcia et al. 1996).  
 
Presentation of foreign antigen to recipient T cells occurs via three routes respectively named the 
direct, indirect and semi-direct pathways (Figure 6,7); each is discussed in the following 
sections. 
1.4.1 Direct allorecognition 
Direct allorecognition pathway involves T cell recognition of determinants on the surface of 
donor cells, in the absence of antigen processing by recipient APCs (Lechler and George 2006) 
(Figure 7). One hallmark of direct allorecognition is the high precursor frequency of alloreactive 
T cells compared with other nominal antigens, estimated to be between 1-7% (Suchin et al. 
2001). The high frequency of alloreactive T cells was explained by significant TCR cross- 
reactivity between self and allogeneic MHC-peptide complexes (Lombardi et al. 1989; Archbold 
et al. 2006). 
 
Two common theories explain the molecular interactions that lead to TCR allo-reactivity : the 
„high determinant density hypothesis‟ (HDDH) (Bevan 1984), and the „multiple binary 
hypothesis‟ (MBH) (Matzinger and Bevan 1977), depending on whether alloreactive T cells 
recognise the polymorphisms in allogeneic MHC (allo-MHC) or the presented peptide in the 
MHC peptide-binding groove (Figure 6). 
 
The HDDH is predicated on a peptide–independent response, which proposes that the 
alloreactive TCR recognises, with moderate to low affinity, the polymorphisms in the allo-MHC 
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molecules directly, independently of the bound peptide. The low affinity of the interaction would 
normally be too low to activate the T cells; however, this is compensated by the avidity of the 
interaction, attributed to the high density of MHC molecules on the allogeneic cells. In this 
model, TCRs recognised the allo-MHC molecules, although they would have never encountered 
them during thymic education.   
 
In contrast, the MBH is predicated on a peptide-dependent response, which suggests that the 
allospecific T cells recognise normal non-polymorphic host peptides presented by non-self 
MHC. As educated T cells are not tolerised to such self-peptides in the context of non-self MHC, 
there is a high frequency of allo-reactive T cells due to large number of such antigens presented 
by the graft. In clinical settings, both mechanisms are likely to contribute to direct 
allorecognition; the overall contribution of each related to the site and magnitude of the structural 
differences in MHC molecules between donor and recipient. The more the structural 
dissimilarity between allo- and self-MHC, the more likely T cells are to recognise the 
polymorphism of the MHC independently of the bound peptide (consistent with HDDH): 
whereas the more the structural similarity between allo- and self-MHC, the more likely T cell are 
to be dependent on recognition of the presented peptide by the allo-MHC (consistent with MBH) 
(Lechler et al. 1990). 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                                        Introduction 
42 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The donor DC is the main cell type that triggers the recipient immune response via the direct 
pathway, which was demonstrated by Lechler et al. in the “kidney parking experiment” (Lechler 
and Batchelor 1982 (a)). A rat kidney allograft was transplanted to an intermediate immune-
suppressed host of different strain for one to three months, prior to transferring the graft to a third 
animal of similar strain to the original recipient. The transplanted graft show prolonged survival 
time. This “intermediate parking strategy” suggested that depletion of donor DCs led to loss of 
immunogenicity; however, re-injecting the original donor DCs to the recipient restored 
immunogenicity and elicited graft rejection (Lechler and Batchelor 1982 (a); Lechler and 
Batchelor 1982 (b)). In transplantation settings, under the influence of pro-inflammatory signals 
provoked by the transplantation procedure, donor DCs traffic to secondary lymphoid tissue of the 
recipient (Larsen et al. 1990; Lakkis et al. 2000). In the lymph node, donor DCs prime CD4
+
 and 
Figure 6. Mechanisms of direct allorecognition 
The high frequency of alloreactive T cells in direct allorecognition can be explained by one of 
two models. (a) The high determinant density hypothesis, in which the recipient T cell 
recognises MHC polymorphism in the donor APC directly and independently of the peptide 
presented in the MHC binding groove. The low binding affinity between MHC and TCR is 
compensated by the multiple reactions formed, as many MHC molecules are presented on donor 
APC surface. (b) The multiple binary hypothesis, in which the T cell recognises normal 
polymorphic peptides presented in the context of non-self-MHC. As T cells are not tolerized to 
self-peptide in the context of non-self MHC (donor MHC), a high frequency of alloreactive T 
cells is generated. 
(b) 
Recipient 
T cell 
MHC 
Antigenic 
peptide 
TCR 
Donor 
APCs 
Donor 
APCs 
(a) High determinant 
density hypothesis 
(b) Multiple binary 
hypothesis 
                                                                                                                                                        Introduction 
43 
 
CD8
+
 recipient T cells, CD4
+
 T cells providing help to CD8
+
 cells. Consequently, activated T 
cells migrate back to the graft and initiate an effector immune response, causing graft rejection.   
1.4.2 Indirect allorecognition  
 
The indirect pathway refers to recognition of processed peptides of allo-MHC antigens presented 
by self-MHC in a self-restricted manner (Lechler and Batchelor 1982 (b); Shoskes and Wood 
1994). The intermediate parking strategy postulated by Lechler et al. to impede direct 
allorecognition did not manage to stop the egress of donor peptides from the graft to the recipient 
draining lymph nodes, resulting in organ rejection. The rationale was that although the graft 
contained enough donor DCs to initiate direct allorecognition, this cell population died with 
time. Rather, rejection was attributed to recipient DCs that constantly traffic through the graft 
and take up alloantigens or apoptotic donor cells, which they further process and present in the 
context of self MHC class II to recipient T cells (Lechler and Batchelor 1982 (b)).  
 
Indirect alloantigen results in alloresponses that are dominated by CD4
+
 T cells, and it is very 
similar to the conventional recognition of normal antigens presented by host APCs to host T cells 
(Figure 7).  There is ample evidence for the involvement of this pathway in graft rejection: in 
mice, presentation of peptides from allogeneic MHC by self-MHC was demonstrated in a study 
conducted by Inaba et al. who showed that after the injection of H2
k
 DCs (H2-E positive) into H-
2A
b 
recipients (H2-E negative), the majority of recipient DCs isolated from draining lymph 
nodes stained positively with an antibody specific for complexes of H-2A
b
 occupied by peptides 
of H-2E (Inaba et al. 1998). Also, CD8-depleted recipients in whom immune functions are 
mediated only by CD4
+
 or MHC class I deficient recipients rejected MHC class II negative grafts 
(Auchincloss et al. 1993). Since the donor grafts lacked class II antigens, recipient CD4
+
 T cells 
recognised donor antigens presented in association with recipient class II molecules 
(Auchincloss et al. 1993). In humans, there is substantial evidence that allo-MHC peptides are 
presented by recipient APCs and recognised by recipient T cells (Benichou et al. 1992; Liu et al. 
1996). 
 
 
                                                                                                                                                        Introduction 
44 
 
The indirect route of allorecognition also accounts for transplant rejection mediated by 
mismatched mHag. These mismatched mHags, when expressed by the graft, can be presented by 
recipient MHC class I and II molecules and induce immune response against the graft 
(Dierselhuis and Goulmy 2009). Studies have shown that multiple differences in mHag between 
MHC-matched donors and recipients are capable of eliciting graft rejection with magnitude 
similar to that of MHC-mismatched tissues, revealing the potential importance of mHag in graft 
rejection (Dierselhuis and Goulmy 2009). 
 
Indirect allorecognition is delayed in comparison with the direct pathway, attributed to the 
relatively longer time taken for antigen processing in indirect allorecognition, in addition to the 
lower frequency of T cells in the normal repertoire with indirect versus direct allospecificity 
(Mason et al. 1996; Hornick et al. 2000). This suggests that the direct response dominates the 
early post-transplant period, whereas the indirect pathway plays a delayed role in alloantigen 
presentation when donor APCs die. However, even though indirect allorecognition is delayed, it 
persists for the life of the graft - unlike the direct pathway, which subsides as donor APCs are 
consumed (Hornick et al. 1998).      
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Figure 7. Schematic representation of direct and indirect allorecogniton  
 
(a) Direct allorecognition: Recipient T cells, CD4+ and CD8+, recognise allo-MHC 
presented by donor APCs (dAPCs). CD4
+
 T cells provide help to CD8
+
 T cells. 
(b) Indirect allorecognition: Donor APCs are degraded and the donor-derived peptide are 
acquired and presented by recipient APCs (rAPCs). Recipient T cells, mainly CD4
+
, 
recognise donor-derived peptide in the context of self-MHC class II expressed by 
recipient APCs. 
 
 
 
 
1.4.3 Semi-direct allorecognition 
 
In 2004, Herrera et al. illustrated the capacity of DCs to acquire intact MHC-peptide complexes 
from other cells and present them to T cells both in vitro and in vivo (Herrera et al. 2004). These 
experiments suggested a mechanism that links the direct and the indirect pathways of 
allorecognition, postulating a third pathway coined by Lechler as the semi-direct allorecognition 
pathway (Herrera et al. 2004). In this pathway, recipient DCs are envisioned to traffic through a 
                Direct allorecogniton                                      Indirect allorecogniton 
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grafted tissue constantly, acquiring intact donor allo-MHC complexes en route and presenting 
them to recipient T cells through the direct pathway Figure 8. Simultaneously, recipient DCs 
would internalise and process donor MHC molecules and present them as peptides in the context 
of MHC class II and MHC class I to CD4
+
 and CD8
+
 T cells, respectively, via indirect anti-donor 
allospecificity (Herrera et al. 2004; Afzali et al. 2007).  
 
Studies have shown that DCs are capable of acquiring intact MHC molecules from other cells - 
other DCs, macrophages, activated endothelial cells (ECs), activated T cells, B cells, and tumour 
cells in vitro (Bedford et al. 1999; Russo et al. 2000; Herrera et al. 2004). DCs are capable of 
shedding soluble MHC molecules and membrane vesicles, called exosomes, which express MHC 
class I and II molecules and costimulatory molecules that may be captured by other DCs 
(Luketic et al. 2007). Thus recipient DCs can acquire intact allo-MHC in a cell contact-
dependent manner or via the release and uptake of exosomes secreted by other DCs (Luketic et 
al. 2007).  
 
In the context of allograft rejection, the semi-direct pathway role has not been established in 
clinical patients. Nevertheless, it is possible that the measures taken to reduce T cell activation 
via the direct pathway should also inhibit activation via the semi-direct pathway. Semi-direct 
allorecognition pathway provides a link between T cells with direct and indirect allospecificity. 
Thus both recipients CD4
+
 and CD8
+ 
T cells are stimulated by recipient APCs, leading to 
sustained stimulation of donor specific T cell whilst the donor DCs would have been exhausted.  
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Figure 8. Schematic representation of semi-direct allorecognition 
In the semi-direct pathway, recipient APCs (rAPCs) traffic through the grafted tissue, acquiring 
intact donor allo-MHC en route.  Recipient APCs acquire allo-MHC donor complex via cell-to-
cell contact with donor APCs (dAPCs), leading to the transfer of of intact membrane components 
between donor and recipient. dAPCs release small vesicles, known as „exosomes‟, that may 
contain intact MHC. These exosomes fuse with the membrane of rAPCs, which can then express 
these allo-MHC complexes on their surface. rAPCs presenting intact allo-MHC complexes of 
donor origin can activate recipient T cells via direct allorecognition pathway, while rAPCs 
presenting processed allo-MHC complexes in the context of self-MHC can activate recipient T 
cells via indirect allorecognition.  
  
1.5 Allograft rejection 
The main immunological problem with transplantation is that the allograft is recognised by the 
immune system as „foreign‟ and hence is attacked by the host immune system, leading to graft 
rejection. The immune response against a transplanted organ results from activation of innate 
immunity, initiating the adaptive immune response (figure 9). Graft rejection can occur in three 
distinctive phases named hyperacute, acute and chronic. 
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Figure 9. Innate and adaptive immunity in allograft rejection 
Immature Dendritic cells (iDCs), both donor and recipient, engulf allogenic peptides from 
damaged graft cells by phagocytosis. In addition, Toll like-receptors (TLRs) identify 
damage/danger-associated molecular patterns (DAMPs) e.g heat shock proteins (HSPs), and 
induce the expression of genes, such as co-stimulatory molecules and proinflammatory 
cytokines/chemokines. The iDCs undergo maturation and migrate via afferent lymphatics to the 
regional lymph node (LN) where they present peptide-MHC (pMHC) complex to naïve T cells 
(direct and indirect allorecognition). Thus the innate immue system is critical for the 
development of the adaptive allogenic response. The expression of costimulatory molecules such 
as ICOSL is important not only for activating T cells, but for determining the nature of the T 
cells response (Th1, Th2) as will be discussed later. 
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1.5.1 Hyperacute rejection 
Hyperacute rejection is the most violent form of rejection, which occurs within minutes to hours 
after transplantation - the organ quickly becoming pale and undergoing necrosis (Lechler and 
George 2006). It is characterised, in most cases by vascular haemorrhage and thrombotic 
occlusion of the graft‟s vascular bed. Hyperacute rejection is an antibody-mediated immune 
response following the binding of pre-existing circulating antibodies to graft vascular endothelial 
antigens (Colvin and Smith 2005). Two main antibody categories are identified: low affinity 
immunoglobulin M (IgM) antibodies, generated mainly against ABO blood group antigens and 
high affinity IgG, generated against MHC antigens (Colvin and Smith 2005; Afzali et al. 2007). 
These pre-formed recipient antibodies are commonly detected in pre-sensitised individuals to 
MHC or blood group antigens for example in the context of previous transplantation, repeated 
blood transfusions or multiple pregnancies (Colvin and Smith 2005). These antibodies trigger the 
complement system and results in the formation of membrane attack complexes (MACs) (Murata 
and Baldwin 2009). MACs bind to the cell plasma membrane, usually endothelial cells, initiating 
a cascade of reactions that result in the direct loss of membrane integrity and necrosis (Nauta et 
al. 2002; Murata and Baldwin 2009). This leads to severe injury of the graft endothelial lining 
with rapid loss of the graft function. Hyperacute rejection has become relatively rare since the 
introduction of routine pre-transplantation screening of graft recipients for anti-donor antibodies, 
ABO blood groups and HLA typing (Lechler and George 2006). Several de-sensitisation 
strategies are applied to reduce cross reactivity in pre-sensitized patients or those with positive T 
cell cross-matches such as pre-transplantation plasmapheresis with low doses of intra-venous 
immunoglobulin (Ig) or treatment with anti-CD20 antibodies (rituximab) (Claas and Doxiadis 
2009).  
 
1.5.2 Acute and chronic rejection 
Acute rejection is defined by an attack of graft functional integrity that takes place over a period 
of days to weeks following transplantation (Lechler and George 2006), while chronic rejection is 
detected over a longer term, months to years after transplantation (Waaga et al. 2000). Chronic 
rejection is characterised by irreversible engraftment fibrosis and graft vascular occlusion with 
loss of normal organ functions. These changes termed graft arteriosclerosis or transplant-
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associated vasculopathy, which is considered to be the main cause of late graft rejection (Womer 
et al. 2001). 
Graft rejection can be summarized as a sequence of immunological reactions initiated by the 
migration of donor APCs, mainly DCs, from the graft to the draining lymph nodes. Donor DCs 
present intact allo-MHC-peptide to recipient T cells, evoking a direct alloresponse that involve 
both CD4
+
 and CD8
+
 effector T cells. Direct allorecognition is believed to dominate the acute 
rejection phase. The high frequency of direct alloreactive T cell is augmented by the involvement 
of many cross-reactive memory self-MHC restricted T cells primed against various 
environmental antigens in the context of self-MHC (Lombardi et al. 1990; Lechler et al. 1991). 
Donor APCs are then eliminated in the draining lymph nodes of the recipient, which attenuates 
the direct alloresponse. Simultaneously, dead donors APCs provide the supply of donor MHC 
antigens to recipient APCs which constantly trafficking through the graft. Recepient APCs 
phagocytose alloantigens and present them to recipient T cells, thus initiating the indirect 
alloresponse. Indirect allorecognition pathway is believed to dominate the chronic rejection 
phase. In the indirect alloresponse CD4
+
 T cells interact with APCs presenting processed donor 
antigens in the context of self-MHC class II molecules; to a lesser extent, CD8
+
 T cells are 
incriminated, interacting with APCs cross-presenting antigens in the context of MHC class I 
molecules (Lee et al. 1994).  
 
CD4
+
 and CD8
+
 T cell subsets both contribute in allograft rejection (Rocha et al. 2003). Their 
fundamental role in graft rejection has been introduced by Rosenberg and co-workers who 
showed that the adoptively transferred CD4
+
 and CD8
+
 caused graft rejection in the athymic 
nude mice, which was a T cell-deficient recipient (Rosenberg et al. 1987). Once T cell subsets 
are activated by alloantigens, they migrate to the graft and cause its damage by three 
immunological effector mechanisms in acute or chronic rejection. These mechanisms are the 
generation of cytotoxic allospecific T cells, induction of delayed-type hypersensitivity reactions 
(DTHR) and antibody-mediated cellular damage (Vella et al. 1997). Other non-immunological 
processes have been mentioned as contributors in graft rejection, including graft injury at the 
time of transplantation, recurrence of the original underlying disease, and drug-related toxicity 
(Lechler and George 2006).  
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CD8
+
 T cells with direct allospecificty recognise allogeneic cells and cause their elimination via 
perforin-granzyme mediated apoptosis (Wever et al. 1998; Taylor et al. 2007). CD4
+ 
T cells with 
direct allospecificity are capable of promoting CD8
+
 T cells effector functions, recruiting 
additional effector cells and mediating DTHR via the production of soluble mediators that 
activate and guide immune cells to the graft (Sirak et al. 1997). Cellular infiltrates in the rejected 
graft have been identified as predominantly T cells, monocytes and macrophages, responsible for 
the histological changes in the graft and consistent with DTHR (Rocha et al. 2003).  
 
CD4
+
 T cells with indirect allospecificity promote B-cell maturation and differentiation into 
antibody-secreting plasma cells via CD40-CD40 ligand interactions (Cai and Terasaki 2005; 
Callaghan et al. 2007; Taylor et al. 2007). Alloantibodies that are produced by B cells exert most 
of their damaging effects on the graft by activating the complement cascade, via the same 
mechanism described for hyperacute rejection, and associated with acute and chronic rejection 
(Collins et al. 1999; Terasaki and Cai 2005).  
 
Although there is significant evidence in support of the assertion that acute rejection is 
dominated by direct allorecognition, while chronic rejection is dominated by indirect 
allorecognition (Hornick et al. 2000; Womer et al. 2001), recent studies have merged the 
boundaries between these pathways. Indeeds, in the absence of direct alloresponses, the indirect 
pathway alone can result in rapid acute graft rejection (Auchincloss et al. 1993). In addition, 
acute rejection of a graft was mediated by the indirect pathway when the frequency of T cells 
with indirect allospecificity was increased by sensitization prior to transplantation (Braun et al. 
2001).  
 
1.6 Dendritic cell-T-cell Interface 
 
The outcome of the cross talk between DCs and allospecific T cells is the key factor driving 
transplant rejection. Advances in understanding the influences that govern their role in 
modulating the immune response would help in the development of a potent and focused 
immune-suppressive strategy, aimed at prevention and management of graft rejection. 
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1.6.1 T Cells  
 
Full activation of T cells in response to alloantigen requires the delivery of two distinct but 
complementary signals (Bretscher 1992). In 1970, Bretscher and Cohn postulated the “two signal 
model” of lymphocyte activation specifically as a theory to account for self-nonself 
discrimination. They proposed that induction of lymphocyte effector function requires the 
delivery of two signals to the antigen-sensitive cell – signal (1) delivered from recognition of 
antigen by the antigen receptor, using antibody to mimic the TCR signal, and signal (2) from 
carrier antibody recognising carrier determinant on APC. They postulated that the presence of 
the binding antigen in the absence of a second signal, delivered by another antigen-specific cell, 
leads to cell paralysis (Bretscher and Cohn 1970; Bretscher 1992). Five years later, Lafferty and 
Cunningham reviewed the two signal model of T cell activation as a theory to account for the 
species specificity of alloreactivity, and not as a mechanism of self-nonself discrimination 
(Lafferty and Cunningham 1975). Their model suggested that alloreactive T cells require two 
signals for induction of effector function: the first signal was alloantigen, the second signal a 
'lymphocyte costimulator' delivered by APC. However, the difference between Lafferty‟s and 
Bretscher‟s models was that the former proposed that the cell delivering the second signal needs 
not to display specificity for antigen.  
 
With further recognition of the APC-T cell molecular interaction and the factors regulating their 
responses, the current version of the two signal model assumes that T cells require two signals to 
be activated by APCs : the first delivered via TCR upon antigen presentation in the context of 
MHC, the second resulting from receptor counter-receptor interactions between T cells and 
APCs that are antigen non-specific (Bernard et al. 2002). 
 
1.6.1.1 T cell costimulatory pathways 
 
Seminal studies by Schwartz and Jenkins demonstrated that TCR-mediated activation of T cells 
in the absence of costimulation resulted in antigen-specific unresponsiveness; a state known as T 
cell anergy (Jenkins et al. 1990; Schwartz 1992). Thus T cell costimulation was postulated to 
have a pivotal role in determining whether the outcome of T cell encounter with antigen would 
be activation or anergy (Snanoudj et al. 2006; Vincenti 2008). The costimulatory molecules that 
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regulate the magnitude and duration of T cell immune responses are categorised in two major 
gene families – the B7-CD28 superfamily and the TNF-TNF receptor (TNFR) superfamily 
(Leitner et al. 2010).  
1.6.1.1.1 CD28-B7 superfamily   
The CD28-B7 superfamily is crucial for effective T cell function, not only providing critical 
positive second signals that initiate and augment T cell responses, but also contributing key 
negative signals that limit or terminate T cell responses. The CD28 family members include:  
 B7-CD28 family members – B7-1 (CD80) and B7-2 (CD86) that bind to the same two 
receptors; CD28 and CTLA-4 (CD152) 
 The inducible costimulator (ICOS) and its ligand ICOS-ligand (ICOSL; B7-H2) 
 Programmed cell death-1 (PD-1) and its ligands PD-L1 (B7-H1) and PD-L2 (B7-DC) 
  B7-H3 
  B7-H4 (B7x or B7S1) 
  B and T lymphocyte attenuator (BTLA) 
ICOS and ICOSL form the main focus of this project; thus, emphasis will be placed on these 
molecules, while the others will be described only briefly. 
1.6.1.1.1.1 ICOS-ICOSL (CD278-CD275) pathway  
 
ICOS is a member of B7-CD28 co-stimulatory family. It was initially identified by Hutloff et al. 
using monoclonal antibody against activated human T cells (Hutloff et al. 1999). Subsequently, 
murine ICOS was identified by both Yoshinaga and Hutloff groups (Yoshinaga et al. 1999; 
Mages et al. 2000), followed by the rat homologue, designated activation-inducible lymphocyte-
immuno-modulatory molecule (AILIM) (Tamatani et al. 2000).    
Whereas CD28 is constitutively expressed on T cells, ICOS is induced on naïve CD4
+
 and CD8
+
 
T cells upon TCR engagement, hence its name; inducible costimulator (Hutloff et al. 1999; 
McAdam et al. 2000). ICOS expression can be upregulated by CD28; stimulation of murine 
splenocytes with anti-CD3 for 24 hours induces ICOS expression on CD4
+
 and CD8
+
 T cells 
(McAdam et al. 2000). However, if the splenocytes are CD80 
-/- 
and CD86 
-/-
 , ICOS expression 
is eight fold less than in the wild type, but can be restored on adding anti-CD28 with anti-CD3, 
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but not anti-CD28 alone to the culture (McAdam et al. 2000). This correlation between ICOS 
and CD28 suggests that CD28 can augment ICOS upregulation but is not essential for ICOS 
initial expression (McAdam et al. 2000). Almost all ICOS
+
 T cells express CD45RO, indicating 
that it plays a role in the memory T cell response, rather than to augment immune activation of 
naïve T cells (Hutloff et al. 1999; Yoshinaga et al. 1999; Burmeister et al. 2008). ICOS is 
expressed at a low level on resting lymphocytes (McAdam et al. 2000) and natural killer (NK) 
cells (Ogasawara et al. 2002); however, no expression was detected on B cells, monocytes, 
granulocytes, DC or platelets (Hutloff et al. 1999). 
Molecular study of human ICOS, as initially described by Hutloff et al. revealed a type-I 
transmembrane molecule consisting of a N-terminal signal sequence, a single extracellular 
domain, a linker segment, a single transmembrane domain, and a short cytoplasmic region with a 
total of 199 aa residues (Bajorath 1999; Hutloff et al. 1999).  
ICOS is expressed on the T cell surface as a glycosylated disulphide-linked homodimer with a 
molecular mass of approximately 55 – 60 kDa, comprising of a 27 kDa and 29 kDa chains 
(Hutloff et al. 1999). The homodimeric ICOS protein subunits are identical, except that the two 
chains differ in their post-transitional modification which results in variably glycosylated 
subunits (Hutloff et al. 1999; Beier et al. 2000). ICOS structural stability is supported by five 
cysteine residues at positions 42, 63, 83, 109, and 137 – from the initiating methionine amino 
acid – which are involved in forming the intra- and inter- disulphide bonds between the 
homodimeric chains of these proteins and maintain its structural integrity (Hutloff et al. 1999; 
Yoshinaga et al. 1999).  
As one of the CD28 family, ICOS shows both similarities with and differences from CD28 and 
CTLA-4. ICOS displays 24% and 17% aa sequence identity with CD28 and CTLA-4, 
respectively, and also shows similarity in cysteine residue distribution (Bajorath 1999; Hutloff et 
al. 1999). However, examination of the ICOS extra-cellular domain sequence shows that, the 
MYPPPY motif which is required for the binding of CD28 and CTLA-4 to B7 ligand (positions 
117-122 in CD28) (Truneh et al. 1996) is not conserved in ICOS; rather, it has been replaced by  
the FDPPPF motif (Hutloff et al. 1999; Beier et al. 2000). The FDPPPF motif is believed to be 
essential for ICOS-specific binding to its ligand, as mutations in this motif result in the loss of 
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ICOS binding to ICOSL (Wang et al. 2002). The cytoplasmic tail of ICOS contains a unique 
YMFM motif (positions 181-184 residues) that binds the p85 α and p50 α subunits of 
phosphoinositide 3-kinase (PI3K) (Coyle et al. 2000; Parry et al. 2003; Fos et al. 2008). 
Recruitment of PI3K leads to an increase of Akt (T cell survival factor) signalling that plays a 
crucial role in T cell survival and the control of cytokine secretion by activated T cells (Okamoto 
et al. 2003; Gigoux et al. 2009). Studies show that blocking of the PI3K pathway in mice 
expressing mutant ICOS-PI3K binding domain or ICOS
-/-
 mice leads to  down-regulation of IL-
4, IL-21 and IL-10 secretion and defect in antibody class switching (Okamoto et al. 2003; 
Gigoux et al. 2009). 
ICOSL was first cloned by Swallow et al. during their study to identify genes induced by the NF-
κB/Rel transcription factor, describing it as a T cell costimulatory ligand that shared aa 
homology with B7.1 and B7.2 family and was expressed by APCs (Swallow et al. 1999). Several 
terms are used for ICOSL by those who initially identified it including B7 homologous (B7h) 
protein (Swallow et al. 1999), B7-related protein-1 (B7RP-1) (Yoshinaga et al. 1999), B7 
homologue-2 (B7-H2) (Wang et al. 2000), Ligand of ICOS (LICOS) (Brodie et al. 2000) and 
human GL50 (hGL50) which is a splice variant of human ICOSL (Ling et al. 2000). The two 
splice variant of ICOSL are identical except for the carboxyl-terminal end in the cytoplasmic tail  
(Ling et al. 2001). 
ICOSL is a type I transmembrane protein composed of a signal peptide, two extracellular Ig–like 
domains, a transmembrane region, and a short cytoplasmic domain with a total of 302 aa 
residues (Swallow et al. 1999; Wang et al. 2000). The extracellular Ig–like domains are 
composed of a membrane distal Ig V-like domain and a membrane proximal Ig C-like domain.  
ICOSL shares approximately 20% aa homology with B7.1 and B7.2 (Wang et al. 2000). Four 
structural cysteine residues are conserved in the B7 and ICOSL sequences responsible for the 
formation of disulphide bond between ICOSL IgV- and IgC-like domains, maintaining the 
conserved molecular structure (Swallow et al. 1999; Ling et al. 2000; Wang et al. 2000). 
Biochemical analysis of ICOSL configuration on cell surface expression showed that ICOSL is 
expressed as a monomer on the surface of endothelial cells, as a single band was 
immunoprecipitated under reducing and non-reducing conditions (Khayyamian et al. 2002). 
Another study conducted by Chattopadhyay et al. demonstrated that ICOSL is present on the cell 
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surface as a mixture of monomers and oligomers, predominantly non-covalent dimers – believed 
to interact optimally with the disulphide-linked ICOS homodimer (Chattopadhyay et al. 2006). 
.ICOSL surface assembly and its potential influence on ICOS:ICOSL signalling has not been 
characterized. 
ICOSL is constitutively expressed by unstimulated B cells in the B cell area of secondary 
lymphoid organs, macrophages, DCs and monocytes. It can be upregulated on non-lymphoid 
cells such as endothelial cells, kidney, heart, peritoneum, testes, lung and thymus, using TNF-α, 
LPS, IFN-γ and IL-1 β (Swallow et al. 1999; Aicher et al. 2000; Yoshinaga et al. 2000; 
Khayyamian et al. 2002). 
ICOS:ICOSL constitutes a single receptor-ligand pair as ICOSL binds specifically to activated T 
cells via ICOS. ICOSL does not bind to CD28 or CTLA-4 molecules : as in vitro study showed 
that ICOSL-Ig binding to activated T cells was not blocked by the use of CTLA-4 Ig or CD28–Ig 
fusion proteins (Swallow et al. 1999). ICOS:ICOSL binding is mediated mainly through the 
ICOSL IgV domain, while the IgC domain is crucial for maintaining structural integrity of 
ICOSL protein (Chattopadhyay et al. 2006).  
1.6.1.1.1.1.2 ICOS-ICOSL functions 
(A) B cell function  
In the human secondary lymphoid organs, the high expression of ICOS occurs on the T cell 
surface of the lymph node germinal center (GC) light zone, the site of terminal B cell 
differentiation into plasma cell and memory cells, and at a lower expression level in the T cell 
zone surrounding the GC providing an important signal in T cell–B cell interactions (Hutloff et 
al. 1999; Beier et al. 2000). ICOS:ICOSL is important for the GCs formation as an in vivo study 
conducted on ICOS
-/-
 mice showed impaired GC formation, where the numbers of GCs were 
fewer and smaller in ICOS
-/-
 mice compared in the wild type mice (McAdam et al. 2001; Tafuri 
et al. 2001). This was due to poor stimulation of B cells with failure to migrate to lymph node to 
form the GCs (Mahajan et al. 2007). In addition ICOS:ICOSL pathway has an important role in 
immunoglobulin class switching as ICOS
-/-
 mice showed reduced levels of IgG1, IgG2 and IgE, 
while IgG3 levels were elevated (McAdam et al. 2001). Common variable immune-deficient 
(CVID) patients – who are homozygously deficient for ICOS – have an adult onset of 
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panhypogammaglobulinaemia characterized by low numbers of B cells and low serum Igs 
(Grimbacher et al. 2003; Salzer et al. 2004). Furthermore an in vivo study showed that 
secondary/memory B cell clonal proliferation required ICOS more than that of naïve B cells, as 
antigen-specific secondary proliferation of B cells in ICOS
-/-
 was significantly reduced compared 
to the primary clonal reaction (Mahajan et al. 2007). 
ICOS:ICOSL interactions are key to the function of follicular B helper T cells (Tfh), CD4
+
 T 
helper cells that foster the production of high affinity antibody. This interaction leads to the up-
regulation of the Tfh transcription factor c-Maf, with subsequent production of high levels of IL-
21 cytokine that acts on Tfh in an autocrine manner (Bauquet et al. 2009). IL-21 enhances the 
expression of the chemokine receptor CXCR5. CXCR5
+
CD4
+ 
Tfh cells then migrate to the 
lymphoid follicles, where they promote GC B-cell development and antibody production 
(Vogelzang et al. 2008; Bauquet et al. 2009).  
ICOS signalling also regulates CD40 ligand (CD40L) expression by T cells, and through its 
ligation with CD40 receptor on B cells enhances B cell maturation and survival (Kaminski et al. 
2009). In ICOS
-/-
 mice, the Ig class switching deficit was restored by CD40 stimulation, showing 
that ICOS promotes T : B-cell collaboration by regulating CD40/CD40L pathway (Tafuri et al. 
2001). 
 (B) T-helper cell function 
The ICOS:ICOSL pathway plays an important role in the development and effector functions of 
Th1, Th2, Th17, Tfh, and regulatory T cells (Tregs) (Tafuri et al. 2001; Nurieva et al. 2003; 
Bauquet et al. 2009). ICOS costimulates T cell proliferation and enhances the secretion of Th1 
and Th2-associated cytokines such as IFN-γ, IL-4, IL-5, IL-10 and IL-13 (McAdam et al. 2000; 
Gonzalo et al. 2001). The exact role of ICOS:ICOSL as whether it predominantly regulates Th2 
or both Th2 and Th1 remains undefined. Ample data suggested that ICOS might have a 
preferential role in the generation of Th2, as ICOS signalling enhanced the secretion of the Th2 
polarizing cytokines such as IL-4 thus activating and generating a Th2 polarizing profile (Coyle 
et al. 2000; Mak et al. 2003; Shilling et al. 2009). An in vivo study showed enhanced Th1 
responses, with increased levels of Th1 cytokines in ICOS
-/-
 and ICOSL 
-/-
 mice (Mak et al. 
2003; Nurieva et al. 2003; Mahajan et al. 2007). Nurieva et al examined ICOSL
-/-
 mice 
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suggesting that the reduction in Th2 cytokine secretion was related to the down-regulation of the 
c-Maf transcription factor, which resulted from the absence of ICOS:ICOSL induced c-Maf 
expression in CD4
+
 T cells (Nurieva et al. 2003). Furthermore, a study showed Th2 cytokine 
levels were higher in BALB/c mice than C57BL/6, thought to be related to increased ICOS 
expression by BALB/c T cells (Arimura et al. 2002).  
 
However, other studies suggest that ICOS co-stimulation does not promote Th2 differentiation, 
but instead promotes expansion of currently-differentiated Th2 cells (Tesciuba et al. 2001). 
Despite the fact that these studies link ICOS signalling to Th2 differentiation or expansion, ICOS 
co-stimulation can also enhance the secretion of Th1 cytokines such as IFN-γ or TNF-α in vitro 
(Kopf et al. 2000; Khayyamian et al. 2002). Ozkaynak et al. showed in their study that blockade 
of the ICOS:ICOSL pathway by anti-ICOS antibody or ICOS-fusion protein (ICOS-Ig) led to the 
prolongation of cardiac allograft survival by down-regulating  IFN-γ production (Ozkaynak et al. 
2001).  
 
The confusing role of ICOS:ICOSL interactions in regulating Th cytokine responses has been 
explained in various ways. Coyle et al. correlated the role of ICOS in Th2 polarization to the 
high level of its expression on Th2 versus Th1 (Coyle et al. 2000). This explanation was 
supported by Lohning et al. who suggested that ICOS expression level correlated with the type of 
cytokine produced – ICOShi T cells secreting IL-10, ICOSmedium T cells secreting  IL-4, IL-5 and 
IL-13, and ICOS
low
 T cells secreting Th-1 cytokines such as IFN-γ (Lohning, Hutloff et al. 
2003). Another view related ICOS costimulation and the functional consequences of ICOS 
blockade in a cardiac transplantation model to several factors such as the nature of immune 
response – whether during antigen priming or the effector/differentiation phase; the responding T 
cell clone size, as in major or minor mismatched recipients; and the timing of intervention – 
whether early or late blockade (Harada et al. 2003). They demonstrated that ICOS signalling in 
the antigen priming phase would favour Th2 development, early blocking of ICOS:ICOSL 
impaired Th2 development and led to Th1 polarization, while in the effector phase, blockade of 
the ICOS:ICOSL pathway would maintain Th2 functions (Harada et al. 2003). Another group 
related the difference in cytokine profile correlated with ICOSL expression by distinct DC 
subsets: CD11c
hi
CD11b
hi
 „myeloid‟ DCs have high ICOSL expression level, inducing Th2 
cytokine production, whereas CD11c
hi
CD11b
–
 „lymphoid‟ DCs do not express ICOSL and 
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promote Th1 polarisation (Pulendran et al. 1999). There are several issues that could contribute 
to theses discordant results, including dissimilarities in model system, targeting ICOS versus 
ICOSL, timing of analysis of the immune response, and the method of generating and 
stimulating T cell subsets. Collectively, these studies show the role of the ICOS:ICOSL pathway 
in the control of both Th1 and Th2 function, suggesting a preferential influence in Th2 
development. 
 
The role of ICOS:ICOSL interactions in Th17 function was addressed in several studies 
(Rottman et al. 2001; Bauquet et al. 2009; Takahashi et al. 2009). The study conducted by 
Baquet et al showed that ICOS signalling promoted secondary immune responses by up-
regulating IL-21and IL-23 receptor (IL-23R) required for the function and expansion of the Th17 
compartment (Bauquet et al. 2009). They showed that ICOS mediated its role through the 
regulation of the c-Maf transcription factor, which in turn regulates IL-21 production (Bauquet et 
al. 2009). This supported the early data published by Rottman et al study who studied an 
experimental allergic encephalomyelitis (EAE), a murine model of human multiple sclerosis 
caused by Th17 cells. Blockade of the ICOS:ICOSL pathway using anti-ICOS mAbs during the 
effector phase of the disease process abrogated clinical signs, leukocyte infiltration and the 
secreted cytokines (Rottman et al. 2001; Aranami and Yamamura 2008). 
 
ICOS:ICOSL signalling also regulates the generation and maintenance of the memory T cell 
subpopulation. Early studies showed that resting memory T cells expressed ICOS, which 
underlined its role in memory T cell function (Yoshinaga et al. 1999). Several later studies 
showed that expansion of the memory T cell pool was impaired in ICOS
-/- 
mice compared to wild 
type control (Mahajan et al. 2007; Burmeister et al. 2008). The reduced number of effector-
memory cells was due to absence of ICOS-induced survival signals that resulted in a defect in T 
cell expansion and increased apoptosis in vitro (Burmeister et al. 2008). On the contrary, an  in 
vivo study conducted on a mice model of cardiac transplantation showed that ICOS deficiency 
did not reduce memory T cells expansion – rather inhibited cells trafficking to the allograft 
(Zhang et al. 2008).  
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1.6.1.1.1.1.3 ICOS:ICOSL and tolerance 
With the initial identification of human ICOS, its role in stimulating IL-10 production was 
clearly demonstrated (Hutloff et al. 1999; Beier et al. 2000). IL-10 is a major regulatory cytokine 
of inflammatory responses (Akdis et al. 1998; Dieckmann et al. 2002). This shows that ICOS as 
a costimulatory molecule with a role in the mediation of peripheral tolerance. An initial 
correlation of ICOS with the development of IL-10 induced regulatory T cell-1 (Tr-1) cells was 
overlooked in a study published by Jonuleit et al who showed that the repetitive stimulation of T 
cells with immature DCs (iDCs), which express high level of ICOSL, resulted in the 
upregulation of several molecules, such as CTLA-4 and ICOS on T cell surface. They showed 
also that the T cells lost their capacity to synthesis IFN-γ, IL-2 and IL-4 and increased IL-10 
production exhibiting a Tr-1 cytokine profile (Jonuleit et al. 2000). These Tr-1 like cells could 
not be inhibited by blocking CTLA-4 or endogenous TGF-β, indicating another molecular 
mechanism, involving an additional surface molecule was responsible for the production of these 
Tregs (Jonuleit et al. 2000). The role of ICOS:ICOSL pathway in developing Tregs was also 
demonstrated in a study on allergen-induced airway hyperactivity in mice, in which blockade of 
ICOS:ICOSL interaction inhibited the IL-10 production, abrogated the inhibitory capacity of 
Tregs and inhibited the induction of T-cell tolerance (Akbari et al. 2002).   
 
A study examined ICOS-deficient patients showed that the loss of ICOS expression led to loss of 
T cell anergy induced by iDCs, which could not be restored by adding IL-10 to the cell cultures 
(Tuettenberg et al. 2009). They postulated that ICOS and IL-10 mediated their effects in a 
complementary manner; ICOS enabling IL-10 to mediate its effect through up-regulation and 
stabilization of IL-10R expression by activated T cells, rendering them more sensitive to IL-10 
(Tuettenberg et al. 2009) 
ICOS is also expressed by CD4
+
 CD25
+
 Foxp3
+ 
Tregs. A recent study reported the identification 
of two subsets of Foxp3
+ 
Treg on the base of ICOS expression – ICOS+Foxp3+ and 
ICOS
−
Foxp3
+
 (Ito et al. 2008). They showed that signalling through the ICOS pathway promoted 
Tregs expansion and survival in vitro (Ito et al. 2008). These two subsets mediated their 
suppressor action through different mechanisms: as ICOS
+
 Tregs suppressed T cell proliferation 
through IL-10 and TGF-β secretion, whereas ICOS- Tregs suppress mainly through TGF-β 
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secretion. This shows that ICOS expression can help to distinguish different populations of Tregs 
(Ito et al. 2008). Furthermore, a study by Burmeister et al. showed a reduction of CD4
+
Foxp3
+
 
Tregs in ICOS 
-/-
 mice; the reduction was not due to impaired generation in the thymus but rather 
ICOS implication of Tregs survival in the periphery (Burmeister et al. 2008) .  
 
ICOS regulatory functions have been demonstrated to be dependent of the presence of an 
allospecific regulatory CD8
+
 T cells (Izawa et al. 2007). The study showed that graft survival 
was prolonged after the transplantation of BALB/c heart in CD8
-/-
 B6 recipients. The recipients 
received CD8
+
 T cell from wild type B6 recipient of BALB/c heart treated with anti-ICOS mAb 
(Izawa et al. 2007). This CD8
+ 
Tregs believed to be antigen specific as no prolongation of graft 
survival was detected if CD8
+
 Tregs were transferred to CD8
-/-
 B6 recipient of a third party heart 
allograft C3H/He (Izawa et al. 2007). 
 
1.6.1.1.1.1.4 Modulating the ICOS:ICOSL pathway for therapeutic gain 
 
Owing to the importance of the ICOS:ICOSL pathway in regulating the allo-immune response, 
enhancing T cell proliferation and cytokine production and mediating regulatory immune 
responses, interest in ICOS and ICOSL has increased. Manipulation of this pathway has been 
attempted in the transplantation setting, tumor therapy as well as ameliorating autoimmune 
diseases.  
In the field of transplantation, the modulation of ICOS:ICOSL pathway has been approached to 
prolong allograft survival. Blockade of the ICOS:ICOSL pathway was achieved by the 
administration of reagents interacting with the ICOS molecule, such as anti-ICOS antibody 
(Taylor et al. 2005) or reagents that interact with the ICOSL, such as anti-ICOSL antibody 
(Harada et al. 2003) or ICOS Fc fusion protein (ICOS Ig) (Ozkaynak et al. 2001; Kosuge et al. 
2003) . Blockade of ICOS:ICOSL pathway was attempted either as a single treatment protocol 
promoting graft tolerance (Harada et al. 2003; Taylor et al. 2005), or as a part of combination 
therapy with other protocol to induce tolerance inducing indefinite graft survival – with CTLA-4 
Ig (Kosuge et al. 2003), CD40L mAb or rapamycin injection (Nanji et al. 2004), CD40 Ig 
(Guillonneau et al. 2005), sub-therapeutic regimen of cyclosporine A (CsA) (Ozkaynak et al. 
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2001), donor-specific cell transfusion (DST) (Sandner et al. 2005), and DST with anti-CD40L 
mAb (MR1)[ DST/MR1] (Zhang et al. 2008).  
Blocking of ICOS:ICOSL interaction was more effective in ameliorating immune response 
during the effector/differentiation phase rather than the priming phase. It was showed that the 
administration of anti-ICOS mAb attenuated chronic GVHD, whilst acute GVHD was 
aggravated by the same treatment (Ogawa et al. 2001). Furthermore, the inhibitory effect of late 
ICOS:ICOSL blockade was significantly more beneficial in promoting long term graft survival 
than was the early blockade (Harada et al. 2003). Therefore, manipulation of the ICOS:ICOSL 
signalling pathway in attempt to prolong graft survival may be best started after T cell priming 
(Harada et al. 2003) . 
The manipulation of ICOS pathway has been studied in cancer immunotherapy. A recent study 
showed that ICOS expression in tumours as a part of tumor gene expression profile was 
associated with improved survival of melanoma patients (Bogunovic et al. 2009). This could be 
related to increased infiltration of tumours with effector memory cells with enhanced anti-tumor 
activity. In addition, ICOSL-Ig injection or ectopic expression of ICOSL in murine tumour 
model produced anti-tumor cytolytic response detected by delayed tumour growth compared to 
the control group (Wallin et al. 2001; Zuberek et al. 2003). Targeting of costimulatory molecules 
on effector T cells might be a promising strategy for inducing anti-tumour responses in patients 
with cancer. 
 
Involvement of the ICOS:ICOSL in the pathogenesis of autoimmune diseases has also been 
demonstrated. Increased expression of T cell ICOS and its continuous interaction with B cell 
ICOSL was shown to be the driving force for the generation of memory B cell and plasma cell in 
systemic lupus erythermatosus (SLE) (Hutloff et al. 2004; Yang et al. 2005). Expansion in the B 
cells compartment resulted in the pathogenic hypergammaglobulinaemia, causing damage of the 
kidneys of SLE patients (Hutloff et al. 2004; Yang et al. 2005). A study conducted on the murine 
lupus nephritis reporting the efficiency of using anti-ICOSL mAb resulting in a significantly 
delay of the onset of proteinuria; it also prevented disease progression and prolonged survival 
time (Iwai et al. 2003). Other autoimmune diseases in which ICOS:ICOSL interactions have 
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played a role include experimental autoimmune uveoretenitis (EAU) (Usui et al. 2006) and 
rheumatoid arthritis (RA) (Ruth et al. 2007) 
 
1.6.1.1.1.2 The B7-CD28 family 
 
CD28 is the prototypic T cell costimulatory molecule and the best studied to date. The B7-CD28 
family consists of two B7 family members, B7- 1 (CD80) and B7-2 (CD86) that bind to the same 
two receptors – CD28 and CTLA-4 (Sharpe and Freeman 2002). These two receptors have 
different expression kinetics and affinities for B7-1 and B7-2: B7-1 binds CTLA-4 13-folds more 
effectively than B7-2, while B7-2 binds CD28 two to three-folds more effectively than B7-1 
(Davis et al. 2003).  
 
CD28 provides, in synergy with TCR engagement, an important co-stimulatory signal for T cell 
activation, while CTLA-4 down-regulates the T cell response (Sharpe and Freeman 2002). CD28 
is constitutively expressed on the surface of naïve CD4
+
 and CD8
+
 T cells, while CTLA-4 
expression is rapidly upregulated following T cell activation. The kinetics of expression of B7-1 
and B7-2 also differs: B7-2 is constitutively expressed at low levels by APCs and rapidly 
upregulated on inflammatory stimulation, whereas B7-1 is inducibly expressed by APCs (except 
by DCs) (Hathcock et al. 1994).  
 
The B7-CD28 pathway presents an immune target in several organ transplantation trials – 
blocking of this co-stimulatory pathway promoting graft tolerance in many murine and rat 
models. The commonly used blocking strategy to B7-CD28 pathway is CTLA-4 Ig fusion 
protein. CTLA-4 Ig has the advantage of having higher binding affinity for B7 molecules than 
CD28, and thus serves as a competitive antagonist to CD28 (Linsley et al. 1991). CTLA-4Ig 
induces graft tolerance in several models of kidney and heart transplantation and promoted graft 
survival (Lin et al. 1993; Kirk et al. 1997).  
 
Several factors limit the application of CD28-B7 costimulatory blockade as a sole strategy in the 
induction of long-term graft tolerance. The CD28-B7 pathway is less effective in regulating 
memory than naïve T cells – as memory T cells can be reactivated in the absence of CD28 
pathway signals if sufficient alloantigen is available (London et al. 2000). Furthermore, CTLA-
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4-B7 is required for adequate Tregs and effector T cells function as blockade of the CTLA-4 
pathway inhibited CD25
+
 Tregs function, leading to graft rejection (Kingsley et al. 2002; Sho et 
al. 2002). In keeping with this observation, CD28-deficient mice can still reject allografts inspite 
of the use of CTLA-4 Ig which suggested that CTLA-4 mediates its role independent of CD28 
pathway (Lin et al. 1998). 
 
Taken together, these findings emphasize the complex interactions of costimulatory molecules, 
in the fine regulation of T cell immune response – arguing for the merit of combination therapy, 
which is more likely to achieve durable tolerance than therapies focusing on only one 
costimulatory pathway. 
1.6.1.1.1.3 PD-1 and PD-L1/2  
 
Programmed death-1 (PD-1) is one of the CD28 superfamily, induced upon programmed cell 
death (Ishida et al. 1992). PD-1 is widely expressed compared to CD28-B7,  PD-1 being induced 
on activated peripheral CD4
+
 and CD8
+
 T cells, B cells, and monocytes (Agata et al. 1996; 
Freeman et al. 2000). PD-1 binds to two distinctive ligands; PD-L1 and PD-L2; PD-L2 has two 
to six fold higher affinity for PD-1 than PD-L1 (Youngnak et al. 2003; Zhang et al. 2004). PD-
L1 and PD-L2 are expressed on resting and activated T cells, B cells, DCs, and CD4
+
 CD25
+
 
Treg cells, in addition to several non-hematopoietic and non-lymphoid tissue including; 
endothelial cell, heart and lung tissue (Freeman et al. 2000; Latchman et al. 2001; Aramaki et al. 
2004). 
 
The general consensus is that the PD-1:PD-L1/L2 pathway triggers an inhibitory signal through 
PD-1, or blocks a positive signal for T cell activation and function, thus helping to maintain 
peripheral tolerance (Aramaki et al. 2004). In transplantation settings, use of the PD-L1 Ig fusion 
protein to activate the PD-1 pathway did not prolong graft survival; however, when combined 
with other measures such as CD40-CD40L blockade, long-term graft survival was feasible 
(Ozkaynak et al. 2002).  In addition, tumour cells expressing PD-L1 grow in wild-type mice but 
were suppressed in PD-1
-/-
 mice (Iwai et al. 2002). The upregulation of PD-L1 on tumours is 
recognised as a mean by which tumours escape T cell recognition. In addition, tumour 
expressing PD-1 enhance tumor reactive T cell apoptosis in vivo and in vitro, promoting tumor 
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growth (Dong et al. 2002). The PD-1:PD-L1/L2 pathway has critical roles in regulating T cell 
activation and maintaining peripheral tolerance. 
1.6.1.1.1.4 B7-H3 (B7RP-2) and B7-H4 (B7x/B7S1) 
 
B7-H3, also known as B7RP-2 (Chapoval et al. 2001), and B7-H4, also known as B7x and B7S1 
(Sica et al. 2003), are members of the CD28 superfamily, both having similar cellular expression 
patterns. They are not constitutively expressed on resting cells, but can be induced on T cells, B 
cells, monocytes and DCs (Sica et al. 2003; Steinberger et al. 2004). The B7-H3 and -H4 ligands 
has not been confirmed, a recent study identified a murine B7-H3 ligand known as Trem-like 
transcript 2 (TLT-2, TERML-2), a member of the triggering receptor expressed on myeloid cells 
(TREM) receptor family (Hashiguchi et al. 2008). This study assumed that binding between B7-
H3 and transduced T cells with TLT-2 induced T cell proliferation and cytokine production. 
Nevertheless, this was not confirmed by other groups as they were unable to show any 
interactions between human B7-H3 and TLT-2 (Leitner et al. 2009).  
  
The role of B7-H3 in regulation of immune response in vivo is still controversial. The studies 
conducted on B7-H3
-/-
 mice suggested a dual action of B7-H3, as a stimulator and inhibitor of 
the T cell response. It was showed that cardiac and islet allografts survival was prolonged in B7-
H3
-/-
 mice treated with rapamycin compared to the wild type (Wang et al. 2005). This could 
suggest a costimulatory role of B7-H3 in promoting T cell response mediating acute and chronic 
allograft rejection. In contrast, other studies suggested that B7-H3 inhibits Th1-mediated 
immune reactions, as B7-H3
-/-
mice developed Th1-mediated hypersensitivity and EAE more 
rapidly than wild-type controls (Suh et al. 2003). 
 
B7-H4 is thought to have an inhibitory effect on T cell responses, as B7-H4
-/-
 mice showed 
enhanced Th1 responses and diminshed parasite infection compared to wild-type mice (Suh et al. 
2006; Zhu et al. 2009). B7-H4 is also expressed in many human cancers including ovarian 
carcinoma, lung cancer with lymph-node metastasis, renal cell carcinoma associated with poor 
survival and prostate cancer, thus B7-H4 is thought to protect tumour cells from 
immunosurveillance and facilitate tumour progression (Yi and Chen 2009).  
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1.6.1.1.1.5 B and T Lymphocyte Attenuator (BTLA) 
 
The BTLA is a member of Ig superfamily expressed by activated T cells with preferential 
expression on Th1 and activated B cell (Watanabe et al. 2003). It differs from the other CD28 
member in that it does not bind to B7-like protein ligands, instead it binds to a member of 
TNF/TNFR family termed herpes virus entry mediator (HVEM), which is expressed on 
activated T cell (Sedy et al. 2005). Studies showed that the BTLA pathway delivers an 
inhibitory signal to suppress T cell activation and effector differentiation (Watanabe et al. 
2003). This negative role for BTLA has been suggested based on a study conducted on BTLA
-/-
 
mice which showed  amplified T cell proliferation response compared to wild type (Watanabe et 
al. 2003). In the transplantation setting, studies showed that BTLA inhibitory effect correlated 
with the degree of MHC mismatch, as BTLA was induced by alloreactive T cells in partial 
MHC- mismatched allograft, mediating tolerance (Tao et al. 2005). The exact role of BTLA in 
transplantation and its interaction with other costimulatory molecule has yet to be fully 
explored.   
1.6.1.1.2 TNF-TNFR Superfamily 
 
Members of this large family are split between TNF receptor (TNF-R) family members and 
their TNF-family ligands (Croft 2003; Watts 2005). TNF-R/TNF interactions are critical for 
promoting T cell clonal expansion and effector phases of the T cell immune response (Watts 
2005). CD40 and CD40L (CD154) were the first members of this family to be identified, and 
the most studied in regard to T cell activation; since then, this super family has expanded 
exponentially.  
 
The CD40:CD40L pathway plays an important role in naïve T cell activation,  B cell activation 
and differentiation and platelet function (Quezada et al. 2004). CD40:CD40L pathway has been 
shown to be essential in the activation of T cells by DCs. Stimulation of T cells through TCR 
engagement up-regulates CD40L surface expression by T cell which facilitates interaction with 
CD40 receptors on DCs. CD40:CD40L interactions induce maturation of DC with the 
upregulation of CD80 and CD86 expression, which increases the DC antigen presentation 
functions and augments T cell activation (Quezada et al. 2004). In addition, activated T cell 
expressing CD40L can interact with B cell expressing CD40, which in the presence of adequate 
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cytokine as IL-4, promotes B cell clonal expansion and differentiation (Quezada et al. 2004). 
The CD40/CD40L pathway has been targeted for modulation in several immune studies. In a 
transplantation model, blockade of the CD40:CD40L pathway with an anti-CD40L mAb 
promoted allograft survival, however, blocking of CD40 pathway rarely induces durable 
tolerance when used alone (Kirk et al. 1997; Gilson et al. 2009). Simultaneous CD40:CD40L 
and B7:CD28 blockade has a synergistic effect and promotes indefinite graft survival even in 
stringent models such as murine skin transplantation (Kirk et al. 1997; Gilson et al. 2009).  
Recently anti-CD40L mAbs have been replaced by trials of anti-CD40 mAb, owing to the 
increase of the incidence of thrombotic episodes with the former, related to activation of 
platelets receptors by anti-CD40L mAb with subsequent activation of the coagulation cascade 
(Vincenti 2008; Robles-Carrillo et al. 2010). 
 
1.6.2 Dendritic cells (DCs) 
 
DCs are specialised bone marrow-derived cells that belong to the APC family, which also 
includes B cells and macrophages (Rossi and Young 2005). DCs are highly efficient APCs that 
are essential to the induction and regulation of the immune response. DCs link the innate and 
adaptive immune system through cytokine production that enhances innate immune responses 
and promotes lymphocyte functions (Banchereau and Steinman 1998; Palucka and Banchereau 
1999). Langerhans cells (LCs), DCs type found in the epidermis, were described by Paul 
Langerhans in 1868, however, it was not until a century later when the role of DCs as APCs were 
appreciated when they were described by Steinman in 1973 (Steinman and Cohn 1973). 
Steinman et al – first identified DCs as a distinct cell type in murine spleens, expressing  variety 
of branches that were constantly extending and retracting (Steinman and Cohn 1973). Following 
DC identification, several groups reported the existence of DCs in non-lymphoid tissues of 
rodents and humans (Hart 1997). In the 1990s, the development of methods to culture and 
generate DCs from blood and bone marrow (BM) provided abundant number of these cells for in 
vitro study. This development led to the substantial growth in knowledge of DCs (Caux et al. 
1992; Inaba et al. 1992; Sallusto and Lanzavecchia 1994).  
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Except for follicular DCs (FDC), which originate from stromal origin, all DCs are 
haematopoeitic cells that are derived from bone marrow leucocytes (Hart 1997). FDCs contribute 
to B cell priming, in which FDC-B cell interactions initiate maturation and maintenance of the 
humoral immune response (Fakher et al. 2001; Tew et al. 2001). The general consensus is that 
DCs are end-stage, non-dividing cells; however, experiments have shown that DCs can divide 
for prolonged periods in vitro, and that in vivo about 5% of the DCs in the spleen are in active 
cell cycle (Zhang et al. 2004; Kabashima et al. 2005).  
1.6.2.1 DC subtypes 
DCs are heterogeneous cell population that can be divided into four cell subtypes (Shortman and 
Liu 2002; Rossi and Young 2005; Shortman and Naik 2007) 
 
a. Non-Lymphoid (migratory) DCs  
b. Lymphoid (tissue-resident) DCs                      
c. Monocyte-derived  DCs 
d. Plasmacytoid DCs  
1.6.2.1.1 Conventional DCs (cDCs) 
 
Classical or conventional DCs (cDCs) describe cells populations that have a typical DCs shape 
and function in the steady state; they are divided into non-lymphoid and lymphoid cDCs.  
(A)Non-lymphoid (migratory) DCs 
 
This DC population is located in non-lymphoid sites and can be divided into two main subtypes. 
DCs located in epidermal surfaces of the skin and the mucosa of intestinal, reproductive and 
respiratory tract, are called Langerhans cells (LCs), which are the most studied non-lymphoid 
DCs. Another DCs subset located in the subepidermal tissues of the skin and the interstitum of 
solid organs are called dermal DC (DDC) and interstitial DC (IDC) respectively (Rossi and 
Young 2005; Shortman and Naik 2007). LCs constitutively express MHC class II, high levels of 
the lectin langerin (CD207) and CD1a – an MHC class I homologue (Shortman and Liu 2002; 
Rossi and Young 2005). 
 
Conventional DCs (cDCs) 
Pre-dendritic or precursor DCs (pre-DCs) 
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Non-lymphoid DCs are also known as migratory DCs as they are in a continuous state of 
migration and capturing antigens, either in steady state or upon microbial or inflammatory 
stimuli (Larsen et al. 1990). They migrate to the tissue draining lymph nodes (LNs) via the 
afferent lymphatics, to T cell areas of LNs, presenting antigens to naïve T cells and inducing 
immune response (Mempel et al. 2004). Migratory DCs then develop to more differentiated 
population of DCs specialised in sensitizing T lymphocytes (Brand et al. 1999). 
 
Migratory DCs can be generated in vitro from two sources – Human CD34+ hemopoietic 
progenitors cells (HPCs) cultured with cytokines, such as granulocyte-macrophage colony-
stimulating factor (GM-CSF), TNF-α, fms-like tyrosine kinase-3 ligand (Flt-3-L) and c-kit ligand 
(Caux et al. 1992; Inaba et al. 1992; Ferlazzo et al. 2000). Human monocytes can be used to 
generate migratory DCs by trans-endothelial migration in which monocytes transmigrate across 
human endothelial cell monolayer into a collagen matrix (Randolph et al. 1998).  
 
(B) Lymphoid (tissue-resident) DCs  
 
Lymphoid DCs, also known as tissue resident DCs, reside mainly in the spleen, thymus and LNs 
(Vremec et al. 2000; Henri et al. 2001; Shortman and Naik 2007). Most of the lymphoid DC 
studies have been conducted on murine DCs. In mice, splenic DCs constitutively express MHC 
class II and the integrin CD11c and classified into 3 subsets according to their phenotype : (1) 
CD4
+
 CD8α- CD205- CD11b+ DCs (termed CD4+ DCs) are predominately located in the 
marginal zone; (2) CD4
-
 CD8α+ CD205+ CD11b- DCs (termed CD8+ DCs) located in the T-cell 
zone; (3) CD4
-
 CD8α- CD205- CD11b+ DCs (termed CD4- CD8- DCs) and called double-
negative DCs located in the red pulp (Vremec et al. 2000; Hochrein et al. 2001). CD8
-
 DCs, 
including CD4
+
 and CD4
- 
CD8
-
 subsets, are specialised in antigen presentation in the context of 
MHC class II to antigen-specific CD4
+
 T cells, while CD8
+
 DCs are specialised in presenting 
antigen in the context of MHC class I to CD8
+
 T cells (Pooley et al. 2001). CD8
+
 DCs can induce 
apoptosis of CD4
+
 T cells through Fas/Fas ligand engagement (Suss and Shortman 1996), down-
regulate CD8
+
 T cells proliferation (Kronin et al. 1996) and cross-prime CTLs (den Haan Joke 
M.M et al. 2000).  
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Thymic DCs are predominately loacted in the medulla and cortico-medullary region of the 
thymus (Ardavin 1997). In the mouse, DCs are categorised according to CD8α expression, most 
of thymic DCs being CD8
+
, generated from early thymocyte progenitors; a smaller DC 
population is CD8α- and generated outside the thymus (Wu and Shortman 2005). CD8α is not 
expressed on human DCs; nevertheless, two distinct DC populations have been identified based 
on CD11b expression. The majority of thymic DCs are CD11c
+
 CD11b
−
 CD45RO
lo
 and lack 
myeloid markers, resembling murine thymic CD8
+
 DCs;  a minority of thymic DCs are CD11c
hi
 
CD11b
+
 CD45RO
hi
 and express many myeloid markers, resembling murine CD8α− myeloid DCs 
(Bendriss-Vermare et al. 2001; Vandenabeele et al. 2001). Another DC population was also 
identified in the human thymus, known as interdigitating DCs (IDCs); this population expresses 
high levels of HLA-DR, CD11c, CD205 and DC-LAMP, similar to mature DCs (mDCs), and is 
located in the thymic  medullary area (Bendriss-Vermare et al. 2001). 
 
Thymic DCs contribute to the development of central tolerance. They play an important role in 
clonal deletion of auto-reactive thymocytes (Bonasio et al. 2006). Highly efficient antigen 
processing and presentation by DCs, coupled with their costimulatory capacity, underline their 
potent role in developing T cell tolerance (Wu and Shortman 2005). Recent studies have 
demonstrated that circulating DCs can gain access to the thymus and contribute to the 
establishment of central tolerance and the induction of antigen specific Tregs (Bonasio et al. 
2006). 
 
Lymph node DCs are blood-derived, tissue-resident DCs that include heterogenous DC subtypes, 
such as migratory non-lymphoid DCs, including LCs in skin-draining LNs and DDC, and 
lymphoid DCs, including CD8
+
, CD4
+
, and CD4
-
 CD8
-
 DCs, which are similar to those in the 
spleen. Lymphoid DCs have an immature phenotype in the steady state, however, after they are 
stimulated for example by inflammatory cytokines, DCs undergo a complex maturation process 
(Wilson et al. 2003).  
 
1.6.2.1.2  Precursor DCs (pre-DCs) 
 
Precursors of DCs or pre-dendritic DC (pre-DCs) are DC subsets that require further 
development to acquire their ultimate form and function. This DC subset includes plasmacytoid 
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DCs (pDCs), immediate precursors of steady-state splenic cDCs, and monocytes-derived DCs 
(Shortman and Naik 2007). 
(A)  Plasmacytoid DCs 
 
The human plasmacytoid DC, also known as the natural interferon-producing cell, are 
characterised by their plasma-cell-like shape, they are round, non-dendritic, relatively long-lived 
circulating cells (Grouard et al. 1997; O'Keeffe et al. 2002). Following their stimulation by viral 
or other microbial infections, they produce large quantities of type I interferon (O'Keeffe et al. 
2002). The same inflammatory stimuli also initiate the conversion of pDCs into a dendritic form 
and the cells acquire some DC antigen-processing and antigen-presentation properties (O'Keeffe 
et al. 2002). pDCs have low expression of MHC and costimulatory molecules which make them 
less efficient in priming T cells compared to cDCs (Rossi and Young 2005). 
 
(B) Inflammatory DCs  
 
Inflammatory DCs, known as tumour-necrosis factor and inducible nitric-oxide synthase-
producing DCs (TipDCs), are DC that are not normally present in the steady state, but are 
generated during the course of inflammation and infections, producing TNF-α and inducible 
nitric oxide synthase (iNOS) (Geissmann et al. 2008). They migrate to the lymph nodes and the 
white pulp of the spleen, where they present antigens and stimulate T cells (Randolph et al. 1999; 
Geissmann et al. 2008).  In the course of inflammation, human CD14
+
 monocytes in the 
peripheral blood represent precursors for the inflammatory DC subset. They develop into 
CD14
neg
, CD11c
+
,CD83
+
, HLA-DR
bright
  monocytes-derived DCs (moDC) under the influence of 
inflammatory cytokines, such as GM-CSF and IL-4 (Sallusto and Lanzavecchia 1994; 
Geissmann et al. 2008). 
1.6.2.2 Immunogenic versus Tolerogenic DCs 
DCs exist mainly in two developmental stages – immature and mature– depending on three 
phenotypic and functional features; expression of MHC and co-stimulatory molecules; the 
capability to capture and present antigens; and the ability to induce naїve T cell activation. The 
general consensus is that immature DCs (iDCs) are tolerogenic or regulatory as iDCs are antigen 
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capturing cells expressing low to moderate MHC and costimulatory molecules, incapable of 
activating naïve T cells. In contrast, mature DCs (mDCs) are immunogenic, they upregulate 
MHC and costimulatory molecules, process and present captured antigen and induce naïve and 
memory T cell stimulation (Palucka and Banchereau 1999; Morelli and Thomson 2003). 
 
This functional classification has been challenged with further studies of the role of DC role in 
the immune response. iDCs can present self-antigens in the context of MHC class II molecules, 
but peptide presentation is kept under control by the continuous endocytosis and  degradation of 
the MHC-peptide complex (Wilson et al. 2004). In addition iDCs can activate T cells but induce 
tolerance instead of an effector response, and in some circumstances mDCs can induce tolerance 
(Hawiger et al. 2001; Villadangos and Heath 2005). mDC functions were reviewed by 
Villadangos et al, who suggested that mDCs can be classified into two subtypes – licensed and 
unlicensed – based on an immune phenomenon they described as DC licensing:  mDCs that are 
phenotypically and functionally mature but are not licensed to foster the differentiation of naїve 
T cells to effector cells, hence, inducing a state of immune tolerant such as T cell deletion, 
anergy or Tregs generation rather than immune effector T cell (Villadangos and Heath 2005).  
 
DC maturation can be induced either directly through recognition of exogenous non-self danger 
signals which induces pro-inflammatory cytokine production (Matzinger 2002), or indirectly 
through endogenous self danger signals, for example following the exposure to cellular 
components, such as heat shock proteins and mitochondrial products after normal physiological 
process of cell death (Matzinger 2002). Both danger signals drive DC towards maturation 
through the upregulation of costimulatory molecules and stimulating T cell activation. However, 
under physiological conditions (the indirect danger signal pathway), DCs mature and express 
low levels of costimulatory molecules and induce a weak transient auto-reactive T cell 
proliferation, developing a state of peripheral tolerance (Villadangos and Heath 2005).  
 
In the transplantation setting, surgical interference can lead to ischaemic injury, release of pro-
inflammatory mediators and tissue necrosis, which can “license” donor as well as recipient DCs, 
initiating their maturation. Licensed DCs migrate to the regional lymph nodes of the recipient 
where they provoke an immune response. In lymph nodes, donor mDCs present donor antigen to 
recipient T cells and  induce direct allorecognition, while recipient mDCs present donor antigen, 
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either intact or processed, to recipient T cells and induce indirect and semi-direct allorecognition 
(Morelli and Thomson 2003). 
1.7 Natural mechanisms of immune tolerance  
 
The ultimate goal of transplantation is to achieve donor-specific tolerance, which is defined as a 
long-term survival of a graft displaying normal histological characteristics and function (Yuan 
2006; Turka and Lechler 2009). Donor-specific tolerance occurs in a non immuno-suppressed 
recipient who retains the capacity to reject a third party graft but to accept a second donor 
specific allograft (Remuzzi 1999; Lechler and George 2006). Advances in therapeutic strategies 
to promote transplantation tolerance will follow a better understanding of the body‟s own 
mechanisms of tolerance.  
 
In central tolerance, thymic negative selection deletes T cell precursors that express TCRs with 
high avidity for self peptide-MHC complexes, leaving behind a population of T cells with low 
avidity for self peptide-MHC complexes to escape to the periphery (Liu et al. 1995; Wraith 2006; 
Mueller 2010). However, peripheral T cells that can recognise self-antigens, either as low-avidity 
auto-reactive T cells or high avidity T cells for tissue-restricted antigens that were not 
encountered in thymus, are found in the secondary (peripheral) lymphoid organs (Schwartz 
1989; Liu et al. 1995). But unlike developing lymphocytes in the thymus, mature naïve 
lymphocytes that recognise antigen in secondary lymphoid tissue may undergo activation, with 
the consequent development of an autoimmune response (Wraith 2006). This underscores the 
substantial significance of peripheral tolerance mechanisms, in which self-reactive T cells are 
deleted or rendered unresponsive to self-antigens. Peripheral tolerance can be maintained 
through several mechanisms reviewed briefly in the following section. 
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1.7.1 Immunologically privileged sites  
 
Potentially self-reactive T-cells may not encounter the cognate antigen, which make T cells 
ignorant of its presence. Consequently, auto-reactive T cells will not be stimulated and may die 
from a lack of stimulation. Immunologically privileged tissues protect their tissue-restricted 
antigens (TRAs) from trafficking T cells by several mechanisms including physical or 
functional. Physical protection can be achieved through physiological barrier for example the 
blood brain barrier in the central nervous system, which prevents T cells gaining access to tissue 
antigens (Bechmann et al. 2007). Functional mechanisms can be mediated by; the absence of 
APCs to present antigens to T cells, as in the testis (Fijak and Meinhardt 2006); by the secretion 
of immunosuppressive cytokines such as TGF-β and IL-10 in the anterior chamber of the eye 
(D'Orazio and Niederkorn 1998); by the production of indolamine 2,3 dioxygenase (IDO) in the 
placenta, which breaks down tryptophan, depriving T cells from an essential amino acid and 
generates immunosuppressive kynurienies (Sedlmayr 2007); by the expression of Fas-ligand 
(FasL) and TNF-related apoptosis-inducing ligand (TRAIL) expression in eye, resulting in the 
apoptosis of inflammatory cells and inhibiting the inflammatory process that can damage the eye 
(Ferguson and Griffith 2007); by the expression of natural regulatory T cells in human organs as 
the liver, as those regulatory cells were identified in human liver allograft in tolerant recipient (Li 
et al. 2008). In addition, antigens expressed at low concentrations fail to sensitise T cell to mount 
an immune response, resulting in ignorance by naïve T cells (Heath et al. 1995; Heath et al. 
1998).  
 
In the transplant setting, immune privilege reduces the incidence of graft rejection, as it 
decreases the ability of the graft to provoke an immune response, for example in cornea 
transplantation (Fu et al. 2008). If the state of ignorance is disrupted as in corneal inflammation 
that leads to corneal vascularization, exposure of corneal antigens to trafficking T cells will 
occur, leading to rejection of the corneal graft.  
1.7.2 Clonal deletion 
 
Peripheral deletion of high avidity auto-reactive T cells after elimination of the stimulating 
antigen is mediated by two molecular mechanisms: activation-induced cell death (AICD) and 
                                                                                                                                                        Introduction 
75 
 
programmed cell death (PCD) (Mueller 2010).  AICD involves the engagement of the so called 
death receptors for example the Fas receptor, a member of the TNFR family, by its cognate 
ligand, Fas ligand (FasL), with subsequent activation of the caspase cascade (Marrack and 
Kappler 2004). PCD is mediated by Bim-dependent triggering of a Bcl-2 and Bcl-xL-regulated 
mitochondrial death pathway, which results in mitochondrial outer membrane permeabilization 
(MOMP), cytochrome C release from the ER, caspase activation and cell death (Marrack and 
Kappler 2004; Mueller 2010).  
1.7.3 Clonal anergy and adaptive tolerance 
 
T cell anergy is a long-term cellular state of antigen-specific T cell hypo- or non-responsiveness 
induced by TCR engagement in the absence of a costimulatory signal; it can be reversed by 
stimulation with exogenous IL-2 (Jenkins et al. 1987; Schwartz 1996). Anergic T cells do not 
require antigen stimulation to maintain the state and are incapable of antigen-specific induced 
transcription of IL-2 gene (Schwartz 1996; Choi and Schwartz 2007). Occupancy of TCR of the 
anergic T cells fail to activate p21
ras
 gene, resulting in down-regulation of both the mitogen-
activated protein (MAP) kinase pathway and the transcription factor AP-1 – an IL-2 gene 
transcription factor. In addition, the negative regulatory factor, Nil-2a which blocks AP-1 is up-
regulated. Consequently, IL-2 gene transcription and secretion are significantly down-regulated 
(Schwartz 1996; Choi and Schwartz 2007). Anergic T cells are capable of exerting immune-
regulatory functions, as they inhibit other antigen-specific T cells (Lombardi et al. 1994); thus 
may be of therapeutic benefit in the transplantation setting.   
 
A similar state of T cell anergy has been identified in the periphery in the steady state known as 
adaptive tolerance. However, adaptive tolerance occurs when peripheral T cells are exposed to 
persistent antigenic stimulation at a constant concentration and T cells are rendered tolerant 
(Tanchot et al. 2001). Such T cells are characterised by downregulation of all TCR-induced 
cytokines and require sustained antigen stimulation to maintain the state: removing the antigen 
inducing tolerance restores T cell responsiveness. The state of adaptive tolerance cannot be 
reversed by the addition of IL-2 (Choi and Schwartz 2007). Singh et al. suggested that T cells 
tune their response to become tolerant to a persistent stimulus, unless stimulus strength is 
changed (Singh and Schwartz 2003). On the molecular level, Zeta-chain-associated protein 
                                                                                                                                                        Introduction 
76 
 
kinase 70 (Zap-70) phosphorylation; a component of the TCR signalling cascade, is down-
regulated with subsequent down-regulation of the transcription of several genes that allow T cell 
differentiation and proliferation (Chiodetti et al. 2006; Choi and Schwartz 2007).   
1.7.4 Regulatory T cells (Tregs) 
 
Regulatory T cells (Tregs) regulate immune responses to self and foreign antigens, playing a 
major role in maintaining the balance between immunity and tolerance (Wing and Sakaguchi 
2010). Based on their origin, specificity, and functionality, two distinctive Treg subsets are 
identified. Natural Tregs (nTregs) develop in and are released from the thymus, and adaptive or 
induced Tregs (iTregs) develop in the peripheral lymphoid tissue from mature CD4
+
 T cells 
under certain conditions of antigenic and cytokine stimulation (Bluestone and Abbas 2003; Tang 
and Bluestone 2008). 
 
Both Treg populations have variable expression levels of surface IL-2 receptor α chain (IL-2Rα, 
CD25), and intracellular expression of a transcription factor known as forkhead box protein P3 
(FoxP3), which regulates Tregs development and function (Fontenot and Rudensky 2004; Tang 
and Bluestone 2008). Mutations in the FoxP3 gene abrogate the development of Tregs and 
impair their suppressive function leading to hyper-activation of self-reactive T cells and the 
development of many autoimmune diseases including immune dysregulation polyendocrinopathy 
enteropathy X-linked syndrome (IPEX) (Gambineri et al. 2003) 
 
Tregs mediate their immune suppressive effect via different mechanisms such as; direct cell-to-
cell contact at the site of inflammation that eventually kills the effector T cells, in a process 
mediated through perforin/granzyme interaction (Czystowska et al. 2010) or Fas:FasL interaction 
inducing ACID (Weber et al. 2006); by increase in IL-2 consumption by Tregs depriving 
reactive T cells of this cytokine and inducing Bim-mediated cell death (de la Rosa et al. 2004; 
Scheffold et al. 2005); by the secretion of immune-regulatory cytokines, for example IL-10 
(Annacker et al. 2001) and TGF-β (Zheng et al. 2004), which attenuate effector T cell cytokine 
production and modulate APCs, with the generation of tolerogenic DCs; by the ligation of 
CTLA-4, expressed by Tregs, with B7 ligands expressed by effector T cells, which leads to 
suppression of T cell proliferation (Paust et al. 2004; Kolar et al. 2009); by the expression of 
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IDO by DCs, following ligation of Treg CTLA-4 with B7 ligand on DCs. IDO catabolizes 
tryptophan, which subsequently depletes T cell of an essential amino acid and down-regulates T 
cell proliferation (Grohmann et al. 2002). In addition, Tryptophan metabolites in the kynurenine 
pathway induce the selective apoptosis of T cell by Bim mediated cell death in vitro (Fallarino et 
al. 2002).   
 
Tregs perpetuate their regulatory effect through two distinct phenomena; infectious tolerance, in 
which Tregs can induce the generation of populations of lymphocytes with regulatory function 
but with different antigenic specifity to the original inducing Tregs population (Qin et al. 1993; 
Zheng et al. 2004); and  bystander tolerance, in which Tregs can suppress antigen-specific 
effector T cell with different specifity (Miller et al. 1991). Through these processes of regulation, 
Treg cell establish and maintain a state of peripheral tolerance.  
 
In the transplantation setting, strategies that employ Tregs have been adopted for the induction of 
graft tolerance. Studies in mice show that adoptive transfer of T cell from a tolerized donor into 
immune-competent mice was successful in inducing tolerance (Chen et al. 1996; Wang et al. 
2008). Tregs with indirect allospecificity provide a potential therapeutic strategy to control 
indirect allorecognition that contribute in acute as well as chronic graft rejection pathogenesis 
(Jiang et al. 2006; Callaghan et al. 2007). 
1.8 Aims of the project 
The principle aim of the study was to develop a “negative-vaccine” approach to induce immune 
tolerance specifically to the indirect allorecognition pathway, the predominant pathway of 
immune recognition in the chronic phase of allograft rejection. The construction of this DNA 
vaccine was based on two main strategies, the first was to develop a method for delivering a 
tolerogenic signal to induce tolerance in the responding cells. The second was to provide the 
alloantigen that can be recognized by the T cells via the indirect pathway of alloresponse.  
 
DC interaction with T cell is the central interaction that depicts the immune response whether 
activation and immunity or anergy and tolerance. DC phenotype is crucial to this interaction and 
by manipulating specific costimulatory pathways; it can be possible to render DC tolerogenic. In 
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order to induce tolerance, it was aimed to develop a strategy to inhibit ICOS:ICOSL interaction 
through down-regulation/inhibition of the surface expression of ICOSL by DCs. Progressing 
from preliminary studies conducted in Prof George‟s Lab: an in vitro research undertaken with 
human DCs expressing CTLA4-KDEL (Tan et al. 2005b) and in vitro and in vivo research 
undertaken with murine DCs expressing CTLA4-KDEL (Ms J Harper and Mr. A Khan PhD), it 
was aimed to employ the KDEL strategy to induce tolerance. The strategy used in this study 
involved the fusion of the KDEL sequence tag to the extracellular domain of ICOS, developing 
an intracellular fusion protein ICOS-KDEL as an immunomodulator to down regulate the newly 
synthesized ICOSL. The hypothesis of this strategy was that the expression of ICOS-KDEL 
fusion protein would result in its  retention in the ER through the interaction of the KDEL-fusion 
protein with the KDEL receptors (ERD2) that cycle between the ER and Golgi (Tang et al. 
1993). Expression of ICOS-KDEL in cells that would normally express ICOSL would result in 
binding of ICOSL with ICOS-KDEL protein, forming a complex. This complex would be 
retained in the ER, where ICOSL will be degraded by a proteasome-dependent process (Tan et 
al. 2005b). This was expected to result in the down regulation/inhibition of ICOSL surface 
expression. The modified DC was expected to be unable to stimulate alloantigen specific T cell 
responses in vitro. Furthermore, the T cell encountering the tolerogenic DC would be rendered 
anergic/regulatory. The strategy that was employed to induce tolerance through tagging ICOS 
with KDEL peptide to inhibit ICOSL cell surface expression is called the “KDEL strategy” 
(Illustrated KDEL strategy is shown in Figure 10).  
 
It has been shown that the administration of CTLA-Ig alone prolonged graft survival, however 
chronic rejection could not be avoided except when the treatment protocol is combined with 
donor-specific therapy, such as the injection of donor derived cells (Sayegh et al. 1997). In the 
absence of concomitant donor specific therapy, allograft was rejected due to the development of 
moderate to severe transplant arteriosclerosis (Sayegh et al. 1997). Therefore, the second aim of 
this study was to provide the alloantigen that can be recognized by the T cells via the indirect 
pathway of alloresponse. To achieve this aim, a fusion protein between the Ii chain where the 
CLIP was replaced by the immunodominant MHC class I epitope (HLA-A2103-120) was created. 
The hypothesis of this strategy was that the antigenic peptide that was used to replace the CLIP 
will be efficiently loaded onto the MHC class II molecules (Illustrated antigen presentation 
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model in Figure 10). This is presumably because of the high affinity nature of the interaction 
between the antigenic peptide loaded onto the MHC class II in the ER. It was expected that this 
antigenic peptide would continue to bind to the MHC class II during its passage through the 
Golgi and the MIIC and even after the cleavage of the Ii chain. Consequently the antigenic 
peptide will be expressed on the cell surface in the context of MHC class II APCs to CD4
+
 T 
cells. This approach has proved efficient in antigen presentation to CD4
+
 cells in vitro (Fujii et 
al. 1998) and in vivo immunization (van Tienhoven et al. 2001). In our lab, a study demonstrated 
that Ii chain with CLIP replaced with ovalbumin peptide (OVA328-339) showed efficient 
presentation to murine DO11.10 T cells which have the transgenic TCR receptor for the peptide 
(Miss Jennifer Harper PhD).  
 
The third aim of this study was to study the interaction between T cells and DCs through the 
ICOS:ICOSL costimulatory pathway. ICOS:ICOSL pathway is the main focus of this study, thus 
it was thought that it would be reasonable to characterize the ICOSL expression on DC surface. 
The analysis of the kinetics of ICOSL expression by DC in different maturation stages and the 
identification of the role of T cells in regulating ICOSL expression were assessed. In addition; 
the identification of the possible molecular mechanisms that regulate ICOSL expression in 
human DCs was investigated. 
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Figure 10.  Diagrammatic representation of the thesis Strategies 
The first strategy: proteins resident in the ER are retained there due to the KDEL peptide tag 
which serves as a signal that retains/retrieves protein to the ER. APCs expressing the ICOS-
KDEL-fusion protein will have low/no surface expression of ICOSL as the newly synthesized 
ICOSL will interact with the ICOS-KDEL-fusion to form ICOSL/ICOS-KDEL complex in the 
ER. The KDEL expressing protein will bind to the KDEL receptor ERD2 that transports the 
KDEL expressing peptide via COP1 coated transport intermediates back to the ER. Therefore, 
the ICOSL cannot be transported to the cell surface and there is a reduced level of ICOSL on the 
cell membrane. The second strategy: MHC will be assembled in the ER with the Ii chain whose 
CLIP sequence is replaced with the antigenic peptide. MHC-Ii-peptide complex will travel 
through the Golgi to the acidic compartment MIIC vesicle. The Ii is cleaved in the MIIC to small 
fragments and the antigenic peptide is still occupying the MHC class II binding groove. The 
antigenic peptide is expressed in the context of MHC class II on the cell surface  
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Trans-Golgi 
Network 
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Nucleus 
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2.1 Cloning: Reagents and Techniques  
2.1.1 Vectors: The following plasmids were used in this study;  
(1) pCMV/myc/ER (Invitrogen; Paisley, UK);  a mammalian expression vector (MEV) that 
encodes a myc epitope 3‟ to the multiple cloning site (MCS) and 5‟ to an ER retention 
sequence signal (KDEL).  
(2)  pCMV/EGFP (Clontech, Palo Alto, CA); a MEV that encodes enhanced green 
fluorescent protein (EGFP) under the transcriptional control of  the CMV promoter.  
(3) pcDNA3.1(+) (Invitrogen; Paisley, UK); a MEV that was used in the cloning of ICOSL 
full length, Ii chain replaced CLIP sequence and the bicistronic genes constructs.  
(4) pFUSE-mIgG2Aae1-Fc2 (InvivoGen; San Diego, USA) ; a MEV that contains Zeocin 
resistant gene. It was used for selection of the stably transfected M1DR1 and M1DR1-
CD80 cell line. 
(5) pmaxa GFP (Lonza; Germany); a control vector that encodes GFP under the 
transcriptional control of CMV promoter. 
(6) pICOS-KDEL-IipOVA; a MEV that encodes the murine Ii chain in which the CLIP has 
been replaced by the ovalbumin peptide (OVA328-339) under the transcriptional control of 
CMV promoter. It encodes also ICOS-KDEL-fusion gene under the transcriptional 
control of SV40 promoter. The plasmid was a kind donation by Miss Jennifer Harper, 
Imperial College, London, UK. 
2.1.2 Primers 
 
Primers used in cloning, polymerase chain reaction (PCR), and Real time PCR are listed in Table 
1. All primers sequences created in this study were based on cDNA sequences submitted to 
NCBI.  All the primers are in the 5‟-3‟ orientation. Primers used for sequencing are listed in 
Table 2. DNA sequencing was performed by the Medical Research Council (MRC) sequencing 
facility at Hammersmith Hospital, London, UK.  
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Primer Name                          Primer Sequence Ta (
0
C) 
ICOS fwd GTC AGC ATT ACT GCA GGA AAT CAA TGG TTC TGC CAA 
T 
58 
ICOS rev CTG CAT AGC AGC GGC GGC CGC CAG CTG GCA CAA AGT 
T 
58 
ICOSL fwd TTG CTA CGA ATT CAT GCG GCT GGG CAG TCC T 64.3 
ICOSL rev TAT GCG CGG CCG CTC AAA CGT GGC CAG TGA G 64.3 
ICOSL fwd (RT) ATG GTA GGC AGC GAC GTG GAG CT 58 
ICOSL rev (RT) TGA CAT CAG GGC TCG GTT CCG GTA 58 
Fusion ICOS-
KDEL fwd 
CGC GGA TCC ATG GGA TGG AGC TGT ATC AT 58 
Fusion ICOS-
KDEL rev 
TCG CTC GAG CTA GAC TAC AGC TCG TCC TT 58 
Ii fwd GAT CGC TCG AGA TGC ACA GGA GGA GAA GCA GG 58.2 
Ii  rev TAA GCT CTA GAT CAC ATG GGG ACT GGG CC 58.2 
Ii-A2 fusion fwd TCC TCC GCG GGT ACC ACC AGT ACG CCT ACG ACG GCG 
GAG CCC TGC CCC AGG GGC CCA TG 
58.2 
Ii-A2 fusion rev GGT ACC CGC GGA GGA AGC GCC AGT CCG ACC CCA CCT 
TCA TCG CAG GTT CTC CAG CTG 
58.2 
Ii-HA fusion fwd AAG CAA AAC ACG TTA AAG TTA GCA ACA GGA GCC CTG 
CCC CAG GGG 
60 
Ii-HA fusion rev AAC TTT AAC GTG TTT TGC TTA ACA TAC TTG GGC TTC 
ATG CGC AGG TTC TC 
60 
pSIi fusion fwd CTA TGC TAG CAT GCA CAG GAG GAG 58.2 
pSIi fusion rev ATA AGA ATG CGG CCG CTC ACA TGG GGA CA 58.2 
HPRT fwd (RT) GCA GAC TTT GCT TTC CTT GGT C  
 
58 
HPRT rev (RT) CTG GCT TAT ATC CAA CAC TTC GTG  
 
58 
 
 
 
 
Table 1. Primers created and used in this project 
Abbreviations; Ta: annealing temperature used for each primer. fwd: forward, rev: reverse, RT: 
Real time-PCR. Restriction endonuclease sites included in the primer sequence were written in 
bold. All primers were designed by hand and were synthesized and purchased from Invitrogen: 
Paisley, UK. 
 
 
 
                                                                                                                     Materials and Methods 
84 
 
 
 
 
 
Construct  
Name 
Plasmid used 
for construct 
cloning 
                Description of the cloned gene 
ICOS-KDEL pCMV/myc/ER Human ICOS extracellular domain fused to ER 
retention signal (KDEL) 
ICOSL pcDNA3.1+ Human ICOSL full length 
pCMV Ii-A2 pcDNA3.1+ Human Ii with the CLIP sequence replaced by HLA-
A2103-120. The fusion gene was transcribed by pCMV 
pCMV Ii-HA pcDNA3.1+ Human Ii with the CLIP sequence replaced by HA ᶲ. 
The fusion gene was transcribed by pCMV 
pIi-A2 pcDNA3.1+ Human Ii with the CLIP sequence replaced by HLA-
A2103-120. The fusion gene was transcribed by pIi 
pCMV-ICOS-KDEL- 
pIi-A2 
 
pcDNA3.1+ Human ICOS-KDEL sequence transcribed by pCMV 
and Ii-A2 gene transcribed by pIi 
pCMV-ICOS-KDEL-
pSV40- Ii-A2 
 
pICOS-KDEL-
IipOVA‡ 
Human ICOS-KDEL sequence transcribed by pCMV 
and Ii-A2 gene transcribed by pSV40. 
pCMV-ICOS-KDEL-
pSV40- Ii-HA 
 
pICOS-KDEL-
IipOVA ‡ 
Human ICOS-KDEL sequence transcribed by pCMV 
and Ii-HA transcribed by pSV40 
 
 
 
 
Primer Name Primer Sequence                                                            Source
BGH seq rev TAGAAGGCACAGTCGAG                                            Invitrogen 
NheNot seq Ii fwdᶲ TCAATTACAGCTCTTAAGGC                                      Donation 
NheNot seq Ii revᶲ AGTTGTGGTTTGTCCAAAC                                        Donation 
pCMV/myc/ER seq fwd GGTCTGGACATATATATGG                                       Sigma-Genosys 
pCMV/myc/ER seq fwd ATCCTCTTCTGAGATGAGTT                                      Sigma-Genosys 
T7promoter seq fwd TAATACGACTCACTATAGGG                                         Invitrogen
Table 2 Primers used to sequence constructs created in this project 
Primers used for sequencing where purchased from; Invitrogen, Paisley, UK, Sigma-Genosys, 
Haverhill, UK. ᶲ kindly donated by Miss Jennifer Harper, Imperial College, London, UK. DNA 
sequencing was performed by the Medical Research Council (MRC) sequencing facility at 
Hammersmith Hospital, London, UK. 
Table 3. Constructs created in this project 
Abreviations; KDEL aa sequence: (SEKDEL), HA: Haemagglutinin peptide, pCMV: Cytomegalovirus 
promoter, pIi: human Ii chain promoter, SV40: Simian virus 40 promoter.ᶲ HA amino acid sequence: 
PKYVKQNTLKLAT. ‡ Fusion plasmid encoding murine Ii–OVA fusion gene transcribed by pCMV 
and ICOS-KDEL transcribed by SV40. It was a kind donation from Miss Jennifer Harper, Imperial 
College, London, UK.   
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2.1.3 Techniques 
2.1.3.1 Complementary DNA (cDNA) preparation 
2.1.3.1.1 RNA Extraction  
 
RNA was extracted from activated human T cells (used to clone ICOS), from Daudi cell line 
(used to clone ICOSL), and from DCs, CHO and CHO ICOSL cell line (used for ICOSL real 
time PCR). Between 1x10
6
 and 5x10
6
 cells were harvested for RNA extraction. Cells were 
washed with PBS for five times prior to RNA extraction using the phenol-chloroform principle. 
Cells were pelleted by centrifugation; 13,000 g, 5 min at room temperature (RT). Cell pellet was 
re-suspended in 1 ml Trizol reagent (Invitrogen) and incubated for 5 min at RT. 200 μl 
Chloroform (Sigma- Aldrich) / ml Trizol reagent was added. The mixture was vortexed for 15 
seconds and incubated for 5 min at RT. The mixture was then centrifuged at 13,000 g, 15 min at 
4
0
C. The aqueous upper layer was transferred to a fresh 1.5 ml epindorff. 500 μl isopropanol 
(Fisher Scientific, Loughborough, UK) / ml Trizol reagent was added to precipitate RNA and 
mixed thoroughly with the aqueous layer and the mixture was left to stand for 30 min at RT. The 
mixture was centrifugated at 13,000 g, 10 min at 4
0
C, and the supernatant was carefully 
removed. The RNA pellet was washed once with 1 ml of 75% ethanol and centrifuged at 13,000 
g, 5 min at 4
0
C.  Supernatant was removed carefully and the pellet was left to air dry for 15-30 
minutes before being resuspended in 30 μl RNA-DNA free H20 (Sigma-Aldrich). RNA samples 
were treated with RNase-free DNase to eliminate potentially contaminating genome DNA. The 
reaction mixture composed of; 1 µl of RQ1 RNase-free DNase 10x reaction Buffer, 1 U/µg RNA 
of RQ1 RNase-free DNase, 5µl RNA and the volume was completed to 10 µl with Nuclease-free 
H2O (All reagents were purchased from Promega, Madison, USA). The mixture was incubated at 
37
0
C for 30 min. DNase action in the mixture was stopped by 1 µl RQ1 DNase Stop Solution 
(Promega) and the mixture was incubated at 65
0
C for 10 min. RNA samples were stored at -80
0
C 
to be used in RT-PCR. 
RNA was quantified using a Biotech Photometer, UV1101 (WPA, Linton, Cambridge, UK) and 
used when ratio of A260 to A280 (RNA) was greater than 1.7. RNA concentration was determined 
using the following equation:  
RNA concentration (mg/ml) = A260nm X Dilution factor X Extinction coefficient (40) 
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2.1.3.1.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR) 
 
cDNA was produced from RNA by RT-PCR. 1-5 µg of RNA was added to 1μl Oligo (dt) Primer 
(10 μg/μl) (Promega, Southampton, UK) and the mixture was completed to 16.25 ul by RNA-
DNA free H20 (BioChemika, Fluka, UK). The Oligo (dt) Primer hybridizes to the poly (A) tail of 
mRNA and is suitable for the first strand cDNA synthesis with reverse transcriptase.  The 
mixture was heated at 65
0
C for 10 minutes and followed by incubation on ice for 2 min. A 
reaction mixture composed of; 5 μl of Reaction Buffer (5x) (Invitrogen), 1 μl Murine Moloney 
Leukaemia Virus Reverse Transcriptase (M-MLV RT) (200 U/µl) (Invitrogen), 1 μl of 10 mM 
deoxynucleotide triphosphates (dNTPs) (Bioline, London, UK) and 0.75 μl RNAsin® 
Ribonuclease Inhibitor (30 U/µl) (Promega) for RNase inhibition were added to the PCR 
reaction mixture. The final reaction mixture was incubated at 42
0
C for 1 hour to allow the 
synthesis of the first strand cDNA. The resulting cDNA was stored at -20
0
C to be used in PCR or 
Real time PCR. ALL RT-PCR reactions were carried using the Hybaid OmniGene TR3SM2 
Thermal Cycler (Lab Extreme, Kent, UK). 
2.1.3.2 Polymerase Chain Reaction (PCR) 
 
Primers used in PCR were listed in Table 1 along with the annealing temperatures (Ta) for the 
primers as been optimized. The PCR reactions were initially optimized for Ta and MgCl2 
concentration (will be shown within the Result Section). This was important as the optimal Ta 
ensures appropriate binding of the primer to the complementary DNA sequence. MgCl2 is an 
essential cofactor for the DNA polymerase in PCR. Many components of the reaction bind to Mg 
ion, including primers, template, PCR products and dNTPs.  
PCR reaction mixture consisted of 1-2 μl of cDNA, 2 units (U) of BIOTAQ DNA polymerase (5 
U/µl) (invitrogen), 2 μl of 10x NH4 reaction Buffer (invitrogen), 0.5 μl of 10 mM dNTP 
(Bioline), 0.6 μl of 50 mM MgCl2 (Bioline), 1 μl of both forward and reverse primer (50 µmole), 
and the mixture was completed to 20 μl with RNA-DNA free H20 (Sigma-Aldrich). The PCR 
programme used for amplification was; initial denaturation step at 95
o
C for 5 minutes, followed 
by 30 cycles of denaturation (95
o
C for 30 sec), annealing (Ta for 30 sec) and extension (72
o
C for 
45 sec), and a final extension step carried out at 72
0
C for 5 min. All PCR reactions were carried 
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out using Techne- Thermal cycler (TC-512) (Techne, Stone, UK). PCR product quality was 
assessed by agarose gel electrophoresis. 
2.1.3.3 Splicing by Overlap Extension Using Polymerase Chain Reaction 
(SOE-ing PCR) 
 
Cloning of HLA-A2103-120 into Ii chain was carried out using splicing by overlap extension by the 
polymerase chain reaction (SOEing-PCR) approach (Horton et al. 1993). This procedure allows 
the introduction of a short sequence into a target gene without the need to introduce novel 
restriction sites. Cloning of Ii-peptide fusion genes, Ii-A2 and Ii-HA were carried out in the same 
way except for the Ii-peptide fusion primers which were specific for the cloned peptide 
sequence. Steps of  cloning of Ii-A2 gene will be the described below.  
2.1.3.3.1 Primers design  
 
Four primers were designed to replace the CLIP part in Ii chain with the HLA-A2103-120 
Ii fwd: encoded the starting sequence of Ii chain and added Xho I restriction enzyme sequence 
(in bold) at the 5‟ end of Ii-A2 fusion gene. 
5‟- GATCGCTCGAGATGCACAGGAGGAGAAGCAGG - 3‟ 
Ii-A2 fusion rev: encoded part of the Ii chain sequence before the start of CLIP sequence and 
the first 12 bases of the HLA-A2103-120 
5‟-GGTACCCGCGGAGGAAGCGCCAGTCCGACCCCACCTTCATCGCAGGTTCTCCAG 
CTG -3‟ 
Ii-A2 fusion fwd: encoded the sequence of the last 12 bases of the HLA- A2103-120 and the part 
of Ii chain sequence after the CLIP sequence 
5‟- TCCTCCGCGGGTACCACCAGTACGCCTACGACGGCGGAGCCCTGCCCCAGGGGC 
CCATG -3‟ 
Ii rev: encoded the terminal sequence of Ii chain and added Xba I restriction enzyme sequence 
(in bold) at the 3‟ end of Ii-A2 fusion gene 
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5‟-TAAGCTCTAGATCACATGGGGACTGGGCC -3‟ 
Overlapping complementary nucleotide sequence was included in the Ii-A2 fusion fwd and rev 
primers. The complementary sequence corresponded to the middle 18 bps of the HLA-A2103-120 
sequence (further description in result section 4.3.3) 
2.1.3.3.2 PCR synthesis of Ii-A2 fusion gene  
 
Ii cDNA, prepared from mRNA extracted from Daudi cells, was amplified by PCR using the 
four previously designed primers in two separate PCR reactions. The 1
st
 PCR product 
corresponded to Ii chain and the first half of HLA-A2 103-120, and was amplified using Ii fwd and 
Ii-A2 fusion rev primers. The 2
nd
 PCR product corresponded to the second half of HLA-A2 103-
120 and the Ii chain, and was amplified using Ii-A2 fusion fwd and Ii-rev primers. PCR reactions 
were carried out as previously mentioned in section 2.1.3.2. 
2.1.3.3.3 Gene Assembly  
 
The two PCR products were added together at a ratio 2:1, 1
st
: 2
nd
 PCR products ratio. PCR 
reaction mixture contained Taq polymerase, dNTPs, NH4 reaction buffer and MgCl2 using the 
same concentrations (in section 2.1.3.2) except that no primers were added.  PCR reaction 
programme was carried for 10 cycles to allow the complementary DNA sequences to partially 
anneal.  
2.1.3.3.4 Amplification of the full length of Ii-A2 fusion gene 
 
PCR reaction was carried out by adding fresh Taq polymerase, dNTPs, MgCl2, NH4 reaction 
buffer to the previous PCR reaction (section 2.1.3.3.3). Ii-fwd and rev primers, flanking the start 
and the end of Ii chain, were added and PCR reaction was run for 30 cycles. PCR product quality 
was assessed by agarose gel electrophoresis. 
2.1.3.4 DNA Purification and Analysis  
 
Plasmid DNA was purified using the Qiagen plasmid purification kits (Qiagen, Crawley, UK), 
and they were used according to manufacturer„s instructions. Plasmid DNA was purified from 
cultures of transformed bacteria using QIA prep Spin Miniprep Kit. Large scale plasmid DNA 
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production and purification for transfection was carried out using QIAfilter Endo-free-Maxiprep 
kit. Purified DNA was resuspended in endotoxin free H20 (supplied with the Kit). Linear 
plasmids obtained after restriction endonuclease digestion were analysed by agarose gel 
electrophoresis, and the correct sized products were excised from the gel and purified by 
QIAquick Gel Extraction Kit. Occasionally, direct DNA purification of PCR products or 
restriction endonuclease digestion was carried out using QIAquick PCR purification Kit    
The DNA concentration and purity were detected using Biotech Photometer, UV1101, WPA 
according to the following formula; 
         DNA concentration (ug/ml)= Absorbance 260nm X 50 X dilution factor X 1 
Purity Analysis = A260 nm / A280 nm   (ideal purity = 1.8 - 2). 
NanoDrop ® ND-1000 Spectrophotometer in the Medical Research Council Sequencing facility 
at Hammersmith Hospital, London, UK was also used. It detects accurate DNA and RNA 
concentration as well as it produces a 260/280 and a 260/230 nm ratio giving further sample 
quality information.        
 2.1.3.5 Restriction Endonuclease Digestion  
 
All the restriction endonuclease reagents were purchased from New England Biolabs, and they 
were used according to manufacturer„s instructions. Digested DNA was checked by agarose gel 
electrophoresis for complete digestion alongside an appropriate DNA ladder (Bioline). Digested 
DNA was then purified using QIAquick Gel Extraction Kit. If the digested DNA was to be used 
directly, it was purified using QIAquick PCR purification Kit. The purified digested DNA was 
used for ligation reaction.  
2.1.3.6 Ligation reaction 
 
Purified digested DNA was ligated using T4 DNA ligase (Invitrogen) according to 
manufacturer„s instructions. Varying volumes of insert DNA were used in ligation reactions to 
produce a molar ratio of 1:1, 1:3, 1:6, vector : insert when mixed with 100 ng plasmid DNA. The 
ligation mixture was then kept overnight at 4
0
C prior to transformation of the ligation mixture 
into competent cells. 
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2.1.3.7 Competent Cell preparation  
Competent cells were prepared using the Rubidium Chloride method (Promega 1996). A single 
colony of Esherichia coli-DH5α bacteria was inoculated into 3 ml of LB broth (Sigma). The 
inoculated broth was incubated with shaking at 200 rpm (round per minute) at 37
0
C overnight. 
The starter culture was sub-cultured into 250 ml of LB broth (Sigma). The larger culture was left 
to grow, under the same conditions as the smaller culture, until the A600nm reached between 0.4 - 
0.6 optical density (measured by Biotech Photometer, UV1101, WPA). Once the required 
density was obtained, the bacterial growth was pelleted by centrifugation: 4500 g, 5min at 4
0
C. 
The cell pellet was resuspended in 100 ml of ice cold Transformation Buffer 1 (TFB1; 100 mM 
RbCl2, 300 mM CH3COOK, 50 mM MnCl2, 10 mM CaCl2, 15% glycerol; pH adjusted 6.4). The 
mixture was incubated on ice for 5 min prior to centrifugation at 4500 g, 5 min, at 4
0
C. The cell 
pellet was resuspended in 10 ml of ice cold Transformation Buffer 2 (TFB2; 10 mM MOPs, 10 
mM RbCl2, 75 nM CaCl2, 15% glycerol; pH adjusted 6.8) for 45 min on ice. Cells were 
aliquoted in 200 ul and snap frozen in liquid nitrogen for storage at -80
0
C. All reagents used in 
TFB1 and TFB2 preparation were purchased from Sigma, Poole, UK. 
2.1.3.8 Competent Cells Transformation  
 
A concentration of 5-10 µl of DNA ligation mixture was added to 200 μl of ice thawed 
competent DH5α bacterial cells. The mixture was mixed gently by swirling the pipette tip, and 
the cells were incubated on ice for 30 min. The bacteria were then heat shocked at 42
0
C for 60 
seconds to permeabilise the cell membrane in order to enhance DNA uptake. The cells were 
placed on ice for 2 min to rest. The transformation mixture was added to 3 ml of LB broth and 
shaked at 150-180 rpm, 45 min at 37
0
C. A volume of 50-100 μl of the cell growth was plated on 
LB agar (Sigma) containing selective antibiotics, Ampicillan (100 µg/ ml) (Sigma). The plates 
were incubated at 37
0
C overnight.  
2.1.3.9 Colony DNA extraction and analysis 
 
Individual colonies were picked and grown in 3 ml of LB broth with the selective antibiotics. 
The mixture was shaked vigorously at 200 rpm at 37
0
C overnight. The bacteria were pelleted and 
the DNA was extracted using QIA prep Spin Miniprep Kit (Qiagen).  
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DNA was digested with the appropriate restriction endonuclease enzymes and the digestion 
products were analysed by agarose gel electrophoresis. DNA extracted from colonies with the 
correct sized insert was sent for DNA sequencing. DNA with the correct sequence of the insert 
was transformed into competent cells, as previously mentioned, but instead of plating the 
bacteria, the mixture was inoculated in 250 ml LB broth and shaked at 200 rpm at 37
0
C 
overnight.  DNA was extracted and purified using QIAfilter Endo-free-Maxiprep kit (Qiagen). 
2.1.3.10 Agarose Gel Electrophoresis 
 
Agrose gel electrophoresis was used to analyze DNA samples. Agarose gels were prepared using 
1x Tris Borate EDTA (TBE) Buffer; 89 mM Tris, 89 mM Boric acid, 2mM EDTA, and the 
appropriate amount of agarose powder (Sigma-Aldrich). Once the agarose gel cooled and prior to 
gel casting, 1 ug/ml ethidium Bromide (Sigma-Aldrich) was added  
PCR products and digested DNA were mixed with 2 ul of loading buffer (Bioline, London, UK) 
and separated on agarose gels. Separated DNA samples were visualized using GelDoc-It
®
 
imaging system, UV 302 nm, (UVP, Cambridge, UK). Appropriate DNA ladder (Bioline) was 
used as molecular weight markers to compare DNA sample sizes. 
2.2 Cell Culture: Medium, Reagents and Cells 
2.2.1 Culture Medium and Reagents 
RPMI, DMEM were purchased from Invitrogen and was supplemented with heat inactivated 
fetal calf serum (FCS) (PAA laboratories, Somerset, UK). FCS was heat inactivated at 65
0
C for 
30 min, aliquoted in 50 ml falcon tubes and stored at -20
0
C. RPMI, DMEM media were 
supplemented with 10 % v/v FCS, 2 mM  L-glutamine (Cambrex, Workingham, UK ), and   
penicillin:streptomycin sulphate (P/S: 100 U/ml:100µg/ml respectively) (lonza, Workingham, 
UK), and named R10 and D10 respectively. Un-supplemented RPMI, DMEM media was named 
RNS and DNS respectively. Opti-MEM I medium was purchased from Invitrogen, and was used 
for cell transfection. Trypsin-EDTA solution (0.05% Trypsin, 0.02%EDTA) was purchased from 
Invitrogen and was used in routine adherent cells subculture and harvesting of cell monolayers. 
Cells were cultured in plastic tissue culture flasks or plates, purchased from Helena Biosciences 
(Sunderland, UK). 
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2.2.2 Cell Lines 
Except for Primary cell, which will be described later, cell lines used in this study are 
summarized in Table 4. Stable cell lines created in this project are listed in Table 5. 
 
 
 
 
 
 
 
 
 
Cell Line Brief Description Culture Medium 
CHO Chinese Hamster Ovary. Cell line derived from the 
ovary of adult Chinese hamster. Adherent. ECACC   
D10 
Daudi  Human Burkitt‟s lymphoma cell line. Suspension. 
ATCC 
R10 
D17 Canine osteosarcoma cell line. Adherent. ATCC  D10 
HEK 293 Human embryonic kidney 293. Adherent. ATCC D10 
OVCAR-3 Human Epithelial Ovarian Cancer (EOC) cell line.  
 
R-10 
M1DR1‡ Human fibroblast cell line transfected with DR1. 
Adherent.  
D10 + 200µg/ml G418 
M1DR1-CD80‡ Human fibroblast cell line transfected with DR1 and 
CD80. Adherent. 
D10 + 200µg/ml G418 
THP-1ᶲ Human acute monocytic leukemia cell line. 
Suspension. ATCC 
R10 
Table 4. Cell lines used in this project 
Cell lines were obtained from ATCC; American Tissue culture Collection, ECACC: European 
Collection of Cell Cultures. ‡M1DR1 and M1DR1-CD80 were kindly donated by Dr. Nicola Rogers 
(Game et al. 2005). ᶲ THP-1 was kindly donated by Dr.PH Tan, Oxford College, UK. G418; G-418 
Sulphate, Geneticin ® liquid solution (50 mg/ml) (Invitrogen).  
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Cell Line Brief Description Culture Medium 
CHO ICOSL CHO cell line that expresses human ICOSL full 
length. Adherent.  
D10 + 2mg/ml G418 
M1DR1-A2 M1DR1 cell line that was transfected with Ii-A2 
gene (Ii chain with the CLIP replaced with HLA-
A2103-120 peptide). M1DR1 expresses A2 peptide 
in the context of DR1 
R10 + 200µg/ml G418  
+ 3.2ng/ml Zeocin 
M1DR1-CD80-A2 M1DR1-CD80 cell line that was transfected Ii-
A2 gene. It expresses A2 peptide in the context 
of DR1 Adherent.  
D10 + 200µg /ml G418   
+ 3.2ng/ml Zeocin 
M1DR1-CD80-HA M1DR1-CD80 cell line that was transfected Ii-
HA gene (Ii chain with the CLIP replaced with 
Haemagglutinin peptide (HA). It expresses HA 
peptide in the context of DR1. Adherent. 
D10 + 1 mg/ml G418  
+ 3.2ng/ml Zeocin 
 
 
 
 
2.2.3 Cell Culture 
All cells used in this project were cultured in humid environment at 37
0
C with 5% CO2. 
Adherent cells were passaged as follows; the incubating medium was discarded and the cells 
were washed once with sterile phosphate buffered saline (PBS) (Oxoid, Basingstoke, UK). Cells 
were incubated with 5-7 ml of warm trypin solution for 3-5 min.  Cells were then harvested and 
warm medium was added to stop trypsin action. Cells were centrifuged at 500 g, 5 min at RT, 
and recultured in fresh medium at density of 1 x 10
6 
cells
 
/ ml medium. Cell passage was done 
every three days or when the medium turned yellow (cells were confluent). Suspension cells 
were passaged by diluting 1:2 with fresh medium. 
2.2.3.1 Daudi cell line Activation 
Daudi cells were seeded at 2-3 x 10
6
 cells / well in 6 well culture plates (TPP; Helena 
Biosciences). Cells were activated using TNF-α (100 ng/ml) and CD40L (50 μl/ml) (All from 
Pepro Tech, London, UK) in a final volume of 2 ml R10 per well. Cells were stimulated for 48 
hours prior to harvesting for flow cytometry analysis and RNA extraction. 
Table 5. Stable Cell lines created in this project 
Stable cell lines created in this project were cultured under selection pressure using the appropriate 
selective drug. Antibiotic used was chosen according to encoded drug resistance gene by the 
transfecting plasmid. G418: G-418 Sulphate, GENETICIN ® liquid solution (50 mg/ml) 
(Invitrogen). Zeocin; (1g/1.25ml) (Invitrogen)  
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2.2.4 Primary Cells Culture and Isolation 
2.2.4.1 Human Dendritic cells 
2.2.4.1.1 Isolation of PBMC by Density Gradient Centrifugation 
Peripheral blood mononuclear cells (PBMC) were isolated from buffy coats donated by healthy 
volunteers (NHS, Colindale, UK). Blood was transferred from blood bags to T75 TPP tissue 
culture flasks (Helena Biosciences), and diluted with a ratio of 1:3, blood: sterile PBS or RNS in 
a final volume of 200 ml. The blood was carefully layered over Lymphoprep (Axis-Shield, 
Cambridge, UK) in a ratio of 1:3, lymphoprep: blood, in 50 ml Falcon tubes (BD Falcon; VWR, 
Lutterworth, UK). The tubes were centrifuged at 800 g, 20 min at RT with no brakes. 
The white mononuclear cells ring was aspirated and transferred to new 50 ml falcon tubes (BD 
Falcon) using sterile Pasteur pipette (BD, Biosciences). The isolated PBMC were washed with 
sterile PBS and centrifuged at 200 g, 10 min at RT with low brakes to remove the platelets. 
Supernatant was discarded and the process was repeated for two times. The cell pellets were 
treated with ice cold ACK lysing buffer (8.3g NH4CL, 1.0g NaHCO3, 1.8ml of 5% w/v EDTA in 
500 ml of autoclaved H20; pH was adjusted at 7) to lyse any remaining erythrocytes. ACK lysis 
buffer was added to the cell pellets and incubated for 5 min on ice. The cells were then washed 
with PBS and centrifuged at 300 g, 10 min at RT. PBMC were then counted and either used 
immediately to isolate CD14
+
 cells, or frozen in filtered freezing media and kept at -80
0
C for 
further use. 
2.2.4.1.2 Generation of monocytes derived DCs (mo-DCs)  
Monocytes derived DCs were generated from CD14
+
 cells isolated from the isolated PBMC 
using a magnetic bead positive selection technique. PBMC was suspended in 80 µl of ice cold 
MACS buffer (0.5 % FCS and 2 mM EDTA in 500 ml sterile PBS; pH adjusted at 7.2) per 1x10
7
 
total cells. CD14 microbeads (MiltenyiBiotec, Surrey, UK) were used to label CD14
+
 cells for 
positive selection. Briefly, 200 µl of CD14 microbeads were added per 1x10
7
 PBMC in 3ml 
MACs buffer, and cells were roll mixed for 25-30 min at 4
0
C. Cells were then washed twice with 
ice cold MACS buffer and centrifuged at 300 g, 10 min at RT. Supernatant was discarded and 
cells were resuspended in 1ml of MACS buffer for 1x10
8 
cells. CD14
+
 cells were isolated using 
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large sized Miltenyi columns (MiltenyiBiotec) according to manufacturer„s instructions. The cell 
suspension was passed through 30 µm pre- separation Miltenyi filters (MiltenyiBiotec) to get rid 
of any cell clumps that can clog the column. The unlabelled cells, CD14
–
, which passed through 
the column were collected and stored as frozen aliquots at -80
0
C for future use. 
The CD14
+ 
monocytes were then counted and seeded at 1x10
7
 in T75 flask in final volume of 5 
ml R10. Granulocyte Macrophage colony stimulating factor, GM-CSF (First link, Birmingham, 
UK) and interleukin-4 (IL-4) (Invitrogen) were added at a final concentration of 20 ng/ml R10. 
On day 2; 1 ml of fresh R10 containing GM-CSF and IL-4 enough for 6 ml medium was added 
to keep the concentration at 20 ng/ml. The day 2 process was repeated on day 4. For DC 
maturation (mDCs), tumor necrosis factor (TNF)-α (20 ng/ml) and interleukin-1 (IL-1)-β (20 
ng/ml) and interferon-gamma (IFN-γ) (20 ng/ml) (All were purchased from peprotech, London, 
UK) were added on day 4 with the other cytokines. On day 6, mDCs or iDCs were collected and 
used for the required experiments.  
2.2.4.2 Human T cells  
2.2.4.2.1 T cell Isolation  
T cells were isolated from either PBMC or CD14
- 
cells (both were used either as freshly isolated 
or from frozen vials). T cells were isolated using a negative selection technique. PBMC or CD14
-
 
cells were washed in 5 ml pre-warmed R10 medium, and centrifuged at 800 g, 5 min at RT. The 
cells were resuspended in 1ml of media containing the antibodies mixture. Mixture of antibodies 
including; Mouse anti-human CD14, CD16, CD19, CD56 antibodies (all Chemicon, Watford, 
UK) along with CD33 beads (BD Biosciences, Oxford, UK) were added to 1ml of R10 at a 
concentration of 0.1µg/ml. The cell mixture was roll mixed for 30 min at 4
0
C. The cells were 
washed by ice cold PBS and centrifuged at 800 g, 5 min at RT. Supernatant was discarded and 
cells were resuspended in 5 ml of pre-washed BioMag goat anti mouse IgG-Fc magnetic beads 
(5mg/ml) (Qiagen, West Sussex, UK) and suspended in 5 ml R10. The cells mixture was roll 
mixed for 30 min at 4
0
C. To select the unlabelled cells, the cell/bead mixture was placed in the 
magnetic holder and the beads were allowed to settle on the side of the tube. The remaining 
supernatant was collected in a fresh tube and this process was repeated to ensure all beads were 
removed until no residue could be observed and cells were then counted. 
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 2.2.4.2.2 T cell Activation  
Isolated T cells were seeded at 3-5 x 10
6 
/ well in 6 well culture plates in a total volume of 2 ml 
R10. T cell were activated with Dynabeads CD3/CD28 (Dynal) added at 3µl per 2x10
6
 T cells, 
and phytohemaglutinin (PHA) (Sigma-Aldrich, Dorset, UK) at a concentration of 5 μg/ml. T 
cells were incubated at 37
0
C, 5% CO2 for the length of time considered optimal for ICOS surface 
expression. Human ICOS cDNA was prepared from RNA extracted from activated T cells. 
2.3 Cell Transfection 
2.3.1 Transient Transfection 
2.3.1.1 Lipid mediated  
Several transfection reagents were used in this project; Lipofectin ® (Invitrogen), Lipofectamine 
TM 
2000 (Invitrogen), and Tfx 
TM
-50 (Promega, Southampton, UK). The best results were 
obtained with Lipofectine ®, which was used in transfection of all adherent cells used in this 
project.  
Cells transfection were carried according to manufacturer instructions. Briefly, cells were seeded 
at 2-3 x 10
5
 cells / well in 6 well culture plates in a final volume of 2 ml D10 for 24 hours or 
until the cell confluence reached 70-80% as examined by light microscopy on the day of 
transfection. For each transfection condition, Lipofectin ® (Invitrogen) was used with DNA 
concentration of 1-4 µg at 6:1 ratio lipofectin: DNA in a final volume of 600 µl of Optimem. The 
required DNA concentration was optimized with each cell line. The DNA/Lipofectine complexes 
were added to cells and incubated at 37
0
C for 5 hours. The transfection process was stopped by 
replacing the transfection mixture with complete culture media. Transfected cells were cultured 
for 48 hours prior to checking for plasmid expression. 
2.3.1.2 Microporation  
Microporation is an electroporation technology that uses pipette tip-style chamber instead of the 
cuvette electrode used in conventional electroporation (Wang et al. 2009). Published studies 
demonstrated that this technology generated a uniform electric field with reduced heat 
generation, pH variation and oxide formation. This technology minimizes cell death and allows 
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good transfection efficiency. MicroPorator MP-100 (Labtech, Ireland, UK) was used to transfect 
THP-1 cell line and human iDCs (harvested on day five or six). All transfection buffers, 
electroporation tubes and golden tips were purchased from Labtech, Ireland, UK. Transfection 
was carried out according to manufacturer instructions. Optimization of transfection conditions 
including voltage, number of pulses and duration of pulse were carried out according to the type 
of cell to be transfected. 
2.3.1.3 Nucleofection  
The Nucleofector technology is a newly introduced non-viral transfection technology, and 
thought to be capable to transfect non-proliferating and difficult-to-transfect primary cells (Lenz 
et al. 2003). This technology is based on a combination of optimized electrical parameters, 
generated by a special device called nucleofector using cell-type specific reagents. Nucleofection 
reagents were purchased from Lonza, Cologne, Germany. Nucleofection was mainly used to 
transfect DCs, and optimization of transfection conditions were described in details in section 
5.2.2.3. 
2.3.2 Stable Transfection  
2.3.2.1 Kill Curve generation 
Individual clones containing transfected DNA that has integrated into the cellular genome were 
distinguished from the untransfected cell by drug selection screening. The appropriate drug was 
selected according to the drug resistance gene encoded by the transfected DNA. The lowest 
concentration of the selective drug necessary to kill untransfected cells, hence select the resistant 
clones, was determined by a kill curve. The cells were seeded at 2-3 x 10
5 
/ well in 6 well culture 
plate and incubated overnight. On the following day, the medium was replaced with fresh 
medium added to it the selective drug at varying concentrations. The medium containing 
selective drug was replaced every 72 hours to maintain sustained concentration of the selective 
drug. The lowest drug concentration that killed all the cells within two weeks was chosen to 
select the transfected cells.  
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2.3.2.2 Selection of stably transfected cells  
The plasmid used for cell transfection was linearized by restriction endonuclease to facilitate its 
incorporation within the cell genome. The transfected cells maintained in non-selective medium 
for 1-2 days post transfection, and then the medium was replaced by the selective medium 
containing the optimized concentration of the selective drug as detected from the kill curve. 
Untransfected cells were included in setting the curve. The drug-containing medium was 
replaced every 3 to 4 days till the untransfected cells were killed. The transfected cells were 
allowed to grow for further 3 weeks under selection pressure to avoid contamination with non-
resistant cells till distinct islands of surviving cells were seen. The mixed cell population was 
serially diluted to give approximately 1 cell / well in 96 well culture plates (Helena, Bioscience). 
The cells were allowed to expand and then screened for the positive clones expressing the target 
gene by PCR or flow cytometry. 
2.4 Analysis of Cell Phenotype and Protein Expression   
2.4.1 Sodium Dodecyle Sulphate - Polyacrylamide Gel 
Electrophoresis (SDS-PAGE) and Western Blotting 
2.4.1.1 Preparation of Cell Lysates 
Cell ready for extraction of proteins for western blotting were harvested and washed with ice 
cold PBS at 600 g, 5 min at RT for 3 times. After the last wash, supernatant was discarded and 
the cells were suspended at 1 x 10
6
 cells per 130 μl Lysis Buffer (150 mM NaCl, 5 mM MgCl2, 
1% NP40, 10mM Hepes Buffer. All reagents were purchased from Sigma) freshly supplemented 
with Protease Inhibitor Cocktail (Sigma-Aldrich). The cell/lysis buffer mixture was incubated for 
30 min on ice. Cells were centrifuged at 13000 g, 5 min at RT to pellet the cell debris. Equal 
volume of 2x Laemmli Sample Buffer (Sigma-Aldrich) was added to the sample and the mixture 
was heated to 80
0
C for 5 min.  The mixture was cleared by centrifugation for 1 min before either 
stored at -20
0
C or set for electrophoresis. ICOSL protein was extracted from CHO ICOSL cells 
and DCs using Mem-PER® Eukaryotic Membrane Protein Extraction Reagent Kit (Pierce, 
Rockford, USA) according to manufacturer instructions. This kit applies a mild detergent based 
protocol to enrich integral membrane protein extracted from mammalian cells. The extracted 
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proteins are separated into hydrophobic and hydrophilic proteins through phase partition; with 
the majority of the membrane protein contained in the hydrophobic fraction. 
2.4.1.2 SDS-PAGE 
The Resolving polyacrylamide gel (10 %) was prepared in a total volume of 10 ml; 4 ml double 
distilled H20, 3.3 ml of 30 % acrylamide mix, 2.5 ml of 1.5 M Tris (ph 8.8), 0.1 ml of 10 % SDS, 
0.1 ml of 10% ammonium persulphate and 0.004 ml TEMED (all reagents purchased from 
Sigma). The mixture was mixed well prior to pipetting into gel casting modules. After 
polymerization of the resolving gel, 4ml of a 5% stacking gel was  prepared by mixing 2.7 ml 
double distilled H20, 0.67 ml of 30 % acrylamide mix, 0.5 ml 1.5 M Tris (ph 6.8), 0.04 ml of 10 
% SDS, 0.04 ml of 10 % ammonium persulphate, 0.004 ml TEMED. The mixture was mixed 
well and casted above the resolving gel. Gels were submerged in Running Buffer (3g Tris base, 
14.42 g glycine and 10 ml SDS (10 %) and the volume was completed to 1 liter double distilled 
H20).  Cell lysates (15-20 μl) were loaded in the stacking gel and the current was allowed at 100 
V for 1 hour. Appropriate volume of BenchMark Pre-Stained protein ladder (Invitrogen) (6.0 
kDa -181.8 kDa) was loaded onto the gels for comparison with the detected proteins.  
2.4.1.3 Western Blotting 
Protein was electro-transferred from the resolving polyacrylamide gel onto Protran
TM
  
nitrocellulose membrane (GE Healthcare, Little Chalfont, UK ) in a transfer buffer (3 g Tris 
base, 14.42 g glycine and 200 μl methanol and the volume was completed to 1 liter double 
distilled H20). Electric transfer was conducted at 100 V for an hour in an ice cooled blotting 
apparatus to minimize heat production. The nitrocellulose membrane was removed from the 
blotting apparatus and washed in a washing buffer (PBS, 0.05% v/v Tween-20) for 5 min. The 
membrane was then incubated with a blocking buffer (PBS, 5% w/v milk powder, 0.05% v/v 
Tween 20) to block non-specific sites for 1 hour with constant agitation. The membrane was 
washed 3 times with the washing Buffer before incubation with the appropriate primary antibody 
diluted in the blocking buffer for 2 hours at RT or overnight at 4
0
C with constant agitation. The 
membrane was washed with the washing Buffer for three 15 min washes at RT with constant 
agitation. The membrane was incubated with a secondary/HRP-conjugated antibody diluted in 
blocking buffer for 1 hour at RT with constant agitation.  The membrane was then washed with 
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washing buffer 3 times, for 15 min each, at RT prior to protein visualization by enhanced 
chemiluminescence using the ECL detection Kit and ECL Hyper film (GE Healthcare). Proper 
sample loading was confirmed by probing the membrane with an anti-β actin antibody. 
Antibodies used on this project for western blotting are listed in Table 6 and 7. 
2.4.2 Flow cytometry 
Several cell populations were stained throughout this study to assess expression (or lack thereof) 
of specific surface markers by flow cytometry. Cell to be analysed by flow cytometry were 
stained with specific fluorescently labeled (direct staining) or unlabelled primary Ab and 
fluorescently labeled secondary Ab (indirect staining) with the use of the appropriate isotype 
control. 
Cells to be analysed by flow cytometry were harvested, washed twice with ice cold PBS at 400 
g, 2 min at 4
0
C and counted. The cells were seeded in a V-bottomed 96 well plate (Nunc, 
Roskidle, Danemark) at 3 -5 x 10
5
 cells in 100 μl of FACS buffer [PBS, 5 % v/v FCS, 0.1 % 
sodium azide (NaN3)], and incubated with the appropriate antibody or isotype control for 30 min 
at 4
0
C in the dark.  The cells were washed 3 times with cold FACS buffer at 400 g, 2 min at 4
0
C 
prior to incubation with the appropriate secondary antibody in a final volume of 100 µl FACS 
Buffer. The cells were washed 3 times with cold FACS buffer at 400 g, 2 min at 4
0
C. Cells were 
resuspended in 200 µl FACS buffer prior to analysis by FACS Calibur (Becton Dickinson 
Immunocytometry Systems, California, USA) and FlowJo V2.1.1 software. All antibodies were 
used according to the manufacturer‟s concentration and titration experiments. All antibodies used 
in this study including primary, secondary and isotype control are listed in Table 6, 7 and 8 
respectively. 
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Anti-human Clone Flurochrome Isotype Dilution Source 
β-actin Ac-15 - Mouse IgG1 1:2000 (WB) Sigma 
CD11c BU-15 APC Mouse IgG1 2.5µg/ml(FC) Caltag 
CD14 47-3D6 FITC Mouse IgG1 2.5µg/ml(FC) Caltag 
CD80 MEM-233 R-PE Mouse IgG1 2.5µg/ml(FC) Caltag 
CD86 BU63 R-PE Mouse IgG1 2.5µg/ml(FC) Caltag 
CD74 (anti-Ii) PIN.1 - Mouse IgG1 1:1000 (WB) Abcam 
Class II TÜ36 R-PE Mouse IgG2b 2.5µg/ml(FC) Caltag 
ICOS C398.4A R-PE Armenian 
Hamester IgG 
2.5µg/ml(FC) Biolegend 
ICOSL 2D3 - Mouse IgG2b 5µg/ml(FC) Lab Vision 
ICOSL 1E2 - Mouse IgG1K 1:1000(WB) Sigma 
myc epitope ‡ 4A6 - Mouse IgG 1:1000 (WB) Millipore 
UL-A51ɸ NA - Human IgG 2.5µg/ml (FC) Donation 
Table 6. Primary antibodies used in flow cytometry and western blotting 
‡ Anti myc antibody is against human myc epitope 410-420 amino acids (MEQKLISEEDL). Conjugates: 
FITC; Fluorescien isothiocyanate, R-PE; Recombinant Phycoerythrin, APC; Allophycocyanin. Abreviations;, 
FC: flow cytometry, WB; Western Blotting, N/A; not available. Source information: Abcam; Cambridge, UK, 
Biolegend; Oxford, UK, Caltag; Invitrogen, UK, Lab Vision; NeoMarkers, USA, Millipore; Watford, UK, 
Sigma-Aldrich; Poole, UK. ɸ:  Kind donation by Prof. G. Lombardi, King‟s College, London, UK.         
 
                                                                                                                     Materials and Methods 
102 
 
Species Reactivity Conjugate Dilution Source 
Goat Mouse IgG R-PE(FC) 1:200 Biolegend 
Goat Human IgG R-PE(FC) 1:200 Caltag 
Rabbit MouseIgG HRP (WB) 1:2000 DAKO  
 
 
 
 
Species Isotype Conjugate Source 
Armenian Hamester  IgG R-PE Biolegend 
Mouse IgG1 R-PE and FITC Caltag 
Mouse IgG2b R-PE Caltag 
Mouse IgG1 APC Biolegend 
Human   IgG - Sigma 
 
 
 
2.5 Cellular Assay 
2.5.1 Mixed Lymphocyte Assay (MLR) 
Activated T cells with anti-CD3/CD28 were co-cultured with several cell types; iDCs, mDCs, 
CHO ICOSL, THP-1 and M1DR1 in a final volume of 200 µl of R10 in a 96 well, round 
bottomed culture plates.  The ratio of T cells to other cells was titrated and a ratio of 10:1 T 
cells:DCs and 5:1 T cells to the other cells were used. T cells numbers were kept the same; 1x10
5 
per condition. CHO ICOSL cells were treated with Mitomycin-C (Sigma), while M1DR1 and 
THP-1 cells were irradiated with 100 Gy and 60 Gy respectively prior to the MLR assay.  T cell 
proliferation was assessed by tritiated Thymidine incorporation; 1 µCi of 
3
[H]–thymidine was 
added to each well on day 3 of the MLR for 16-18 hours. On day 4 of the MLR, tritiated 
Table 8. Isotype Control used in this project 
Conjugates: R- PE; Recombinant Phycoerythrin, FITC: Fluorescien isothiocyanate Source 
information: Biolegend; Oxford,UK, Caltag; Invitrogen, UK, Sigma-Aldrich, UK.  
 
Table 7. Secondary Antibodies used in this project 
Conjugates: R- PE; Recombinant Phycoerythrin, HRP; Horse radish peroxidase. Source information: 
Caltag; Invitrogen, UK, DAKO; Ely, UK, Biolegend; Oxford, UK.Abbreviations; FC: flow 
cytometry, WB; Western Blotting            
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thymidine incorporation was analysed by harvesting MLRs (Harvester 96, MACH III M, TOM 
TEC (Receptor Technologies, Adderbury, UK) and counting the radioactive incorporation using 
a Wallac Trilux 1450 Microbeta Liquid scintillation and Luminescence counter (PerkinElmer, 
Beaconsfield, UK).  
2.5.2 Enzyme Linked Immunosorbant Assay (ELISA) For Cytokine 
Production 
Cytokine levels in the supernatant collected from the MLRs of activated T cells with DCs or 
CHO ICOSL were detected using Cytokine sandwich ELISA Kits. Human IL-10 ELISA Ready 
SET-Go! Kit ®, human IL-4 ELISA Ready SET-Go! Kit ® and human IFN-γ ELISA Ready 
SET-Go! Kit ® were purchased from eBioscience, USA and used according to manufacturers‟ 
instructions. The sensitivity of IL-10 kit is 2 pg/ml, the IL-4 kit is 2 pg/ml and the IFN-γ is 4 
pg/ml which provide accurate detection of low levels of the respective cytokines in supernatants 
collected on day 3.  the ELISA plate was read at 450 nm using a microplate spectrophotometer. 
Samples were assayed in duplicates and were quantified by comparison with standard curves 
obtained with purified recombinant cytokines provided with the ELISA kits and the results were 
represented as means and standard deviation of duplicates. 
2.6 Deconvolution Fluorescence Microscopy 
Transfection efficiency optimization relied in part upon the visualization of transfected cells for 
GFP protein expression by deconvolution fluorescence microscopy. Cell visualization was done 
48 hours after transfection. Adherent transfected cells were washed by PBS prior to visualization 
to remove any dead cells, whilst suspension cells were visualized directly. GFP expression was 
visualized using FITC filter using Olympus CK40 (Olympus, UK) fluorescence microscope. 
2.7 Immunocytostaining 
Co-localization of ICOS-KDEL protein expression in human ER was visualized using Confocal 
Microscopy. ER - Tracker
TM
 Green (glibenclamide BODIPY® FL) (Molecular Probes, 
Invitrogen) was used to live stain the ER in transfected cell. AlexaFluor 555 conjugated anti-
human myc Ab (Millipore) was used to stain the myc epitope in ICOS-KDEL plasmid. M1DR1 
                                                                                                                     Materials and Methods 
104 
 
cells were seeded at 2 x10
5
 onto glass cover slips (22 mm) in 24 well culture plates (Helena). 
Staining protocol was optimized on transfected cells after 48 hours of transfection. Transfected 
cells were washed with 1x Hank‟s Balanced Salt Solution (HBSS) (Invitrogen) for 3 times prior 
to fixation by 4 % formaldehyde for 15 min at 37
0
C. Cells were then washed with HBSS for 2 
times for 5 min each at RT prior to cell permeabilisation with 0.2% Trition x-100 for 10 min at 
RT, and rewashed with HBSS for two 5 min washes at RT.  Cells were stained with ER-Tracker 
TM
 Green at the optimized concentration (5µM) for 30 min at 37
0
C and then rewashed with 
HBSS for two 5 min washes at RT. Cells were then stained with AlexaFluor 555 conjugated anti-
human myc Ab at optimized concentration (2µg/ml) for 30 min at 37
0
C, and then rewashed with 
HBSS for two 5 min washes at RT. The cover slips were then mounted on glass slides and were 
visualized by Leica Confocal TCS SP5 microscope. 
 2.8 Real Time PCR (RT-PCR)   
ICOSL mRNA expression levels in iDCs and CHO ICOSL cells following coculture with 
activated T cells was analysed by Real Time PCR using double stranded DNA dye SYBER 
GREEN based analysis. Real time PCR was performed using Applied Biosystems 7300 Real-
time PCR machine and the data were analysed by SDS 7000 software.  
 
The reaction mixture was performed as follows; 1 µl of cDNA, 10 µl SYBR ® Green Taq Ready 
Mix (AB applied Biosystems, UK), 1 µl of both forward and reverse primers (100 µmole), and 
the mixture was completed to 20 µl with RNA-DNA free H2O (Sigma-Aldrich). The reaction 
was carried using MicroAmp® Optical 384-Well Reaction Plate with Barcode and was sealed by 
Optical Adhesive Film (both were purchased from AB applied Biosystems). RT-PCR 
programme used for gene amplification was; 95
0
C 10 min for 1 cycle, followed by 40 cycles of  
denaturation at 95
0
C for 15 sec, annealing at 58
0
C for 30 sec, and elongation at 72
0
C for 30 sec, 
then  72
0
C 10 min for 1 cycle. A dissociation step was added at the end of the reaction; 95
0
c for 
15 sec, 60
0
C for 15 sec and 95
0
C for 15 sec. Transcripts were normalized to levels of 
Hypoxanthine phosphoribosyl transferase (HPRT) gene that was used as a house keeping gene. 
Normalization of sample values permitted accurate comparison of gene expression in different 
conditions and avoided errors arising from mRNA extraction/purification and reverse 
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transcription in vitro. Experiments were performed in duplicates and average of relative mRNA 
expression was used for analysis. 
 
2.9 Statistical Analyses 
Statistical differences carried out in this thesis were calculated using non-parametric two-tailed t- 
test. A Mann-Whitney U test was used to calculate statistical differences using GraphPad Prism 
version 5.00 for Windows. A value of p<0.05 was regarded as statistically significant. 
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3.1 Introduction  
3.1.1 Co stimulation and T cell activation  
 
Optimal T cell activation requires synchronous signals through TCR engagement and co 
stimulatory molecules in a dual signal model for efficient T cell response (Lafferty and 
Cunningham 1975). CD28 is a key T-cell surface receptor mediating co-stimulation in primary T 
cell activation (June et al. 1990). However, the generation of effector/memory cells which are 
important mediators of allograft loss requires further contributions from other co stimulatory 
signals (Yamada et al. 2002). Several studies have shown that CD28 pathway blockade is an 
effective tolerogenic strategy promoting allograft survival in many transplant models, 
nevertheless T cell activation and transplant rejection can still proceed in the absence of CD28 
signalling. Studied showed that CD28
-/-  
mice
 
acutely rejected a skin allograft (Ha et al. 2001) 
and CTLA-4 Ig failed to prevent graft loss due to chronic rejection in a murine cardiac 
transplantation model (Sayegh et al. 1997). Alternatively, other co-stimulatory pathways such as 
ICOS:ICOSL has been targeted as a possible second tier which provides a necessary signal for T 
cell activation. Studies showed that ICOS:ICOSL blockade may provide a potential strategy for 
achieving reproducible and robust tolerance in transplantation (Ozkaynak et al. 2001; Schenk et 
al. 2009) and autoimmune diseases (Iwai et al. 2003; Ansari et al. 2008). 
3.1.2 Intracellular retention of ICOSL using ICOS- KDEL strategy 
 
Previously in Prof. George‟s lab, a novel genetic construct has been established and employed to 
render DCs tolerogenic. This genetic construct consisted of human extracellular domain of 
CTLA4 fused to the ER retention sequence KDEL (Tan et al. 2005b). The principle of this 
construct was that the expression of CTLA4-KDEL would be retained in the ER. There, the 
CTLA4-KDEL bound to CD80/86 in the ER and prevented the surface expression of these 
proteins on DCs surface without altering other aspects of DC maturation. Furthermore, human 
DCs expressing CTLA4-KDEL-fusion protein induced T cell anergy and alloantigen-specific 
tolerance. These anergic T cells expressed regulatory functions and inhibited a primary immune 
response in cultures of unmodified DCs and T cells. Another study was presented by this lab 
where CTLA4-KDEL gene cassette was cloned into a lentiviral vector (vCTLA4-KDEL) (Khan 
et al. 2008). The study showed that DCs transduced with vCTLA4-KDEL expressed reduced 
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levels of CD80 and CD86 on DCs surface. In addition, transduced DCs induced donor specific T 
cell anergy in allogenic T cells to both direct and indirect pathway in vivo and in vitro. As the 
KDEL strategy proved to be effective, it was aimed to use it to modulate ICOS:ICOSL 
costimulatory pathway in this study.  
Maintenance of the complex architecture of the secretory pathway in the cells depends on the 
precise sorting of the newly synthesized proteins (Tekirian 2002). Moreover, proteins localized 
in the organelles of the secretory pathway have to be retained at their proper position despite the 
continuous flow of proteins and lipids to and fro between intra cellular organelle compartments 
(Tekirian 2002). The newly synthesized proteins targeted for secretion enter the secretory 
pathway during their translation at the ER (Vitale and Denecke 1999). There are number of 
membrane proteins, soluble proteins and molecular chaperones which are involved in core 
glycosylation, folding, assembly and maturation of nascent proteins (Vitale and Denecke 1999). 
The chaperones and other soluble proteins located in the ER have a conserved carboxyl-terminal 
sequence known as KDEL – Lys-Asp-Glu-Leu – in mammalian cells (Pelham 1989), and as 
HDEL – His-Asp-Glu-Leu – in yeast (Pelham et al. 1988). Proteins bearing this sequence bind to 
KDEL receptor, ERD2 which is an integral membrane protein located in the Golgi apparatus and 
the ER (Lewis and Pelham 1990; Tang et al. 1993). Upon KDEL ligand binding, conformational 
change/oligomerization of the KDEL receptor takes place, followed by receptor phosphorylation 
by protein kinase A (PKA) (Aoe et al. 1997; Cabrera et al. 2003). These conformational changes 
promote the recruitment of COP1-coated transport intermediates that are important for retrograde 
trafficking of the KDEL occupied receptor to the ER (Orci et al. 1997). Finally, the KDEL 
receptor-ligand complex dissociates upon their arrival in the ER, resulting in the release of the 
KDEL proteins into the lumen of the ER and returning of the KDEL receptor to the Golgi 
apparatus to await further rounds of retrieval (Wilson et al. 1993; Cabrera et al. 2003). 
A study conducted by Wilson et al. suggested that the affinity of the KDEL receptors for KDEL 
ligands is pH- dependent in vitro. The study showed that under acidic conditions, KDEL 
receptor–KDEL ligand binding was very efficient, however, at neutral or basic pH, this binding 
became significantly weaker (Wilson et al. 1993). This could explain the association of the 
KDEL-containing proteins with the KDEL receptor in the Golgi complex and their release into 
the ER as the cis-Golgi pH is lower than that in the ER (Wilson et al. 1993). 
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The approach of employing KDEL fused to the extracellular domain of a cell surface protein is 
similar in some respects to the use of intracellular antibodies (intrabodies) and intracellular 
chemokines (intrakines) (Engel et al. 2000; Kirschning et al. 2010). In intrabodies strategy, 
KDEL is fused to antibodies fragments to prevent cell surface expression and neutralize the 
function of the target proteins, while in intrakine approach KDEL is fused to chemokines to 
block cell surface expression of chemokine receptors (Wheeler et al. 2003). The KDEL-fusion 
proteins are degraded intracellularly in a proteosome dependent process, as the intrabodies tend 
to either aggregate, coalesce and form aggresome structures or retranslocated from ER to be 
finally degraded via proteasomes in the cytosol (Cardinale et al. 2004). It was shown that 
degradation of CTLA4-KDEL-CD80/86 complex could be inhibited by proteosome inhibitor, 
with subsequent increase in CD80/86 expression levels (Tan et al. 2005b). This is particularly 
important as degradation of the KDEL-fusion protein in a proteosome dependent process 
suggests that the KDEL complex is likely to enter the antigen-processing pathway.   
One of the objectives of using cell surface molecule as ICOS in the KDEL-construct rather than 
antibody is the expected low immunogenicity of the fusion protein construct as the construct to 
be used in cell transfection would be derived from human origin. This would be important as 
KDEL-fusion proteins are likely to enter antigen-processing pathway (Tan et al. 2005b). In 
addition, the KDEL technology offers an advantage over small interfering RNA (siRNA) 
mediated knockdown of ligands, which is the specificity of KDEL-fusion protein in down- 
regulating the targeted molecules. The siRNA may result in non specific silencing of genes with 
the potential of cell toxicity (Fedorov et al. 2006).  
 
Furthermore, using KDEL-fusion construct has a privilege over the administration of blocking 
antibodies or soluble proteins as ICOS-Ig fusion proteins in that it would be specific to antigen 
expressed by the modified APCs and will not induce generalized immunosuppression. This 
approach also has the advantage over the administration of intrabodies which can cause 
activation of the ER stress pathway due to poor folding of intrabodies in the ER, whereas the use 
of CTLA4-KDEL did not induce ER stress response (Tan et al. 2005b). Induction of ER stress 
response could result in rapid degradation of the fusion protein or non specific effects that could 
make interpretation of results difficult.  
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In this chapter, the potential of developing a negative-vaccine approach to induce immune 
tolerance using the KDEL strategy was assessed. A fusion construct composed of KDEL 
sequence and human extracellular domain of ICOS was created. As stated above, KDEL peptide 
signals for retention or retrieval of protein to the ER, so ICOS-KDEL construct was expected to 
inhibit/down regulate the ICOS:ICOSL co stimulatory signal required for T cell activation. The 
inhibition of ICOS:ICOSL signalling was expected because we reasoned that the ICOS-KDEL-
fusion protein would bind to the newly synthesized ICOSL molecules in the ER and prevent the 
surface expression of ICOSL on the cell surface . 
3.2 The aims of this chapter  
The experiments described in this chapter were designed to achieve the following aims: 
1. Construction of a fusion construct encoding extracellular domain of human ICOS fused 
to the KDEL peptide. 
2. Demonstration of the expression of ICOS-KDEL-fusion protein in transfected 
mammalian cell line. 
3. Demonstrate the function of the ICOS-KDEL construct in knocking down ICOSL 
expression on transfected cell lines. 
4. Establishment of a cell line that stably express human ICOSL to study the function of 
ICOS-KDEL in knocking down ICOSL on human T cells.  
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3.3 Results 
3.3.1 ICOS expression on human T cell surface  
 
ICOS has been shown to be preferentially expressed by activated T cells (Hutloff et al. 1999). 
Hence, the kinetic of ICOS expression was studied on activated T cell surface at different time 
points. T cells were isolated by a negative selection technique from PBMC using mixture of 
mAbs as; mouse anti-human CD14, CD16, CD19, CD56 antibodies and CD33 beads (section 
2.2.4.2). Isolated T cells were activated using Dynabeads CD3/CD28 (3µl per 2x10
6 
T cells) and 
PHA (5µg/ml). Activated T cells were stained for ICOS surface expression and the data were 
analysed by flow cytometry. In (Figure 11) histograms of ICOS expression by T cells over 4 
days of stimulation show low ICOS expression after 24 hours of T cell activation, followed by 
upregulation with maximum ICOS expression detected after 96 hours (4 days). In the guide of 
these results, activated T cells on day 3 or day 4 were used to extract mRNA to amplify ICOS 
cDNA. 
3.3.2 Cloning of ICOS-KDEL construct 
 
Primers used in cloning of ICOS-KDEL gene were designed to amplify the extracellular domain 
of hICOS (aa 21-139). The restriction enzymes Pst I and Not I recognition sequences were 
included to allow the PCR product to be cloned in frame with the multiple cloning sites (MCS) 
of pCMV/myc/ER plasmid (Figure 12). ICOS was cloned between an upstream CMV promoter 
to permit efficient and high-level of cloned DNA transcription and a downstream ER retention 
signal, KDEL to permit the retention of ICOS protein in the ER.  
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Figure 11. Kinetics of ICOS expression on 
activated T cell 
 T cells were stimulated using Dynabeads 
CD3/CD28 (3µl per 2x10
6 
T cells) and PHA 
(5µg/ml) on day zero of cell culture. Activated T 
cells were stained for ICOS surface expression at  
different time points; 24, 48, 72 and 96 hours and 
the data were analyzed by flow-cytometry. 
Histograms show low ICOS expression level on 
activated T cells after 24 hours. ICOS expression 
level was upregulated to reach the highest 
expression levels after 96 hours.  
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Figure 12. ICOS-KDEL Cloning Strategy into pCMV/myc/ER plasmid 
The extracellular domain of ICOS was cloned in pCMV/myc/ER plasmid between an upstream 
CMV promoter and a downstream ER retention signal. The site where ICOS was inserted was 
denoted by asterisks (*) in the nucleotide sequence map of pCMV/myc/ER. Graphics; 
pCMV/myc/ER map and nucleotide sequence were adapted from Invitrogen product information. 
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3.3.2.1 PCR amplification of human ICOS extra cellular domain  
3.2.2.1.1 Optimization of annealing temperature (Ta) 
 
PCR Ta was optimized to improve ICOS cDNA yield. PCR reactions were carried out for 30 
cycles applying gradient of Ta; 50
0
C, 52
0
C, 54
0
C, 58
0
C and 60
0
C. The amplified PCR products 
were analysed by 2% agarose gel electrophoresis Figure 13. Bright PCR products were detected 
between 300-400 bps [which were consistent with the expected size of ICOS extracellular 
domain (357 bps)] in cDNA samples amplified using the Ta 58
0
C and 60
0
C. A faint PCR product 
was detected at 54
0
C, while no PCR products were detected at 50
0
C and 52
0
C. Accordingly, the 
Ta 58
0
C and 60
0
C were used as the optimum Ta for the PCR amplification of ICOS cDNA. 
3.2.2.1.2 Optimization of MgCl2 concentration 
 
MgCl2 concentration was optimized by conducting PCR reactions using varying concentrations 
of MgCl2 such as: 1, 1.5, 2, 3, 5 and 10 mM at the two optimized Ta 58
0
C and 60
0
C. The PCR 
products were visualized by 2% agarose gel electrophoresis. The appropriate MgCl2 
concentration was chosen according to the brightness of the amplified PCR product visualized on 
the agarose gel (Figure 14). Bright DNA bands were detected between 300-400 bps, consistent 
with the expected size of ICOS extracellular domain (357 bps) and corresponded to ICOS cDNA 
amplification using MgCl2 concentrations 1.5 and 2 mM at Ta 58
0
C and 1, 1.5, 2, 3 and 5 mM at 
Ta 60
0
C. Accordingly, the lowest effective concentration 1.5mM was chosen as the appropriate 
MgCl2 concentration for PCR amplification of ICOS cDNA.             
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Figure 13. Optimization of the Ta for the PCR amplification of ICOS cDNA 
ICOS cDNA prepared from mRNA extracted from activated T cells (for 72 hours) was amplified 
by PCR using five different Ta: 50
0
C, 52
0
C, 54
0
C, 58
0
C and 60
0
C. PCR products were visualized 
by 2% agarose gel electrophoresis. Bright PCR products are detected between 300-400 bps 
which were consistent with the expected size of ICOS extracellular domain (357 bps) in samples 
amplified using the Ta 58
0
C and 60
0
C. A faint PCR product is detected at Ta 54
0
C, while no 
PCR products is detected at Ta 50
0
C and 52
0
C. Hyperladder IV was used as molecular weight 
marker to compare PCR product sizes. 
 
 
 
 
 
 
 
Figure 14.  Optimization of MgCl2 concentration for the PCR amplification of ICOS cDNA 
ICOS cDNA was amplified by PCR using varying concentration of MgCl2; 1, 1.5, 2, 3, 5 and 10 
mM (denoted above the corresponding lanes). PCR amplification was carried out using the two 
optimized Ta 58
0
C and 60
0
 C. PCR products were visualized by 2 % agarose gel electrophoresis. 
Bright bands are detected between 300-400 bps (ICOS extracellular domain= 357 bps) in lanes 
corresponding to ICOS cDNA amplification using MgCl2 concentrations 1.5 and 2 mM at Ta 
58
0
C and 1, 1.5, 2, 3 and 5 mM at Ta 60
0
C. Hyperladder IV was used as molecular weight 
marker to compare PCR product sizes. 
        Ta      500C          520C      540C        580C       600C 
 Ta                   580C                                           600C 
            1       1.5       2        3       5        10        1       1.5      2        3        5     10mM 
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3.3.2.2 Cloning of ICOS –KDEL construct 
 
ICOS cDNA was amplified by PCR using the optimized conditions previously obtained in 
section 3.3.2.1. The amplified ICOS DNA and pCMV/myc/ER plasmid were digested with Pst I 
and Not I restriction endonuclease enzymes. The digested plasmid and ICOS were ligated (as in 
section 2.1.3.6) and the ligation mixture was chemically transformed to DHα competent cells (as 
in section 2.1.3.8). Ten growing colonies were screened for the correct size insert by double 
digestion of the extracted DNA with Pst I and Not I restriction enzymes and the digested 
products were visualized by 1% agarose gel electrophoresis. All of the ten screened digested 
clones contained the correct insert, where two DNA bands were seen from each digested clone 
[Figure 15 (a,b)]. A higher band was detected between 5 - 6 Kbps which was consistent with the 
expected size of the plasmid (5.1 kbps) and a lower band was detected between 300-400 bps 
which was consistent with the expected size of the insert (357bps).   
DNAs from three positive clones were sequenced using the CMV promoter sequencing primers 
and the clone with the correct insert was selected for the rest of this project. That plasmid was 
designated “ICOS-KDEL” (Figure 16).  
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Figure 15. Screening of ICOS-KDEL positive clones 
The amplified ICOS DNA and pCMV/myc/ER plasmid were double digested by Pst I and Not I 
restriction endonuclease enzymes. The digested DNA products were ligated and transformed into 
DHα competent cell. Ten growing colonies were picked and screened for the correct size insert 
by double digestion of the extracted DNA with Pst I and Not I restriction enzymes. The digested 
products were visualized by 1% agarose gel electrophoresis. (a) Screening of nine colonies 
shows two DNA bands; a higher band detected between 6-5 kbps which corresponded to 
pCMV/myc/ER plasmid (expected size 5.1 kbps) and a lower band detected between 300-400 
bps which corresponded to ICOS extracellular domain ( expected size 357 bps). (b) More DNA 
was loaded in clone 10 for better demonstration of the digested DNA.  LI; hyperladder I and 
LIV; hyperladder IV were used as molecular weight marker to compare digested DNA sizes. 
pCMV/myc/ER LI      1     2     3     4     5     6     7      8      9   LIV 
LI       10      LIV PCMV/myc/ER 
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ICOS extracellular 
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400             
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Figure 16. Nucleotide sequence of the 5’ and 3’ ends of ICOS insert in ICOS-KDEL 
construct 
The complete nucleotide sequence of the extracellular domain of human ICOS after been cloned 
in frame into the multiple cloning sites (MCS) of pCMV/myc/ER plasmid using the restriction 
endonuclease enzymes Pst I and Not I. The nucleotide sequence shows the sequences of; ER 
signal peptide, ICOS extracellular domain, myc epitope and ER retention signal 
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3.3.3 Expression of ICOS-KDEL-fusion protein  
 
After ICOS-KDEL construct was cloned, it was necessary to confirm that transfection of the 
mammalian cell with the newly generated construct induced the expression of the KDEL-fusion 
protein. Expression of the 19 kDa ICOS-KDEL protein in the cell lysates of transfected HEK 
293 and D17 cell lines with ICOS-KDEL or pCMV/EGFP (as mock control) was analysed by 
western blotting 48 hours after cells transfection. The transfected cell lysates were probed with 
antibody directed against the human myc epitope incorporated in the construct and the human β-
actin. Expression of ICOS-KDEL was detected relative to cell expression of the 42 kDa β-actin 
housekeeping protein. 
Western blots confirmed that the 19 kDa c-myc tagged ICOS-KDEL was expressed in D17 cells 
[Figure 17 (a)] and HEK 293 cells [Figure 17 (b)] transfected with ICOS-KDEL, predictably, 
the fusion protein was not detected in cells transfected with the pCMV/EGFP. Western blots of 
all transfected cells lysates showed the expression of protein bands at approximately 42 kDa (β-
actin protein expected size 42 kDa) which confirmed appropriate loading of the samples. The 
generated data from the western blots confirmed that ICOS-KDEL-fusion protein of expected 
size was expressed from the cloned construct in transfected mammalian cells. 
 
 
 
 
 
 
 
 
 
 
 
                                                                                                                                             Chapter 3 
120 
 
 
(a) D17 cell line                                 (b) HEK 293 cell line 
 
 
 
 
 
 
 
                                                                                                                                                   
                                 
Figure 17. ICOS-KDEL protein expression by ICOS-KDEL construct 
D17 (a) and HEK (b) cell lines were transfected by ICOS-KDEL or pCMV/EGFP as mock 
control. Cell lysates were prepared from transfected cell after 48 hours of transfection. Cell 
lysates were probed with anti human myc Ab to detect the expression of myc-tagged ICOS-
KDEL and anti human β-actin to confirm proper sample loading. D17 and HEK transfected cells 
lines with ICOS-KDEL construct express protein bands at approximately 19 kDa which are 
consistent with the expected size of ICOS-KDEL protein. All transfected cell lines express β-
actin protein bands which are detected at approximately 42 kDa. Samples were loaded in 
duplicates.   
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3.3.4. Stable cell line expressing human ICOSL 
 
After the expression of ICOS-KDEL-fusion protein in HEK 293 and D17 cells was 
demonstrated, it was aimed to investigate whether transfection of cell expressing ICOSL with the 
ICOS-KDEL construct could down-regulate the surface expression of ICOSL and the function of 
ICOS-KDEL construct in knocking down ICOSL on transfected cells. In the attempts to conduct 
this investigation, CHO-ICOSL (stable cell line expressing ICOSL) was created. 
3.3.4.1 Cloning of human ICOSL  
3.3.4.1.1 Induction of ICOSL expression on the Daudi cell line 
 
ICOSL is constitutively expressed at low levels on resting APCs and non-lymphoid cells such as 
endothelial cells and is upregulated upon cytokine-triggered cellular activation (Swallow et al. 
1999; Yoshinaga et al. 2000). The Daudi cell line (human Burkitt‟s lymphoma cell line) were 
activated using TNF-α (100 ng/ml) and CD40L (50 μl/ml) for 48 hours. Stimulated Daudi cells 
were stained for ICOSL expression and the data were analysed by flow cytometry (Figure 18). 
Daudi cells upregulated ICOSL expression after 24 hour of cytokine stimulation reaching high 
expression levels after 48 hours. In the light of these results, Daudi cells stimulated for 48 hours 
were used to extract mRNA for ICOSL cDNA preparation. 
3.3.4.1.2 PCR amplification of ICOSL DNA  
 
Primers used in cloning of ICOSL gene were designed to amplify ICOSL full length 
(nucleotides; 135-1043). The restriction endonuclease enzymes EcoR I and Not I sequences were 
added to allow the PCR product to be cloned in frame with MCS of pcDNA 3.1(+) plasmid 
(Figure 19). To improve ICOSL cDNA yield, optimization of PCR Ta was carried out by 
applying a gradient of Ta; 51.8 
0
C, 53.5
0
C, 56.4
0
C, 60.3
0
C and 64.3
0
C, and the PCR program 
was set for 30 cycles. The PCR products were visualized by 1% agarose gel electrophoresis. In 
(Figure 20) a PCR product band was detected between 800-1000 bps (expected size of ICOSL 
DNA= 909 bps) at Ta 64.3
0
C, while the bands seen between 400-600 bps at Ta 56.4
0
C and 
60.3
0
C were presumably non specific bands. No PCR products were detected at Ta 51.8
0
C and 
53.5
0
C. From these results, Ta 64.3
0
C was used as the optimum Ta for PCR amplification of 
ICOSL cDNA. 
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Figure 18. ICOSL expression by Daudi cells 
3-5x10
6
 Daudi cells were stimulated with TNF-α (100 ng/ml) and CD40L (50 μl/ml) for 48 
hours. Daudi cells were stained for ICOSL surface expression with anti human ICOSL Ab or 
mouse IgG2b (isotype control) and ICOSL expression was analyzed by flow-cytometry. 
Histograms show that Daudi cells do not constitutively express ICOSL, however ICOSL surface 
expression is slightly up-regulated after 24 hours of cytokine stimulation reaching high level 
after 48 hrs.  
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Figure 19. ICOSL cloning into 
pcDNA3.1
+
 plasmid 
Schematic map shows the negative (-) and 
positive (+) orientation of the pcDNA 3.1 
plasmid. pcDNA3.1(+) orientation was 
used in this study, unless otherwise stated. 
EcoR I and Not I restriction enzymes were 
used in cloning ICOSL DNA in the 
plasmid. Graphics; pcDNA 3.1 map was 
adapted from Invitrogen product 
information. 
 
 
 
 
 
3.3.4.1.3 Cloning of ICOSL into pcDNA 3.1(+) plasmid  
 
The amplified ICOSL DNA (insert) and pcDNA3.1(+) (plasmid) were double digested using 
EcoR I and Not I restriction endonuclease enzymes. The double digested DNAs were ligated and 
the ligation mixture was chemically transformed to DHα competent cells. Seventeen colonies 
were picked and screened for the correct insert by double digestion of the extracted DNA with 
EcoR I and Not I restriction endonuclease enzymes. The products of enzyme digestion were 
visualized by 1% agarose gel electrophoresis (Figure 21). All of the screened 17 colonies, except 
for the 3
rd
 colony, showed a higher band detected between 5-6 kbps which was consistent with 
the expected size of the plasmid (5.4 kbps) and a lower band detected between 800-1000 bps 
which was consistent with the expected size of ICOSL ( 909 bps). The 3
rd
 colony yielded a 
wrong sized insert and was discarded.  DNAs from three positive clones were sequenced using 
the CMV promoter sequencing primers and the correct construct was designated “ICOSL 
construct”.  
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Figure 21. Screening of ICOSL positive 
clones 
Ligation of the double digested ICOSL 
and pcDNA plasmid was carried out and 
chemically transformed in DHα 
competent cells. Seventen clones were 
screened by double digestion of the 
extracted DNA with EcoR I and Not I 
restriction endonuclease enzymes. 
Digestion products were visualized by 1 
% agarose gel electrophoresis. Two DNA 
bands are detected; a higher band is 
detected between 5-6 kbps (consistent 
with the plasmids size 5.1 kbps), another 
lower band is detected between 0.8-1 
kbps (consistent with ICOSL size 909 
bps) as indicated next to each gel. The 
number of the clone is indicated above 
the corresponding lane. The 3
rd
 clone 
yields incorrect insert size.  
             13        14        15         16        17     
Figure 20. Optimization of Ta for the 
PCR amplification of ICOSL cDNA 
ICOSL cDNA was amplified by PCR 
using Ta gradients; 51.8 
0
C, 53.5
0
C, 
56.4
0
C, 60.3
0
C and 64.3
0
C (indicated 
above each lane). The PCR products were 
visualized by 1% agarose gel 
electrophoresis. PCR amplification using 
Ta 64.3
0
C yields PCR product between 
0.8-1 kpbs which was consistent with 
ICOSL expected size = 909 bps. 
Hyperladder I was used as molecular 
weight marker to compare PCR product 
sizes. 
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3.3.4.2 Stable transfection of CHO cells with ICOSL construct 
3.3.4.2.1 Optimization of CHO cells transfection 
 
After ICOSL construct was cloned, a cell line that stably expressed ICOSL was created. CHO 
cell line is a robust cell line that divides rapidly and can propagate as an isolated colony, which 
made the generation of the stable cell line easier and successful. Prior to stable transfection of 
CHO cell line, optimization of transfection conditions was carried out using pCMV/EGFP (a 
plasmid encoding the reporter gene Enhanced Green Fluorescent Protein) or pCMV/myc/ER 
(plasmid with no insert) as mock DNA. CHO cell line was transfected using Lipofectin reagent 
(as described in section 2.3.1.1) and the expression of the EGFP was visualized by deconvolution 
fluorescence microscopy and analysed by flow cytometry 48 hours after cells transfection 
[Figure 22 (a,b)] . The percentage of GFP positive cells was used as a proportional read-out of 
transfection efficiency. The highest CHO transfection efficiency (77%) (as analysed by flow 
cytometry) was obtained by transfecting the cells with 2 µg of pCMV/EGFP DNA at a ratio of 
Lipofectin (µl): DNA (µg) 6:1. The results were shown relative to cell transfected with mock 
control or untransfected cells. These optimized transfection conditions were used later in the 
generation of CHO-ICOSL cell line.  
3.3.4.2.2 CHO ICOSL cell clones 
 
CHO cells were transfected with ICOSL construct using the optimized transfection conditions 
obtained in section 3.3.4.2.1. As ICOSL construct encoded a neomycin resistance gene, G418 
was used to select CHO-ICOSL positive clones. Titration of G418 concentration needed for the 
selection of positive clones was done as described in section 2.3.2.1, where the appropriate G418 
concentration used for selecting CHO-ICOSL clone was 2.5 mg/ml. After 24 hours of CHO 
transfection, G418 (2.5 mg/ml) was added to the transfected cells and untransfected cells 
(negative control) culture. When the un-transfected CHO cells were completely killed, the 
remaining transfected cells were allowed to grow. The mixed cell population was serially diluted 
in 96 well plates to allow the growth of isolated clones. Cell surface expression of ICOSL was 
screened for 48 picked clones by staining cells with anti human ICOSL Ab and mouse IgG2b 
(isotype control) and analyzed by flow cytometry. Ten clones were selected based on their 
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expression of ICOSL that ranged from 50% to 98%. The clones positive for ICOSL expression 
were designated “CHO-ICOSL” (Figure 23). 
(a) 
 
(b) 
 
 
 
 
 
 
Figure 22. CHO cells transfection  
CHO cells were seeded a concentration of 2 x 10
5
/ well overnight in a 6 well plates. The cells 
were transfected with pCMV/EGFP or pCMV/myc/ER (as mock DNA) plasmids using 
Lipofectin reagent in varying ratio of DNA/Lipofectin transfection mixture. (a) Fluorescent 
images captured by deconvolution fluorescence microscope for the highest transfection 
efficiency obtained using 2µg pCMV/EGFP in 12µl Lipofectin after 48 hours of cell 
transfection. Images show CHO cells in the bright field and cells transfected with pCMV/EGFP 
or pCMV/myc/ER using FITC filter. (b) EGFP expression was analysed by flow cytometry after 
48 hours of cell transfection. The gate was set at <2% for the mock transfected cells, this value 
was substracted from the values obtained from cells transfected with EGFP plasmid to give the 
transfection efficiency (percent of EGFP+ve). Histogram shows the highest transfection 
efficiency of CHO cells with EGFP plasmid (77%) as compared to cells transfected with mock 
DNA or untransfected cells. 
 Untransfected CHO cells 
CHO cells transfected with pCMV/myc/ER 
CHO cells transfected with pCMV/EGFP   
 
 
                Bright Field                                     pCMV/EGFP                                    pCMV/myc/ER 
CHO cells 
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Figure 23. CHO-ICOSL clones 
2x10
5
 CHO cells were transfected with ICOSL construct (2 µg) using Lipofectin reagent (12 µl). 
After 24 hours, G418 was added at concentration of 2.5 mg/ml to select the transfected cells. The 
mixed cell population was serially diluted in 96 well plates to give approximately 1 cell per well. 
Growing cell clones were transferred to 24 well plates to allow them to expand. Cells from 48 
selected colonies were stained for ICOSL expression with anti human ICOSL (green line) and 
mouse IgG2b as isotype control (black line) and analysed by flow-cytometry. Ten cell clones are 
selected based on their expression of ICOSL that ranged from 50% to 98%. Positive cell clones for 
ICOSL expression were designated CHO ICOSL cells. Untransfected CHO cell line (not expressing 
ICOSL) is presented at the first histogram. 
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3.3.5 Transfection of CHO ICOSL cells with ICOS-KDEL construct 
 
The next step following the creation of CHO-ICOSL cell line was to investigate the capability of 
ICOS-KDEL construct to down-regulate the surface expression of ICOSL by transfected CHO 
ICOSL cells.  
CHO-ICOSL cells were transfected with ICOS-KDEL construct or pCMV/myc/ER plasmid as 
mock DNA. Cell transfection was carried out using Lipofectin reagent applying the optimized 
transfection conditions in section 3.3.4.2.1. After 48 hours of transfection, cells were harvested 
and stained for ICOSL expression and were analysed by flow cytometry. ICOSL surface 
expression was down-regulated in CHO ICOSL cells transfected with ICOS-KDEL construct in 
comparison to cell transfected with pCMV/myc/ER or untransfected cells (Figure 24). Flow 
cytometric analysis of the mean fluorescence intensity (MFI) of ICOSL expression by 
untransfected, pCMV/myc/ER and ICOS-KDEL transfected cells revealed that ICOSL 
expression was down regulated by 87 % following cell transfection with ICOS-KDEL construct 
compared with cells transfected with pCMV/myc/ER where ICOSL expression remained 
unchanged.   
Although the potential of ICOS-KDEL construct to down regulate ICOSL surface expression on 
CHO-ICOSL was shown, unexpectedly transfection of CHO ICOSL cells with ICOS-KDEL did 
not consistently down-regulate ICOSL surface expression. Furthermore, occasionally ICOSL 
expression was down-regulated following transfection of CHO ICOSL cells with pCMV/EGFP 
plasmid (a plasmid encoding EGFP) as mock DNA (data not shown). This inconsistency of the 
results made drawing conclusions about ICOS-KDEL efficiency to down-regulate ICOSL 
surface expression unfeasible. A possible explanation for the inconsistency in the results was the 
similarity of the transcriptional control of ICOSL and ICOS-KDEL genes, as both genes were 
transcribed by pCMV. Thus, the transcription of ICOS-KDEL gene was probably interfered by 
the transcription of ICOSL gene integrated in CHO ICOSL cell genome. To investigate this 
suggestion transfection of other cell lines expressing ICOSL was carried out. 
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Figure 24. CHO ICOSL cells transfection with ICOS-KDEL Construct 
2x10
5 
CHO ICOSL cells were transfected with ICOS-KDEL construct or pCMV/myc/ER 
plasmid as mock DNA. After 48 hours of transfection, cells were harvested and stained for 
ICOSL surface expression using anti human ICOSL and mouse IgG2b (isotype control), and 
ICOSL expression was analysed by flow cytometry. Histogram shows down-regulation of 
ICOSL surface expression on CHO ICOSL cells transfected with ICOS-KDEL construct as 
compared with control DNA and untransfected cells. Mean fluorescence intensity (MFI) of 
ICOSL expression on untransfected CHO ICOSL cells was 494, cells transfected with 
pCMV/myc/ER was 472 (100%), and in cells transfected with ICOS-KDEL transfection 61 
(13%). 
 
3.3.6 Transfection of THP-1 cell line with ICOS-KDEL construct 
 
As transcription interference between ICOS and ICOSL gene could be the possible explanation 
for the inconsistence results detected with CHO ICOSL cells transfection with ICOS-KDEL 
(section 3.3.5), transfection of a cell line expressing ICOSL under the transcriptional control of a 
promoter different from ICOS-KDEL gene promoter (CMV) was carried out. THP-1 cell line is a 
monocytic cell line that constitutively expresses ICOSL and ICOSL gene is transcribed by 
endogenous ICOSL promoter. Thus THP-1 was thought of to be used to investigate the ability of 
ICOS-KDEL to down regulate of ICOSL surface expression. 
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3.3.6.1 Optimization of THP-1 cells transfection conditions 
 
THP-1 transfection was tried using different strategies as lipid mediated transfection including 
Lipofectin and Lipofectamine 
TM
 2000, but the transfection efficiency was less than 5%.  
Microporation was an alternative method of transfection that was tried. Microporation employs 
the electroporation technology and uses pipette tip-style chamber instead of the usual cuvette 
electrode as the electroporation space (Wang et al. 2009).  
To improve THP-1 cells transfection efficiency, optimization of pulse voltage (v), pulse width 
(ms), pulse number and DNA concentration was carried out. Optimization of transfection was 
conducted using pCMV/EGFP or empty pCMV/myc/ER plasmid as a control. The optimum 
transfection conditions were selected according to EGFP expression analysis by deconvolution 
fluorescence microscope and flow-cytometry after 48 hours of transfection [Figure 25 (a)]. The 
highest transfection efficiency ranged from 25-30 % as analysed by flow cytometry analysis 
(data not shown) compared to cells transfected with empty pCMV/myc/ER plasmid or 
untransfected cells. The highest transfection efficiency was obtained in cell transfected with 10 
µg pCMV/EGFP DNA and applying the following parameters: 1350 v for 40 ms at 2 pulses. 
These parameters were used as the optimal transfection conditions in THP-1 cells transfection.  
3.3.6.2 Transfection of THP-1 cells with ICOS-KDEL construct  
THP-1 cells were transfected with ICOS-KDEL construct and pCMV/EGFP plasmid (as mock 
DNA) using the microporation. 1x10
6
 THP-1 cells were transfected using 10 µg DNA, applying 
the optimized transfection conditions (previously mentioned in section 3.3.6.1). After 48 hours of 
transfection, the cells were harvested and stained for ICOSL, CD14 and CD80 surface 
expression and analysed by flow cytometry. ICOSL expression was down regulated by 27% in 
THP-1 cells transfected with ICOS-KDEL, whereas no ICOSL down regulation was detected in 
THP-1 cells transfected with pCMV/EGFP (mock DNA) as ICOSL surface expression was 
similar to untransfected cell [Figure 25(b)]. In addition, transfection of THP-1 cells with ICOS-
KDEL did not affect the expression of other surface markers as demonstrated by the unchanged 
levels of CD14 and CD80 surface expression relative to mock transfection or untransfected cells. 
ICOSL down-regulation by THP-1 cells transfection with ICOS-KDEL was statistically 
significant and reproducible as it could be obtained from six independent experiments of THP-1 
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cells transfection with ICOS-KDEL construct or mock DNA [Figure 25 (c)]. The data 
demonstrated that ICOS-KDEL construct down-regulated ICOSL surface expression in cell 
transfected with ICOS-KDEL as compared to cell transfected with mock DNA or untransfected 
cells. In addition, ICOSL down-regulation by ICOS-KDEL construct was a specific inhibition to 
ICOSL surface expression as no changes were detected in other cell surface markers.  
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Figure 25. THP-1 cells transfection with ICOS-KDEL 
THP-1 cells were transfected with pCMV/EGFP or pCMV/myc/ER using microporation. To improve 
THP-1 transfection efficiency, optimization of pulse voltage (v), pulse width (ms), pulse number and 
DNA concentration was carried out. EGFP expression analysis by deconvolution fluorescence 
microscope and flow-cytometry was carried out 48 hours after cell transfection. (a) Images captured by 
the fluorescence microscope for THP-1 transfected with pCMV/EGFP using microporation (1350 v, 40 
ms, 2 pulses) and 10 µg DNA after 48 hours of transfection. (b) THP-1 cells were transfected with 
ICOS-KDEL construct or pCMV/EGFP, and the surface expressions of ICOSL, CD14 and CD80 on 
transfected THP-1 were assessed by flow cytometry 48 hours after transfection. Histograms show down-
regulation of ICOSL expression in THP-1 transfected with ICOS-KDEL relative to pCMV/EGFP or 
untransfected cells, while the expression of CD14 and CD80 are unchanged. (c) Results shown are the 
Mean ± SD of MFI of ICOSL expression in THP-1 cells transfected with ICOS-KDEL or pCMV/EGFP 
from six independent experiments. The MFI of the isotype control was substracted from MFI of ICOSL 
to give the corrected MFI. A value of p <0.05 was regarded as statistical significant and denoted by 
asterisk. 
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3.3.7 Transfection of M1DR1 cells with ICOS-KDEL  
 
Data generated from the previous experiments demonstrated the potential of ICOS-KDEL 
construct to induce specific down-regulation of ICOSL surface expression. As M1DR1 cells, a 
human fibroblast cell line stably expressing DR, were aimed to be used as an antigen 
presentation cell model later in this study, transfection of M1DR1 cells with ICOS- KDEL 
construct was carried out.   
Transfection efficiency of M1DR1 cells was optimized using Lipofectin reagent. M1DR1 cells 
were transfected with pCMV/EGFP or pCMV/myc/ER as mock DNA. Transfection efficiency of 
M1DR1 cells was assessed by deconvolution fluorescence microscope and by flow cytometry 48 
hours after transfection. The percentage of GFP positive cells was used as a proportional read-
out of transfection efficiency. The highest transfection efficiency 45% (as analysed by flow 
cytometry) was obtained using 2 µg of pCMV/EGFP at a ratio of lipofectin (µl): DNA (µg) 6:1 
[Figure 26 (a)]. These transfection conditions were used in this study wherever M1DR1 cells 
transfection was carried out. 
M1DR1 cells transfection with ICOS-KDEL or pCMV/EGFP (mock control) was carried out 
using the optimized transfection conditions. The cells were harvested and stained for ICOSL and 
DR surface expression and analysed by flow cytometry 48 hours after transfection. The ICOSL 
surface expression was down-regulated in M1DR1 transfected with ICOS-KDEL relative to 
pCMV/EGFP or untransfected cells 48 hours after transfection [Figure 26 (b)]. Furthermore, 
ICOS-KDEL transfection of M1DR1 cells did not affect DR surface expression relative to 
pCMV/EGFP or untransfected cells. The data generated in this experiment and the previous one 
(section 3.3.6) confirmed the ability of ICOS-KDEL construct to down-regulate ICOSL surface 
expression in two different cell lines. In addition the detected ICOSL down regulation by ICOS-
KDEL was specific to ICOSL without affecting the expression of other surface molecules. 
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Figure 26. M1DR1 cells transfection with ICOS-KDEL Construct 
M1DR1 cells were seeded at 2 x 10
5
/ well in 6 well plates overnight and transfected with 
pCMV/EGFP or pCMV/myc/ER (mock DNA) using varying DNA/Lipofectin transfection 
concentration mixture. The transfection efficiency of M1DR1 was assessed by deconvolution 
fluorescence microscope and flow cytometry 48 hours after cell transfection. (a) Fluorescence 
images captured by deconvolution fluorescence microscope for the highest transfection 
efficiency obtained using pCMV/EGFP (2 µg) with Lipofectin (12 µl) for 48 hours. Histogram 
shows green fluorescence of GFP transfected cells versus cells transfected with mock DNA and 
untransfected cell with 45% transfection efficiency after 48 hours of cell transfection. (b) 
M1DR1 cells were transfected with ICOS-KDEL or pCMV/EGFP. ICOSL and DR surface 
expression was analysed 48 hours after transfection by flow cytometry. Histogram shows down-
regulation of ICOSL in M1DR1 cells transfected with ICOS-KDEL compared to the mock 
transfected cells or untransfected cells. DR expression is not change in M1DR1 cells transfected 
with ICOS-KDEL relative to mock transfection and untransfected cells. 
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3.3.8 ICOS-KDEL-fusion protein is localized in the ER 
 
The capability of ICOS-KDEL to specifically down-regulate ICOSL surface expression was 
shown in THP-1 and M1DR1 cells (section 3.3.6 and 3.3.7). As the principle of ICOS-KDEL 
function based on the retention of ICOS-KDEL protein in the ER, it was important to 
demonstrate that the ICOS-KDEL-fusion protein was ER localized when expressed in the cells 
transfected with ICOS-KDEL construct.   
To demonstrate the ER localization of ICOS-KDEL-fusion protein, confocal microscopy was 
carried out on M1DR1 cells transfected with ICOS-KDEL or pcDNA (used as a negative 
control). Transfected M1DR1 cells were stained with ER green tracker probe for ER staining and 
Alexa Fluor 555 conjugated anti human myc antibody to stain the myc epitope tag incorporated 
in ICOS-KDEL construct. Each fluorescent marker was excited and detected independently to 
avoid any false signals. In (Figure 27), parts A and B (the left panel) show images of the ER 
staining in all conditions of M1DR1 cells exhibiting green perinuclear fluorescence that extend 
towards the periphery of the cell which is a characteristic staining pattern of the ER. Parts C and 
D (the middle panel) show anti- myc staining, where part D correspondes to M1DR1 cells 
transfected with myc-tagged ICOS-KDEL and shows red perinuclear fluorescence with the same 
distribution pattern as the ER staining without staining in any other organelle of the cell. Part C 
correspondes to M1DR1 cells transfected with pcDNA with no myc staining. Parts E and F (the 
right panel) show an overlay of the ER and anti-myc stains. Part F shows clear yellow 
perinuclear fluorescence resulted from merging of the green and red fluorescence, which is 
absent in part E. Overlay analysis by the Leica confocal software gave an overlay efficiency of 
85%. These results suggested that the myc-tagged ICOS-KDEL-fusion protein was expressed and 
correctly localized in the ER as determined by the overlap of the fluorescent markers.  
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Figure 27. ICOS-KDEL-fusion protein is localized in the ER 
M1DR1 cells were seeded at 1 x 105 on cover slips in 24 well plates and the cells were transfected 
with ICOS-KDEL or pcDNA plasmids. 48 hours after transfection, cells were permeabilised, fixed 
and stained with ER green tracker probe (green) [parts A, B] and Alexa Fluor 555 conjugated anti 
human myc antibody (red) [parts C, D].  Each fluorescent stain was excited independently of one 
another and merged to show any colocalization of the two stains [parts E, F]. The ER stain exhibits 
green perinuclear fluorescence extending towards the periphery of the cell, and ICOS-KDEL myc 
tagged protein shows red perinuclear fluorescence with the same distribution pattern as the ER 
staining. Overlapping stains appear as yellow fluorescence in the left column. (G) A zoomed image 
at 40x magnification of ER and myc staining in M1DR1 cells transfected with ICOS-KDEL construct 
and the overlap stains. These pictures represent 10 randomly chosen positions on each slide.  
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3.4 Discussion 
Activation of T cells is a central feature in the immune response which made targeting 
costimulatory molecules to inhibit their stimulatory signals a potential strategy for induction of 
immunological tolerance. In the work presented in this chapter, the creation of the first 
component of the negative vaccine which is related to the development of a strategy to deliver a 
tolerogenic signal was set out. It was aimed to block the ICOS-ICOSL costimulatory pathway by 
an ICOS-KDEL construct. ICOS-KDEL is a fusion protein between human extracellular domain 
of ICOS and the KDEL peptide, a signal peptide which causes retention/retrieval of proteins in 
the ER. The idea of the ICOS-KDEL construct was that ICOS-KDEL protein expressed in the 
transfected cell was expected to be retained in the ER and bind to ICOSL, hence preventing 
ICOSL trafficking to the cell surface. This would lead to the down-regulation/inhibition of 
ICOSL cell surface expression by cells transfected with ICOS-KDEL construct.  
Cloning of ICOS-KDEL construct (section 3.3.2) involved the amplification and the ligation of 
human ICOS extra cellular domain to the KDEL sequence present in pCMV/myc/ER plasmid. 
Human T cells were isolated from peripheral blood and activated by CD3/CD28 beads, and 
ICOS surface expression was analysed by flow cytometry (section 3.3.1). It was shown that low 
level of ICOS expression could be detected after 24 hours of T cell stimulation whereas 
maximum ICOS expression was detected after 96 hours. This result agrees with the published 
data that show that the ICOS-ICOSL pathway provides a necessary costimulatory boost to the 
activated and effector T cell rather than naïve T cell in immune response (Hutloff et al. 1999). 
Activated T cells were used to extract mRNA to produce cDNA used to amplify ICOS 
extracellular domain. Following successful amplification and ligation of ICOS extracellular 
domain into the pCMV/myc/ER plasmid, the construct was sequenced which confirmed the 
correct fusion of the insert in frame with the KDEL sequence (section 3.3.2.2). 
After successful cloning of the ICOS-KDEL construct, the ability of the newly generated KDEL 
construct to produce protein product in transfected cell was demonstrated in section 3.3.3. 
Western blotting data showed that ICOS-KDEL-fusion protein was expressed in two different 
transfected cell lines; HEK 293 and D17 with ICOS-KDEL construct relative to transfection with 
mock DNA. 
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As the construct was confirmed on the basis of sequencing and protein expression, it was decided 
to create a CHO ICOSL stable cell line to be used for the demonstration of the ability of ICOS-
KDEL to down-regulate ICOSL surface expression and to study the functional effect of 
knocking down ICOSL on transfected cells. ICOSL construct was created from ICOSL full 
length cloned into pcDNA plasmid under the transcriptional control of pCMV (section 3.3.4.1). 
Activated Daudi cells expressing ICOSL were used to extract mRNA and generate cDNA that 
was used to amplify ICOSL full length. After successful cloning of ICOSL full length in pcDNA 
plasmid, the correct sequence was confirmed, and ICOSL construct was used to create CHO-
ICOSL stable cell line (section 3.3.4.2). An initial experiment showed ICOSL down-regulation 
in CHO-ICOSL cells transfected with ICOS-KDEL construct as compared to cells transfected 
with mock and untransfected cell (Figure 24). Unexpectedly, the results showed that CHO-
ICOSL transfected with ICOS-KDEL did not consistently down-regulate ICOSL surface 
expression. Furthermore, ICOSL expression was down-regulated, on some occasions, following 
transfection of CHO ICOSL cells with pCMV/EGFP plasmid as mock DNA. At this point, it was 
not possible to demonstrate the ability of ICOS-KDEL to down regulate ICOSL surface 
expression. One possible suggestion to explain this inconsistency was the interference between 
the transcription of ICOS-KDEL gene and ICOSL gene integrated in CHO ICOSL cell genome, 
resulting in the suppression of ICOS-KDEL gene transcription. Consequently, ICOS-KDEL 
protein was not produced and no ICOSL down-regulation could be detected. To investigate this 
suggestion, other cell lines in which ICOSL is transcribed by a different promoter were 
transfected with ICOS-KDEL. 
It has been demonstrated in section 3.3.6 and 3.3.7 that ICOS-KDEL down-regulated ICOSL 
surface expression in THP-1 and M1DR1 cells, after 48 hours of cells transfection with ICOS-
KDEL as compared to mock transfection and untransfected cells. These cells lines constitutively 
expressed ICOSL gene under the transcriptional control endogenous ICOSL promoter. 
Furthermore, transfection of these cells with ICOS-KDEL did not affect the surface expression 
of other cell markers as demonstrated by the unchanged levels of CD14 and CD80 in THP-1 
cells transfected with ICOS-KDEL relative to untransfected and mock transfected cells [Figure 
25 (a)]. Similar results were obtained with M1DR1 cells transfected with ICOS-KDEL where 
DR surface expression did not change relative to untransfected or mock transfected cells 
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[Figure26 (b)].  In the light of these generated data, the ability of ICOS-KDEL construct to 
down-regulate ICOSL surface expression in two different cell lines was demonstrated. In 
addition ICOSL down regulation by ICOS-KDEL was specific to ICOSL without affecting the 
expression of other surface markers.  
The localisation of the ICOS-KDEL protein in the ER was demonstrated using confocal 
microscopic examination of stained ER and myc tagged KDEL-fusion protein in M1DR1 cells 
transfected with ICOS-KDEL (after 48 hours of transfection) or pcDNA (section 3.3.8). 
Confocal microscopy is a very high resolution technique which can produce clear images at high 
magnification. The software on the microscope is also able to overlay two fluorescent stains and 
calculate the co-localisation efficiency. The results suggested that the ICOS-KDEL was retained 
in the ER and not in any other cell organelles as shown by the overlap of the fluorescent images. 
This same cell line, M1DR1, showed down regulation of ICOSL expression by ICOS-KDEL 
construct in section 3.3.7. These results demonstrated that ICOS-KDEL was properly sorted to 
ER in transfected cells where it bound to newly synthesized ICOSL and retained it in the ER.  
The ability of the newly generated ICOS-KDEL construct as regards ICOSL down regulation 
and the correct localization in the ER was shown. These data helped us to explain the unexpected 
data obtained from transfection of the CHO-ICOSL cell line with ICOS-KDEL construct. The 
inability of ICOS-KDEL to down-regulate ICOSL was due to causes that were cell related rather 
than construct related. A suggested explanation of the results was that the transcription of ICOS-
KDEL gene encoded by the plasmid was suppressed by the transcription of ICOSL gene 
integrated in CHO ICOSL cell genome. Gene suppression could have resulted from transcription 
interference between both genes – ICOS-KDEL and ICOSL – as they share the same transcribing 
promoter, pCMV.  In transcription interference (TI), active transcriptional unit suppresses gene 
transcription by another unit (Eszterhas et al. 2002; Shearwin et al. 2005). TI could result from 
the competition between the promoters for the same transcription factors, producing imbalance 
between the transcriptions of both genes. It has been reported that binding of one promoter with 
RNA Polymerase (RNAP), that is responsible for initiation of gene transcription, could prevent 
RNAP binding to another promoter (Shearwin et al. 2005). In support of this suggestion, a study  
demonstrated that two genes – GFP and YFP – transcribed by two independent identical 
transcription unit (composed of CMV promoter and SV40 large T antigen polyadenylation 
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signal) suppressed each other expression with varying degree in transfected cells (Eszterhas et al. 
2002). This suppression of gene expression was detected whether both genes were integrated in 
the cell genome or one gene was integrated and the other transiently expressed (similar to the 
case in this study). Eszterchas et al study demonstrated that only 5% of transfected cells 
expressed the transiently transfected gene while the integrated gene expression was not affected 
or slightly suppressed (Eszterhas et al. 2002). In support to our suggestion, the data generated in 
section 3.3.6 and 3.3.7 showed that transfecting cells that constitutively express ICOSL with 
ICOS-KDEL down-regulated ICOSL surface expression. In these cells, ICOSL gene is 
transcribed by endogenous ICOSL promoter, which may explain the absence of transcriptional 
interference with the ICOS-KDEL gene transcription by pCMV. Consequently in these cells, 
ICOS-KDEL-fusion protein was properly transcribed and down-regulated ICOSL surface 
expression.  
Overall this chapter set out to an ICOS-KDEL construct that has the potential to down-regulate 
ICOSL surface expression by cell transfected with ICOS-KDEL. For complete assessment of the 
function of the newly generated ICOS-KDEL construct, a more in depth functional analysis of 
the role of ICOSL down-regulation on T cell proliferation should be performed. The ICOS-
KDEL construct was used in the negative-vaccine construction described in the following 
chapter.  
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For Antigen Presentation via Indirect 
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4.1 Introduction  
The aim of this study was to develop a negative-vaccine to induce tolerance specifically to 
indirect allorecognition pathway. The first component of this DNA vaccine related to the 
development of a strategy that can induce tolerance was discussed in chapter 3. In this chapter 
the second component of the DNA vaccine related to the developing of a strategy to provide the 
antigen that can be recognized by allospecific T cells via indirect pathway will be investigated. 
The strategy employed in this thesis was an Ii chain construct in which the CLIP was replaced by 
immunodominant alloantigen-derived peptide, Ii-peptide fusion construct. This strategy is 
expected to ensure efficient presentation of alloantigen that can be recognized by the antigen 
presentation pathway. 
Several approaches were applied for alloantigens presentation by the host APCs via indirect 
pathway. Of these approaches was T cell priming by immunization using synthetic immunogenic 
MHC derived peptides introduced either through systemic injection (Chen et al. 1996; Waaga et 
al. 1998) or as peptide-pulsed host APCs (Garrovillo et al. 1999) which induced acquired 
tolerance to allograft via indirect allorecognition pathway. Another approach introduced 
allogeneic lysate-pulsed host DC that was treated with pharmaceutical agents as Rapamycin 
(Rapa-DC) (Taner et al. 2005) or cyclosporine A (CsA) and anti-lymphocyte serum in 
transplantation models (Kuo et al. 2009). T cells primed by treated allogeneic lysate-pulsed host 
DC showed hypo-responsiveness to subsequent challenge via both the direct and indirect 
pathways in antigen-specific manner and promoted graft survival. Modified DCs derived from 
F1 hybrid (LEW X AUG) rat co-expressed both donor and self MHC molecule that when 
transplanted to LEW rat in kidney transplant led to the emergence of a peripherally induced 
tolerance specifically to the indirect pathway of alloresponse (Mirenda et al. 2004). These 
approaches are effective experimentally, however, the problem with these approaches hides in 
the difficulty to use them in clinical sessions. These difficulties include immunogenicity of the 
used products, inefficient antigen uptake and presentation and batch to batch inconsistency. 
In this project an alternative approach was investigated which was the use of a fusion protein 
between immune-dominant MHC class I epitope and Ii chain of MHC class II. The fused 
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allogenic peptide is expected to be presented in the context of MHC class II APCs to CD4
+
 T 
cell.  
4.1.1 Ii-peptide Fusion Construct  
 
The chaperone molecule Ii is critical for the proper assembly of MHC class II αβ heterodimers in 
the ER and their transport into the endocytic pathway (Claesson et al. 1983; Wolf and Ploegh 
1995). In the ER, Ii complexes with MHC class II αβ dimers to form a nonameric (αβIi)3 
complex that itself is incapable of binding peptide. The CLIP peptide which is a part of  Ii chain 
binds to MHC class II peptide binding groove, preventing the loading of antigenic peptides in the 
ER (Riberdy et al. 1992; Romagnoli and Germain 1994; Ghosh et al. 1995). During antigen 
processing, the Ii is proteolytically degraded in the endosomal/lysosomal compartments (MIIC), 
producing an intermediate complex, αβCLIP molecules. The release of CLIP, which binds to 
MHC class II with relatively low affinity, allows the peptide loading of class II molecules which 
is catalyzed by HLA-DM (H-2M in mice) in the acidic MIIC environment (Fling et al. 1994; 
Wolf and Ploegh 1995; Jensen et al. 1999)  
Several strategies employed MHC class II trafficking pathway to load a specific peptide onto 
MHC-class II molecules. These include constructing a fusion protein between OVA peptide to 
the C-terminal end of Ii which allowed the intracellular binding of the peptide to MHC-class II 
and the generation of peptide-MHC-class II complex that induced MHC class II restricted T cell 
activation in vitro (Sanderson et al. 1995; Diebold et al. 2001). Other study groups constructed 
fusion protein utilizing the lysosomal-associated membrane protein LAMP-1 sorting signal that 
targeted the human papillomavirus 16 E7 (HPV-16 E7) (Wu et al. 1995) or lymphocytic 
choriomenigitis virus (LCMV) derived glycoprotein (Holst et al. 2008; Grujic et al. 2009) into 
the endosomal/lysosomal compartments, where the antigens were processed and presented to 
CD4
+
 T cells. Another in vitro study used a peptide spacer that covalently linked between 
antigenic peptide and the N terminus of the MHC class II β chain or peptide spacer that linked 
between the C terminus of a truncated β chain and the N terminus of full-length DR α chain such 
that these covalently attached peptide occupied virtually all MHC-class II molecules in cells 
(Zhu et al. 1997). 
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In addition previous work has demonstrated that if the CLIP sequence was replaced by an 
antigenic peptide, antigens were efficiently loaded onto the MHC class II molecule (Fujii et al. 
1998; Bonehill et al. 2003; Gregers et al. 2003). This efficient antigen loading is probably 
because the high affinity nature of the interaction between the peptide loaded in the ER and the 
MHC class II binding groove. In our lab, murine Ii chain with the CLIP replaced by sequence 
encoding the OVA328-339 peptide (HAAHAEINEAGR) showed efficient presentation to murine 
antigen specific T cells (Miss Jennifer Harper PhD). Taking advantage of this approach, a plan 
was established to create Ii chain with the CLIP replaced with donor derived MHC peptide.  The 
theme of this Ii-peptide fusion protein was that the fused epitope is expected to be presented in 
the context of MHC class II of recipient APCs to recipient CD4
+
 T cell – recognized by the 
indirect allorecognition pathway.  
4.2 The aims of this chapter 
 
The experiments described in this chapter were designed to achieve three main aims;  
1. Construction of the Ii peptide fusion construct where the CLIP was replaced by MHC 
class I peptide, which can provide the antigen to be recognized by the responding cells. 
2. Construction of a bicistronic construct that combine the two main thesis strategies, the 
KDEL (as immunomodulator to induce tolerance) and Ii-CLIP replaced peptide (which 
provides antigen that can be recognized by T cells via indirect pathway).  
3. Investigate the capability of the bicistronic vector strategy to induce T cell 
hyporesponsiveness in an Ag specific manner.     
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4.3 Results 
4.3.1 Cloning of Ii-peptide fusion constructs  
 
Four different Ii isoforms in human are known; p33, p35, p41 and p43 (Strubin et al. 1986; 
O'Sullivan et al. 1987), and because of the predominance of p33 isoform of the human Ii chain, it 
was used in Ii-peptide cloning work. The p33 isoform is 216 aa long and referred to as p33 in 
human (and often termed p31 in mouse) based on its apparent molecular mass (Claesson et al. 
1983). 
4.3.1.1 pCMV-Ii-A2 
 
The first Ii-peptide fusion construct (pCMV-Ii-A2) was designed to substitute the CLIP sequence 
of the Ii chain with the immunodominant domain of HLA-A2103-120. This Ii-peptide fusion gene 
was cloned into pcDNA3.1(+) plasmid. 
4.3.1.1 Identification of CLIP and HLA-A2 immunodominant domain sequence  
In the Ii-peptide fusion construct designed in this section, the CLIP sequence was substituted 
with the immunodominant domain of HLA-A2 restricted by HLA-DRB1*1502. The CLIP region 
corresponded to 81–104 aa residues in p33 isoform of the human Ii peptide (Riberdy et al. 1992; 
Bijlmakers et al. 1994; Castellino et al. 1997; Doebele et al. 2003), and HLA-A2 sequence 
corresponded to the aa residues 103-120 (Loffler et al. 1998; Frasca et al. 2000). Figure 28 
shows schematic representation of the constructed Ii-A2 fused gene where the CLIP region 
coding sequence was replaced by HLA-A2103-120 sequence. 
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                                                                   (a) 
 
(b) 
 
 
 
 
 
 
 
 
 
 
 
                                                               
 
 
 
 
 
Figure 28. Schematic representation of pCMV-Ii-A2 cloning 
(a) Nucleotide sequence of the 5‟ and 3‟ ends of the MHC-class II Ii chain full length. The 
starting coding sequence atg (M) and the terminal coding sequence tga (stop codon) are in green. 
The sequence written in blue corresponds to CLIP region coding sequence. (b) HLA-A2 
immunodominant domain nucleotides sequence are written in purple. (c) The complete 
nucleotides sequence of Ii after replacing the CLIP with HLA-A2103-120 domain and designated 
Ii-A2 fusion gene. 
MHC-class II invariant Chain (CD74) mRNA 
cagggtcccagatgcacaggaggagaagcaggagctgtcgggaagatcagaagcca
gtcatggatgaccagcgcgaccttatctccaacaatgagcaactgcccatgctgggccg
gcgccctggggccccggagagcaagtgcagccgcggagccctgtacacaggcttttcc
atcctggtgactctgctcctcgctggccaggccaccaccgcctacttcctgtaccagcagc
agggccggctggacaaactgacagtcacctcccagaacctgcagctggagaacctgcg
catgaagcttcccaagcctcccaagcctgtgagcaagatgcgcatggccaccccgct
gctgatgcaggcgctgcccatggagccctgccccaggggcccatgcagaatgccacc
aagtatggcaacatgacagaggaccatgtgatgcacctgctccagaatgctgaccccctg
aaggtgtacccgccactgaaggggagcttcccggagaacctgagacaccttaagaaca
ccatggagaccatagactggaaggtctttgagagctggatgcaccattggctcctgtttga
aatgagcaggcactccttggagcaaaagcccactgacgctccaccgaaagagtcactgg
aactggaggacccgtcttctgggctgggtgtgaccaagcaggatctgggcccagtcccc
atgtga 
 
HLA-A2 immunodominant domain 
gtggggtcggactggcgcttcctccgcgggtaccac
cagtacgcctacgacggc 
MHC-classII  Ii Invariant Chain with HLA-A2 (Ii-A2)            
cagggtcccagatgcacaggaggagaagcaggagctgtcgggaagatcagaagccagtcatg
gatgaccagcgcgaccttatctccaacaatgagcaactgcccatgctgggccggcgccctgggg
ccccggagagcaagtgcagccgcggagccctgtacacaggcttttccatcctggtgactctgctc
ctcgctggccaggccaccaccgcctacttcctgtaccagcagcagggccggctggacaaactga
cagtcacctcccagaacctgcagctggagaacctgcgcatgaaggtggggtcggactggcgctt
cctccgcgggtaccaccagtacgcctacgacggcgagccctgccccaggggcccatgcagaat
gccaccaagtatggcaacatgacagaggaccatgtgatgcacctgctccagaatgctgaccccct
gaaggtgtacccgccactgaaggggagcttcccggagaacctgagacaccttaagaacaccatg
gagaccatagactggaaggtctttgagagctggatgcaccattggctcctgtttgaaatgagcagg
cactccttggagcaaaagcccactgacgctccaccgaaagagtcactggaactggaggacccgt
cttctgggctgggtgtgaccaagcaggatctgggcccagtccccatgtga   
 
Ii Ii HLA-A2 
Ii Ii CLIP 
HLA-A2 
CLIP 
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4.3.1.2 Cloning of pCMV-Ii-A2 using SOE-ing - PCR approach 
 
Cloning of HLA-A2103-120 into Ii chain was achieved using splicing by overlap extension by the 
polymerase chain reaction (SOEing - PCR) approach (Horton et al. 1993) This procedure allows 
the introduction of a short sequence into a target DNA without the need to introduce novel 
restriction sites. Cloning of Ii-peptide fusion gene was carried out through several stages;  
(A) First stage: Oligonucleotides synthesis 
 
(I) Primers design 
Four primers were designed (described in section 2.1.3.3) where Ii fwd and Ii rev primers 
flanked the Ii chain sequence and added Xho I and Xba I endonuclease restriction sites at the 5‟ 
and 3‟ end of Ii-A2 fusion protein, respectively. The Ii-A2 fusion fwd and rev primers encoded 
the HLA-A2103-120 sequence. An overlapping complementary nucleotides sequence were 
included in the Ii-A2 fusion fwd and rev primers, which corresponded to the middle 18 bps of the 
HLA-A2103-120 sequence. This was designed to allow the DNA segments obtained from the first 
stage PCR reaction to anneal when mixed in the second stage which was the gene assembly. 
These overlapped nucleotides acted as primers for the extension of the complementary strand.  
 
(II) PCR synthesis of Ii replaced CLIP with HLA-A2103-120  immunodominant sequence 
 
Ii cDNA, prepared from mRNA extracted from Daudi cells, was amplified by PCR using the 
four previously designed primers. The 1
st
 PCR product (which corresponded to the starting 
sequence of Ii chain till the beginning of the CLIP sequence and the first 12 bases of the HLA-
A2103-120) was amplified using Ii fwd and Ii-A2 fusion rev primers. The 2
nd
 PCR product (which 
corresponded to the last 12 bases of HLA-A2103-120 and Ii chain sequence starting after the CLIP 
sequence to the Ii chain terminal sequence) was amplified using Ii-A2 fwd and Ii-rev primers. 
Optimization of the Ta was carried out for the both PCR reactions using gradients of Ta; 54.2
0
C, 
55.9
0
C, 58.2
0
C, 60.2
0
C and 61.8
0 
C and the PCR products were visualized by 1.5% agarose gel 
electrophoresis to check the correctly amplified segments. In (Figure 29) two groups of DNA 
bands were detected from the PCR amplification between 300-400 bps. The first group of bands 
represented the 1
st
 PCR product with expected size 344 bps, and the second group of bands 
represented the 2
nd
 PCR product with expected size 387 bps. Compared to the intensities of the 
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bands, the two Ta 58.2
0
C and 60.2 
0
C where used as the optimum Ta later in the gene assembly. 
PCR products were extracted and purified to be used as templates for the following step.  
 (B) Second Stage: Gene assembly & Amplification of the full length of Ii-A2 fusion gene 
This stage was subdivided into two steps;  
(I) Gene assembly; both purified and unpurified first stage PCR products were mixed together 
in an asymmetric PCR reaction where no primers were used in this step. The overlapped 
nucleotides between the two amplified DNA segments acted as primers for the extension of the 
complementary strand. The asymmetric PCR reaction was carried out for 10 cycles to allow the 
overlapping complementary DNA segments to partially anneal and produce the second stage 
PCR product. 
 
(II) Amplification of the second stage PCR product; The PCR mixture resulted from the gene 
assembly stage was used in a regular PCR reaction using the Ii fwd and rev primers, which 
flanked the Ii chain sequence, for 30 cycles at the optimized Ta 58.2
0
C and 60.2
0
C. PCR 
products were visualized by electrophoresis on 1% agarose gel. (Figure 30) shows PCR products 
bands detected between 700-800 bps which were consistent with the expected size of Ii-A2 
(expected size = 713bps).   
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Figure 29. First stage PCR products of Ii-A2 cloning by SOEing - PCR 
Ii cDNA was amplified in two separate sets of PCR using the Ii-A2 fusion gene cloning primers, 
applying gradient of Ta; 54.20C, 55.90C, 58.20C, 60.20C and 61.80C (denoted above the 
corresponding lanes). PCR products were then visualized on 1.5% agarose gel electrophoresis. The 
two first-stage PCR products were detected between 300-400 bps. A group of bands on the left 
obtained from PCR reaction using Ii fwd and Ii-A2 fusion rev primers, which corresponded to the 1st 
PCR product (expected size = 344 bps). On the right, the bands obtained from the PCR reaction using 
Ii-A2 fusion fwd and Ii-rev primers and corresponded to the 2nd PCR product (expected size = 387 
bps).  L= Hyper ladder IV was used as DNA molecular weight marker. 
 
 
 
 
 
 
 
Figure 30. Second stage PCR products of Ii-A2 cloning by SOEing - PCR 
The first stage PCR products were used as a template for the second stage gene assembly and 
amplification. Asymmetric PCR reaction was set out using purified and unpurified first stage PCR 
products. No primers were used in the gene assembly step and the reaction was run for 10 cycles. A 
regular PCR reaction was then set out, where Taq polymerase, dNTPs, MgCl2, NH4 buffer, ddH2O 
and the Ii fwd and rev primers were added. The reaction was run for additional 30 cycles using the 
two optimized Ta; 58.20C and 60.20C. PCR products were visualized by 1% agarose gel 
electrophoresis. Bands were detected between 700-800 bps which corresponded to the full length of 
Ii where CLIP was replaced by HLA-A2103-120, Ii-A2 (expected size = 713bps). The PCR reactions 
were done in duplicate. P: purified, Unp: unpurified PCR product, L: hyperladder IV was used as 
DNA molecular weight marker. 
54.2   55.9    58.2   60.2    61.8   54.2   55.9    58.2   60.2  61.8   LIV 
 
Ta         58.2 0C                 60.20C 
P            Unp           P           Unp             LIV 
Ii-A2         
713 bps 
2nd PCR product                     
387bps 
 
1st PCR product                     
344bps 
 
Size                    
in bps  
    
800 bps                           
700 bps 
Size      
in bps 
 
400 bps                           
300 bps 
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(C) Third stage: Cloning of the pCMV-Ii-A2 
The final step in the construction of Ii-A2 fusion gene was cloning of the assembled DNA into a 
plasmid. The amplified Ii-A2 DNA was cloned into pcDNA 3.1(+) plasmid [Figure 31 (a)], 
where both the insert and the plasmid were double digested using Xho I and Xba I restriction 
enzymes, and the ligation mixture was chemically transformed to DHα competent cells. More 
than 50 colonies were screened but only one band was detected and the ligated insert could not 
be demonstrated [Figure 31 (b)].  
In [Figure 31 (b)], ten of the screened colonies – 2, 3, 5 and 13-19 – had DNA band size at a 
higher position compared to the remaining screened colonies. This discrepancy of DNA sizes 
suggested the presence of an additional insert. To confirm the presence of Ii-A2 insert, PCR 
amplification of Ii using Ii fwd and rev primers, flanking the Ii chain full sequence, was 
conducted for the ten suspected colonies and visualized by 1% agarose gel electrophoresis. The 
products of the Ii chain PCR amplification in these colonies showed a band between 600-800 bps 
which was consistent with the Ii-A2 band expected size 713 bp [Figure 31 (c)]. This verified that 
the ligation process was successfully conducted but the ligated insert could not be demonstrated 
by enzyme digestion. This was caused by the inability of Xba I restriction enzyme to digest the 
DNA to reveal the insert (data not shown). This was due to blocking of the Xba I restriction site 
by the overlapping Dam methylation. The methylation of Adenine in the sequence GATC by the 
enzyme DNA adenine methyltransferase (Dam) overlaps the endonuclease recognition site of 
Xba I and blocks the restriction endonuclease cleavage (Geier and Modrich 1979). Blocking of 
Xba I occurs if the recognition site is preceded by GA (to create gaTˆCTAGA) or followed by 
TC (to create TˆCTAGAtc) (which was in the Ii-A2 sequence), where Dam methylase the 
adenine in the GATC sequence and overlapped the Xba I recognition site and blocked it. Dam 
methylation blocking could be avoided by using Dam deficient E-coli strains where the Xba I 
would not be inhibited. DNA was extracted from the positive colonies, purified and was 
sequenced using the primers for T7 promoter (fwd) and BGH sequence (rev). The correct 
sequences were confirmed and the construct was designated “pCMV-Ii-A2” construct (Figure 
32).  
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(a)                                                                           (b) 
                                                         
                                                                           (c) 
 
 
 
 
 
 
Figure 31. pCMV-Ii-A2 Cloning                                                                                        
Ii-A2 insert was ligated into (a) pcDNA plasmid where Xho I and Xba I endonuclease restriction sites 
were at 5‟ and 3‟ ends respectively. (b) Screening of 50 clones (23 clones are shown) was done to 
select the positive clone with the correct insert. The digested clones were visualized by 1% agarose 
gel electrophoresis which revealed only one DNA band in all the clones due to improper DNA 
digestion. Ten clones: 2, 3, 5, and 13-19 (pointed by white arrow head) were at higher position than 
the other bands which suggested the presence of additional insert. (c) PCR amplification of Ii chain 
using Ii fwd and rev primers was conducted for the suspected clones and the PCR products were 
visualized by 1% agarose gel electrophoresis. A band was detected between 600-800 bps, which 
corresponded to Ii-A2 insert (expected size =713bps) in the tested clones. The number of the clone is 
denoted above each corresponding one.  The hyperladder I was used as DNA molecular weight 
marker. Graphics; pcDNA map was adapted from the Invitrogen product information. 
1      2     3    4      5     6      7      8    9   10     11   12   LI 
   13   14   15   16   17   18   19   20   21   22 
Ii-A2 
(713bps) 
 13    14     15    16    17   18     19      1      2       3      5 
Size           
(bps) 
800                      
600  
Ii-A2 
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Figure 32. Nucleotide Sequence of the 5’ and 3’ ends of the pCMV-Ii-A2 plasmid. 
The complete nucleotides sequence of pCMV-Ii-A2 plasmid, showing the restriction 
enzymes Xho I and Xba I at the 5‟ and 3‟ end respectively. Ii nucleotides sequence with 
HLA-A2103-120 domain in replace of the CLIP is displayed. 
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4.3.1.2 pCMV- Ii-HA cloning 
 
The control Ii-peptide fusion construct was designed where the CLIP sequence in the Ii chain 
was replaced by the haemagglutinin peptide (HA) and cloned into pcDNA plasmid. (Figure 33) 
shows schematic representation of the constructed Ii-HA fused gene where the CLIP region 
coding sequence was replaced by HA peptide. 
The control Ii-peptide fusion gene using HA peptide (aa sequence = PKYVKQNTLKLAT) was 
constructed in the same way as Ii-A2 using SOEing - PCR technique, following the same steps 
as previously mentioned in section 4.3.1.2. In the primer design step, Ii-HA fusion fwd and rev 
primers were designed with an overlapping complementary nucleotides of 20bps in HA 
nucleotides sequence to help in the gene assembly step. 
Amplification of the two first stage PCR products was conducted in similar manner as with Ii-A2 
cloning. In [Figure 33 (a)], 1% agarose gel electrophoresis shows bands between 300-400 bps 
which corresponded to the 1
st
 PCR product with expected size = 342 bps (left panel) and the 2
nd
 
PCR product with expected size = 376 bps (right panel). The two PCR products were used for Ii-
HA gene assembly and amplification. In [Figure 34 (b)], 1% agarose gel electrophoresis shows a 
band between 600-800 bps which corresponded to Ii-HA full length with expected size of 698 
bps. 
Cloning of the Ii-HA fusion gene was done following the same steps as with Ii-A2 cloning into 
pcDNA3.1(+) plasmid. Screening for positive clones containing the plasmid with the correct 
insert was done by DNA digestion. DNA extracted from the clones was digested by Afl III 
endonuclease restriction enzyme with the recognition sequence (ACRYGT), where R is either A 
or G and Y is either C or T. The restriction recognition sequence was present in HA peptide 
sequence which was “ACACGT” and at another two positions in the pcDNA3.1(+) plasmid 
(229, 3616 bps). DNA digestion by Afl III expected to reveal three DNA fragments: 2980, 2041 
and 1107 bps. Twenty two colonies were screened and the digested products were visualized by 
1% electrophoresis agarose gel [Figure 34 (c)].  Gel electrophoresis showed that three colonies 
had the three DNA bands detected between 1-3 kbps corresponded to the three predicted DNA 
fragments. DNAs extracted from the positive clones were sequenced and the correct construct 
was designed pCMV-Ii-HA.  
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                                                                (a) 
 
 
(b) 
 
 
 
 
 
 
 
 
 
 
                                                                  (C) 
 
 
 
 
 
 
 
Figure 33. Schematic representation of pCMV-Ii-HA cloning 
The nucleotides sequence of the 5‟ and 3‟ ends of the MHC class II-Ii full length. The starting 
coding sequence atg (M) and the terminal coding sequence tga (stop codon) are in green. The 
sequence written in blue corresponds to CLIP region coding sequence, (B) HA nucleotides 
sequence in purple. (C) The complete nucleotides sequence of Ii chain after replacing CLIP with 
HA domain and designated Ii-HA fusion gene. 
MHC-class II invariant Chain (CD74) mRNA  
cagggtcccagatgcacaggaggagaagcaggagctgtcgggaagatcagaagcca
gtcatggatgaccagcgcgaccttatctccaacaatgagcaactgcccatgctgggccg
gcgccctggggccccggagagcaagtgcagccgcggagccctgtacacaggcttttc
catcctggtgactctgctcctcgctggccaggccaccaccgcctacttcctgtaccagca
gcagggccggctggacaaactgacagtcacctcccagaacctgcagctggagaacct
gcgcatgaagcttcccaagcctcccaagcctgtgagcaagatgcgcatggccaccc
cgctgctgatgcaggcgctgcccatggagccctgccccaggggcccatgcagaatgc
caccaagtatggcaacatgacagaggaccatgtgatgcacctgctccagaatgctgacc
ccctgaaggtgtacccgccactgaaggggagcttcccggagaacctgagacaccttaa
gaacaccatggagaccatagactggaaggtctttgagagctggatgcaccattggctcct
gtttgaaatgagcaggcactccttggagcaaaagcccactgacgctccaccgaaagagt
cactggaactggaggacccgtcttctgggctgggtgtgaccaagcaggatctgggccc
agtccccatgtga 
 
Haemagglutinn peptide 
cccaagtatgttaagcaaaacac
gttaaagttggcaaca 
Ii Ii 
Ii CLIP 
HA 
MHC-classII  Ii Invariant Chain with HA (Ii-HA) 
cagggtcccagatgcacaggaggagaagcaggagctgtcgggaagatcagaagcca
gtcatggatgaccagcgcgaccttatctccaacaatgagcaactgcccatgctgggccg
gcgccctggggccccggagagcaagtgcagccgcggagccctgtacacaggcttttc
catcctggtgactctgctcctcgctggccaggccaccaccgcctacttcctgtaccagca
gcagggccggctggacaaactgacagtcacctcccagaacctgcagctggagaacct
gcgcatgaagcccaagtatgttaagcaaaacacgttaaagttggcaacagagccct
gccccaggggcccatgcagaatgccaccaagtatggcaacatgacagaggaccatgt
gatgcacctgctccagaatgctgaccccctgaaggtgtacccgccactgaaggggagct
tcccggagaacctgagacaccttaagaacaccatggagaccatagactggaaggtcttt
gagagctggatgcaccattggctcctgtttgaaatgagcaggcactccttggagcaaaag
cccactgacgctccaccgaaagagtcactggaactggaggacccgtcttctgggctgg
gtgtgaccaagcaggatctgggcccagtccccatgtga 
 
CLIP 
Ii 
HA 
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(a) 
 
 
 
(b)                                
 
 
 
 
(c)   
 
 
 
 
 
 
Figure 34. pCMV-Ii-HA cloning 
(a)PCR synthesis of Ii with the CLIP replaced with HA. Using the designed cloning primers, two 
separate sets of PCR were conducted applying gradient of Ta; 58, 60, 61.2, 63 and 64.20C (denoted 
above the lanes). Two sets of bands were detected; the left group corresponds to the 1st PCR product 
(expected size = 342 bps) and the right group corresponds to the 2nd PCR product (expected size = 
376 bps). (b) Gene assembly and amplification of Ii-HA full length. The DNAs obtained from the 
first stage PCR reactions were assembled and amplified then visualized by 1% agarose gel 
electrophoresis. The bands were detected between 600-800 bps (Ii-HA expected size = 698 bps). (c) 
Screening of pCMV-Ii-HA positive clones. Ii-HA insert was ligated into pcDNA3.1(+) plasmid and 
22 clones were screened for clones with the correct insert. Extracted DNA was digested by Afl III 
enzyme and visualized by 1% agarose gel electrophoresis. Three clones (indicated by white arrows) 
showed three DNA fragments between 1-3 kps (expected sizes of the DNA fragments are = 2980, 
2041 and 1107 bps). 
  L 
    L     58  60  61.2  63  64.2             60  61.2  63  64.2     L 
 
     LIV          Ta   600C                  61.20C                     LI 
Ii-HA 
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800 bps           
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  Size 
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1
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Ta 
                                                                                                                                             Chapter 4 
156 
 
4.3.2 Expression of Ii-peptide fusion genes constructs 
 
Following the pCMV-Ii-A2 and -HA cloning, each construct was examined for appropriate Ii-
peptide fusion protein expression by western blotting. HEK 293 and D17 cells were transfected 
with pCMV-Ii-A2 and M1DR1 cells were transfected with both pCMV-Ii-A2 or –HA plasmids. 
All the cell lines were transfected with pcDNA plasmid with no insert as mock control. 
Transfected cells were cultured for 48 hours and the expression of the 33 kDa Ii-fusion protein in 
the cell lysates was determined by western blotting. The cell lysates were probed with both 
mouse anti-human Ii Ab to detect the expression of Ii protein in transfected cells and with mouse 
anti-human β-actin Ab to detect β-actin as a housekeeping protein.  
The western blot shown in [Figure 35 (a,b)] confirmed that the cells transfected with pcDNA 
plasmid did not express human Ii chain protein, as there was no detectable band on the SDS gels. 
In addition, cells transfected with pCMV-Ii-A2 or -HA expressed a protein band at 
approximately 33 kDa which corresponded to Ii-peptide fusion protein. Furthermore, the 
transfected cells showed a single protein band at approximately 42 kDa corresponded to β-actin 
protein which confirmed appropriate loading of the samples. The previously presented western 
blotting data established that the newly generated constructs expressed the Ii-peptide fusion 
proteins at the expected sizes in the transfected cells. 
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 (a) 
 
 
 
  
 
 
 (b) 
 
                    
 
 
 
Figure 35.  Ii-peptide fusion protein expression by pCMV-Ii-A2 and –HA constructs  
HEK 293 and D17 cells were transfected with pCMV-Ii-A2 or pcDNA plasmid as a mock 
control, and M1DR1 cells were transfected with pCMV-Ii-A2, -HA or pcDNA plasmid. 
Transfection was done using Lipofectin: DNA at a ratio 6:1 for 48 hours. Transfected cells were 
processed and cell lysates were probed with mouse anti-human Ii Ab and anti-human β-actin Ab 
after 48 hours of cells transfection. (a) HEK 293 and D17 express protein bands at approximately 
33 kDa which were consistent with the expected size of the Ii fusion protein (samples were 
loaded as duplicates). (B) M1DR1 cells transfected with pCMV-Ii-A2 or -HA constructs express 
protein bands at the expected size of the Ii chain 33 kDa. The expression of Ii-fusion proteins is 
shown relative to the β-actin protein as a control housekeeping protein which is detected at 
approximately 42 kDa, as expected. 
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4.3.3 M1DR1, a cell model for antigen specific presentation  
 
To investigate the thesis strategy and save the use of DCs for the main experiments, a cell model 
for antigen specific presentation required for T cells proliferation was created. The M1DR1, a 
human fibroblast cell line stably transfected with DR1 was chosen to be the antigen presenting 
cell model. M1DR1 cells were used as they express HLA-DR in an adequate level as analysed by 
flow cytometry which showed that approximately 80% of M1DR1 cells expressed DR [Figure 
36(a)]. This level of DR expression by M1DR1 cells was expected to be adequate for the peptide 
expression. Furthermore, transfection of M1DR1 cells was previously optimized using 
pCMV/EGFP DNA (section 3.3.7) with transfection efficiency of approximately 45% [Figure 
36(b)]. In addition, we have the advantage of having a monoclonal antibody (UL-5A1) that 
recognizes HLA-DR1 on activated APCs only if they co-express endogenously derived HLA-A2 
or they have been loaded with HLA-A2 derived peptide – exogenously provided. UL-5 A1 
monoclonal Ab demonstrates T cell-like recognition of the peptide-MHC complex (Loffler et al. 
1998; Wolpl et al. 1998). For these objectives, M1DR1 was thought to be a good model to be set 
out for antigen presentation.  
M1DR1 were transfected with pCMV-Ii-A2 or pcDNA3.1(+) as a mock control and after 48 
hours, A2 peptide expression in the context of DR1 was examined by staining the cells with UL-
A51 Ab or human IgG (isotype control) and analysed by flow cytometry. The data analysis 
showed that approximately 19% of M1DR1 cells expressed A2 in context of DR1 [Figure 
365(c)]. This level of A2 peptide expression was below the predicted levels, taking in 
consideration that the transfection efficiency of M1DR1 cells was approximately 45%. 
Furthermore, Ii-fusion gene was transcribed by CMV-promoter, which is one of the strongest 
and most commonly used promoters that should ensure sufficient gene transcription and 
adequate peptide expression. The low level of A2 peptide expression was thought to be related to 
the varying intensities of DR expression by the cells, as there were cells expressing low to null 
DR receptors. In attempt to improve the expression level of A2 by M1DR1 cells, sorting of the 
cells was conducted to enrich cells with high DR surface receptor expression levels. 
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Figure 36.  M1DR1, a cell model for antigen presentation  
M1DR1 were stained with PE-conjugated mouse anti human DR to assess DR expression level 
and analysed by flow cytometry. (a) Histogram shows approximately 80% of the cells expressed 
DR with disparity in DR expression level. (b) The transfection efficiency of M1DR1 cells 
transfected with pCMV/EGFP was approximately 45% relative to mock transfection as analysed 
by flow cytometry 48 hours after transfection. Fluorescent image captured by deconvolution 
fluorescence microscope for the transfected cells with 2 µg of GFP plasmid.(c) M1DR1 were 
transfected with pCMV-Ii-A2 or pcDNA3.1(+) as a mock control. After 48 hours, A2 peptide 
expression in the context of DR1 was tested by staining the cells with UL-A51 Ab or human IgG 
(isotype control). Histogram shows approximately 19% of M1DR1 cells transfected with pCMV-
Ii-A2 expressed A2 peptide in the context of DR1. 
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4.3.4 M1DR1 cells sorting 
  
To improve the peptide expression levels by M1DR1 cells, the cells were sorted in order to 
separate out those cells that have null or low density of DR receptors on their surface, and enrich 
M1DR1 cells on the basis of high DR surface receptor density. This was achieved by using the 
fluorescence cell sorting approach (Herzenberg et al. 2002). Fluorescence activated cell sorting 
was performed using by BD FACSVantageSE (DiVa) machine which provides a method for 
sorting a heterogeneous mixture of cells.  
M1DR1 cells were stained with PE conjugated mouse anti-human DR, and the cells expressing 
high level of DR receptor were gated and sorted. The purity of the sorted cells was tested by 
staining the cells for DR receptors and analyzed by flow cytometry. In [Figure 37 (a.i)], a 
fluorescence image shows histogram of DR expression by M1DR1 cells at the start of the sorting 
process with cells expressing DR with varying intensities. In [Figure 37 (a.ii)], the image shows 
a histogram of DR expression by the sorted cells with high fluorescence intensity of the 
expressed DR receptors. Thus, a cell population expressing DR with high fluorescence intensity 
was obtained.  
To investigate the A2 peptide expression in the context of DR1 by the newly sorted M1DR1 
cells, transfection of cells with pCMV-Ii-A2 or pcDNA was performed and after 48 hours the 
cells were stained with UL-A51 Ab and analysed by flow cytometry. In [Figure 37 (b)] a 
histogram shows that A2 peptide expression by the sorted M1DR1 cells transfected with pCMV-
Ii-A2 was improved, where >90% of the cells expressed A2 peptide in the context of DR1 as 
compared to mock transfection. Furthermore, this data showed that Ii-peptide fusion protein was 
expressed in a functional form, and fusion of the peptide to the Ii chain did not affect the Ii-
peptide fusion chain proper folding or trafficking as A2 peptide was presented to the antigen 
presentation pathway and expressed adequately on the cell surface. 
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Figure 37. Fluorescence cell sorting of M1DR1 cells and re-transfection with pCMV-Ii-A2 
construct  
(a)Sorting of M1DR1 to enrich the cells population that express high DR surface receptor was 
performed using by BD FACSVantageSE (DiVa) machine. (i) Histogram of M1DR1 cells before 
cell sorting show cells expressing DR with varying fluorescent intensities. (ii) Histogram of 
M1DR1 cells after cell sorting shows only the cells that have high DR expression fluorescence 
intensity. (b) Sorted M1DR1 cells were transfected with pCMV-Ii-A2 or pcDNA plasmid. After 
48 hours of transfection, cells were stained for A2 expression in context of DR1 with UL-A51 
Ab and analysed by flow cytometry. Histogram shows that >90% of the cells express A2 peptide 
in the context of DR1 as compared to mock transfection.  
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4.3.5 M1DR1-expressing A2 peptide stable cell line  
Having established the expression of A2 peptide encoded by Ii-A2 fusion construct in a transient 
expression system, it was aimed to generate a stably transfected M1DR1 cell line with pCMV-Ii-
A2 construct. M1DR1-expressing A2 stable cell line was aimed to be used in the optimization of 
T cells proliferation assay, and to save on the DR1
+
 donor cells. The cells were co-transfected 
with pCMV-Ii-A2 construct and pFUSE-hIgG2-Fc1 plasmid encoding Zeocin resistant gene for 
cells selection, as M1DR1 cells are G418 resistant. The Zeocin concentration needed to kill non-
transfected cells was 2.5 µg/ml detected from an established kill curve using different Zeocin 
concentrations with the M1DR1 cells. Co-transfection of M1DR1 cells was conducted and un-
transfected cells were used as a negative control. Cells were cultured under Zeocin selective 
pressure till the un-transfected cells were completely killed, following which the transfected cells 
were allowed to grow for further 3 weeks under Zeocin selective pressure to avoid contamination 
with non-resistant cells. The resulting mixed cells populations were serially diluted to obtain 
isolated colonies which were cultured and screened for positive clones that expressed Ii-A2 
peptide.  
Reserving the use of UL-A51 Ab for the main experiments, screening for the positive clones was 
done by PCR amplification of Ii chain using cDNA prepared from mRNA extracted from the 
tested clones.  PCR amplification was conducted using Ii fwd and rev primers, flanking the start 
and the end sequence of Ii chain respectively. Hundred cell clones were harvested and screened 
by PCR, and the PCR products were visualized by 1% agarose gel electrophoresis [Figure 38 
(a)].  Out of the hundred screened cell clones, only four clones were positive for Ii chain.  The 
PCR products detected in the four positive clones were between 700-800 bps which were 
consistent with the Ii-A2 expected size = 713 bps. For the complete checking of these positive 
clones, cells from each clone were stained for A2 expression in the context of DR1 using UL-
A51 Ab and examined by flow cytometry. The data showed four positive clones which expressed 
A2 peptide in the context of DR1 with varying levels ranging from 62-90% [Figure 38 (b)]. 
These data confirmed that a stable M1DR1 cell line expressing A2 was successfully created and 
was called M1DR1-A2 cell line. The positive clones were allowed to grow and expand for the 
future work.  
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Figure 38. M1DR1-A2 stable cell line 
M1DR1 cells were co-transfected with pCMV-Ii-A2 and pFUSE-hIgG2-Fc1 plasmid encoding 
Zeocin resistant gene for cells selection. M1DR1 cells (transfected or untransfected) were 
allowed to grow in 2.5 ug/ml Zeocin concentration. After the untransfected cells were killed, the 
co-transfected cells were serially diluted in 96 well plates to get 1 cell / well. The cells were 
cultured in D10 under Zeocin selection pressure. The cell clones were screened by PCR 
amplification of Ii chain using Ii fwd and rev primers, flanking the start and end of Ii chain 
respectively, using cDNA prepared from mRNA extracted from the tested clones. (a) 1% agarose 
gel electrophoresis image shows a single band in the 4
th
 and the 11
th
 clone, detected between 
700-800 bps which corresponded to Ii-A2 fusion DNA (expected size = 713 bps). Two positive 
clones out of the selected four clones are shown. (b) The four selected clones were stained for A2 
peptide expression in context of DR1 by UL-A51 Ab and analysed by flow cytometry. 
Histograms show that the four cells clones express A2 peptide on their surface with varying level 
of protein expression ranging from 60-90%. The stable cell lines were designated M1DR1-A2 
cell line.                                       
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4.3.6   Bicistronic vector design 
 
Each of the previously designed constructs: ICOS-KDEL and pCMV-Ii-A2 has been confirmed 
on the basis of protein expression. The next step was to create a plasmid, a bicistronic vector 
encoding both fusion genes cassettes and to confirm that all genes were properly expressed in a 
mammalian cell line. Developing this expression system, the bicistronic vector would enable 
transfection of cells in a single step, using a single plasmid that expresses the two gene cassettes 
simultaneously. 
In the previous chapter (section 3.3.2), ICOS KDEL cloning into pCMV/myc/ER plasmid was 
described, where the gene transcription was under the control of CMV promoter. Early in this 
chapter (section 4.3.1.1 and 4.3.1.2) cloning of the Ii-peptide fusion gene into pcDNA plasmid 
was demonstrated where the gene transcription was also under the control of CMV promoter.  To 
ensure the efficient transcription of the two genes in the bicistronic vector and to avoid 
transcriptional interference, a new promoter was cloned to transcribe Ii-peptide fusion gene so 
the expression of the two genes will be controlled by two independent different promoters.  
Ii chain promoter (pIi) was selected to be the transcriptional promoter for the Ii-peptide fusion 
gene in the bicistronic vector. The pIi was selected based on several considerations: MHC II and 
Ii-chain have cooperative roles in the Ag presentation pathway (Wolf and Ploegh 1995) and their 
expressions are co-regulated (Zhu and Jones 1990; Moore et al. 1998; Tai et al. 1999). In 
addition, the basal expression of these genes shows the same tissue specificity; B cells (Doyle et 
al. 1990), macrophages (Paulnock-King et al. 1985), DCs (Saudrais et al. 1998), activated T 
lymphocytes (Moore et al. 1998). Furthermore, MHC II and Ii-chain expression can be induced 
by the same cytokines most notably IFN-γ and IL-4 (Guo et al. 1996; Lombard-Platet et al. 
1997). These factors suggest that MHC class II expression will be associated with Ii-peptide 
fusion protein expression in the same cell. Taking these points in consideration, the pIi was 
expected to be a suitable promoter to transcribe Ii-peptide fusion gene. (Figure 39) shows 
schematic representation of the bicistronic vector cloning strategy, where pIi was included. The 
strategy to clone the bicistronic vector was composed of several steps; first, pIi was cloned in 
pCMV-Ii-A2 plasmid. Second, to confirm proper Ii-A2 gene transcription by pIi, the pCMV was 
digested and Ii-A2 gene expression was compared under the transcriptional control of pCMV 
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versus pIi. Finally ICOS-KDEL gene was cloned into the plasmid to be expressed under the 
transcriptional control of pCMV. 
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Figure 39. Schematic representations of the bicistronic vector cloning strategy 
(1) Ii promoter (pIi) was cloned in pCMV-Ii-A2 plasmid. (2) Ii-A2 peptide expression by Ii-A2 gene was tested under the transcriptional control of 
pCMV versus pIi. (3) ICOS-KDEL gene was cloned in the plasmid to be expressed under the transcriptional control of pCMV.
 
(1) 
pIi cloning 
        (3) 
Cloning of 
ICOS-KDEL       
(2) 
Testing Ii-A2 gene expression 
under the transcriptional control 
of pIi versus pCMV  
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4.3.6.1 Invariant chain promoter (pIi) cloning  
4.3.6.1.1   pIi primers  
 
The DNA sequence of the pIi gene is shown in (Figure 40) (Doyle et al. 1990). The forward 
primer used in pIi cloning into pCMV-Ii-A2 plasmid added two restriction endonuclease sites; 
EcoR II and BgI II at the 5‟ end of the PCR product. EcoR II was used in pIi cloning into the 
bicistronic plasmid, while BgI II was introduced to be used in the second step of bicistronic 
vector design, where pCMV was digested to compare the transcription of Ii-A2 gene by pIi 
versus pCMV.  BgI II was chosen because its recognition sequence is present at only one site in 
the plasmid and not in the pIi (insert). In addition, the position of BgI II was upstream to the 
pCMV, which aided in the removing of the pCMV with a single digestion reaction. In (Figure 
41) a schematic representation shows an overview of the pIi cloning strategy into pCMV-Ii-A2 
plasmid. The reverse pIi primer added a Not I restriction endonuclease site to the 3‟ end of the 
PCR product. 
4.3.6.1.2   pIi cloning into pCMV-Ii-A2 construct 
 
The pIi was amplified by PCR using cDNA prepared from mRNA extracted from Daudi cell 
line, and the PCR products were visualized by 1.5% agarose gel electrophoresis. In [Figure 42 
(a)], the PCR products were detected between 300-400 bps which were consistent with the pIi 
expected size = 344 bps.  The pIi and pCMV-Ii-A2 DNA were double digested by EcoR I and 
Not I, ligated and the ligation mixture was chemically transformed into DHα competent cells. 
Nineteen clones were screened for positive clones that contained the correct insert. [Figure 42 
(b)] shows 1% agarose gel electrophoresis for the 19 double digested clones with EcoR I and Not 
I, where only one clone (the 19
th 
clone) showed 2 bands; one was detected between 6-8 kbps 
which was consistent with pCMV-Ii-A2 expected size = 6141 bps. The other band was detected 
between 300-400 bps which was consistent with pIi expected size = 344 bps. The rest of the 
clones did not show the insert, suggesting that they contained empty vectors. For further 
confirmation, the positive clone was digested with Bgl II alone or with the combination of EcoR 
I and Not I restriction enzymes and the digested products were visualized by 1% agarose gel 
electrophoresis. In [Figure 42 (c)] two bands were detected following pCMV-pIi-Ii-A2 plasmid 
digestion with Bgl II restriction enzyme alone; a higher band which corresponded to the vector 
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and a lower band between 8-10 kbps consistent with pCMV expected size = 952 bps.  The same 
plasmid was digested by EcoR I and Not I restriction enzymes and revealed two bands: a higher 
band corresponded to the vector and another band between 300-400 bps which was consistent 
with pIi expected size =344 bps. These data confirmed that the newly constructed plasmid had 
the two promoters: pCMV and pIi along with the Ii-A2 insert, and they were in the correct 
orientation. DNAs extracted from the positive clones were sequenced and the correct construct 
was designed pCMV-pIi-Ii-A2. 
 
 
 
 
 
 
 
Figure 40. Schematic representation and DNA sequence of the human pIi gene 
Initiation sites for the start of Ii gene transcription are indicated at +1, +3 and +8 bps by carats. 
Conserved X box from -234 to -220 bp (written in red), the Ii-1 protected region from -213 to -
186 bp (written in green) which contains the conserved Y box from -205 to -196 bp and two NF-
kB recognition sequences (designated by dotted arrows) are indicated. The TTTAA and CAAGT 
boxes are delineated by boxes (Doyle et al. 1990).  
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Figure 41. Schematic representation of pIi cloning in pCMV-Ii-A2 plasmid.  
(i) pCMV-Ii-A2 (plasmid) and pIi (insert) were digested with EcoR I and Not I and 
ligated to produce pCMV-pIi-Ii-A2 plasmid.  
(ii) pCMV-pIi-Ii-A2 plasmid was digested with BgI II, where EcoR I and pCMV were 
removed and the plasmid was religated to produce pIi-A2 plasmid.  
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     (a)                                   (b) 
 
 
 
 
 
 
 
 
 
 (c) 
                                                                                                          
 
 
 
 
 
 
 
 
 
 
 
Figure 42. pIi cloning in pCMV-Ii-A2 construct 
(a)cDNA was prepared from mRNA extracted from 
Daudi cells and  used to amplify pIi by PCR. The 
PCR products were visualized by 1% agarose gel 
electrophoresis, where bands between 300-400 bps 
(pIi expected size = 344 bps) are seen. Samples were 
run in triplicates. (b) Ligation of double digested pIi 
and pCMV-Ii-A2 plasmid was done. Screening for 
clones that contained the correct insert was 
conducted. Nineteen clones were tested and the clone 
19th shows 2 bands; one between 6-8 kbps (pCMV-Ii-
A2= 6.1 kbps) and a band between 300-400 bps (pIi = 
344 bps). The construct was called “pCMV-pIi-Ii-
A2.” For better demonstration of the positive clone, it 
was run separately with a negative control (plasmid 
with no insert). (c) In the left lane, pCMV-pIi-Ii-A2 
was digested by BgI II restriction enzyme and the 
digest products were visualized by 1% agarose gel 
electrophoresis. Two bands are seen; a higher band 
corresponds to the vector and a lower band between 
8-10 kbps corresponds to pCMV (expected size = 952 
bps). In the right lane, pCMV-pIi-A2 was digested by 
EcoR I and Not I, where two bands are seen; a heavy 
band corresponds to the vector and the other between 
300-400 bps corresponds to pIi.  
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4.3.6.1.3 Ii-A2 fusion gene transcription by pIi  
 
Having established the cloning of pCMV-pIi-Ii-A2 construct, transcription of Ii-A2 gene under 
the transcriptional control of pIi was to be tested before proceeding to the next step of the 
bicistronic vector cloning. The efficiency of Ii-A2 gene transcription by pIi was compared to 
pCMV to confirm pIi efficacy. To achieve this step, pCMV-pIi-Ii-A2 was digested with Bgl II 
which removed pCMV promoter, as Bgl II flanked pCMV sequence, leaving only the pIi 
controlling the Ii-A2 gene transcription and the construct was named pIi-Ii-A2. 
To test Ii-A2 protein expression by pIi-Ii-A2 construct, the phenotype of the cell line to be 
transfected required to be A2–ve (not expressing A2), DR1+ve and Ii chain +ve.  Unfortunately, 
a cell line with this phenotype was not available to our hands. Alternative cell lines such as THP-
1 (A2+ve and DR+ve and Ii+ve) and OVCAR-3 cell lines (DR+ve, Ii+ve, while no available 
information on A2 expression) were transfected with pIi-Ii-A2, pCMV-Ii-A2 or pcDNA (mock 
DNA). Changes in the expression level of the 33 kDa Ii chain protein in the lysates of transfected 
cells was determined by western blotting. The only source for the changes in Ii protein 
expression was expected to be caused by Ii-A2 fusion gene expression by the Ii-peptide fusion 
constructs. Lysates of transfected cells were probed by anti-human Ii Ab (to detect the Ii chain 
protein) and anti-human β-actin (to detect the 42 kDa β-actin protein) after 48 hours of cells 
transfection. In (Figure 43), the results showed increase in the 33 kDa Ii chain protein 
expression in cell transfected with pCMV-Ii-A2 as compared to mock transfected cells, which 
suggested additional Ii protein expression by pCMV-Ii-A2 construct. On the contrary, no 
detectable changes were shown in the Ii chain protein expression in cells transfected with pIi-Ii-
A2 as compared to mock transfected cells. At this point, it could not be confirmed that pIi could 
transcribe Ii-peptide fusion gene in pIi-Ii-A2 construct. Unexpectedly, M1DR1 cells which are 
A2 –ve, DR1 +ve and Ii –ve expressed A2 peptide in the context of DR1 when transfected with 
pIi-Ii-A2 construct. M1DR1 was transfected with pIi-Ii-A2, pCMV-Ii-A2 or pcDNA and 48 
hours after transfection, the cells were stained with UL-5A1 Ab to detect A2 peptide expression 
in the context of DR1 and analysed by flow cytometry (Figure 44). The results showed A2 
expression in context of DR1 in M1DR1 cells transfected with pCMV-Ii-A2 or pIi-Ii-A2 
constructs, while no A2 expression was detected in cells transfected with pcDNA. These data 
confirmed that pIi successfully transcribed Ii-A2 fusion gene with A2 peptide expressed on the 
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cell surface. Although the data demonstrated the ability of the cloned pIi to transcribe the Ii-A2 
fusion gene, it was not clear how the Ii-fusion gene was expressed in Ii–ve cell line (M1DR1 
cells) transfected with pIi-Ii-A2 (discussed later in the discussion).  
 
 
 
 
Lane 1= cell transfected with pIi-Ii-A2 
Lane 2= cell transfected with pcDNA 
Lane 3= cell transfected with pCMV-Ii-A2 
Lane 4= cell transfected with pcDNA 
 
 
Figure 43. Ii-A2 fusion protein expression by pIi-Ii-A2 construct  
THP-1 and OVACAR-3 cells were transfected with pIi-Ii-A2, pCMV-Ii-A2 or pcDNA. THP-1 
cells were transfected with 5 µg of the forementioned plasmids using microporation, while 
OVCAR-3 cells were transfected with 2 µg of the forementioned plasmids using Lipofectin 
reagent. The expression of the 33 kDa Ii in the cell lysates of the transfected cells was 
determined by western blotting 48 hours after cells transfection using an antibody directed 
against human Ii. Expression of the Ii protein is shown relative to the 42 kDa β-actin 
housekeeping protein. The results show increase in the 33 kDa Ii chain protein expression in cell 
transfected with pCMV-Ii-A2 as compared to pcDNA transfected cells, which suggest additional 
Ii protein expression by pCMV-Ii-A2 construct. No detectable changes were seen in the Ii chain 
protein expression in cells transfected with pIi-Ii-A2 as compared to pcDNA transfected cells   
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Figure 44. Transcription of Ii-A2 fusion gene by pIi versus pCMV  
M1DR1 cells were transfected with pCMV-Ii-A2, pIi-Ii-A2 or pcDNA. The transfected cells 
were stained for A2 peptide expression in the context of DR1 using UL-5A1 Ab after 48 hours of 
transfection and analysed by flow cytometry.  Histograms show A2 peptide expression by 
M1DR1 cells under the transcriptional control of pIi or pCMV in cells transfected with pIi-Ii-A2 
or pCMV-Ii-A2 respectively. No detectable A2 peptide expression in cells transfected with 
pcDNA. This experiment demonstrated the ability of pIi to transcribe Ii-A2 fusion gene with the 
A2 peptide expressed on the cell surface.  
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4.3.6.2   ICOS- KDEL gene cloning in pCMV-pIi-Ii-A2 plasmid  
With the Ii-A2 gene transcription under the control of pIi was demonstrated, the next step was to 
clone the ICOS-KDEL gene in the bicistronic vector. This step was achieved by designing 
primers that amplified several signal sequences (flanking ICOS-KDEL gene) in addition to the 
ICOS-KDEL gene. These signal sequences were important for adequate ICOS-KDEL protein 
translation, ER sorting and staining. The arrangement of the amplified DNA sequence was in the 
following order: ER signal peptide (to direct the fusion protein to the ER), the extracellular 
domain of ICOS gene (the target gene), the myc epitope (required for protein staining), ER 
retention signal (to permit the retention of the protein in the ER), BGH reverse priming site (to 
permit the sequencing of the insert) and BGH polyadenylation signal for efficient transcription 
termination and polyadenylation of mRNA. ICOS-KDEL plasmid (previously cloned in section 
3.3.2.2) was used as a template for the amplification of the target genes by PCR. The primers 
used in this cloning step added Hind III and BamH I restriction endonuclease sites at 5‟ and 3‟ 
end of the PCR product respectively. (Figure 45) shows the 5‟and 3‟ ends of the complete 
nucleotides sequence that were amplified and cloned into the bicistronic vector under the 
transcriptional control of pCMV.  
Following the amplification and cloning of ICOS-KDEL gene and the flanking sequences, 
screening for the positive clones containing the correct insert was conducted. Eighteen clones 
were screened and the products of the double digested DNA using the Hind III and BamH I 
restriction endonuclease enzymes were visualized by 1% agarose gel electrophoresis. As shown 
in (Figure 46), positive clones (from the 5
th
 to the 17
th
 clone) show 2 bands; one band was 
detected between 6-8 kbps which corresponded to the vector and another band was detected 
between 600-800 bps, which corresponded to ICOS-KDEL gene and the flanking sequences 
(expected size = 701 bps). The first three clones showed three bands – one was detected at the 
expected size of the vector and the other at that of the insert, but the third was detected at 400 
bps which was unidentified band. For the fourth clone; it showed one band at the expected size 
of the vector and the other at 400 bps which was also unidentified. The first four clones were 
discarded as they suggested incorrect ligation. Four positive clones were sequenced and all 
contained the correct insert, one was chosen for further experiments and called “pCMV-ICOS-
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KDEL-pIi-A2” where ICOS-KDEL gene was under the transcriptional control of pCMV and Ii-
A2 fusion gene was under the transcriptional control of pIi. 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 45. Nucleotide sequence of the 5’ and 3’ ends of the ICOS-KDEL gene and the 
flanking sequences that were cloned into the pCMV-pIi-Ii-A2 construct 
The amplified nucleotide sequence is highlighted in blue. ICOS-KDEL plasmid was used as a 
template for the amplification of ICOS-KDEL gene with the flanking signals. The arrangement 
of the amplified DNA sequence cloned in pCMV-pIi-Ii-A2 construct was in the following order; 
ER signal peptide, the extracellular domain of ICOS gene cloned between Pst I and Not I at its 5‟ 
and 3‟ ends respectively (the site is indicated by two arrows), myc-epitope, ER retention signal, 
BGH reverse priming site and BGH polyadenylation signal. Graphics; the nucleotides sequence 
was adapted from the Invitrogen product information 
ICOS SEQUENCE 
 
ICOS extracellular domain 
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Figure 46. Screening of the positive pCMV-ICOS-KDEL-pIi-A2 clones 
The ICOS-KDEL and the flanking sequences were amplified by PCR and cloned into pCMV-
pIi-Ii-A2 plasmid. The cloning products were double digested with Hind III and BamH I. The 
products of restriction enzymes digest were visualized by 1% agarose gel electrophoresis. 
Eighteen clones were screened: clones from 5 to 17 show 2 bands; one band is seen between 6-8 
kbps which was consistent with the vector and the other is seen between 600-800 bps which was 
consistent with  ICOS-KDEL and the flanking signals (the insert) with expected size = 701 bps. 
The first four clones were discarded as they show incorrect inserts suggesting incorrect ligation. 
Four positive plasmids were sequenced and the plasmid with correct insert sequence was called 
pCMV-ICOS-KDEl-pIi-Ii-A2.   
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4.3.7 Protein expression by the double genes encoded into 
bicistronic construct 
 
As the bicistronic vector (pCMV-ICOS-KDEL-pIi-Ii-A2) was successfully cloned in which 
ICOS-KDEL gene was under the transcriptional control of pCMV and Ii-A2 fusion gene was 
under the transcriptional control of pIi, the next step was to confirm the expression of both genes 
simultaneously by the bicistronic vector. Another two bicistronic vectors were designed in 
parallel with the former. The two target genes were cloned into pICOS-KDEL-IipOVA plasmid 
(section 2.1.1) where human ICOS-KDEL-fusion gene was under the transcriptional control of 
pCMV and human Ii-peptide fusion gene was under the transcriptional control of SV40. The 
newly generated bicistronic construct were called pICOS-KDEL-pSV40-A2 and -HA. 
4.3.7.1 By western blotting  
 
To demonstrate the expression of the target proteins – ICOS-KDEL, Ii-A2 and Ii-HA  – M1DR1 
cells were transfected with the pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2 or -
HA, ICOS-KDEL (positive control to ICOS-KDEL protein expression) or pcDNA (negative 
control) plasmids. Expression of the 19 kDa ICOS-KDEL-fusion protein and the 33 kDa Ii-
peptide fusion protein were detected in the cell lysates of transfected M1DR1 cells by western 
blotting after 48 hours of cells transfection. The cell lysates were probed with anti-myc Ab (to 
detect myc tagged ICOS-KDEL protein), human anti-Ii chain Ab (to detect Ii chain protein), and 
anti β-actin Ab as to detect the β-actin as a housekeeping protein.  
The 19 kDa ICOS-KDEL-fusion protein was expressed in M1DR1 cells transfected with pCMV-
ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2, -HA or ICOS-KDEL plasmids. ICOS-KDEL 
protein was not expressed in M1DR1 cells transfected with pcDNA (plasmid with no insert) as 
predicted (Figure 47). The 33 kDa Ii-peptide fusion protein was expressed in M1DR1 cells 
transfected with pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2 or -HA plasmids 
while no Ii-peptide fusion protein was detected in cells transfected with ICOS-KDEL or pcDNA 
plasmids. These data showed that M1DR1 cells did not express myc epitope or Ii chain proteins 
as these proteins were not detected in M1DR1 cells transfected with pcDNA. Expression of myc 
tagged ICOS-KDEL and Ii-peptide fusion protein were detected relative to the expression of the 
42 kDa β-actin housekeeping protein.  
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These data confirmed that the two encoded genes; ICOS-KDEL and Ii-peptide fusion were 
inserted into the plasmid in-frame and that the genes in the constructed bicistronic plasmids were 
expressed in transfected cells simultaneously and the translated proteins were detected at the 
expected sizes.  
 
 
                                                                         
 
 
 
 
 
  
 
 
Figure 47. Analysis of the expression of the double gene constructs by western blotting 
M1DR1 cells were transfected pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2 or –
HA, pICOS-KDEL (positive control) or pcDNA (negative control) for 48 hours. Expression of 
the 19 kDa myc-tagged ICOS-KDEL, 33 kDa Ii and 42 kDa β-actin proteins in the cells lysates 
of transfected cells were determined by western blotting 48 hours after transfection. Blots were 
probed with anti-human myc epitope, anti-human Ii or ant-human β-actin antibodies to detect the 
relevant proteins. The expression of the 19 kDa ICOS-KDEL protein is seen in M1DR1 cells 
transfected with pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2 or –HA or pICOS-
KDEL compared to cells transfected with pcDNA where the 19kDa ICOS-KDEL protein is not 
expressed. The expression of the 33 kDa Ii was detected in M1DR1 cells transfected with 
pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2 or –HA compared to cells transfected 
with pICOS-KDEL or pcDNA where the 33 kDa Ii protein was not expressed. The 19kDa ICOS-
KDEL and the 33 kDa Ii protein expressions are shown relative to the 42 kDa β-actin in every 
lane. These data indicate that the two genes: ICOS-KDEL and Ii-peptide fusion genes were 
successfully cloned and the relevant proteins were translated. 
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4.3.7.2. By flow cytometry 
 
Further investigation of the bicistronic vector was carried out. M1DR1 cells were transfected for 
48 hours with the same constructs used in the section 4.3.7.1) except for ICOS-KDEL construct 
(which was not used in this experiment). Cells were stained with UL-5A1 Ab and anti-human 
ICOSL to demonstrate A2 peptide expression in the context of DR1 and ICOSL expression, 
respectively and the results were analysed by flow cytometry.   
For Ii-peptide fusion protein expression, it was demonstrated that A2 peptide was expressed in 
the context of DR1 by M1DR1 cells transfected with pCMV-ICOS-KDEL-pIi-Ii-A2 or pCMV-
ICOS-KDEL-SV40-A2. Predictably, A2 expression was not detected in cells transfected with 
pCMV-ICOS-KDEL-SV40-HA or pcDNA plasmids which lack the Ii-peptide fusion gene 
[Figure 48 (a)]. These data were consistent with those obtained from western blotting (section 
4.3.7.1). 
As regards ICOSL expression by cells following transfection it was not possible to demonstrate 
any down-regulation in ICOSL expression due to the absence of the basal constitutive expression 
of ICOSL by the cells [Figure 48 (b)]. The unexpected changes in ICOSL basal expression by 
M1DR1 cells was investigated as ICOSL down-regulation was successfully demonstrated 
following transfection of M1DR1 cells with ICOS-KDEL construct (in section 3.3.7). 
Stimulating the cells with inflammatory cytokines, known to up-regulate ICOSL expression such 
as TNF-α or a combination of TNF-α and IFN-γ (Swallow et al. 1999) was tried, but it was not 
possible to induce ICOSL basal expression (data not shown).  
To further investigate the changes in ICOSL basal expression by M1DR1 cells, ICOSL real time 
PCR was performed to assess ICOSL gene transcription. CHO ICOSL cells were used as a 
positive control, while H2O was used as a negative control. ICOSL mRNA copy numbers were 
normalized to those of HPRT to correct errors arising from mRNA extraction/purification and 
reverse transcription in vitro. Comparing the relative ICOSL mRNA expression in M1DR1 cells 
to that in CHO ICOSL cells demonstrated that ICOSL mRNA transcription by M1DR1 cells was 
very low compared to ICOSL expression by CHO ICOSL cells, and it was undetected in H2O 
samples (Figure 49). These data could suggest that ICOSL gene was still transcribed in M1DR1 
cells but at an extremely low level (possible solutions are discussed later in the discussion) 
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Figure 48. Analysis of the expression of the double gene constructs by flow cytometry 
M1DR1 cells were transfected with pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-KDEL-SV40-A2 or -
HA or pcDNA (as mock control) for 48 hours. The cells were stained with UL-5A1 Ab and anti 
human ICOSL to detect A2 peptide expression in the context of DR1 and ICOSL expression, 
respectively, and analysed by flow cytometry. (a) Histograms show A2 peptide expression in the 
context of DR1 by M1DR1 cells transfected with pCMV-ICOS-KDEL-pIi-Ii-A2 and pICOS-
KDEL-SV40-A2 but is undetected in cells transfected with pCMV-ICOS-KDEL-SV40-HA, 
pcDNA and the untransfected cells. (b) ICOSL expression is not detected in all conditions 
whether M1DR1 cells were untransfected or transfected. This was due to the absence of the basal 
expression of ICOSL by M1DR1 cells as detected in untransfected cells. 
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Figure 49. Analysis of ICOSL gene transcription in M1DR1 cells by RT- PCR  
ICOSL gene transcription was assessed by real time PCR in unstimulated M1DR1, CHO ICOSL 
(positive control) and H2O (negative control). HPRT gene was assessed as a housekeeping gene to 
normalize ICOSL mRNA copy number. (a) Histogram of the relative ICOSL mRNA expression in 
M1DR1 and CHO ICOSL cells demonstrates that the ICOSL mRNA transcription in un-stimulated 
M1DR1 cells is detectable, but at a very low level relative to ICOSL expression by CHO ICOSL 
cells and slightly above zero level as compared to H2O sample. (b) Dissociation curves for the 
ICOSL and HPRT genes yield distinct peak for all of the tested samples, except in H20 sample. This 
indicates that there were no contaminating products in these reactions. Contaminating DNA or 
primer dimers would show up as an additional peak separate from the desired amplicon peak. HPRT, 
a house keeping gene, is expressed in M1DR1 and CHO ICOSL cells which confirmed adequate 
template concentration. 
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4.3.8 Stable transfection of M1DR1- CD80 cell line with the 
bicistronic vector  
To allow the optimization and exploration of the thesis strategies, stable transfection of M1DR1-
CD80 with the cloned bicistronic vector was generated. Stable M1DR1-CD80 cell line would 
help in saving on the DR1
+
 donors and reserving the DR1 DCs for the main experiments. This 
stable cell line was expected to be A2
+
 and in the meanwhile down-regulating ICOSL expression 
compared to untransfected M1DR1-CD80 cell line. 
The cells were co-transfected with pICOS-KDEL-SV40-Ii-A2 or -HA constructs and pFUSE-
hIgG2-Fc1 plasmid encoding Zeocin resistant gene for the selection of the transfected cells, as 
M1DR1-CD80 cells are G418 resistant. M1DR1-CD80 stable cell line generation was carried 
out, as described in section 4.6. Screening of the positive clones was conducted by PCR 
amplification of Ii chain and the products of the PCR amplification were visualized by 1% 
agarose gel electrophoresis.  
Screening of four pCMV-ICOS-KDEL-pSV40-A2 and -HA transfected clones showed a single 
band between 600-800 bps which was consistent with Ii peptide fusion gene = 713 bps (Figure 
50). The Ii-peptide fusion band was detected in all the four selected A2 clones and in the 2
nd
 and 
3
rd
 HA clones. These data confirmed that the selected clones expressed Ii chain, but further 
confirmation of the selected clones were done by staining the cells from the positive clones for 
A2 peptide expression in the context of DR1 using UL-5A1 Ab. The data were analysed by flow 
cytometry, which showed A2 peptide expression in the A2 positive clones, while it was 
undetected in the selected HA clones, as predicted (Figure 51).  
These data demonstrated that all the selected clones expressed Ii chain protein as detected by 
western blotting, but A2 positive clones only expressed A2 peptide in the context of DR1 on the 
cell surface as analysed by flow cytometry. The A2 positive clones were called M1DR1-CD80-
A2 cell line, while the control clone was called M1DR1-CD80-HA cell line. One clone was 
selected from each and allowed to grow for further experiments. 
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Figure 51. M1DR1-CD80 stable cell line 
The M1DR1-CD80 cells stably transfected with A2 and HA constructs were stained for A2 
peptide expression in the context of DR1 by UL-A51 Ab and analysed by flow cytometry. The 
left histogram shows A2 expression by the cells from the selected A2 positive clone, while the 
right histogram shows absence of A2 expression by the cells from the selected HA clones. All 
the four selected A2 cell clones were A2 positive and the two selected HA clone were A2 
negative. One positive clone from each cell clones is shown. A2 positive clone was called 
M1DR1-CD80-A2 and the control clone was called M1DR1-CD80-HA. 
 Isotype control 
 A2 peptide expression 
Figure 50. PCR screening of M1DR1-CD80 
stable cell line 
M1DR1 cells were co-transfected with pICOS-
KDEL-pSV40-Ii-A2 or -HA and pFUSE-hIgG2-Fc1 
plasmid which encodes Zeocin resistant gene, for 
the selection of transfected cells. Growing cells 
were serially diluted in 96 wells plates to get 1 cell / 
well and were cultured in D10 under selection 
pressure. Clones were screened by PCR 
amplification of Ii chain using Ii fwd and rev 
primers, flanking the Ii chain sequence, and the 
PCR products were visualized by 1% agarose gel 
electrophoresis. A single band is detected between 
600-800 bps which was consistent with the Ii-A2 
fusion band expected size = 713bps. This band is 
detected in all the four A2 clones and in the 2
nd
 and 
3
rd 
HA clones. The A2 positive clones were called 
M1DR1-CD80-A2 cell line while the control clone 
was called M1DR1-CD80-HA cell line.   
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4.4 Discussion  
The experiments described in this chapter were designed to establish the second component of 
the negative-vaccine approach that was studied in this thesis. This component was related to the 
development of an approach to provide the antigen that can be recognized by the responding 
cells. As mentioned early (section 4.1), there have been several strategies by which alloantigen 
can be provided to APCs for antigen presentation via indirect alloresponse. The work in this 
chapter investigated the use of the fusion between the immunodominant MHC class I derived 
peptide (HLA-A2103-120) and the Ii of MHC class II to efficiently direct the allopeptide to the 
antigen presentation pathway. 
In the attempt to achieve this target, the creation of three single gene constructs; pCMV-Ii-A2, –
Ii-HA and pIi-Ii-A2 were described. In addition three double gene constructs; pCMV-ICOS-
KDEL-pIi-Ii-A2, pCMV-ICOS-KDEL-SV40-A2 and –SV40-HA which represented the 
bicistronic vectors were created. 
4.4.1 Cloning of the Ii-peptide fusion gene 
 
The approach applied to generate the Ii-peptide fusion gene was Gene Splicing by Overlap 
Extension using PCR (SOEing-PCR), which is a method used for the production of chimeric 
genes by combining two DNA fragments without a need for novel restriction sites (Horton et al. 
1989) . SOEing-PCR is an approach that is based on the idea that a PCR product can be 
engineered, by adding or changing sequences at its ends, so that the product can itself be used to 
prime DNA synthesis in a subsequent overlap-extension reactions to create mutant or 
recombinant molecules.  
SOEing-PCR technique has passed through several modifications; the original overlap extension 
PCR method, described by Horton and his co-workers consisted of two rounds of PCRs where 
two mutant fragments were amplified and purified separately in the first-round PCR and then 
annealed and extended as template in the second-round PCR (Horton et al. 1993). Then, Urban et 
al. modified the original overlap extension PCR method, using asymmetric PCR in a one-step 
overlap extension PCR method without any intermediate purification (Urban et al. 1997). 
However, this method required the target DNA to be present in both orientations.  Therefore, 
                                                                                                                                             Chapter 4 
185 
 
DNA had to be cloned into two vectors that differ only with respect to the orientation of their 
multiple cloning sites. The DNA fragments cloned into these plasmids served as templates in a 
single PCR reaction in the presence of one universal and two mutagenic primers. The major 
disadvantage about this improvement was the requirement for several steps of cloning, with its 
technical problems that can complicate the procedure. To increase the efficiency of overlap 
extension PCR, Warrens et al. introduced an asymmetric PCR step to produce an excess of single 
strands with overlapped 3‟ ends before the second-round PCR (Warrens et al. 1997). In addition, 
an additional step was added to avoid sequence mutation caused by the addition of non-
templated nucleotide at the 3‟end by Taq DNA polymerase (Clark et al. 1987). This overhang 
produced in the first stage PCR intermediate products were rendered blunt by T4 DNA 
polymerase (Warrens et al. 1997). Although this modification step enhanced the efficiency of 
overlap extension PCR, it added more time-consuming steps. 
Xioas et al. suggested another modification, as he used two steps SOEing-PCR technique, carried 
out for 30 cycles of asymmetric PCR and one cycle of annealing and extension. They used the 
mutant primers 10 times diluted than the flanking primers, so that the intermediate PCR products 
were exponentially amplified till the mutant primers (with the lower concentration) were 
exhausted. The main amplification products in the late cycles would be single strands amplified 
by the flanking primers (Xiao et al. 2007).  
In this project, few modifications had been tried to enhance the efficiency of the SOEing-PCR 
technique. First; taking in consideration, the non-templated nucleotide that is usually added at the 
3‟ end overhang produced by Taq polymerase, the two mutant primers were designed so that, the 
first added nucleotide to the 3‟end of the first mutant DNA fragment would be adenosine 
nucleotide, which would be in the actual nucleotide sequence. Whilst for the second DNA 
fragment, the first nucleotide to start with at its 5‟ end would be thymidine nucleotide, which 
corresponded to the adenosine nucleotide that was expected to be added. Applying this step, 
blunting the ends of the DNA fragments  by T4 DNA polymerase was omitted (Warrens et al. 
1997), also it decreased the possibility of altered mutation. For clarity, a schematic Figure 52 
was blotted for demonstration.  
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Second; in the gene assembly step, an asymmetric PCR reaction was run for 10 cycles using the 
first step PCR products as templates using no primers. Thus the overlapping complementary 
DNA segments partially annealed and produced the second stage PCR product. 
It is thought that with these modifications, we were able to clone Ii-peptide fusion gene (section 
4.3.1) in an efficient and easy approach. A relatively short sequences as HLA-A2103-120 or HA 
were introduced into Ii chain protein without the need for introducing novel restriction sites. 
Figure 52. Schematic representation of the primers used in the Ii-peptide fusion gene 
cloning.   
The Ii segments composed of the first half of Ii sequence before the CLIP region is drawn in red, 
while the second part of Ii sequence after the CLIP region is drawn in black. The fusion peptide 
segments are represented as blue zigzag lines, and the primers are denoted by dotted arrows.  In 
the upper segment, where the red and blue lines constitute the 1
st
 mutant DNA fragment, the 
mutant primer was designed so that the first added nucleotide to the 3‟ end of the first DNA 
mutant sequence would be adenosine, and its position is pointed by a twisted arrow. In the lower 
segment, where the blue and black lines constitute the 2
nd
 mutant DNA fragment, the mutant 
primer was designed so that the first nucleotide at the 5‟ end to start with would be thymidine, 
and its position is pointed by a twisted arrow. 
4.4.2 Ii-peptide fusion gene 
 
The hypothesis in creating the Ii-peptide fusion construct as a strategy for antigen presentation 
was that the peptide of interest replaced the CLIP region of the MHC class II. The MHC class II 
would be loaded with the peptide in the ER and before entering the endocytic compartment. This 
was expected to significantly reduce the competition from other peptides for MHC class II 
molecules binding groove. Also, the high affinity nature of the interaction between peptides and 
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class II molecules is expected to ensure that the Ii-peptide fusion protein will remain bound to 
MHC class II binding groove during its passage through the Golgi and the MIIC and even after 
the cleavage of the Ii chain. Consequently, the peptide will be expressed on the cell surface in the 
context of MHC class II to CD4
+
 T cells. In our lab, there has been an experience in applying 
this strategy, where the Ii chain with the CLIP replaced by a peptide from ovalbumin, OVA 328-
339 [kindly denoted by Dr S Thirdborough (Southampton University, UK)] was used and showed 
antigen presentation and induced efficient proliferation to murine DO11.10 CD4
+
 T cells (which 
have the transgenic TCR specific for the peptide). Thus, this strategy was expected to be an 
effective method for the expression of specific peptide–MHC complexes. 
The data generated in this chapter demonstrated that the replacement of CLIP with an antigenic 
peptide was an efficient mean of loading class II complexes in our hands. In section 4.3.2, the Ii-
peptide fusion protein expression, from both constructs pCMV-Ii-A2 and -HA, was confirmed by 
western blotting. Ii-peptide fusion protein was expressed in three different mammalian cell lines; 
HEK 293, D17 and M1DR1 cells transfected with the Ii-peptide fusion constructs at the expected 
sizes. In addition, the flow cytometry data in section 4.3.3 showed that A2 peptide expression 
was expressed in the context of DR1 by M1DR1 cells transfected with the pCMV-Ii-A2 
construct as compared to mock transfection. A2 peptide expression by transfected M1DR1 cells 
was rendered more efficient following M1DR1 cell sorting, where the cell population having no 
or low DR molecules expression was eliminated as demonstrated in section 4.3.4. These data 
demonstrated that the newly generated Ii-peptide fusion construct efficiently provided the 
allopeptide to the antigen presentation pathway to be expressed on M1DR1 cell surface in the 
context of DR1. Furthermore the cloning procedures did not affect Ii chain proper folding or 
trafficking, thus the generated Ii-peptide fusion construct was functional and its capability to 
present the peptide was established. 
Having established the capability of Ii-peptide fusion construct to efficiently provide antigen in a 
transient expression system, M1DR1 stably expressing the target peptide under the 
transcriptional control of pCMV was created (section 4.3.5). M1DR1 stably expressing A2 
represented a cell model for antigen specific presentation. This cell model is expected to enable 
us to optimize and investigate the employed approach while saving the use of donor DCs for the 
main experiments.  
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4.4.3 Bicistronic Vector construct 
 
Designing a bicistronic vector encoding the main two gene cassettes was the second target in this 
chapter. The selection of the transcribing promoter is crucial to the level and persistence of 
transgene expression in different tissues. To avoid transcriptional interference that may result 
from competing for the transcriptional factors (as previously encountered in this study), 
promoters of different origins were used for the target genes expression. 
pcDNA plasmid was chosen to be the back bone for the bicistronic vector design, as it has a 
multiple cloning site (MCS) with a wide variety of endonuclease restriction sites. This MCS 
variety  made cloning of the genes easier as regard choosing the restriction sites that are absent in 
the genes sequence. The Ii-peptide fusion gene was initially cloned into pcDNA plasmid under 
the transcriptional control of the pCMV (section 4.3.1) and protein expression by the encoded 
gene was confirmed by western blotting and flow cytometry (section 4.3.2 and 4.3.3). In the 
newly generated bicistronic vector, pCMV transcribed the ICOS-KDEL gene transcription and 
the human pIi, as a tissue-specific promoter, was chosen to be the promoter transcribing Ii-
peptide fusion gene. 
To achieve successful transgene expression, tissue-specific promoters offer improved specificity 
and safety for non-viral vectors, as transgene products that are foreign to the host can trigger an 
immune response and hamper the therapeutic effect. Tissue specific promoter also expresses its 
activity in only certain cell types and the use of it in the expression cassette can facilitate 
transgene expression in the relative tissue.  
4.4.3.1 Ii-Chain Promoter (pIi) 
 
Ii chain promoter (pIi) was used to be the transcribing promoter for the Ii-peptide fusion gene. 
The pIi chain was chosen relying on several considerations where the most important factor was 
that Ii chain expression shows tissue specifity. Ii is mostly expressed by APCs such as B cells 
(Polla et al. 1986; Doyle et al. 1990), macrophages (Paulnock-King et al. 1985), DCs (Saudrais 
et al. 1998), activated T lymphocytes and thymic epithelial cells (Momburg et al. 1986; 
Arudchelvan et al. 2003). This tissue specific pattern of expression would ensure that the Ii-
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fusion protein would be expressed in APCs, where the allopeptide will be presented via the 
indirect pathway, as it was planned to be expressed.  
pIi sequence contains two NF-κB/Rel binding sites – Ii κB -1 and Ii κB -2 (Doyle et al. 1990). 
The functional analysis of these sites revealed that, these NK-κB sequences served multiple 
purposes depending on the cell type; where Ii κB -1 was a positive regulatory element in B and T 
lymphocytes, and a negative regulatory element in brain glial cell lines (Brown et al. 1994). Ii 
κB-2 was a positive regulator in B cells but negative regulator in Ii- expressing T cell line. The 
opposite function of these NF-κB/Rel sites was related to the difference in binding to disparate 
NF-κB/Rel factors in different cell types (Brown et al. 1994).   
NF-κB binding sites have an important regulatory role in the TNF-α-induced expression of MHC 
class I, class II genes and Ii genes (Pessara et al. 1988). The three genes are regulated by TNF-α 
and the promoter of these genes contains sequences with a high degree of similarity to the κB 
enhancer. Mutations introduced into the Ii-κB elements abolished the stimulatory effect of TNF-
α on the Ii promoter (Pessara and Koch 1990). The TNF-α induced factor also interacts with κB-
like sequences of the MHC class II and β2-microglobulin promoter, suggesting a common TNF-
α mediated regulatory signal for expression of both MHC and Ii proteins. In addition, MHC class 
II and Ii chain expression reported to be simultaneously induced by the same cytokines most 
notably IFN-γ (Collins et al. 1984; Chang and Lee 1986), TNF-α (Pessara and Koch 1990) and 
IL-4 (Polla et al. 1986; Lombard-Platet et al. 1997). Sharing of the regulatory signals between 
MHC class II and Ii will ensure their simultaneous expression by the cells with particular 
importance in the inflammatory environment.  
Another similarity in MHC class II and Ii chain profile is that although both are encoded on 
separate chromosomes, co-ordinate regulation of class II and Ii is controlled at the level of 
transcription and is accomplished through common cis-acting DNA sequences in their 
promoters. The shared regulatory DNA sequences are a composite motif consisting of four well-
defined sequence elements; the S, X, X2, and Y boxes, known as the S-Y module, present in a 
definite order, spacing and orientation. This stable regulatory complex is shared between MHC 
class II gene and its accessory genes including Ii, HLA-DO and HLA-DM genes (Benoist and 
Mathis 1990; Krawczyk et al. 2004) .  
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The X and Y regulatory elements serve as recognition sequences for a number of DNA-binding 
proteins and these elements are required for appropriate tissue-specific gene expression. Brown 
et al. suggested that IFN-γ regulation of Ii expression was mainly checked by S-Y regulatory 
motifs which were essential for IFN-γ inducible Ii transcription in human glioblastoma cell line 
(Brown et al. 1993). Sharing these putative recognition sequences between the promoters of class 
II and Ii suggested the coordinate regulation of class II and Ii genes at the level of transcription. 
Thus, Ii expression by the cells is coordinated with MHC class II expression, which made the pIi 
a suitable promoter to be cloned in the bicistronic vector to drive Ii-peptide fusion gene 
transcription. This co-ordination of transcription would ensure that, whenever the MHC class II 
is stimulated to be transcribed in APCs, the Ii-peptide fusion gene will be transcribed 
simultaneously with the expression of the target allopetide in the context of MHC class II.   
After successful cloning of pIi into pcDNA plasmid (section 4.3.6.1) and constructing the pIi-Ii-
A2 construct, Ii-peptide fusion protein expression by the pIi-Ii-A2 construct was assessed 
(section 4.3.6.1.3). MHC class II expressing cells such as THP-1 and OVCAR-3 cells were 
transfected with pIi-Ii-A2, pCMV-Ii-A2 (positive control) or pcDNA (as negative control). 
Expression of the 33 kDa Ii chain protein in the lysates of transfected cells was determined by 
western blotting (Figure 42). The results showed increase in the 33 kDa Ii chain protein 
expression level in cell transfected with pCMV-Ii-A2 as compared to mock transfected cells, 
which suggested that the additional source of Ii protein was translated by pCMV-Ii-A2 construct. 
On the contrary, no detectable changes were detected in the Ii chain protein expression by cells 
transfected with pIi-Ii-A2 as compared to mock transfected cells. On the basis of these results, it 
could not be confirmed that pIi was capable of transcribing the Ii-peptide fusion gene. More 
sensitive assay was required to assess Ii-peptide fusion gene transcription by pIi as western 
blotting is not sensitive to detect slight changes in protein expression. Expression of Ii mRNA 
was assessed in THP-1 cells transfected with pIi-Ii-A2, pCMV-Ii-A2 or pcDNA and in the 
untransfected cells by real time PCR. The results showed relative increase in the Ii mRNA 
transcription by cells transfected with pIi-Ii-A2, pCMV-Ii-A2 constructs as compared to pcDNA 
transfected cells and untransfected cells (data not shown). This data demonstrated that pIi 
transcribed Ii-peptide fusion gene in transfected cells. 
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More interesting was the unexpected detection of A2 peptide expression in the context of DR1 in 
M1DR1 cells transfected with pIi-Ii-A2, where Ii-peptide fusion gene was under the 
transcriptional control of pIi. It was shown in the flow cytometric data that M1DR1 cells 
transfected with pIi-Ii-A2 expressed A2 peptide in the context of DR1 as compared to cell 
transfected with pCMV-Ii-A2 (which showed adequate A2 peptide expression) or pcDNA 
(where no A2 peptide was detected) (Figure 43). Furthermore, the western blot data showed Ii 
protein expression in M1DR1 cells transfected with pCMV-ICOS-KDEL-pIi-Ii-A2 (Figure 46). 
Although both data clearly demonstrated the expression of Ii-peptide fusion gene by pIi, these 
data showed that M1DR1 cells which are Ii chain negative (as shown with M1DR1 cells 
transfected with mock DNA and untransfected cells) expressed the Ii chain protein under the 
transcriptional control of pIi.  
The unanticipated expression of Ii protein under the transcriptional control of pIi in M1DR1 cells 
transfected with pIi-Ii-A2 plasmid suggested that the M1DR1 cells possessed the required 
transcriptional machinery needed to direct the Ii gene expression by the exogenous pIi. In 
support to our suggestion, similar findings were reported in a study conducted by Brown et al. 
which showed the expression of pIi/CAT plasmid in transfected Jurkat cells (Brown et al. 1993). 
The expression of the exogenous pIi in transfected Jurkat cells was in contrast to the endogenous 
expression of Ii gene, as Jurkat cells are Ii/ MHC class II negative. They related this ectopic pIi 
expression to the presence of the available transcriptional factors required for the pIi expression, 
while the endogenous pIi may not be accessible to these factors. Similarly, a study demonstrated 
that transient transfection of cells not expressing endothelial nitric oxide synthetase (eNOS) with 
eNOS promoter/luciferase reporter construct expressed strong eNOS promoter activity (Chan et 
al. 2004). The expression of eNOS promoter in eNOS non-expressing cells was in contrast with 
the reported endothelial cell-restricted expression of endogenous eNOS, which is known to be 
restricted to the vascular endothelium of large and medium sized arteries (Teichert et al. 2000). 
In Chan et al. study, they showed the expression of the transcriptional factors needed for the 
eNOS promoter expression in the eNOS-non-expressing cells transfected with eNOS 
promoter/luciferase reporter construct (Chan et al. 2004). Thus, to confirm our suggestion, 
cellular levels of the pIi transcriptional factors such as NF-Y or regulatory factor X (RFX) 
(Linhoff et al. 1997) could be assessed in transfected or untransfected M1DR1 relative to Ii-
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expressing cells such as DC or Raj B cells by western blotting. Probing of protein extracts from 
the cells with antibodies directed against the pIi transcriptional factors would confirm the 
presence of these factors in M1DR1 cells.  
Three bicistronic plasmids encoding two genes cassettes were cloned ; pCMV-ICOS-KDEL-pIi-
A2 (ICOS-KDEL gene under the transcriptional control of pCMV and Ii-A2 gene under the 
transcriptional control of pIi), pCMV-ICOS-KDEL-pSV40-A2 (ICOS-KDEL gene under the 
transcriptional control of pCMV and Ii-A2 gene under the transcriptional control of pSV40) and 
pCMV-ICOS-KDEL-pSV40-HA (ICOS-KDEL gene under the transcriptional control  of pCMV 
and HA peptide under the transcriptional control of pSV40). In section 4.3.7.1, the western blot 
data demonstrated that the M1DR1 cells transfected with pCMV-ICOS-KDEL-pIi-Ii-A2, pICOS-
KDEL-pSV40-A2 or –HA constructs expressed the 19 kDa and 33 kDa proteins which were 
consistent with the ICOS-KDEL and Ii proteins, respectively. No Ii-peptide fusion protein was 
detected in cells transfected with pcDNA or ICOS-KDEL constructs. In addition, the flow 
cytometric data (section 4.3.7.2) showed A2 peptide expression in the context of DR1 by 
M1DR1 cells transfected with pCMV-KDEL-pIi-Ii-A2, pICOS-KDEL-pSV40-A2 constructs as 
compared to transfection with pCMV-ICOS-KDEL-pSV40-HA or pcDNA and untransfected 
cells.  
Unfortunately, it was not possible to express ICOSL down regulation in the transfected cells due 
to the absence of the constitutive ICOSL basal expression by M1DR1 (which was unexpected). 
The absence of ICOSL expression by M1DR1 cells, as detected by flow cytometry, made 
checking of ICOS-KDEL gene function in the bicistronic gene unfeasible. It is worth noting that, 
the capability of ICOS-KDEL to down-regulate ICOSL expression was previously shown on the 
same cell line (section 3.3.7) using ICOS-KDEL single gene cassette. In addition, the expression 
of ICOS-KDEL-fusion protein encoded in the bicistronic plasmid was confirmed by western 
blotting (section 4.3.7.1). These suggested that the inability to check the function of ICOS-
KDEL to down-regulate ICOSL in M1DR1 cells transfected by the bicistronic vectors was due to 
problems related to the cell line rather than the constructs.   
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The profile changes in ICOSL expression by M1DR1 cells was investigated, where cell 
stimulation with cytokines in order to drive ICOSL expression was carried out, but no ICOSL up 
regulation could be detected. ICOSL gene transcription by M1DR1 cells was assessed by real 
time PCR (section 4.3.7.2 Figure 48) which showed that ICOSL gene was transcribed by the 
cells but at an extremely low level compared to ICOSL mRNA transcription by CHO ICOSL 
(positive control). This could assume that, the cells might have been exposed to a continuous low 
level of stimulation that managed to upregulate ICOSL expression. The possible source of this 
stimulation could be related to the culturing conditions. Although the cells were cultured using a 
consistent protocol, the only variable element was the fetal calf serum FCS (batch-to-batch 
variations). 
The FCS variability between batches could lead to an unpredictable cell culture system in which 
the cells growth and/or experimental results might not be reproducible. It has been previously 
reported that FCS can interfere with genotypic and phenotypic cell stability, as well as 
experimental results (Even et al. 2006; Naseer MI et al. 2009).  This irreproducibility caused by 
the culturing FCS could be avoided by careful testing of the batches.  
Regarding M1DR1 cells profile changes, upregulation of ICOSL expression by M1DR1 cells 
will be tried  which is planned to be achieved by trying different protocols of cell stimulation 
using variable concentrations of cytokines known to upregulate ICOSL expression e.g. TNF-α 
and IL-4. Once ICOSL expression is re-established, the cells will be transfected with the 
generated bicistronic plasmid and ICOSL down- regulation by ICOS-KDEL-fusion gene will be 
investigated.  
4.4.3.2 Functional analysis of the bicistronic plasmid as an antigen 
presentation strategy  
 
Testing the functional effect of the suggested combined strategies of this thesis – KDEL strategy 
as an immune-modulator combined with Ii-fusion protein as antigen presentation model – on T 
cell proliferation was the final target of this project. M1DR1-CD80 cells which stably expressed 
A2 or HA peptides and ICOS-KDEL (section 4.3.8) were created and were called M1DR1-
CD80-A2 or -HA. These stable cell lines were created to provide an artificial antigen presenting 
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cells with stable and consistent expression of the target proteins in the functional assay 
experiments.  
The main limitation for the proceedings with the functional assay was the unavailability of the 
needed T cells clones to be used to in the functional analysis of the newly generated plasmids. 
These T cell clones are designed to be indirect allospecific clones, generated from HLA-A2 
negative patients who has chronically rejected an HLA-A2 positive kidney allograft, where the 
generated T cells clone will be allospecific for HLA-A2 103-120 restricted by HLA-DR1 (Frasca et 
al. 2000). The T cell clones were expected to be a kind donation from Prof. Lombardi, as their 
laboratory has a good experience in culturing T cell clones. Unexpectedly, due to technical 
problems with growing of theses clones, it was not possible to get the needed clones. For future 
experiments, two possible alternatives are suggested to assess the function of the bicistronic 
plasmids in modulating the indirect allorecognition pathway. Primary T cells from patients 
fulfilling the HLA phentoype criteria can be used. However, the main limitation in this 
alternative is the problem of using polyclonal T cells, where the frequency of antigen specific T 
cells may not be enough, which could make the interpretation of the results difficult. The other 
alternative is to design another cell model were HLA-A2 could be expressed in the context of 
different DR phenotype in a way to fit with the available T cells clone. Then, the functional 
assays of T cell proliferation could be assessed.  
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5.1 Introduction  
Genetic modification of DC is an attractive approach to treat diseases either using iDC to induce 
tolerance in autoimmune disease and transplantation (Fu et al. 1996) or mDC to immunize 
patients as in cancer and infectious diseases (Schuler and Steinman 1997; Lu et al. 2004). 
Developing the use of genetically modified DCs is challenged by two main factors including an 
efficient mean to transfect DC and the optimal target gene to be transfected. There is no 
consensus on which transgene delivery system is superior, since all of the gene transfer systems 
have their advantages and disadvantages. The ideal vector for gene delivery should accomplish 
most of the following criteria such as target cell specificity, resistance to metabolic degradation 
and/or immune system, minimal side effects, appropriate regulated gene expression pattern as 
long as it is required.  
5.1.1 DC transfection 
 
As the approach of this project required transfection of DNA into human DC, it was thought of 
optimizing a DC transfection method that could be applied later in this project. To decide the 
suitable DC transfection method to be carried out, several parameters were considered such as 
transfection efficiency and immunogenicity. Although viral transduction strategies can lead to 
higher transfection efficiencies compared to nonviral vectors, several disadvantages are usually 
encountered with the use of viral gene delivery systems. The immunogenicity of the viral 
particles and the residual viral gene products generates an antiviral response that reduces the 
effectiveness of repeated administration in the setting of vaccination strategy (Lundqvist et al. 
2002; Lundqvist and Pisa 2002). In addition, viral transduction of DCs can interfere with DC 
functions as adenoviral transduced mDC showed impaired capacity to stimulate autogenic and 
allogenic T cell proliferation in an MLR (Jonuleit et al. 2000; Newton et al. 2008). Furthermore, 
adenoviral transduced iDC showed increased capacity to stimulate allogenic T cell response 
which was related to changes in iDC phenotype with the upregulation of DC maturation markers 
following viral transduction (Tan et al. 2005a). Maturation of DCs by viral transduction could be 
a problem if the genetically modified iDC were initially used to induce immune tolerance.  
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The problems related to clinical safety with the potential of developing infections and 
malignancies and the problems of large-scale manufacture and quality control are regarded as 
additional obstacles for the clinical application of viral gene delivery systems.  
Nonviral gene transfer, or transfection, involves treatment of the cells by chemical or physical 
methods. In the chemical non viral systems, an array of complexes between DNA and diverse 
cationic polymers (polyplexes), cationic lipids (lipoplexes) or inorganic nanoparticles are used. 
These DNA complexes protect the DNA and facilitate its cellular uptake and intra-cellular 
delivery. In the physical method, the aim is to create transient holes in the cell membrane using 
physical forces to transfer DNA from extracellular to the nucleus. Physical methods utilize 
several techniques as gene microinjection (Capecchi 1980), gene gun (particle bombardment) 
(Yang et al. 1990; Zelenin et al. 1993), electroporation (Neumann et al. 1982), sonoporation 
(Kim et al. 1996), laser irradiation (Tsen et al. 2009), and magnetic field enhanced transfection 
(magentofection) (Scherer et al. 2002).  
The non-viral system is more flexible as regard the size of the DNA being transferred and is 
relatively less toxic and biologically safer due to their reduced immunogenicity compared to the 
viral system with the potential for repeated administration. In addition, the non-viral vectors are 
easy to produce and to scale-up at the manufacturing stage, which make them more plausible for 
clinical application. However, transfection efficiency and gene targeting using non-viral gene 
delivery systems remain to be optimized. The main aim of this chapter was to optimize a non-
viral strategy to transfect DC, which can help in achieving an appropriate expression of the target 
genes cloned in this project. 
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5.2 Results 
5.2.1 Primary Dendritic cells 
 
Human DCs can be prepared using CD34
+
 progenitor cells from several sources as human cord 
blood or bone marrow (Romani et al. 1994; Lardon et al. 1997), Langerhan‟s cells (Caux et al. 
1992) or CD14
+
 progenitors of the monocyte lineage from peripheral blood (Sallusto and 
Lanzavecchia 1994). This study focused on the latter approach for DCs preparation because it is 
the simplest, generally applicable for research work, and large number of DCs can be generated 
and purified.  
CD14
+
 monocytes were isolated from PBMC obtained from buffy coats, concentrated cellular 
fraction of blood, using CD14 MACs microbeads (described in section 2.2.4.1). The purity of the 
retrieved cell population was evaluated by staining the cells for CD14 and the data were analysed 
by flow cytometry. In [Figure 53 (a)] histogram shows that > 90% of the isolated cell population 
expressed CD14 as compared to the isotype control. The isolated population was homogonous 
and pure as represented by a single sharp histogram peak, indicating the absence of cell 
contamination. Isolated CD14 cell purity was kept consistent throughout the study. 
The isolated CD14
+
 monocytes were induced to differentiate into immature DCs (iDCs) and 
mature DCs (mDCs). CD14
+
 cells were seeded at 1x10
7
 in T75 flask in final volume of 5 ml 
R10. GM-CSF and IL-4 cytokines were added at a final concentration of 20ng/ml on day 0, 2 
and 4. For DC maturation, TNF-α, IL-1β and IFN-γ cytokines were added at a final 
concentration of 20 ng/ml on day 4 with the other cytokines. On day 6, non-adherent cells were 
stained for CD11c (DC marker) and analysed by flow cytometry which showed that > 99% of the 
stained cells expressed CD11c [Figure 53 (b)]. The differentiated iDCs and mDCs were stained 
for CD80, CD86, MHC class II and the data were analysed by flow cytometry and shown in 
[Figure 53 (c)]. The protocol employed to isolate CD14
+
 cells and differentiate them to DCs was 
used throughout the rest of this study, as it provided a consistently pure and reliable cell source. 
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Figure 53. Primary Dendritic cells 
CD14
+
 monocytes were isolated from PBMC using CD14 MACs microbeads. The purity of the 
isolated cell population was determined by staining the cells for CD14 and the data was analysed 
by flow cytometry. (a) Histogram shows a single sharp peak of > 90% of the cells were positive 
for CD14 staining which confirmed a homogonous and pure cell population. (b) The isolated 
CD14+ were seeded at 1x10
7
 in T75 flask in final volume of 5 ml R10 and were differentiated to 
iDCs by GM-CSF and IL-4 cytokines which were added at a final concentration of 20 ng/ml on 
day 0, 2 and 4.  iDCs were matured using TNF-α, IL-1β and IFN-γ cytokines that were added at 
a final concentration of 20 ng/ml on day 4. Non-adherent cells were stained for CD11c (DC 
marker) and analysed by flow cytometry on day 6. Histogram showed that > 99% of the stained 
cells expressed CD11c which show successful differentiation of CD14
+ 
cells to DC. (c) 
Histograms show CD80, CD86, MHC class II expression by iDCs and mDCs on day 6.  
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5.2.2 Transfection of DCs  
5.2.2.1 Transfection of DCs using Lipid based transfection reagent TfxTM -
50 
 
Our laboratory had an experience with transfecting human DCs using immunolipoplexes 
complex, where a combined mixture of the lipid reagent Tfx
TM
 -50 and anti-transferrin receptor 
Ab (TfR) was used with CTLA4-KDEL construct to transfect human DCs (Tan et al. 2003; Tan 
et al. 2005a; Tan et al. 2005b). Similarly, a mixture of Tfx
TM
 -50 and holo-Transferrin (Tf) was 
used with plasmid DNA to transfect murine DCs (Tan et al. 2001) 
Optimization of DCs transfection using the Tfx
TM
 -50 reagent was carried out using several 
protocols, guided by the previous experience in the laboratory as well as manufacturer‟s 
instructions. Tfx
TM
 -50 was used to transfect DCs either alone or in mixture with either anti-TfR 
Ab or Tf using varying concentrations of the reagents. EGFP encoded by pCMV/EGFP plasmid 
was used as a reporter gene to assess DCs transfection efficiency. Cells of different 
differentiation stage were used including; CD14
+
 cells on day of isolation or day 2 and day 5 
iDCs. Following transfection, cells were cultured for 24 and 48 hours prior to analysis of green 
fluorescence expression by deconvolution fluorescent microscopy and flow cytometry. With all 
the changes implemented to transfection protocol, transfection efficiency did not exceed 5% in 
all the attempts of cell transfection in our hands (data not shown). It was then decided to try an 
alternative non-viral method to transfect DCs which was the microporation. 
5.2.2.2 Transfection of iDCs using microporation 
 
Electroporation has been used to transfect human DCs with DNA, with 10% to 40% reported 
transfection efficiency (Van Tendeloo et al. 1998; Strobel et al. 2000; Lundqvist et al. 2002) or 
mRNA with 80% reported efficiencies (Bonehill et al. 2009).   
In this study, the efficiency of the microporation technology in iDCs transfection was 
investigated. Microporation is a modified electroporation technology that uses pipette tip-style 
chamber instead of the usual cuvette electrode as an electroporation space. In the course of 
assessing the feasibility of this technique in transfecting DC, the protocol provided by the 
manufacturer was initially followed and was further optimized to determine the best 
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microporation conditions. Different pulsing parameters were optimized including; DNA 
concentrations as 1, 2, 5 and 10 µg per condition, pulse voltage; from 1500 V to 2200 V, 
pulsation width; from 10 to 40 msec and pulses numbers; 1 and 2 pulses using 1x10
6
 cells per 
condition. Several combinations between these parameters were tried, and EGFP expressing cells 
were visualized at 24 and 48 hours after microporation by deconvolution fluorescence 
microscopy and flow cytometry. The highest transfection efficiency was obtained using the 
following conditions; 2000v-20 msec-1p-10 µg DNA for 48 hours, however it did not exceed 
11% with poor cell viability which was not sufficient for in vitro studies [Figure 54 (a,b)]. 
Selection was not tried because it was thought that <15% transfection efficiency with poor cell 
viability was too low to obtain reasonable yield of transfected cells for in vitro study. 
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Figure 54. iDCs transfection by Microporation. 
Day 5 iDCs (1x10
6
) were microporated with pCMV/EGFP or pCMV/myc/ER (mock DNA) 
using several combination of microporation parameters. The transfected cells were cultured in 
R10 supplemented with GM-CSF and IL-4 cytokines. After 48 hours of DC microporation, the 
GFP expressing cells were examined by deconvolution fluorescent microscopy (a) and flow 
cytometry (b). The data are from iDCs microporated using these setting parameters: 2000 V 
(pulse voltage) – 20 msec (pulse width) -1p (pulse number) and 10 µg DNA which produced the 
highest transfection efficiency (<11%) as detected by flow cytometry.  
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5.2.2.3 Transfection of iDCs using Nucleofection 
 
No satisfactory transfection efficiencies were achieved with the abovementioned non-viral 
methods. At this time we had gained access to a nucleofection technique of transfection into 
primary cells and cell lines. The Nucleofector is an electroporation technique based on a 
combination of optimized electrical parameters generated by a special device called nucleofector 
using cell-type specific reagents. Nucleofection can transfect DNA directly into the nucleus of 
cells and therefore achieve a more successful transfection. iDCs were nucleofected using the 
manufacture settings U-02 (pre-programmed settings supplied by the company and no further 
detail is known other than the code chosen on the machine). 
 
Nucleofection of iDCs with pmaxGFP (Amaxa, Cologne, Germany) or pcDNA (mock DNA) 
was carried out and GFP expression was assessed by deconvolution fluorescence microscopy and 
flow cytometry after 48 hour of transfection. The percentage of GFP positive cells was used as a 
proportional read out of transfection efficiency. Initially, transfecting 1x10
6
 iDCs with 2 µg 
pmaxGFP produced ~26% transfection efficiency (as analysed by flow cytometry) relative to 
mock-transfection (data not shown). With the increasing the DNA concentration, transfection of 
1x10
6
 iDCs with 5 µg pmaxGFP produced the maximum transfection efficiency of ~ 42% 
compared to mock transfection and untransfected cells as examined by deconvolution 
microscopy in [Figure 55 (a)] and flow cytometry in [Figure 55 (b)]. iDC nucleofection was 
carried in six independent experiments with a mean transfection efficiency of 30 ± 10.28% 
(mean ± SD) [Figure 55 (c)]. Cell viability was approximately 70% as assessed by the standard 
approach using trypan-blue staining 48 hours post nucleofection. Transfection of day 5 iDCs 
(1x10
6
) with 5 µg pmaxGFP using nucleofection technology with the setting U-02 for 48 hours 
were the settings used and applied for the future experiments of iDCs transfection. 
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Figure 55. iDCs transfection by Nucleofection. 
Day 5 iDCs (1 x 10
6
) were nucleofected with 5 µg pmaxGFP or pcDNA (mock DNA) using the 
U-02 nucleofection program. Transfected cells were examined for GFP expression after 48 hours 
of transfection by deconvolution fluorescence microscopy (a) and flow cytometry (b). The data 
shown are for one representative experiment using the optimized transfection settings. (c) The 
chart shows the mean ± SD of percentage of iDCs expressing GFP by iDCs nucleofected with 
pmaxGFP or pCMV/myc/ER constructs and are representative of six independent experiments. 
Transfection efficiency was set at < 2% for mock transfected DCs (left density blot, panel b). 
This value was substracted from the values obtained for GFP transfected cells to give a corrected 
transfection efficiency value. 
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5.3 iDCs phenotype after Nucleofection 
 
On account of the cellular damage that transfection methods incur over the cells, an important 
consideration when working with DC was the impact of transfection on the cells phenotype. It 
was essential that the used transfection technique did not significantly modify DC phenotype in 
terms of maturation and expression of differentiation markers. To assess the effect of 
nucleofection on iDCs phenotype, day 5 iDCs were transfected with 5 µg pcDNA (mock control) 
or pmaxGFP construct. After 48 hours of transfection, the phenotype of transfected iDCs was 
compared to untransfected iDCs and mDCs (as positive control) with respect to CD80 and CD86 
surface expression and the data were analysed by flow cytometry (Figure 56). Transfection of 
iDCs with mock control or pmaxGFP DNA using nucleofection did not result in changes in the 
surface expression of CD80 and CD86 (except for slight down regulation of CD86 in transfected 
iDCs) as compared to untransfected iDCs phenotype. In addition, transfected iDCs did not show 
sign of maturation as compared to untransfected mDCs phenotype.  These data show that the 
nucleofection procedure retained the phenotypic characteristics of iDCs and that neither the 
buffers nor the technique applied induced upregulation of DCs maturation markers 48 hours post 
transfection. Based to the previously perceived data, it was decided that nucleofection would be 
the selected technique here after.  
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Figure 56. iDCs phenotype before and after nucleofection 
iDCs (1x10
6
) were transfected with 5 µg pmaxGFP or pCMV/myc/ER plasmids using the 
nucleofection optimized settings. After 48 hours of transfection, iDCs were examined for the 
surface expression of CD80 and CD86 relative to the untransfected iDCs and mDCs and the data 
were analysed by flow cytometry. Histograms show no significant changes in the expression 
pattern of CD80 and CD86 in transfected iDCs (with mock control or pmaxGFP) compared to 
untransfected iDCs. Transfected iDCs do not show signs of maturation as compared to mDCs 
surface expression of CD80 and CD86. The experiment was done twice and the data is from one 
representative experiment.   
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5.4   DC nucleofection with KDEL-fusion plasmid 
 
Following the optimization of DCs nucleofection using pmaxGFP plasmid, the next step was to 
use ICOS-KDEL plasmid to transfect DCs and analyze the effect on ICOSL surface expression. 
It was expected that transfecting DCs with the KDEL-fusion gene would produce down-
regulation of ICOSL.   
Day 5 iDCs were transfected with 5µg ICOS-KDEL-fusion gene or pCMV/myc/ER as mock 
control for 48 hours. ICOSL expression by iDCs transfected with ICOS-KDEL was analysed and 
compared to iDCs transfected with mock and untransfected iDCs using flow cytometry (Figure 
57). ICOSL surface expression was down regulated by <10% in iDCs transfected with ICOS-
KDEL compared to mock transfected DCs and iDCs. This result was consistently detected in 
three independent experiments using the optimized nucleofection conditions previously set out.  
Three possible explanations were postulated for the perceived very low ICOSL down regulation 
in iDCs transfected by ICOS-KDEL-fusion gene. First, ICOS-KDEL-fusion protein might not 
been expressed by the transfected cells to bind and retain the newly synthesized ICOSL in the 
ER; consequently no significant ICOSL down regulation was detected. This could be tested by 
analyzing the expression of ICOS-KDEL protein by iDCs transfected with the ICOS-KDEL 
construct using western blotting. Second, the turnover of ICOSL on the surface of the DCs was 
too slow for a down-regulation to appear after 48 hours, which might be due to ICOSL long 
protein half life. To assess this postulation, DC ICOSL protein half life was analysed. Third, the 
optimization of nucleofection conditions was conducted using pmaxGFP plasmid and not the 
tested ICOS-KDEL gene plasmid which might need further setting up for the used nucleofection 
parameters.  
 
 
 
 
 
 
                                                                                                                                             Chapter 5 
208 
 
 
 
 
 
 
 
 
 
 
 
Figure 57. iDCs nucleofection with ICOS-KDEL plasmid 
Day 5 iDCs were transfected with ICOS-KDEL or pCMV/myc/ER (mock control) using 
nucleofection. Cells were harvested and stained for ICOSL surface expression using anti-human 
ICOSL Ab or mouse IgG2b (isotype control) and analysed by flow cytometry 48 hours after cells 
transfection. iDCs transfected by ICOS-KDEL down-regulated ICOSL expression by <10% as 
compared to iDCs transfected with pCMV/myc/ER and untransfected iDCs. 
 
5.4.1 ICOS-KDEL protein expression 
 
To investigate the first suggested cause for the low ICOSL down-regulation following iDCs 
transfection by ICOS-KDEL construct; the expression of the 19 kDa ICOS-KDEL protein in cell 
lysates of iDCs transfected with ICOS-KDEL or mock plasmid samples were analysed by 
western blotting 48 hours after transfection. The transfected cell lysates were probed with anti-
myc antibody to detect myc tagged ICOS-KDEL-fusion protein and anti β-actin to ensure proper 
loading of the samples (Figure 58). Western blots of iDCs transfected with ICOS-KDEL lysates 
showed the expression of the 19 kDa protein (which was consistent with ICOS-KDEL) in iDCs 
transfected with ICOS-KDEL, while iDCs transfected with mock control did not express the myc 
tagged ICOS-KDEL-fusion protein. The expression of the ICOS-KDEL was detected relative to 
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the 42 kDa β-actin housekeeping protein. These data confirmed that ICOS-KDEL protein was 
expressed in iDCs transfected with ICOS-KDEL construct. 
 
  
 
 
 
 
 
 
Figure 58. Expression of ICOS-KDEL protein by iDCs transfected with ICOS-KDEL 
construct 
Day 5 iDCs were transfected with ICOS-KDEL or pCMV/myc/ER (mock control) using 
nucleofection, and the cells were cultured for 48 hours. Cells were harvested and the cell lysates 
were analysed by western blotting. Samples were blotted with anti-myc Ab to detect myc tagged 
ICOS-KDEL-fusion protein and anti-β actin Ab to ensure proper loading of the samples. Western 
blots show ICOS-KDEL protein expression in iDCs transfected with ICOS-KDEL at 
approximately 19 kDa compared to mock transfected iDCs. Expression of ICOS-KDEL is shown 
relative to iDCs expression of the 42 kDa β-actin housekeeping protein. 
 
5.4.2 Kinetics analysis of ICOSL surface expression by iDCs 
 
To investigate the second possible explanation for the low ICOSL down-regulation in iDCs 
transfected with ICOS-KDEL construct, kinetics of ICOSL expression by iDCs was analysed 
using cycloheximide (CHX) – an inhibitor of protein biosynthesis. Analysis of ICOSL 
expression kinetics would help in determining the suitable timing for detecting ICOSL down-
regulation following iDCs transfection with ICOS-KDEL construct. 
CHX exerts its effect at the posttranscriptional level by interfering with the translocation step in 
protein synthesis, thus blocking translational elongation (Schneider-Poetsch et al. 2010). ICOSL 
expression kinetics was examined relative to other surface molecule with established expression 
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kinetics as CD86. The previously reported data on mDC-CD86 kinetics using CHX showed that 
the half life of the surface expression of CD86 was 3 to 5 hours (Lelouard et al. 2007). The 
kinetic of CD86 expression by mDC was used in the titration of the working concentration of 
CHX to be used in the ICOSL expression assay.  mDCs were treated with varying CHX 
concentrations; 0, 50, 100, 200, 300 and 500 µM and CD86 expression was analysed by flow 
cytometry at 3 and 5 hour time points.  
The results showed that 50% of the CD86 surface expression by mDCs was down-regulated after 
5 hour of treatment with CHX (100 µM ) compared to 20% CD86 down-regulation after 3 hours 
of DC treatment using the same CHX concentration [Figure 59 (a)]. The CD86 down-regulation 
produced by treating mDCs with 100 µM CHX was comparable to that produced by treating 
mDCs with 200, 300 and 500 µM CHX [Figure 59 (b)]. As the required CHX working 
concentration is the lowest concentration that can be used whilst giving the effective protein 
synthesis inhibition in DCs, it was decided that 100 µM was the optimal CHX working 
concentration. Guided by this experiment data, iDC was treated with CHX (100 µM) and ICOSL 
surface expression was analysed by flow cytometry analysis at 24 hour time course: 0, 1, 3, 5 , 8, 
16 and 24 hours of CHX treatment. The results showed that ICOSL surface expression by iDCs 
was relatively stable for the first 8 hours of CHX treatment but thereafter progressively declined 
to reach approximately 50% of the initial ICOSL surface expression after 16 hours of CHX 
treatment [Figure 59 (c)].  
The data showed that 50% of ICOSL down-regulation on iDCs surface was induced within 
approximately 16 hours. Therefore, detecting ICOSL down-regulation in iDCs transfected with 
ICOS-KDEL after 48 hours would provide enough time to detect down-regulation of ICOSL 
surface expression due to the retention of the newly synthesized ICOSL protein. 
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Figure 59. Kinetic analysis of ICOSL expression by iDCs 
1x106 mDCs were treated with varying concentrations of CHX. CD86 surface expression was 
analysed after 3 and 5 hours of CHX (100 µM) treatment by flow cytometry. (a) Histogram shows 
CD86 expression by treated mDCs after 3 and 5 hours as compared to untreated mDCs. (b) A graph 
shows CD86 expression in mDCs treated for 5 hours with 0, 50, 100, 200, 300 and 500 µM CHX. 
The vertical axis represents the corrected MFI as a percentage of values determined with untreated 
mDCs. The MFI of isotype control was subtracted from MFI of CD86 positive cells to give the 
corrected value. (c) 1x106 iDCs were treated with CHX (100 µM) and ICOSL expression was 
monitored in a 24 hours time course and analysed by flow cytometry. A graph shows ICOSL 
expression kinetics by iDCs where the vertical axis represents mean ± SD of the corrected MFI as a 
percentage of value determined at zero point (untreated iDCs). The data were obtained from two 
independent experiments. The results showed that ICOSL surface expression by iDCs treated with 
CHX (100 µM) was stable for the first 8 hours but progressively declined to reach approximately 
50% of the initial ICOSL surface expression after 16 hours of CHX treatment.  
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5.4.3 Optimization of iDCs nucleofection with ICOS- KDEL construct 
 
To further investigate the third possible explanation for the low ICOSL down-regulation in iDCs 
transfected with ICOS-KDEL construct, additional optimization of iDCs transfection with ICOS-
KDEL construct was carried out. 1 x10
6 
day 5 iDCs were transfected with 5, 10 and 15 µg ICOS-
KDEL or pCMV/myc/ER (mock DNA) using the U-02 nucleofection program. ICOSL surface 
expression by the transfected iDCs was analysed by flow cytometry 48 hours after iDCs 
transfection. ICOSL surface expression was down regulated by iDCs transfected with 10 µg 
ICOS-KDEL by approximately 25% compared to mock transfected iDCs and untransfected DCs 
[Figure 60 (a)]. Meanwhile, very low level of ICOSL down-regulation was detected in iDCs 
transfected with 5 µg ICOS-KDEL [Figure 60 (a)]. Increased cell death was detected in iDCs 
transfected with 15 µg ICOS-KDEL or mock constructs (samples were not enough for analysis). 
Expression of the 19 kDa protein in the lysates of iDCs transfected with 5 and 10 µg ICOS-
KDEL or mock DNA was determined by western blotting using anti-human myc Ab to detect the 
myc-tagged ICOS-KDEL protein. Expression of ICOS-KDEL was detected relative to the 42 
kDa β-actin housekeeping protein. The 19 kDa ICOS-KDEL protein was detected in iDCs 
transfected with ICOS-KDEL construct in contrast to iDCs transfected with mock DNA [Figure 
60 (b)]. The strength of the protein band in iDCs transfected with 10 ug ICOS-KDEL was 
relatively stronger than in iDCs transfected with 5 ug ICOS-KDEL. This could be explained by 
the increase in KDEL-fusion protein expression by iDCs transfection with higher DNA 
concentration. This suggested that transfection of iDCs with higher ICOS-KDEL DNA 
concentration induced more KDEL-fusion protein expression which could explain the more 
ICOSL down-regulation detected in the transfected iDCs. ICOS-KDEL protein expressed by 
iDCs transfected with ICOS-KDEL appeared as two bands; one strong band at approximately 19 
kDa, which was consistent with ICOS-KDEL protein expected size, and another fainter lower 
band, which might be degradation products of the full sized protein.  
.  
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Figure 60. Optimization of iDCs transfection with ICOSL KDEL 
1x10
6 
iDCs were transfected with 5 and 10 µg ICOS-KDEL or pCMV/myc/ER using U-02 
nucleofection program. (a) ICOSL expression was analysed by flow cytometry after 48 hours of 
transfection. ICOSL expression is down regulated by ~25% in iDCs transfected with 10 µg 
ICOS-KDEL compared to mock transfected and untransfected iDCs. Very low ICOSL down 
regulation is shown in iDCs transfected with 5 µg ICOS-KDEL compared to mock transfected or 
untransfected iDCs. (b) Expression of the 19 kDa ICOS-KDEL protein in the lysates of 
transfected iDCs was determined by western blotting using anti human myc Ab after 48 of cells 
transfection. Expression of ICOS-KDEL is shown relative iDCs expression of the 42 kDa β-actin 
protein as housekeeping protein. ICOS-KDEL appears as two band; one strong band (at ~19 
kDa) and one lower faint band probably results from the degradation of the ICOS-KDEL protein.  
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5.5 Discussion  
The experiments in this chapter were designed to optimize a non-viral gene delivery system for 
DCs transfection. The non-viral vector will be an alternative to viral vectors for DC transduction 
in order to avoid the disadvantages associated with the viral vectors. Human DCs were prepared 
using CD14
+
 progenitors of the monocytes lineage from buffy coats (section 5.2.1) donated by 
healthy volunteers. It was thought that this approach is simple and generally applicable for 
therapy as large number of DCs can be generated and purified. Optimization of the transfection 
methods (in section 5.2.2) was carried out using GFP as a reporter gene, where the expression of 
fluorescence positive GFP transfected DCs was analyzed using both fluorescence microscopy 
and flow cytometry. In section 5.2.2.1, a chemical non viral method was made to transfect DCs 
using plasmid DNA and lipid compound, Tfx
TM
 -50
®
, either alone or in combination with either; 
anti-transferrin receptor Ab (TfR) or holo-Transferrin (Tf). However, the method used resulted in 
low cell viability and low transfection efficiency in our hands.  
Electroporation principle for DC transfection was evaluated in section 5.2.2.2 using 
microporation. The method applies electric field pulses to induce transient increase in cell 
membrane permeability which would be followed by intracellular DNA delivery. Microporation 
differs from the conventional electroporation as in the former pipette tip-style chamber is used 
instead of the usual cuvette electrode as the electroporation space.  The highest transfection 
efficiency obtained with iDCs transfection with microporation was < 11 %.   The adverse effects 
produced by this method of transfection such as increase in cell death were related to the 
increased voltage or pulse number used in cells transfection. Cell selection was not tried with 
iDCs transfected with microporation because it was thought that <11% transfection efficiency 
was too low to obtain reasonable yield of transfected cells for in vitro study. 
In the context of evaluating an efficient transfection method, transfecting DCs using 
nucleofection was then evaluated in section 5.2.2.3. Nucleofection is the latest introduced 
approach and can transfect DNA directly into the cell nucleus and therefore achieve higher 
transfection efficiency. This is of particular importance as it can facilitate transfection of non-
proliferating primary cells  as DCs (Lenz et al. 2003).  
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In this study, it was shown that with the use of the optimal transfection conditions, the maximum 
transfection efficiency obtained was 42 %, with a mean transfection efficiency of 30 ± 10.28% 
(mean ± SD of six independent experiments) as examined by flow cytometry 48 hours after iDCs 
transfected with pmaxGFP compared to pCMV/myc/ER as mock control. The detected cell 
viability was around 70%, as assessed by the standard approach using trypan-blue staining. The 
achieved transfection efficiency agrees with other research groups published data, where 
Gerdemann and his group transfect monocyte derived-DC with mean of 38 ± 11 % SD GFP 
positive cells at 6-hour post nucleofection and remained stable over a 60-hour time course 
(Gerdemann et al. 2009), while Lenz et al.  documented DC transfection efficiency of up to 55% 
(Lenz et al. 2003). 
 
Given these promising results, nucleofection was thought to be a potential method for iDCs 
transfection in this project. However, it was an important concern to assess the impact of 
nucleofection on iDCs phenotype, taking in consideration the cellular changes that transfection 
methods bring upon the cell. It was essential that the used transfection technique did not 
significantly modify iDC phenotype in terms of the expression of maturation markers (as the 
broad aim of this project was to use iDCs to induce transplantation tolerance). In section 5.3, the 
effect of nucleofection on these parameters was assessed by comparing CD80 and CD86 surface 
expression by transfected iDCs with pCMV/EGFP or pCMV/myc/ER (after 48 hours of 
transfection) to untransfected cells using flow cytometry. It was demonstrated that nucleofection 
did not adversely affect the DC phenotypes, as there were no changes detected in CD80 and 
CD86 expression by transfected iDCs as compared to untransfected iDCs. This suggested that 
the transfected iDC functional capacity should not be impaired. However for complete 
assessment of the effect of nucleofection on DCs, maturation of the transfected iDCs should be 
tried to verify that nucleofection did not affect DC antigen presentation capacity. In addition, the 
functional effects of nucleofection on DCs should be assessed in an MLR to examine their 
allostimualtory function and to verify that they can stimulate T cells proliferation in an MLR 
assay in comparison with untransfected DCs. 
It was aimed, after optimizing DC nucleofecting conditions, to transfect iDCs with ICOS-KDEL 
construct and analyze the effect on ICOSL expression by DC using flow cytometry. It was 
expected that transfection of iDC with the KDEL-fusion gene would result in ICOSL down-
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regulation of approximately 25-30 %, relative to the transfection efficiency of iDCs with 
pmaxGFP. 
However, in section 5.4 it was shown that ICOSL down regulation was < 10% in iDCs 
transfected with ICOS-KDEL construct as compared to mock transfected iDCs, and this was 
consistently detected in repeated experiments. The very low ICOSL down regulation in iDCs 
transfected with ICOS-KDEL construct could be caused by inadequate expression of ICOS-
KDEL-fusion protein. This could result from the unexpression of ICOS-KDEL protein by the 
transfected cells or the translated fusion protein was rapidly degraded. Consequently the newly 
synthesized ICOSL will not be retained in the ER and no significant ICOSL down-regulation 
will be detected. To assess this cause, analysis of ICOS-KDEL protein expression in iDCs 
transfected with ICOS-KDEL was done by western blotting of transfected cell lysates using anti-
human myc Ab after 48 hours of cell transfection (section 5.4.1). It was shown that ICOS-KDEL 
protein was expressed in transfected iDCs with ICOS-KDEL construct as a single protein band 
after 48 hours of iDCs transfection.  
As it is likely for a considerable decrease in surface ICOSL to be detected, ICOS-KDEL needed 
to be present for enough time to bind and retain newly synthesized ICOSL in the ER. For this 
effect to be sustained, ICOS-KDEL-fusion protein should continue forming a complex with 
ICOSL molecules till the already present surface ICOSL is broken down, as part of the normal 
protein turnover. Thus it was though that the inability to detect ICOSL down regulation might be 
due to long ICOSL protein half life. Consequently, the analysis of the effect of ICOS-KDEL 
protein on ICOSL down-regulation should be prolonged beyond 48 hours. To investigate this 
postulation, kinetics of ICOSL expression by iDCs was assessed in section 5.4.2 using CHX as 
protein synthesis inhibitor, and a 24 hour time course analysis of ICOSL expression was carried 
out by flow cytometry. The ICOSL kinetics study showed that ICOSL surface expression by 
iDCs was relatively stable for the first 8 hours of treatment with CHX (100 µM) but declined to 
reach approximately 50% of the initial ICOSL surface expression level (corresponding to 
untreated iDC) after 16 hours of CHX treatment. In agree with our data, an in vitro study showed 
ICOSL expression by activated B cell was down regulated by >50% after 24 hours and was 
extinguished over 72 hours through shutoff of ICOSL gene expression (Liang et al. 2002). This 
suggested that analysis of ICOSL expression in iDCs transfected with ICOS-KDEL after 48 
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hours would provide enough time to detect ICOSL down-regulation (if produced) by ICOS-
KDEL-fusion protein due to the retention of the newly synthesized ICOSL protein in the ER. 
The other possible cause for the low level of ICOSL down-regulation detected in iDCs 
transfected with ICOS-KDEL was that higher DNA concentrations might be needed to transfect 
iDCs in order to improve the effect of ICOS-KDEL in ICOSL down regulation. In section 5.4.3 
several DNA concentrations: 5, 10 and 15 µg per transfection condition were used for iDCs 
transfection and ICOSL down regulation was analysed by flow cytometry after 48 hours. It was 
demonstrated that transfecting of iDCs with 10 ug of ICOS KDEL DNA down regulated ICOSL 
surface expression by ~25% compared to mock transfected and untransfected iDCs. This 
suggested that the increase in ICOS-KDEL protein translation by transfected cells, which was 
translated by more DNA concentration, improved ICOSL down-regulation by transfected iDCs. 
The only limitation to the increase of DNA concentration was the relative increase in cell death. 
This could be avoided by improving the culturing condition as by increasing the FCS or the 
feeding cytokines that might help the transfected cells to endure the harsh transfection 
conditions. 
Although the efficiency of DCs transfection using nucleofection was not as high as that achieved 
with viral vectors that reached >90% with adenoviral transduction (Dietz and Vuk-Pavlovic 
1998), still it can be adequate in some clinical applications. Human DCs transfected with cationic 
peptide CL22 at 20% efficiency were able to stimulate in vitro and in vivo activation and 
proliferation of antigen specific autologous CD8
+
 T cells resulting in cellular and humoral anti-
tumour response in murine model of melanoma (Yang et al. 1999; Irvine et al. 2000). In addition, 
DCs expressing antigen-encoding genes at low levels can be effective in stimulating antigen-
specific T cells response, meanwhile the antigens can be transferred from DCs expressing them 
to be acquired by other DCs thus enhance T cells response (Bedford et al. 1999). Furthermore, in 
our hands, 3x10
7
 DCs can reliably be generated from 200 ml of peripheral blood and transfection 
of iDCs using nucleofection can result in approximately 1-3 x10
6
 transfected DCs (taking in 
consideration the cell death). This is thought to be adequate for in vitro as well as in vivo study. 
The number of transfected DC can be increased more if larger amount of blood was used to 
generate monocytes derived DCs.  Moreover, the transfected DCs yield can be improved 
following antibiotic (G418) selection of transfected DCs, as the ICOS-KDEL construct encodes 
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neomycin-resistance gene. In this study, a non-viral nucleofection protocol was set out as a 
successful method of DC gene transfer, and it is a potential method that can be capable of 
achieving adequate transfection efficiencies with limited toxicity to the cell. 
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6.1 Introduction  
6.1.2 Unregulated co-stimulatory signals expression and Immune 
diseases 
Immune homeostasis requires the continuous regulation of the cell molecules expression to 
maintain a balance between immune stimulation and inhibition. Several pathological conditions 
as autoimmune diseases, transplantation rejection and allergy can be mediated through 
uncontrolled sustained expression of co-stimulatory impulses. A recent study conducted on 
experimental autoimmune encephalomyelitis (EAE), an animal model for multiple sclerosis, 
showed a temporal up-regulation of surface expression of CD80 and CD86 on APCs and CNS-
infiltrating cells which correlated with the disease progression (Dudhgaonkar et al. 2009). 
Furthermore, the blocking of the CD80 co-stimulatory axis by CD80-competitive antagonist 
peptide (CD80-CAP) suppressed the severity and relapse in EAE (Dudhgaonkar et al. 2009).  
 
The ICOS-ICOSL costimulatory pathway is important for effective T cell functions, and 
dysregulation of this pathway enhances or induces pathological immune responses. ICOS:ICOSL 
pathway plays a role in the development of the pathological changes underlying diabetes mellitus 
in NOD mice, where ICOS
-/-
 mice did not develop insulitis, had low titers of auto-antibodies and 
remained normo-glycemic (Hawiger et al. 2008). Additionally, the administration of anti-ICOSL 
mAb to block ICOS functions suppressed the diabetes incidence by 50% in treated NOD mice 
(Hawiger et al. 2008). Yoshinaga et al. showed that transgenic mice expressing soluble ICOSL-
Ig fusion protein developed lymphoid hyperplasia in the spleen, lymph nodes and Peyer‟s 
patches due to sustained stimulation of B and T cells via ICOS:ICOSL pathway (Yoshinaga et al. 
1999). In addition, pre-sensitized mice treated with intra-peritoneal injection of ICOSL-Ig fusion 
protein during Ag challenge expressed enhanced contact hypersensitivity (Yoshinaga et al. 
1999). 
 
In the transplantation field, blocking of  ICOS functions through knocking down ICOS 
expression (ICOS
-/-
 mice) or anti-ICOS mAb administration resulted in significant inhibition of 
GVHD in murine transplantation model and reduced the number of alloantigen-specific effector 
cells in secondary lymphoid and GVHD target organs (Taylor et al. 2005). 
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 6.1.2 Cell Regulation of surface molecules 
 
Regulation of cell surface regulatory molecules turn over following stimulation is mediated 
through two mechanisms; ligand-dependent process known as endocytosis (or down-regulation) 
(Besterman and Low 1983) and non ligand-dependent process known as trans-modulation (or 
down-modulation) (Downing et al. 1989).  
Endocytosis and its counterpart exocytosis were first introduced in 1963 by de Duve as a 
substitute for the word cytosis to describe all different forms of this basic cellular transport 
mechanism as phagocytosis and pinocytosis (de Duve 1983). Endocytosis is the process of 
internalization of extracellular material within an invagination of the plasma membrane that 
gives rise to an independent cytoplasmic vesicle known by several names as phagosome, 
pinosome, coated or uncoated vesicle (Besterman and Low 1983). These vesicles pass either 
through a short pathway following fusion with plasma membrane and then exocytosed or get 
processed intracellularly by fusing with primary lysosomes to form secondary lysosmes. Each of 
these lysosmes give rise to a vesicle and a residual body where the former will fuse with the 
plasma membrane and exocytosed and the latter will reside in the cytosol (Besterman and Low 
1983). Classically, endocytosis has been divided into two types: “phagocytosis” a term used to 
describe the internalization of particulate matter visible by light microscopy and “pinocytosis” 
which is used to describe the uptake of all smaller substrates, ranging from insoluble particles to 
low molecular weight solutes or fluids. Endocytosis of specific receptor after ligand binding is a 
process known by receptor mediated endocytosis (a form of pinocytosis) which regulates the 
expression of several cell molecules as epidermal growth factor, insulin and alpha-2 
macroglobulin (Maxfield et al. 1978). 
Trans-modulation (or down modulation) is another well recognized mechanism of regulating cell 
surface molecules. Trans-modulation is mediated by direct targeting of the cell surface 
regulatory molecules as substrates of group of enzymes, known as membrane protein-
solubilizing proteases (MPSPs) or sheddases (Downing et al. 1989). The action of these enzymes 
results in the release (shedding) of a large portion, often the whole extracellular region 
(ectodomain), of the substrate proteins. Transmembrane proteins are likely to be cleaved in their 
stalk sequences which is a segment located between the cell surface proximal, folded, 
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extracellular domain and the transmembrane region (Ehlers et al. 1996). Susceptibility to 
cleavage is regulated by either a defined recognition motif that signal stalk cleavage (Brakebusch 
et al. 1994) or by the accessibility to a cleavable stalk (Ehlers et al. 1996). Several studies 
indicated that the release of membrane proteins may require the presence of a juxtamembrane 
stalk with at least 10 residues in length, but the exact length and characteristics of the stalk that 
control cleavage susceptibility needs further determination (Ehlers et al. 1996). 
 
Ectodomain shedding modulates the function of substrate proteins via different mechanisms. 
Cleavage of the ectodomain results in the reduction of the ligand function due to the decrease of 
the targeted molecules concentration on the cell surface which leads to direct inhibition of ligand 
receptor interaction (Rovida et al. 2001). Another mechanism is the generation of a soluble 
ligand-binding cognates (soluble receptors) which can compete with their similar membrane 
protein for their ligand resulting in either preventing (antagonist) or favouring (agonist)  the 
formation of active signalling complexes (Rose-John and Heinrich 1994). In addition, the 
function of the substrate protein can be modulated due to the generation of a trans-membrane 
cytoplasmic domain which can be a substrate of another proteolytic system, and has a signalling 
function different from the full length one (Vecchi and Carpenter 1997). Proteins subjected to 
trans-modulation are large group of transmembrane proteins including receptors, receptor ligands 
and cell adhesion molecules (Arribas and Borroto 2002). Ectodomain shedding of cell surface 
molecules through activation of different sheddase pathways has been reported with TNFR 
(Howard et al. 1993), IL-6R (McLoughlin et al. 2004), Fas-ligand (Xia et al. 2002) and CD40 
Ligand (Pietravalle et al. 1996). 
 
6.1.3 Regulation of ICOSL cell surface expression 
  
ICOS binds selectively to ICOSL and not to CD80 or CD86 (Aicher et al. 2000; Ling et al. 2000) 
and ICOSL is expressed by various cell types in various tissue (Swallow et al. 1999). This 
implies their specific and important role as co-stimulatory complex. Kinetic of ICOS-ICOSL 
expression during the course of immune response are properly regulated. This proper kinetic 
control ensures appropriate T cell responses and prevents dysregulation of immune reaction. 
Most of the conducted studies investigated the regulation of murine ICOSL mainly by B cells 
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(Liang et al. 2002; Watanabe et al. 2008). To our knowledge, no work has been conducted to 
investigate the regulation of ICOSL expression by human DCs. In this chapter, study of the 
pattern of ICOSL regulation in human DC was conducted to understand the underlying immune 
regulatory system, which may help in the comprehension of the pathogenesis of immune diseases 
and developing appropriate treatments. 
6.3 The aims of this chapter 
The experiments in this chapter were designed to achieve the following aims;  
1. Analyse the kinetics of ICOSL expression by DCs in different maturation stages  
2. Identification of  the role of activated T cells in regulating ICOSL expression by DCs 
3. Identification of the possible molecular mechanisms that regulate ICOSL expression in 
human DCs. 
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6.4 Results 
6.4.1 Kinetics of ICOSL expression by monocytic-derived DC (mo-
DC) 
 
The kinetics of ICOSL expression in DC and its correlation with the stage of DC maturation was 
studied in monocytic-derived DCs. CD14
+
 monocytes were differentiated into iDCs and mDCs 
(as described in section 2.2.4.1.2). CD14
+
 cells were differentiated to iDCs by culturing cells in 
GM-CSF and IL-4 or to mDC using two protocols, either through combination of GM-CSF, IL-4 
with IL-1β, TNF-α and IFN-γ or with LPS. iDCs and mDCs were stained for ICOSL expression 
that was compared to other DC markers expression as; CD80, CD86 and MHC class II.  
Flow cytometric analysis of iDCs showed that ICOSL expression was highly expressed on their 
surface with moderate expression of CD80 and low expression of CD86 and MHC class II 
[Figure 61 (a)]. Whereas mDCs, generated using both protocols, showed up-regulation of DC 
maturation markers CD80, CD86 and MHC class II, while ICOSL surface expression was down 
regulated [Figure 61 (b,c)]. No significant differences in the expression of DCs markers were 
detected between mDCs matured using different protocols. These data illustrated that 
differentiation of iDCs to mDCs, a cell stage that involved mainly in antigen presentation to T 
cells, was accompanied by upregulation of both CD28 ligands (CD80 and CD86) and MHC class 
II, whereas the level of ICOSL surface expression was down regulated. In addition, 
ICOS:ICOSL costimulatory role is mediated mainly via iDCs.  This pattern of cell markers 
distribution by DC suggests that the interaction between mDCs and T cells are mainly mediated 
via CD28-B7 costimulatory pathway, while the interaction between iDCs and T cells are 
mediated mainly via ICOS:ICOSL pathway.  
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Figure 61. iDCs express high level of ICOSL that was down regulated on maturation. 
(a) iDCs were differentiated from CD14
+
monocytes cultured for 6 days in GM-CSF and IL-4. (b) 
Day 4 iDCs were matured using cytokines cocktail: IL-1β, TNF-α and IFN-γ or using LPS (c) for 
additional 2 days. Day 6 DCs were stained for ICOSL, CD80, CD86 and MHC class II and the 
data were analysed by flow cytometry. iDCs express high level of ICOSL with low expression of 
CD80, CD86 and MHC class II while  mDCs (generated using both protocols) show down 
regulation of ICOSL expression with up-regulation of the other DC maturation markers; CD80, 
CD86 and MHC class II. These histograms demonstrate that ICOSL expression level by DC is 
related to DC maturation stage. Histograms are from one representative experiment out of seven 
independent experiments. 
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6.4.2 Analysis of ICOS:ICOSL signal contribution  to T cell functions 
6.4.2.1 T cell proliferation assay 
 
The functional relevance of ICOS:ICOSL interaction on T cells proliferation was assessed by 
setting out an allogenic mixed lymphocytic reaction (MLR) in the presence and absence of anti-
ICOSL blocking antibody. T cells isolated by negative selection from PBMC, were used as 
responder cells and DCs, either iDCs or mDCs, were used as stimulator cells. For effective 
ICOS:ICOSL interaction, T cells were activated using anti-CD3/CD28 coated beads for 3 days 
prior to MLR to allow the up-regulation of ICOS expression. 1x10
5
 activated T cells were seeded 
in triplicate in 96-well U-bottom plates at a 1:10 DC : activated T cell ratio. Co-cultures were 
either treated with anti- ICOSL blocking Ab or IgG2a (control antibody) or untreated for 72 
hours and then pulsed with 1 µCi of [
3
H]-thymidine for the last 16-18 hours of co-culture 
[Figure 62 (a)]. Results of the MLR assay demonstrated that T cells proliferation was partially 
inhibited by anti-ICOSL blocking Ab in cocultures of both activated T cells and iDCs or mDCs 
as compared to isotype control or untreated co-cultures. T cells proliferation inhibition was more 
detected with iDCs coculture treated with anti-ICOSL mAb which could be related to the high 
ICOSL surface expression by iDCs compared to mDCs.   
For further demonstration of the functional relevance of ICOS:ICOSL interaction on T cell 
proliferation, different cell lines were used as stimulators in MLR assays. CHO ICOSL cells 
treated with mitomycin–C [Figure 62 (b)], M1DR1 cells irradiated with 100 Gy [Figure 62 (c)] 
or THP-1 cells irradiated with 60 Gy [Figure 62 (d)] were cocultured with activated T cells 
(using anti-CD3/CD28 for 3 days prior to the assay) at a 1:5  stimulator : responder ratio. The 
cocultures were treated in the same manner as with the previous activated T cells and DCs co-
cultures. Results from the MLRs demonstrated that the T cells proliferation was partially 
inhibited in all the MLR conditions treated with anti-ICOSL blocking mAb as compared to 
isotype control or untreated cells. Inhibition of activated T cells proliferation was statistically 
significant in cocultures of activated T cells with CHO ICOSL treated with anti-ICOSL blocking 
Ab. These data suggested that activated T cells proliferation was partially dependent on ICOS-
ICOSL signal and ICOS co-stimulation required to induce activated T cell expansion could be 
inhibited by blocking the signal pathway by anti-ICOSL blocking Ab.  
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Figure 62. Functional analysis of ICOS: ICOSL pathway blocking on T cells proliferation in 
allogenic MLR 
Allogenic MLR of pre-activated T cells with anti-CD3/CD28 beads for 3 days and a) DCs either 
as iDCs or mDCs, b) CHO ICOSL cells treated with mitomycin-c, c) M1DR1 cells irradiated with 
100 Gy or d) THP-1 cells irradiated with 60 Gy. Co-cultures were either treated with anti-ICOSL 
blocking Ab or IgG2a (isotype control) or untreated. T cells proliferation was assessed by 
3
[H]-
Thymidine incorporation after 72 hours. All results shown are the Mean ± SD of triplicate wells. 
Activated T cells proliferation is partially inhibited by treating co-cultures with anti-ICOSL 
blocking mAb compared to isotype control. Thymidine incorporation counts show statistical 
significant [p <0.05 indicated by asterisk (*)] reduction in activated T cell proliferation in 
coculture of T cells and CHO ICOSL cells. Histograms are from one representative experiment 
out of three independent experiments. 
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6.4.2.2   Cytokine profile secretion by activated T cells in MLR assay 
 
Further to assessing the contribution of ICOS:ICOSL interactions to T cells functions, the level 
of cytokines IL-4, IFN-γ and IL-10 secreted by activated T cells cocultured with DCs (iDCs or 
mDCs) or CHO ICOSL cells in allogenic MLRs were assessed by ELISA. Similar to the MLRs 
settings used in section 6.4.2.1, 1x10
5
 activated T cells (using anti-CD3/CD28 beads for 3 days 
prior to MLR assay) were cocultured with DC (iDCs or mDCs) at a 1:10 DC:T cell ratio or CHO 
ICOSL cells at a 1:5 CHO ICOSL: activated T cell ratio. The cocultures were treated with anti-
ICOSL blocking Ab or IgG2a (isotype control) or untreated for 72 hours. The culture 
supernatants (SN) from the MLRs were harvested for the detection of IL-4 [Figure 63 (a)], IFN-
γ [Figure 63 (b)] and IL-10 [Figure 63 (c)] by ELISA.   
Results of IL-4 analysis by ELISA [Figure 63 (a)] showed high IL-4 concentration levels in 
culture SN from activated T cells cocultured with iDCs relative to mDCs. In contrast, IL-4 was 
below detection level in culture SN from activated T cells with CHO ICOSL. Blocking of 
ICOS:ICOSL pathway by anti-ICOSL blocking Ab showed a statistical significant decrease in 
IL-4 levels by 75% in culture SN from activated T cells and iDCs coculture. These data 
suggested that ICOS:ICOSL was crucial for upregulation of IL-4 secretion by activated T cells. 
However, ICOS:ICOSL interaction was not the inducer for IL-4 secretion, as IL-4 could not be 
detected in coculture with CHO ICOSL cells (as a stimulator), as the activated T cells received 
only ICOS:ICOSL signal missing other essential co-stimulatory signals. Results of IFN-γ 
analysis by ELISA [Figure 63 (b)] showed high IFN-γ concentration levels in culture SN from 
activated T cells with mDCs compared to iDCs. On the contrary, very low concentration levels 
of IFN-γ were detected in culture SN from cocultures where CHO ICOSL cells were used as 
stimulators. IFN-γ concentration levels were not significantly changed following blocking of 
ICOS:ICOSL interaction with anti-ICOSL blocking Ab in all culturing conditions. This 
suggested that ICOS:ICOSL pathway has no regulatory role in the upregulation of IFN-γ 
secretion by activated T cells, however, ICOS:ICOSL interaction could be one of the inducing 
signals for IFN-γ production.  
Results of IL-10 secretion analysis by ELISA [Figure 63 (c)] showed high IL-10 concentration 
levels in culture SN from activated T cells with mDCs compared to iDCs. In addition, IL-10 
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concentration levels were decreased in culture SN from activated T cells and iDCs or mDCs 
treated with anti-ICOSL blocking Ab but it did not reach statistical significance.  
From the activated T cells cytokine profile analysis, it was shown that ICOS:ICOSL signal is 
mainly involved in the regulation of Th-2 cytokines secretion. Blocking of ICOS:ICOSL 
costimulatory pathway significantly decreased IL-4 concentration levels secreted by activated T 
cells. Similarly, IL-10 secretion was decreased following blocking of ICOS:ICOSL interaction. 
The decrease in IL-10 concentration levels was detected in three independent experiments; 
however, it did not reach statistical significance. ICOS:ICOSL signalling has no regulatory role 
in Th-1 cytokines secretion as no changes were detected in IFN-γ concentration levels secreted 
by activated T cells following the blocking of ICOS: ICOSL costimulatory pathway.  
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Figure 63. Functional analysis of ICOS:ICOSL pathway blocking on cytokine production 
by activated T cells 
1x10
5
 activated T cells (using anti-CD3/CD28 beads for 3 days) were cocultured with DC (iDCs 
or mDCs) or CHO ICOSL cells at a 1:10 or 1:5 DC/CHO ICOSL cell: activated T cell ratio, 
respectively. The cocultures were treated with anti-ICOSL blocking Ab or IgG2a as isotype 
control or untreated for 48 hours. Culture SNs were harvested and cytokines concentration levels 
were assessed by ELISA. (a) IL-4 concentration levels are higher in MLRs where iDCs were 
used as stimulator compared to mDCs. IL-4 concentration is below detection level in SN from 
coculture of CHO ICOSL cells and activated T cells. IL-4 concentration levels are significantly 
decreased by 75% (marked by asterisk * p<0.05) when anti-ICOSL blocking Ab was added to 
iDCs co-culture. b) IFN-γ concentration levels show no changes in SNs from cocultures treated 
with anti-ICOSL blocking Ab. c) IL-10 secretion is slightly decreased following blocking of 
ICOS:ICOSL pathway using ICOSL blocking Ab. Data are shown as mean ± SD of triplicate 
wells of one representative experiment out of three independent experiments. 
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6.4.3 ICOSL Surface expression  is down regulated following 
coculture with activated T cell  
  
In the present section, the relative contribution of activated T cells in the regulation of ICOSL 
expression on human DC surface was analyzed. Activated T cells (using anti-CD3/CD28 beads 
for 72 hours) to allow ICOS up-regulation [Figure 64 (a)] were co-cultured with DCs – iDCs or 
mDCs [Figure 64 (b)] – or CHO ICOSL cells [Figure 64 (c)] at a 1:1 or 1:5 DC/CHO ICOSL 
cell: activated T cell ratio, respectively for 48 hrs (these culturing conditions were applied in all 
of the following experiments unless otherwise stated). DCs and CHO ICOSL cells were stained 
for ICOSL expression and analyzed by flow cytometry.  
The analysis of the data showed down-regulation of ICOSL surface expression by 80% in iDCs 
and 75% in mDCs following coculture with activated T cells, whereas CHO ICOSL cells down- 
regulated ICOSL surface expression by 88%. This data suggested that endogenously expressed 
ICOSL on DC as well as ectopically expressed ICOSL on CHO ICOSL cells was down regulated 
following culturing with activated T cell expressing ICOS. (Table 9) shows changes in MFI of 
ICOSL expression following coculture of DC and CHO ICOSL cells with activated T cells as 
percentage of ICOSL reduction, calculated by comparing ICOSL surface expression before and 
after culturing of cells with activated T cells. 
To investigate the correlation between the detected ICOSL down-regulation and activated T 
cells; iDCs or mDCs were cultured with activated or unactivated T cells for 48 hours. DCs 
cultured alone or after coculture were stained for ICOSL expression and the data were analysed 
by flow cytometry (Figure 65). The results showed that ICOSL expression by iDC slightly 
changed following coculture with unactivated T cells as compared to iDCs alone, while ICOSL 
expression was clearly down-regulated following coculture with activated T cells as compared to 
iDCs alone. Whereas, mDCs relatively down-regulated ICOSL expression following coculture 
with unactivated T cells as compared to mDCs alone or mDCs cocultured with activated T cells. 
From these data, it could be suggested that activated T cells triggered ICOSL down regulation on 
DCs and CHO ICOSL cell surface. 
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 Isotype control 
DC alone 
DC+ activated T cells 
 
 
 Isotype control 
CHO  ICOSL alone 
CHO  ICOSL + activated T cell 
 
 
 Cells 
Alone 
After 
cocult-
ure  
% of ICOSL  
Reduction(*) 
iDC 153 31 80% 
mDC 40 10 75% 
CHO  
ICOSL 
1796 217 88% 
            Activated T cell                                    iDC                                                          mDC  
 
 
ICOSL 
        CHO ICOSL cells                          CHO ICOSL cells+ activated T cells ICOS 
 
ICOSL Table 9. MFI of ICOSL 
expression following cocult-
ure with activated T cells 
 
Figure 64. Activated T cells down-regulate ICOSL cell surface 
expression 
Activated T cells were cocultured with iDCs or mDCs at 1:1 DC: 
activated T cell ratio for 48 hrs, after which DCs were stained for 
ICOSL expression and analyzed by flow cytometry. a) Left 
histogram shows ICOS expression by T cells following activation 
with CD3/CD28 beads for 72 hours. The middle histogram shows 
ICOSL down-regulation by iDCs following coculture with 
activated T cells for 48 hr compared to iDCs cultured alone.  The 
right histogram shows ICOSL down-regulation by mDCs 
cocultured with activated T cells compared to mDCs cultured alone 
b) CHO ICOSL cells were cultured with activated T cells at a 1:5 
CHO ICOSL cell : T cell for 48 hours and ICOSL expression by 
CHO ICOSL cells was analysed by flow cytometry. The left 
histogram shows ICOSL expression by CHO ICOSL cells cultured 
alone, and the right one shows ICOSL down regulation by CHO 
ICOSL cells co-cultured with activated T cells. Histograms are 
representative of one experiment out of five experiments.  
 
 % of ICOSL reduction = 100% (represents 
ICOSL MFI of cell alone) - ICOSL MFI after 
culturing with activated T cells  / ICOSL MFI  
of cells alone X 100. The MFI of isotype control 
was subtracted from MFI of ICOSL positive 
cells to give the corrected MFI value. 
 
ICOS 
%
 o
f 
M
ax
 
%
 o
f 
M
ax
 
                                                                                                                                             Chapter 6 
233 
 
c) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 65. ICOSL expression by DCs cultured with unactivated versus activated T cells 
iDCs or mDCs were cultured with activated or unactiveted T cells at a 1:1 DC : T cell ratio for 
48 hours. DCs were stained for ICOSL expression and the data were analysed by flow 
cytometry.  In the left panel histograms, ICOSL expression on iDCs is slighthly down-regulated 
following coculture with unactivated T cells, while it is clearly decreased following coculture 
with activated T cells compared to level of expression on iDCs alone. In the right panel 
histograms, ICOSL expression is down regulated by mDCs cultured with activated T cells as 
compared to mDCs cultured alone or mDCs cultured with unactivated T cells. Histograms are 
repesentative of one expermients out of three experiments. 
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iDCs and mDCs phenotype were examined following  coculture with activated or unactivated T 
cells and compared with DCs phenotype cultured alone. [Figure 66 (a)] shows that iDCs 
differentiated to mature stage following coculture with activated T cells compared to iDCs alone, 
as iDCs upregulated the maturation markers CD80, CD86 and MHC class II. This suggested that 
the detected ICOSL down-regulation by iDCs cultured with activated T cells was partly caused 
by iDCs differentiation to mDCs. This was consistent with the results generated in section 6.4.1 
which showed the mDCs down-regulated ICOSL compared to iDCs as a part of the DC 
maturation phenotype. Whereas, mDCs showed no significant changes in the phenotype markers 
following coculture with activated versus unactivated T cells [Figure 66 (b)]. This suggested 
that ICOSL down-regulation by mDCs cultured with activated T cells could be caused partially 
by another mechanism apart from DC maturation. The possibility of ICOS binding induced 
ICOSL down-regulation was assessed in the following section.  
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Figure 66. DCs phenotype in cultures with activated or unactivated T cells 
(a) iDCs or mDCs were cocultured with unactivated or activated T cells at a T cell :DC 1:1 ratio for 
48 hours. DCs were stained for CD80, CD86 and DR and analysed by flow cytometry.  iDC shows 
up-regulation of maturation markers; CD80 CD86 and DR following coculture with activated T cells, 
while slight changes were detected following coculture with unactivated T cells. (b) mDC shows no 
significant changes in the phenotype markers following coculture with activated versus unactivated T 
cells. Histograms are from one representative experiment out of five independent experiments. 
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6.4.4 ICOSL down regulation can be inhibited by ICOS:ICOSL 
pathway blocking 
 
To investigate the role of ICOS in inducing ICOSL down-regulation on DCs and CHO ICOSL 
cells, anti-ICOSL blocking mAb or IgG2a (isotype control) were added to cocultures of activated 
T cells and iDCs or CHO ICOSL cells for 48 hours. iDCs and CHO ICOSL cells were stained 
for ICOSL expression and the data were analysed by flow cytometry. The results showed partial 
inhibition of ICOSL down regulation by iDCs or CHO ICOSL cells in cocultures treated with 
anti-ICOSL blocking Ab as compared to istotype control (Figure 67). Blocking of ICOS:ICOSL 
pathway preserved 75% of  ICOSL expression by iDCs and 37% by CHO ICOSL cells.  (Table 
10) shows changes in MFI of ICOSL expression following coculture of iDCs or CHO ICOSL 
cells with activated T cells before and after adding anti-ICOSL blocking Ab.  
 
From these data, it could be suggested that ICOSL down-regulation was induced by ICOS 
binding as ICOSL down-regulation was partially inhibited by blocking ICOS:ICOSL interaction 
using anti-ICOSL blocking Ab. Thus activated T cells regulated ICOSL expression by cells via 
ICOS:ICOSL binding i.e. cell-cell contact dependent ICOSL down-regulation.  
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Figure 67. ICOSL down regulation can be inhibited by blocking of ICOS:ICOSL pathway  
iDCs and CHO ICOSL cells were cocultured with activated T cells at ratio 1:1 or 1:5 DC/CHO 
ICOSL cell : activated T cell respectively for 48 hours. The cocultures were treated with anti-ICOSL 
blocking Ab or IgG2a (isotype control).  Flow cytometric analysis of ICOSL expression by iDCs (a) 
or CHO ICOSL cells (b) shows ICOSL down-regulation by cells cultured with activated T cells.  
ICOSL down-regulation is partially inhibited by adding anti-ICOSL blocking Ab to the cocultlure. 
Histograms are from one representative experiment out of two independent experiments. 
    
Table 10. MFI of ICOSL expression by iDCs and CHO ICOSL cells cocultured with activated T 
cells before and after adding anti-ICOSL blocking Ab. 
 
(a) % of ICOSL reduction = 100% (represents ICOSL MFI of cells alone) - ICOSL MFI of cells in coculture + 
isotype control  / ICOSL MFI of cells alone X 100 
(b) % of ICOSL reduction = 100% (represents ICOSL MFI of cells alone) - ICOSL MFI of cells in coculture + 
anti-ICOSL blocking Ab  / ICOSL MFI of cells alone  X 100 
N.B MFI of the isotype control was subtracted from MFI of ICOSL positive cells to give the corrected 
MFI value. 
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6.4.5 ICOSL down-regulation occurs without ICOS- ICOSL ligation   
 
In order to reveal whether ICOSL down-regulation can occur in the absence of ICOS expressing 
T cells, iDCs, mDC or CHO ICOSL cells were cultured in SN from activated T cells (using 
CD3/CD28 beads for 72 hours) or R10 media as negative control for 48 hours.  iDCs, mDCs and 
CHO ICOSL cells were stained for ICOSL expression and DCs were also stained for CD86 
expression and the data were analysed by flow cytometry. [Figure 68 (a)] shows that all the cells 
partially down-regulated ICOSL expression on their surfaces by 33% in iDCs, 37% by mDCs 
and 50% in CHO ICOSL cells. These data suggested that ICOSL was down-regulated in the 
absence of ICOS:ICOSL interaction. (Table 11) shows MFI of ICOSL expression following 
culturing of DC or CHO ICOSL cells with SN from activated T cells versus R10 media.  
 In addition, analysis of CD86 expression by DC showed that iDCs upregulated CD86 expression 
on their surface, which  suggested that the iDCs were matured by culturing in SN from activated 
T cells, while no changes were detected with CD86 expression by mDCs [Figure 68 (b)]. These 
results showed that ICOSL down-regulation detected in iDCs cultured in SN from activated T 
cells was partially caused by iDCs maturation as detected by the upregulation of CD86 surface 
expression. Maturation of iDCs cultured in SN from activated T cells was probably caused by the 
cytokines secreted by activated T cells which initiated DC maturation, consequently the matured 
DCs down-regulated ICOSL. This data agrees with the previous data [in section 6.4.3 Figure 66 
(a)], where iDCs expressed maturation markers following culturing with activated T cells. These 
results suggested that ICOSL regulation could be mediated in a non-ligand binding way, as it 
was detected in the absence of ICOS molecule to bind i.e cell-cell contact independent ICOSL 
down-regulation. The data generated in this section and in section 6.4.3 suggested that ICOSL 
regulation could be mediated partially through ICOS:ICOSL engagement and partly through a 
signal independent on cell contact. 
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Figure 68. ICOSL down-regulation can occur without ICOS- ICOSL ligation.  
iDCs, mDCs or CHO ICOSL cells were cultured in the SN from activated T cells (using 
CD3/CD28 beads for 72 hours) for 48 hours and ICOSL and CD86 expression (by DCs) were 
analyzed by flow cytometry. A) Histograms show down-regulation of ICOSL expression by 
iDCs, mDCs or CHO ICOSL cells cultured in the SN from activated T cells. ICOSL down-
regulation on cell surface occurred in the absence of ICOS:ICOSL binding. b) CD86 is up-
regulated by iDCs but not by mDCs cultured in the SN from activated T cells. Histograms are 
from one representative experiment out of two independent experiments. 
Table 11. MFI of ICOSL expression by DCs and CHO ICOSL cells cultured in the SN of  
activated T cells versus R10 media 
 Cells cultured in 
R10 
Cells cultured in 
activated T cells 
SN 
% of ICOSL 
reduction (*) 
iDCs 90 60 33 
mDCs 43 23 37 
CHO ICOSL 289 144 50 
 
 % of ICOSL reduction = 100% (represents ICOSL MFI of cells cultured in R10) -  ICOSL MFI of cells cultured in  
activated T cell SN / ICOSL MFI of cells cultured in R10 X 100.   
- N.B. MFI of the isotype control was subtracted from MFI of ICOSL positive cells to give the 
corrected MFI values. 
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6.4.6 Mechanisms of surface ICOSL down-regulation 
 
As previously mentioned, the cell response to external signalling can be interpreted in a form of 
a reduction in the available cell surface molecules transmitting this signal to avoid continuous 
stimulation. As the precise mechanisms of ICOSL regulation are still to be evaluated, in this 
section regulatory mechanisms and the possible molecular explanation will be assessed. 
6.4.6.1 ICOSL is regulated by ectodomain shedding 
 
Study conducted on ICOSL expression by murine B cells reported that ectodomain shedding 
mediated by proteolytic enzymes could be a possible regulatory mechanism for ICOSL surface 
expression (Logue et al. 2006). To investigate whether ICOSL down-regulation on human DCs 
is mediated by the same mechanism, varying concentrations of two different protease inhibitor 
cocktails (PI A and PI B) were added to coculture of iDCs or CHO ICOSL cells with activated T 
cells at a 1:1 and 1:5 DC/CHO ICOSL cell : activated T cell ratio, respectively for 48 hours. H20 
was used as negative control and was added to the cells coculture. iDCs and CHO ICOSL cells 
were stained for ICOSL expression and the data were analysed by flow cytometry. [Figure 
69(a)] shows that iDCs maintained nearly all the ICOSL surface expression in cocultures treated 
with both protease inhibitor cocktails. iDCs cocultured with activated T cells and treated with 
protease inhibitor A or B expressed respectively, 86% and 94% of ICOSL expression levels 
compared to ICOSL expression level by iDCs alone. Similar results were obtained with CHO 
ICOSL cells which partially maintained its ICOSL expression with 15% (with PI A) and 25% 
(with PI B) compared to ICOSL expression levels by CHO ICOSL cells cultured alone [Figure 
69 (b)]. (Table 12) shows changes in MFI of ICOSL expression following culturing of iDCs and 
CHO ICOSL cells with activated T cells before and after adding proteases inhibitors. These data 
suggested that ICOSL down-regulation resulted from culturing of DCs or CHO ICOSL cells with 
activated T cells was mediated via ectodomain shedding which could be inhibited by protease 
inhibitor cocktails. These cocktails inhibit a broad spectrum of proteolytic enzymes that targets 
molecules on the cell surface as enzyme substrates. These enzymes cause shedding of a large 
portion often the whole extracellular region (ectodomain) of the substrate proteins. In case of 
ICOSL, this was interpreted as ICOSL down-regulation on the cell surface.  
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Figure 69. ICOSL is down-regulated by ectodomain shedding. 
iDCs and CHO ICOSL cells were cocultured with activated T cells at ratio 1:1 and 1:5 DC/CHO 
ICOSL cell: T cell, respectively for 48 hours. Protease inhibitor A (PI A) was added at dilution 1:25, 
12.5, 6 and 3 while protease inhibitor B (PI B) was added at dilution 1:100, 200, 400 and 800 to the 
cocultures. H20 was used as negative control. After 48 hours, ICOSL expression by iDCs (a) and 
CHO ICOSL cells (b) was examined by flow-cytometry. Histograms show down-regulation of 
ICOSL expression by cells cultured with activated T cells. ICOSL down-regulation by iDCs and 
CHO ICOSL cells is partially to completely inhibited by protease inhibitor cocktails. Histograms are 
from one representative experiment out of two independent experiments. Histograms shown are of 
culture conditions using the dilutions 1:25 and 1:800 for PI A and PI B, respectively. 
Table 12. Changes of ICOSL expression MFI following culturing of iDCs and CHO ICOSL 
cells with activated T cells before and after adding the proteases inhibitors cocktails 
 
PI A; protease inhibitor A, PI B; protease inhibitor B, PIs; protease inhibitors A and B. 
 
(a) % of ICOSL reduction = 100% (represents ICOSL MFI of cells alone)  - ICOSL MFI  of cells after culturing 
with activated T cells  / ICOSL MFI of cell alone X 100 
(b) % of ICOSL expression after PIs = ICOSL MFI in of cells in culture treated with PI A / ICOSL MFI of cells 
alone X 100  or ICOSL MFI in culture treated with PI B / ICOSL MFI of cell alone X 100  
 Isotype control 
  iDCs alone 
 iDCs + activated T cell + H2O 
 iDCs + activated T cell+ PI 
 Isotype control 
  CHO ICOSL cells alone 
  + activated T cell + H2O 
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coculture 
+ PIA 
Coculture   
+ PIB 
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MFI 
% of ICOSL 
reduction (a) 
 
MFI 
 
MFI 
iDCs 70 42 40 60 66 86-94 
CHO  ICOSL 1320 105 92 372 200 15-25 
PI A (1:25)                                              PI B (1:800) 
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6.4.6.2 ICOSL is not regulated on the transcriptional level  
 
The data generated in section 6.4.5 showed ICOSL down-regulation in the absence of 
ICOS:ICOSL binding. This prompted the analysis of the molecular mechanism underlying 
ICOSL expression to investigate whether ICOSL down-regulation resulted from changes in the 
levels of ICOSL mRNA transcription.  
 
ICOSL mRNA was quantified using quantitative RT-PCR to detect the changes in ICOSL gene 
transcription in iDCs cultured in the SN from activated T cells (to avoid contamination with T 
cell ICOSL) and in CHO ICOSL cells cocultured with activated T cells for 48 hours. HPRT 
mRNA, a housekeeping gene, was assessed simultaneously to normalize ICOSL mRNA 
expression and to avoid the possible errors of mRNA preparations. Quantification of mRNA was 
done at a 48 time course; 1, 6, 24 and 48 hours to investigate the dynamics of ICOSL mRNA 
changes. The data were compared with ICOSL mRNA expression levels by iDCs or CHO 
ICOSL cells cultured alone which were referred to as negative. 
 
The relative ICOSL mRNA expression in iDCs cultured in SN from activated T cell showed 
initial increase of ICOSL mRNA expression after 1 hour of culturing iDCs, reaching the highest 
expression levels after 5 hours and then ICOSL mRNA expression decreased to approach the 
negative level after 48 hours of culturing iDCs [Figure 70 (a)]. The ICOSL mRNA changes 
were not statistically significant which suggested that down-regulation of ICOSL expression by 
iDCs cultured in the SN from activated T cells was mainly mediated at the posttranscriptional 
levels. Intriguingly, CHO ICOSL cells showed different pattern of ICOSL mRNA expression 
[Figure 70 (b)]. The relative ICOSL mRNA expression by CHO ICOSL cells showed a 
reduction in ICOSL mRNA expression after 1 hour of coculturing CHO ICOSL cells with 
activated T cells, reaching lowest expression after 5 hours and then it increased reaching 
approximately the negative level after 48 hours of coculturing CHO ICOSL cells with activated 
T cells. The ICOSL mRNA changes were not statistically significant. These data suggested that 
ICOSL mRNA transcription was down-regulated at the early hours of CHO ICOSL cells 
coculture with activated T cells, which returned to normal transcriptional levels in 48 hours. It is 
worth noting that ICOSL in CHO ICOSL cells is transcribed by pCMV while in iDCs, ICOSL is 
transcribed by endogenous ICOSL promoter, which could explain the difference detected in 
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late in the discussion.  
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Figure 70. Analysis of ICOSL mRNA expression in iDCs cultured in SN from activated T 
cells and in CHO ICOSL cells cocultured with activated T cells. 
 
1x10
6 
iDCs were cultured in 1 ml of SN from activated T cells (using anti CD3/CD28 beads for 
72 hours) for 48 hours. 1x10
5
 CHO ICOSL cells were cultured with 5x10
5
 activated T cells for 
48 hours. cDNAs were prepared from mRNA extracted from iDCs or CHO ICOSL cells at a 48 
hours time course; 1, 6, 24 and 48 hours. ICOSL mRNA expression by iDCs and CHO ICOSL 
cells was quantified using quantitative RT-PCR to investigate the changes in ICOSL gene 
expression. HPRT mRNA, a house keeping gene, was assessed and was used to normalize the 
ICOSL mRNA copy number. ICOSL mRNA levels transcribed by iDCs or CHO ICOSL cells 
alone were denoted as negative. iDCs cultured in SN from activated T cells show no statistical 
significant changes of ICOSL mRNA expression compared to iDCs cultured alone. CHO ICOSL 
cells show statistical significant reduction in ICOSL mRNA after 1 and 5 hours of coculturing 
with activated T cells, which starts to upregulate after 24 hours to reach the negative levels after 
48 hours. Results shown are mean ± SEM of duplicates from four independent experiments.  
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6.4.7   ICOSL protein expression by cells following coculture with 
activated T cells  
 
ICOSL protein expression by iDCs and CHO ICOSL cells cultured with activated T cells was 
analysed by western blotting. Analysis of ICOSL protein expression was conducted to 
investigate the possibility to identify ICOSL cleaved domain following ICOSL ectodomain 
shedding. iDCs and CHO ICOSL cells were cocultured with activated T cells or alone for 48 
hours. Cell lysates were prepared from iDCs, CHO ICOSL or CHO (as negative control) cells 
using Mem-PER ® eukaryotic membrane protein extraction kit which was used for the 
enrichment of integral membrane protein from the cells (section 2.4.1.1). The expression of the 
60 kDa ICOSL protein in the cell lysates from all samples was determined using anti-ICOSL Ab. 
Expression of the ICOSL protein was detected relative to the 42 kDa β-actin housekeeping 
protein. The 60 kDa ICOSL protein was detected in CHO ICOSL cells [Figure 71 (a)] and iDCs 
[Figure 71 (b)] cultured alone or with activated T cells, predictably, the 60 kDa was not detected 
in CHO cells. An approximately 30 kDa faint protein band was detected in CHO ICOSL cells 
and iDCs cocultured with activated T cells for 48 hours and was absent in cell cultured alone. 
This second band could be the remaining part of ICOSL extracellular domain after cleavage. The 
size of the second band suggested that ICOSL cleavage site could be in the Ig C-like domain. 
However, further investigations are needed to identify the site of ICOSL cleavage which could 
help in further identification of this second band.  
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Figure 71. ICOSL protein expression by iDCs or CHO ICOSL cells following coculture 
with activated T cells. 
 
iDCs and CHO ICOSL cells were cocultured with activated T cell at ratio 1:1 and 1:5 DC/CHO 
ICOSL cell: T cell, respectively for 48 hours. iDCs, CHO ICOSL or CHO cells (negative control) 
lysates were prepared using Mem-PER ® membrane protein extraction kit. The expression of the 
60 kDa ICOSL protein was determined in cell lysates by western blotting using anti-ICOSL Ab. 
Expression of the 60 kDa ICOSL is shown relative to the 42 kDa β- actin housekeeping protein. 
A protein band is seen at approximately 60 kDa which is consistent with the expected ICOSL 
protein size and is shown in (a) CHO ICOSL cells and (b) iDCs lanes cultured alone or with 
activated T cells and absent in CHO cells. An approximately 30 kDa protein band is seen in (a) 
CHO ICOSL cells and (b) iDCs cultured with activated T cells and not in cells cultured alone.  
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6.5 Discussion 
The experiments described in this chapter were designed to delineate the kinetics of ICOSL 
expression by human DCs and the possible mechanisms that regulate ICOSL surface expression. 
ICOSL expression kinetics by DCs was demonstrated in section 6.4.1 and compared with the 
expression pattern of other DCs phenotype markers such as CD80, CD86 and MHC class II. The 
data showed reciprocal relation between the expression of ICOSL and the other DC markers in a 
manner related to the stage of DC maturation. iDCs expressed high levels of ICOSL with low 
expression of the other maturation markers, whereas mDCs – matured by cytokines cocktail or 
LPS – down-regulated ICOSL expression and up-regulated the other maturation markers. Similar 
data were reported by in vitro studies on mDCs that showed up-regulation of the co-stimulatory 
molecules CD80, CD86 and MHC class II while ICOSL expression was down-regulated (Wang 
et al. 2000; Witsch et al. 2002).  
 
These findings may help to understand the role played by ICOSL in the interaction between DCs 
and T cells. iDCs are tissue cells and they interact with T cells in the tissue microenvironment, 
where T cells are mainly memory cells (CD45
+
RO) which express high levels of ICOS, as ICOS 
is up-regulated by activated and memory T cells (Hutloff et al. 1999). This promotes the 
interaction between activated effector or memory T cells with ICOSL on iDCs in the context of 
weak CD28-B7 signalling. The costimulatory signal induced by ICOS:ICOSL interaction to the 
T cells promotes the acquisition of T cells effector functions. On the other hand, in the lymph 
node microenvironment, naïve T cells that lack ICOS expression required for ICOSL binding 
(Hutloff et al. 1999) are primed by mDCs in a process that is conducted mainly by CD28-B7 
costimulatory pathway which dominates ICOS:ICOSL signalling. This suggests that 
ICOS:ICOSL costimulatory role retreats when mDCs interact with naïve T cells.  
Thus the pattern of ICOSL expression by iDCs versus mDCs could suggest that ICOS:ICOSL 
pathway may play an important role when CD28-B7 is weakly expressed. ICOS:ICOSL role is 
mainly to augment the immune response by co-stimulation of T cells after their primary 
activation in lymph nodes by a process mediated mainly via CD28-B7 role.  
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The data generated in section 6.4.1 demonstrated that maturing DC by LPS down-regulated 
ICOSL expression. This was consistent with our finding concerning TNF-α effect in down-
regulating ICOSL expression, as a part of DC maturation, since LPS is a potent inducer of TNF-
α (Beutler et al. 1985). As for other cell types, it has been shown that LPS can up-regulate 
ICOSL on non-lymphoid cells as human endothelial cells and kidney cells but it could not be 
induced in liver tissue, while LPS down-regulated ICOSL expression in spleen (Swallow et al. 
1999; Khayyamian et al. 2002). These data suggest that in the context of inflammatory 
conditions, LPS induces TNF-α which mature DC with the up-regulation of CD28 ligands. 
Consequently, mDCs will prime naïve T cells and enhance an effective immune response to the 
inflammatory stress. Meanwhile, in the non-lymphoid tissues, LPS can induce ICOSL expression 
which suggests an ICOS:ICOSL role in mediating local tissue response to inflammatory 
conditions. 
In section 6.4.2, the functional relevance of ICOS:ICOSL interaction to T cells functions was 
assessed. In section 6.4.2.1, it clearly shown in MLRs where activated T cells was co-cultured 
with variable cell types (as stimulators) such as DCs, THP-1, CHO ICOSL or M1DR1 cells that 
blocking of ICOS:ICOSL interaction using anti-ICOSL blocking Ab reduced T cell proliferation 
by a range of ~20-60% compared to isotype control. These data agree with an in vitro study 
which showed that T cell proliferation was stimulated when ICOSL Ig was added to CD3
+
 T 
cells activated with anti-CD3 Ab, which could be inhibited by anti-ICOSL Ig Ab (Yoshinaga et 
al. 1999). Furthermore, an in vitro study showed inhibition of T cell proliferation on using ICOS 
Ig that blocked ICOS:ICOSL interaction  (Aicher et al. 2000).   
ICOS:ICOSL costimulation plays an important role in the development and the effector 
functions of Th cells. Most of the early data suggested that ICOS:ICOSL has a preferential role 
in the generation of Th2, with the enhancement of Th2 polarizing cytokines secretion as IL-4, 
IL-10 and IL-4 receptor signalling. Thus blocking of ICOS:ICOSL interaction leads to defect in 
Th2 differentiation (Coyle et al. 2000; Mak et al. 2003; Shilling et al. 2009). Coyle et al. 
correlated ICOS role in Th2 polarization to ICOS high expression levels on Th2 compared to 
Th1 (Coyle et al. 2000).  
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IL-4, a Th2 cytokine, plays a central role in humoral and cell mediated immunity as it promotes 
B-cell proliferation, Ig class-switching and the survival and differentiation of T cells (Nelms et 
al. 1999). In this study, ICOS role in IL-4 production was analysed in section 6.4.2.2. An MLR 
was set out using iDCs, mDCs or CHO ICOSL cells as stimulators and activated T cells as 
responders. The MLRs were treated with anti-ICOSL blocking Ab or isotype control or untreated 
for 48 hours. Analysis of IL-4 concentration levels in the SN from MLRs by ELISA showed 
increase in IL-4 concentration levels in SN from activated T cells cocultured with iDCs relative 
to mDCs. On the contrary, IL-4 was below detection level in SN from activated T cells 
cocultured with CHO ICOSL cells. Furthermore, blocking of ICOS:ICOSL signalling by anti-
ICOSL blocking Ab showed statistically significant decrease in IL-4 levels by 75% in SN from 
activated T cells cocultured with iDCs. These data suggested that ICOS:ICOSL was crucial for 
up-regulation of IL-4 secretion by activated T cells. However, ICOS:ICOSL signalling was not 
the inducer for IL-4 secretion, as IL-4 could not be detected in the SN from activated T cells 
cocultured with CHO ICOSL cells, as T cells received only ICOS:ICOSL signal missing other 
essential co-stimulatory signals. This could propose that CD28-B7 signal initiates IL-4 secretion 
while ICOS:ICOSL signal enhances its secretion levels.  
These data are supported by in vitro study that showed significant enhancement of IL-4 
production by ICOS costimulation with anti-ICOS Ab in an MLR of CD4
+
 T cells and allergen 
pulsed autologus mature DCs (Bellinghausen et al. 2004). In addition, an in vivo study showed 
that IL-4 could not be detected in ICOS
-/-
 mice with increased generation of Th1 cells (McAdam 
et al. 2001).   
As regards the role of ICOS:ICOSL interaction in IL-10 cytokine secretion, it was shown in 
section 6.4.2.2 that IL-10 secretion level was reduced in MLRs following ICOS:ICOSL 
signalling blocking by anti-ICOSL blocking Ab. Although IL-10 reduction did not reach 
statistical significance, nevertheless it was possible to show trend of decrease in IL-10 secretion 
in three independent experiments. An in vivo study conducted on ICOS
-/-
 mice showed minimal 
reduction in IL-10 secretion level as compared to WT mice (Mahajan et al. 2007). Several other 
studies demonstrated showed significant reduction in IL-10 concentration levels following 
blocking of the ICOS:ICOSL interaction (Witsch et al. 2002; Harada et al. 2003). This difference 
could be explained in the light of an in vivo study which reported that the effector T cells 
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expressing high level of ICOS represented about 50% of all IL-10 secreting cells, implicating 
that there may be another element, beside ICOS:ICOSL signal, regulated IL-10 secretion 
(Lohning et al. 2003). In addition, it was shown that for ICOSL Ig to induce IL-10 production by 
T cells, high doses of anti-CD3 mAb were needed to stimulate T cells in an in vitro study (Wang 
et al. 2000). This implies that  ICOS:ICOSL signalling plays role in IL-10 secretion levels, but 
the effect of ICOS:ICOSL blocking on IL-10 concentration levels could be related to the 
protocol used to stimulate T cells and the level of ICOS expression by activated T cells. The role 
of ICOS:ICOSL pathway in the secretion of IL-10 and the development of Tregs was 
demonstrated in an in vivo study which showed that blockade of ICOS:ICOSL interaction 
inhibited the IL-10 production, abrogated the inhibitory capacity of Tregs and inhibited the 
induction of T-cell tolerance (Akbari et al. 2002).A recent study described two subsets of Foxp3
+ 
natural Tregs defined by the expression of the ICOS in the human thymus and periphery – ICOS+ 
Tregs which suppressed T cells proliferation through IL-10 and TGF-β secretion, and ICOS- 
Tregs which suppressed T cells proliferation mainly through TGF-β secretion (Ito et al. 2008). 
This suggests that ICOS:ICOSL interaction plays role in the induction of tolerance partially 
through regulation of IL-10 secretion.  
 
The results in this study (section 6.4.2.2) showed no apparent contribution of ICOS:ICOSL 
pathway on IFN-γ concentration levels which were not changed following blocking of 
ICOS:ICOSL signalling by anti-ICOSL blocking Ab. This agrees which previous studies that 
showed blocking ICOS:ICOSL interaction did not affect Th-1 cytokine secretion (Mahajan et al. 
2007). Collectively from these data, it can be concluded that ICOS shares in depicting the 
cytokine profile secreted by T cells, where it mainly governs Th2 secretion with particle 
importance in IL-4 production, leading to Th2 polarization.  
 
Th1 cytokines were always recognized to dominate in transplantation rejection, whereas Th2 
cytokines, particularly IL-4, inhibit Th1 responses which can improve transplant outcomes (Chen 
et al. 1996). Lately, there are mounting evidences that Th2 cytokines can promote graft 
dysfunction as IL-4 can be both immunosuppressive and immunostimulatory (Tay et al. 2009). 
Th2 responses role in allograft rejection was demonstrated in rat liver allograft rejection 
following the induction of IL-4 that led to marked T cells and macrophage infiltration of the graft 
and massive liver damage (Wang et al. 2005). Similarly, in renal transplant patients, protection 
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from chronic rejection was associated with high IL-10 and low IL-4 producing genotype (Uboldi 
de Capei et al. 2004). This raises the importance of understanding the factors that regulate 
ICOS:ICOSL signalling and its functional relevance which could help in the development of  
treatment tools and the improvement of transplant outcome.  
 
Studies have been conducted to investigate ICOSL regulatory mechanisms on murine B cells 
(Liang et al. 2002; Logue et al. 2006; Watanabe et al. 2008) or human B cells (Witsch et al. 
2002). In this study, ICOSL expression kinetics and the possible regulatory mechanisms by 
human DCs were addressed. In section 6.4.3, the contribution of activated T cells in the 
regulation ICOSL expression was demonstrated. ICOSL down-regulation was detected in 
cocultures of iDCs, mDCs or CHO ICOSL cells with activated T cells [Figure 64 and 65]. In 
addition, ICOSL down-regulation was inhibited in cocultures treated with anti-ICOSL blocking 
Ab, preventing ICOS:ICOSL interaction, as compared to isotype control (section 6.4.4). These 
data suggested that ICOS:ICOSL interaction triggered ICOSL down-regulation. Regulation of 
ICOSL expression through binding to ICOS is not unprecedented as CD40L down-regulation is 
triggered by binding to CD40 receptors (Yellin et al. 1994). ICOSL down-regulation could 
represent an integrated regulatory negative feedback loop for ICOS:ICOSL pathway, as the high 
level of ICOS expression on activated T cells results in the reduction of ICOSL expression by 
APCs. This negative feedback prevents continuous signalling during immune response that could 
lead to the development of immune diseases (Usui et al. 2006).  
 
These data suggest a hierarchy of T cell costimulation in vivo upon the initial interaction of T 
cells with APC. CD28/B7 interaction induces ICOS upregulation by stimulated T cells (which 
was mimicked in vitro by using CD3/CD28 beads for T cells activation). Subsequently, CTLA4 
is upregulated and terminates CD28 interaction with B7-1 and B7-2 in vivo. In the second phase 
of cellular cross talk, ICOS:ICOSL signalling continues to stimulate T cells response and 
modifies the pattern of the secreted cytokines. This is followed by ICOS induction of ICOSL 
down-regulation to avoid the continuous T cells stimulation through ICOS:ICOSL pathway and 
preventing pathological immune responses. ICOS:ICOSL signalling may not be essential in 
initiating the immune response but most likely plays an important role in the later immune 
response.  
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In section 6.4.6, the possible regulatory mechanisms of ICOSL surface expression were 
investigated. An in vitro study conducted on ICOSL expression by murine B cells reported that 
ectodomain shedding mediated by proteolytic enzymes could be a possible regulatory 
mechanism for ICOSL expression (Logue et al. 2006). To investigate whether ICOSL down-
regulation on human DCs is mediated by the same mechanism, protease inhibitor cocktails were 
added to cocultures of iDCs or CHO ICOSL cells with activated T cells. Analysis of ICOSL 
expression by iDCs and CHO ICOSL cells after 48 hours of coculture by flow cytometry showed 
that iDCs restored ICOSL expression completely in coculture treated with protease inhibitor 
cocktails compared to negative control. Same results were demonstrated with CHO ICOSL cells, 
cocultured with activated T cells, which partially restored ICOSL expression in cocultures 
treated with protease inhibitor compared to negative control. These proteases inhibitors inhibit a 
broad spectrum of proteolytics; metallo-proteases, amino-peptidedases, serine and cysteine 
protease. The protease inhibitor cocktails inhibited ICOSL down-regulation expression via the 
inhibition of proteolytic enzymes. These results suggested that a possible mechanism of ICOSL 
regulation on human DCs surface is mediated through ectodomain shedding.  
It is worth noting that, the study conducted by Logue et al. reported that the use of hydroxamate 
compounds, that inhibit a broad spectrum of the metalloproteases, inhibited murine B cell 
ICOSL shedding following BCR stimulation using PMA or anti-IgM Ab. However, the study 
could not show the same findings in ICOSL expression following coculture with activated T 
cells, which induced ICOSL down regulation on murine B cells (Logue et al. 2006). Logue et al. 
study related the difference in the inhibition of ICOSL shedding by B cells using protease 
inhibitor to the difference in the sensitivity of the pathways inducing ICOSL down-regulation. 
This could also suggest that there may be another regulatory mechanism for ICOSL expression 
in addition to ectodomain shedding.  
This finding directed our study to another question which was related to whether ICOS:ICOSL 
binding is the only trigger for ICOSL down-regulation. To answer this question, in section 6.4.5, 
iDCs, mDCs and CHO ICOSL cells were cultured in SN from activated T cells and ICOSL 
expression was examined by flow cytometry. Interestingly, ICOSL down-regulation was 
detected in the absence of ICOS binding and this was noted in iDCs, mDCs and CHO ICOSL 
cells as compared to cell cultured in R10 medium. Other DCs makers were also tested, which 
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showed that iDCs upregulated CD86, a DC maturation maker. This could suggest that ICOSL 
down-regulation detected in iDCs was partly due to DC maturation.  
These findings led to the assumption that there may be a transmitted signal in the absence of 
ICOS:ICOSL binding that induced ICOSL down-regulation. To evaluate whether ICOSL is 
regulated at the transcriptional level of ICOSL mRNA, changes in ICOSL gene expression in 
iDCs cultured in SN from activated T cells (to avoid contamination with ICOSL mRNA from T 
cells) or in CHO ICOSL cells cocultured with activated T cells were analysed at a 48 hour time 
course (in section 6.4.6.2). ICOSL mRNA was quantified using quantitative RT-PCR, which 
showed no statistical significant changes in ICOSL mRNA expression by iDCs cultured in SN 
from activated T cells as compared to iDCs cultured in R10 medium.  Intriguingly, CHO ICOSL 
cells cocultured with activated T cells showed different pattern of ICOSL mRNA expression, 
where there was an initial reduction in ICOSL mRNA expression after 1 hour, reaching lowest 
expression levels after 5 hours of coculture. This was followed by ICOSL mRNA up-regulation 
reaching the negative level (corresponded to CHO ICOSL cultured alone) after 48 hours.  
 
The differences detected between iDCs and CHO ICOSL cells expression pattern of ICOSL 
mRNA could be related to the differences in the ICOSL transcriptional promoters. It is worth 
pointing out that, ICOSL is transcribed by endogenous ICOSL promoter in iDCs, while in CHO 
ICOSL cells, ICOSL is transcribed by pCMV. The pCMV is often thought of as an active 
unregulated promoter, but there are several studies pointed that CMV promoter can be down-
regulated by IFN-γ or TNF-α (Harms and Splitter 1995; Qin et al. 1997). This suggests that the 
down-regulation of ICOSL mRNA detected by CHO ICOSL cells was probably mediated by 
cytokines secreted by the activated T cells. This reduced the transcrpition of ICOSL gene 
through down-regulation of pCMV, in a process apart from ICOSL signalling. Thus these data 
suggested that ICOSL regulation in iDCs was mainly at the posttranscriptional levels In support 
of this suggestion, an in vivo study conducted on ICOS
-/-
 mice showed that ICOSL protein level 
was markedly increased in murine B cells with no significant changes at mRNA level compared 
to WT and ICOS transgenic mice (Watanabe et al. 2008). For further confirmation of our data, a 
suggested experiment in which stimulation of CHO ICOSL cells with ICOS Ig fusion protein can 
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be used and then ICOSL mRNA can be assessed. Thus it will be possible to rule out the 
interfering role of activated T cells cytokines. 
 
The data generated in this chapter suggested that ectodomian shedding could be an ICOSL 
possible regulatory mechanism. To investigate the possibility to identify ICOSL cleavage part, 
ICOSL protein expression by iDCs or CHO ICOSL cells cultured alone or with activated T cells 
for 48 hours was analysed by western blotting (in section 6.4.7). The results showed that the 60 
kDa ICOSL protein was detected in CHO ICOSL cells and iDCs cultured alone or with activated 
T cells and was not detected in CHO cells (as expected). An additional 30 kDa faint protein band 
was detected in iDCs and CHO ICOSL cells cocultured with activated T cells and was absent in 
cell cultured alone. This second band could be the remaining part of ICOSL extracellular domain 
after cleavage. This suggested that the cleavage site could be within the ICOSL Ig C-like 
domain. The study conducted by Logue et al. on murine B cells suggested that both the C-like Ig 
domain and the stalk peptide of ICOSL were involved in ICOS-induced shedding of ICOSL 
(Logue et al. 2006). Further investigations are required to identify the protease that regulate 
ICOSL shedding and its cleavage site. In addition, analysis of the SN from cells cocultured with 
activated T cells for soluble ICOSL (sICOSL) by western blotting or mass spectrometry could 
help in identifying ICOSL cleaved domain and understanding ICOSL shedding process. 
Endocytosis was investigated as a possible ICOSL regulatory process by other studies, as 
Watanabe et al. study used cytochalasin B, an endocytosis inhibitor in treating coculture of 
murine B cells with activated T cells; however, ICOSL down-regulation was still detected by 
murine B cells (Watanabe et al. 2008). Similar results were obtained with Logue et al. as they 
showed that ICOSL down-regulation did not involve intra-cellular internalization or require re-
localization of ICOSL within the cell membrane (Logue et al. 2006). The endosomal-lysosomal 
sorting signals were examined within the cytoplasmic domain of ICOSL. Generally, two major 
classes of endosomal-lysosomal sorting signals are identified which are either tyrosine–based 
motif – NPXY or YXXO consensus motif – and dileucine-based motif –[DE]XXXL[LI] or 
DXXLL consensus motif – signals owing to the identity of their most critical residue (Bonifacino 
and Traub 2003). The defining property, that sets sorting signals apart from other motifs, is their 
occurrence within the cytoplasmic domains of the transmembrane proteins. Analysis of ICOSL 
cytoplasmic domain revealed the absence of both motifs. The tyrosine motif detected in human 
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ICOSL cytoplasmic domain is YAGA which does not match with any of the reported motifs. In 
the guide of this information, endocytosis is thought not to be a possible ICOSL regulatory 
mechanism.  
The study conducted in this chapter demonstrated that the kinetic changes of ICOSL expression 
by DCs are related to the maturation state of the DC, which reflects the correlation between the 
level of ICOSL expression and the stage of immune response. In addition, ICOSL down-
regulation is a negative feedback loop that regulates the immune response. When T cells get 
activated, they up-regulate ICOS receptors that bind to ICOSL on APCs. This is followed by 
down-regulation of ICOSL expression causing modulation of the immune response. ICOSL 
down-regulation was mediated through a dependent cell to cell contact pathway following 
binding to ICOS on T cells and an independent cell to cell contact following incubation with SN 
from activated T cells. This study showed that also that down-regulation of ICOSL probably 
occurred through ectodomain shedding of ICOSL extracellular domain after binding to ICOS 
receptor on activated T cells. Thus, ICOS induced ICOSL down-regulation could be a novel 
regulatory mechanism in human DCs.  
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7.1 Thesis aims 
Gene therapy entails the development of non-immunogenic gene delivery vectors to the target 
cell with the potential for long-term gene expression and the production of therapeutic effect 
(Laurence et al. 2009). In early 1970, Friedmann and Roblin reported their first attempt for gene 
therapy in human genetic disease (Friedmann and Roblin 1972). Since then, gene therapy 
strategies have developed through vector technology and the identification of potential 
therapeutic targets. The realization that it may have broad potential for the delivery of 
therapeutic protein agents has stimulated interest in many biological fields as transplantation 
(Comer et al. 2002; Sandovici et al. 2008; Vassalli et al. 2009).  
In the transplantation setting, gene therapy is a potential approach to improve transplant survival. 
If the target gene is expressed adequately in the targeted graft, it can induce durable drug free 
antigen-specific tolerance to transplanted organ; hence the harmful systemic effects of 
immunosuppression drugs can be avoided. Prof George‟s laboratory has a wide experience in 
developing gene therapy strategies in attempt to induce transplantation tolerance. In vitro study 
has shown that human DCs expressing CTLA4-KDEL-fusion protein induced T cell anergy and 
alloantigen-specific tolerance (Tan et al. 2005b). These anergic T cells expressed regulatory 
functions and inhibited a primary immune response in cultures of unmodified DCs and T cells. 
The theme of this strategy was to inhibit CD28 pathway through the reduction of CD80 and 
CD86 surface expression on DCs using the KDEL-fusion protein. The work was further 
expanded by other lab colleagues, where a study presented by Mr. Adnan Khan used the 
CTLA4-KDEL gene cassette cloned into a lentiviral vector (vCTLA4-KDEL) (Khan et al. 2008). 
It was demonstrated that DC transduced with vCTLA4-KDEL expressed reduced levels of CD80 
and CD86 on the DC surface. In addition, transduced DC induced donor specific T cell anergy in 
allogenic T cells to both direct and indirect pathway in vivo and in vitro. The role of IDO in 
generation and maintenance of regulatory cell function and the potential of using in gene therapy 
has also been studied in corneal allograft (Beutelspacher et al. 2006). 
 
As the KDEL strategy proved to be effective, it was decided to expand the strategy in this study.  
The potential of developing a negative-vaccination strategy for tolerance induction in the context 
of transplantation setting was assessed. The main strategy involved the development of an 
                                                                                                                                             Chapter 7 
257 
 
intracellular fusion protein ICOS-KDEL, as an immune-modulator to down regulate ICOSL, 
combined with an invariant chain expressing alloantigen derived peptide to target allopeptide 
presentation via indirect pathway.  
7.2 Summary of the project strategies and results   
In attempt to approach the thesis aims, several constructs encoding human genes were made. 
Constructs encoding single gene cassette were; ICOS-KDEL (encoded ICOS extracellular 
domain), ICOSL (encoded ICOSL full length), pCMV Ii-A2 (encoded Ii chain with the CLIP 
sequence replaced by HLA-A2103-120 and under the transcriptional control of pCMV), pCMV Ii-
HA (encoded Ii chain with the CLIP sequence replaced by HA and under the transcriptional 
control of pCMV), pIi-Ii-A2 (encoded Ii chain with the CLIP sequence replaced by HLA-A2103-
120 and under the transcriptional control of pIi). Constructs encoding two genes cassettes were; 
pCMV-ICOS-KDEL-pIi-A2 (ICOS-KDEL gene under the transcriptional control of pCMV and 
Ii-A2 gene under the transcriptional control of pIi), pCMV-ICOS-KDEL-pSV40-A2 (ICOS-
KDEL gene under the transcriptional control of pCMV and Ii-A2 gene under the transcriptional 
control of pSV40), pCMV-ICOS-KDEL-pSV40-HA (ICOS-KDEL gene under the 
transcriptional control  of pCMV and HA peptide under the transcriptional control of pSV40).   
7.2.1 Intracellular retention of ICOSL using KDEL strategy 
 
The data generated during the course of this study has demonstrated the potential of ICOS-
KDEL approach to down regulate the ICOS-ICOSL pathway. The use of KDEL-fusion construct 
to inhibit this pathway has a privilege over the use of other modalities as the administration of 
blocking antibodies, intra-bodies or soluble proteins as ICOS-Ig fusion proteins. ICOS-KDEL is 
expected to be specific to antigen expressed by the modified APCs and will not induce 
generalized immunosuppression. In addition, the immunogenicity of the ICOS-KDEL fusion 
protein is expected to be low as the construct to be used in cell transfection would be derived 
from human origin.  
 
This study has shown that cells expressing ICOS-KDEL-fusion protein, retained ICOSL protein 
intracellularly and down regulated the surface expression of ICOSL by transfected cell. The 
created ICOS-KDEL construct was confirmed for encoding the target gene in the first part of this 
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study. ICOS-KDEL protein expression was tested in transfected HEK 293 and D17 cell lines. 
Western blotting of transfected cell lysates showed the expression of ICOS-KDEL protein at the 
expected size 48 hours after cells transfection. The ability of ICOS-KDEL to down-regulate 
ICOSL expression was examined in CHO ICOSL cell line – a stable cell line expressing human 
ICOSL full length under the transcriptional control of pCMV. Unexpectedly, transfection of 
CHO ICOSL cells with ICOS-KDEL construct did not consistently reduce ICOSL surface 
expression. The inconsistent results made drawing conclusions about ICOS-KDEL efficiency 
difficult. It was important to determine the causes for these inconsistent results.  
 
The results obtained from transfecting CHO ICOSL cells with ICOS-KDEL construct could 
suggest that either the ICOS-KDEL protein was produced at appropriate levels but did not bind 
with ICOSL, or there has not been enough ICOS-KDEL protein to bind with and retain ICOSL 
in the ER. The former possibility could be resulted from non-functional KDEL-fusion protein or 
from ICOS-KDEL protein not being sorted to the appropriate location, the ER. In order 
investigate these possibilities; transfection of other cell lines was carried out. THP-1 and M1DR1 
cells – which constitutively express ICOSL – were transfected with the ICOS-KDEL construct. 
Consistent reduction in ICOSL expression was detected in both cell lines after 48 hours of cells 
transfection as shown by flow cytometry. These data confirmed that the KDEL-fusion protein 
was properly functioning and complexed appropriately with newly synthesized ICOSL protein. 
In the context of investigating appropriate ICOS-KDEL protein trafficking, a confocal 
microscopy study was conducted on transfected M1DR1 cells with ICOS-KDEL which showed 
that the KDEL-fusion protein was localized in the ER 48 hours following transfection. These 
data confirmed that the ICOS-KDEL-fusion protein could be properly sorted to the ER.  
 
The other possible explanation for the transfected CHO ICOSL cells results could be related to 
insufficient production of ICOS-KDEL protein to bind to and retain ICOSL in the ER. This 
could have resulted from degradation of misfolded KDEL-fusion protein leading to protein loss. 
As misfolded proteins stress ER functions, the misfolded proteins are targeted to degradation via 
protective cellular mechanisms as ER Associated Degradation Pathway (ERAD) and the 
Unfolded Protein Response (UPR) (Rasheva and Domingos 2009). The response of stressed ER 
to the misfolded proteins aims to remove the accumulated protein load and protect the cell from 
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any further stress, so that the normal function of the ER can be restored (Rasheva and Domingos 
2009). This assumption was investigated by analysis of the western blot data of ICOS-KDEL 
transfected cell lysates. The data showed the expression of the fusion protein 48 hours after 
transfection at the expected size as a single band. This showed that the majority of the detected 
full length protein were not mal-folded and were not degraded. These data may exclude the 
possibility that the protein degradation could be the cause for the undetected ICOS-KDEL down 
regulation of ICOSL expression.  
 
Insufficient production of ICOS-KDEL protein, as a possible cause for the absence of ICOS-
KDEL function, could have resulted from suppression of ICOS-KDEL gene transcription. Fusion 
KDEL gene suppression could lead to subsequent reduction of ICOS-KDEL protein translation 
and decreased protein synthesis. Gene suppression could result from transcription interference 
between both genes; ICOS-KDEL (transfecting gene) and ICOSL (stably integrated in the cell 
genome) as they share the same transcribing promoter, pCMV. Transcription Interference (TI) is 
the suppressive influence of one active transcriptional unit on another unit (Eszterhas et al. 2002; 
Shearwin et al. 2005). In CHO ICOSL cells transfected with ICOS-KDEL, TI could result from 
promoter competition for the same transcription factors producing an imbalance in the 
transcriptions of both genes. It has been reported that binding of one promoter with RNA 
Polymerase (RNAP), responsible for initiation of gene transcription, could prevent RNAP 
binding to another promoter (Shearwin et al. 2005). Suppression of gene expression was detected 
whether both genes were integrated in the cell genome or one gene was integrated and the other 
transiently expressed (similar to the case in this study) (Eszterhas et al. 2002).  
 
It was possible from the data to confirm the capability of ICOS-KDEL-fusion protein to down 
regulate the surface expression of the newly synthesized ICOSL protein. The research conducted 
in this study on ICOS-KDEL-fusion protein offers the possible use of the KDEL-fusion protein 
to down-regulate the ICOS:ICOSL pathway. This could result in decrease of the ICOS:ICOSL 
costimulatory signal and hence modify the functions of ICOSL expressing cells.  
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7.2.2 Targeting the allopeptide for antigen presentation via indirect 
allorecognition pathway  
 
The second aim of this thesis was to provide the alloantigen that can be recognized by the T cells 
via indirect pathway. There have been several approaches by which alloantigen was provided to 
APCs for presentation via indirect allorecognition pathway. These approaches include the 
presentation of alloantigen such as synthetic peptide (Chen et al. 1996; Waaga et al. 1998), donor 
derived apoptotic cells (Xu et al. 2004), allogenic cell lysates (Horibe et al. 2008) or the use of 
transgenically derived APCs that co-express both recipient and donor MHC (Mirenda et al. 
2004). These approaches have proved effective on the experimental level; however, practical 
obstacles associated with their clinical application made their use unfeasible. These obstacles 
include inefficient antigen uptake and presentation, immunogenicity of the used products and 
quality inconsistency of the produced batches (e.g. synthetic peptide). 
 
In this study an alternative approach was examined, where a fusion protein between the immuno-
dominant MHC class I epitope (HLA-A2103-120) and Ii of MHC class II was created. It is 
expected that the fused epitope would be presented in the context of MHC class II APCs to CD4
+
 
T cell. In this study, APCs were modified by gene therapy as cells were transfected with the Ii-
fusion protein using a non-viral vector. The administration of genetically modified APCs 
continuously expressing donor derived alloantigen is expected to be more advantageous, as the 
problem of ineffective antigen uptake and presentation would be overcome. In addition, the Ii-
fusion protein can be targeted to APCs that can also express an immunomodulatory protein like; 
ICOS-KDEL (as the case in this study), CTLA4-KDEL or TGF-β. 
 
Ii-peptide fusion construct was cloned as a single gene cassette encoding the human Ii chain with 
the CLIP substituted by HLA-A2103-120 to generate the Ii-A2 fusion gene. The premise of this 
fusion gene construct was that recipient DCs transfected with Ii-A2 would present A2 peptide in 
the context of MHC class II. Recipient derived (autologous) T cells with TCR specific for A2 
peptide would recognize the A2 peptide in the context of self MHC class II when stimulated with 
autologous transfected DCs. Thus the allopeptide will be presented to recipient T cell in a 
manner similar to the indirect allorecognition pathway.  
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In this study, the Ii-A2 and –HA (construct encoding HA as a control peptide) constructs were 
checked for appropriate protein expression by transfecting HEK 293, D17 and M1DR1 cell lines 
for 48 hour. Western blotting of transfected cell lysates showed the expression of Ii fusion 
protein at the expected size. It was important to confirm the absence of endogenous Ii chain 
protein expression which was demonstrated in western blotting of lysates from the transfected 
cell with empty vector. These data confirmed that the Ii protein detected in transfected cells 
originated from the transfecting Ii fusion construct and was not endogenously produced.  
 
Surface Ii-A2 protein expression was demonstrated in transfected M1DR1 cells, where A2 
peptide expression in the context of DR1 was detected using UL-A51 Ab. This data confirmed 
that fusion of the immunodomiant allopeptide to Ii chain did not affect the proper folding or 
trafficking of the Ii chain protein, as A2 peptide could be detected on the surface of the cell 
transfected with the Ii-fusion gene. After each of the previously designed constructs, ICOS-
KDEL and pCMV-Ii-A2 was established on the basis of protein expression, a bicistronic vector 
encoding both gene cassettes was created. Developing this expression system would enable cell 
transfection in a single step, using single plasmid that can result in the expression of the two gene 
cassettes simultaneously. As cells transfection is not always an easy approach, thus using a 
bicistronic vector will minimize the manipulation of the APCs and the disadvantages of repeated 
transfection will be avoided. The bicistronic plasmids (summarized early in this section) were 
checked for relevant protein expression, KDEL- and Ii-fusion proteins by western blotting of 
M1DR1 transfected cell lysates. A2 peptide expression in the context of DR1 in transfected 
M1DR1 cells was also confirmed by flow cytometry, with the absence of A2 peptide expression 
in M1DR1 cells transfected with control HA plasmids. As regards the ability of ICOS-KDEL to 
down regulate ICOSL expression in the bicistronic vector, it was not feasible to be demonstrated. 
The absence of ICOSL expression by M1DR1, as detected by flow cytometry, made checking of 
ICOS-KDEL gene function in the bicistronic gene difficult. However, it is worth noting that the 
capability of ICOS-KDEL to down-regulate ICOSL expression was previously shown on the 
same cell line, M1DR1 cells, early in this study using single gene cassette. Furthermore, the 
expression of ICOS-KDEL protein in the bicistronic plasmid was confirmed by western blotting. 
These suggested that the capability of the bicistronic vector to encode the two genes could be 
confirmed and the problem faced was related to the cell line rather than the construct itself.  
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To reserve the use of human DCs and ensure stable expression of the relevant protein and 
facilitate optimization of the T cell proliferation assay, stable cell lines were created; M1DR1 - 
A2, M1DR1 -CD80 - A2 and M1DR1 - CD80 - HA. These stable cell lines were designed to be 
used as stimulators for antigen specific T cell clones in an MLR. T cell clone has been generated 
from HLA-A2 negative patients who chronically rejected an HLA-A2 positive kidney allograft, 
and the T cell clone is specific for HLA-A2 103-120 and restricted by HLA-DR1 (Frasca et al. 
2000). This T cell clone was expected to be a kind donation from Prof G. Lombardi. 
Unfortunately, there was technical issue with growing these cells which prevented their use. In 
order to prove the thesis principle, two alternatives are suggested. First, primary T cells from 
patients fulfilling the HLA phenotype criteria can be used. However, the problem with this 
approach is the use of polyclonal T cells, with the possibility that the frequency of antigen 
specific T cells could be low. This could make the interpretation of the results difficult. The other 
alternative would be the creation of another APC model where HLA-A2 is expressed in the 
context of different DR phenotype for which T cell clones are available. This approach could 
offer consistent experiment conditions with more reliable results.  
The future plan, once T cells clone are available, would involve the use of recipient derived class 
II HLA matched DC, genetically modified through transfection with the bicistronic constructs. 
An MLR reaction would be set out using T cell clones and the modified recipient DCs. The 
expected scenario is that the T cells will recognize alloantigen in the context of self MHC class II 
presented by the genetically modified DC (first signal for T cell stimulation) in a way simulating 
the indirect alloimmune response. However, in the absence/decrease ICOS:ICOSL costimulatory 
signal (second signal), DC will be rendered tolerogenic and will not stimulate the alloantigen 
specific T cells. Instead a state of anergic allospecific T cells will be generated.  
7.2.3 DC transfection using nucleofection technology 
The central interaction between DCs and T cells determines the nature of the immune response 
as activation/immunity or anergy/tolerance. DCs are important targets for genetic modification to 
induce transplantation tolerance as they can be a powerful tool to modulate allorecognition 
response and thus allograft survival. For a gene therapy strategy to be successful, an effective 
gene delivery vector is mandatory. Verma et al. summarized the characteristics for an ideal gene 
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delivery vector such as easy to prepare and inexpensive to produce, induces a mild to minimal 
immune response, expressed in a tissue specific manner as to get the utmost of its therapeutic 
effect, the transfected transgene is continuously expressed within the target cell as it divides as 
well as in non-dividing cells (Verma and Weitzman 2005). Despite the success in using gene 
vectors for vaccination in cancer and infectious diseases (Kikuchi et al. 2000; Lu et al. 2004), the 
development of gene vectors remains a great concern for improved gene therapy technologies. 
In this lab, several work have been conducted on genetic modification of human and murine 
primary DCs. Transfection of DCs has been tried using viral (Khan et al. 2008) and non-viral 
methods (Tan et al. 2005b) with DNA or RNA (Miss Jennifer Harper PhD) gene vectors. Taking 
in consideration the inherit problems with the use of viral methods for cell transfection 
(previously mentioned in section 6.1), it was decided in this study to transfect human DCs with a 
non-viral method.  
The data generated in this study employed nucleofection technology as a method for DC 
transfection with transfection efficiency of approximately 30%. It was important to assess the 
effect of nucleofection on DCs phenotype, in terms of maturation and expression of 
differentiation markers. The results showed that nucleofection did not adversely affect the DCs 
phenotype, as measured by the expression of the costimulatory molecules such as CD80 and 
CD86, before and after nucleofection. These data suggested that the nucleofected DCs antigen 
presenting capacity should not be impaired. Thus DC nucleofection can be considered as a 
potential method to achieve high transfection efficiencies with limited cell toxicity. DCs were 
nucleofected with ICOS-KDEL-fusion gene and ICOSL expression was analyzed 48 hours after 
nucleofection by flow cytometry. Initially, ICOSL down regulation in nucleofected DCs was 
poor <10 % as compared to mock transfected DCs. However, with increasing the DNA 
concentration to 10 µg / transfection condition, ICOSL expression was down-regulated by 25 % 
as compared to mock transfection.  
Although the efficiency of DCs transfection using nucleofection was not as high as that achieved 
with viral vectors that reached >90% with adenoviral transduction (Dietz and Vuk-Pavlovic 
1998), still it is expected to be adequate in clinical applications. Human DCs transfected at 20% 
transfection efficiency were able to stimulate in vitro and in vivo activation of antigen specific T 
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cell response cells for recall antigens, resulting in cellular and humoral anti-tumor immune 
response (Yang et al. 1999; Irvine et al. 2000). Furthermore, the ability of DCs expressing 
antigens at low levels to stimulate T cells can be augmented partly because it can stimulate 
antigen-specific T cell responses and partly because the antigen can be transferred and acquired 
by other DCs enhancing T cell response (Bedford et al. 1999). It is worth noting that, in our 
hands, 3x10
7
 DCs can be generated from 200 ml of peripheral blood and transfection of iDCs 
using nucleofection can result in approximately 1-3 x10
6
 transfected DCs, which is expected to 
be adequate for in vitro as well as in vivo study. The transfected DC yield can be improved with 
the use of larger amount of blood to generate DCs or using antibiotic selection of the transfected 
DCs. Therefore, genetic modification of DC using nucleofection could be considered a 
promising non-viral approach that can be applied in gene therapy. It would be preferably that the 
functional effects of nucleofection on DCs to be assessed in an MLR to examine their 
allostimualtory function and to verify that they can stimulate T cells proliferation in an MLR 
assay in comparison with untransfected DCs. 
7.2.4 Activated T- Cells regulate immune response through ICOS 
induced ICOSL down-regulation on human DCs 
Immune homeostasis entails the continuous regulation of the expression of cell molecules to 
maintain an effective balance between immune stimulation and inhibition (Nurieva et al. 2006; 
Mueller 2010). The ICOS-ICOSL costimulatory pathway is important for effective T cell 
function, and dysregulation of this pathway enhances or induces autoimmune responses 
(Hawiger et al. 2008; Her et al. 2009).  ICOS is induced on naïve T cells following TCR 
stimulation and almost all ICOS
+
 T cell express CD45RO
+
 (memory T cells). This expression 
pattern suggests that ICOS:ICOSL pathway provides co-stimulatory signals to activated or 
resting memory T cells rather than to augment immune activation response in naïve T cells 
(Hutloff et al. 1999; Yoshinaga et al. 1999; Burmeister et al. 2008). ICOS binds selectively to 
ICOSL which is expressed at low levels on resting APCs and non-lymphoid cells, and can be 
induced upon cytokine-stimulation (Swallow et al. 1999).  
The study of the interaction between T cells and DCs through ICOS:ICOSL pathway was set as 
one of the aims of this thesis, it was important to understand ICOSL expression dynamics on DC 
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surface. ICOS:ICOSL pathway is the main thesis target to modify for tolerance induction, and 
DC is the target cell for genetic modification. Hence, analysis of the kinetics of ICOSL 
expression by DC in different maturation stages, and identify the role of T cells in regulating 
ICOSL expression were investigated. In addition, identification of the possible molecular 
mechanisms that regulate ICOSL expression in human DCs was carried out. 
Expression of ICOSL, CD80, C86 and MHC class II by iDCs and mDCs were analyzed by flow 
cytometry. The data demonstrated that iDC expressed high levels of ICOSL, which were down 
regulated on DC maturation. The other maturation markers such as CD80, CD86 and MHC class 
II were expressed at low level on iDC surface and upregulated with DC maturation. This specific 
ICOSL expression kinetic underscores that ICOSL is more important in mediating iDC functions 
than in mDCs.  
This pattern of ICOSL expression by DC could be important in the context of T cell and DCs 
cross talk. In the lymph node microenvironment, priming of naïve T cells by mature DC is 
conducted mainly by CD28-B7 costimulatory pathway which dominates the ICOS signalling 
(Inaba et al. 1990). In addition, naïve T cell (CD45
+
RA) lacks ICOS expression which is needed 
for ICOSL binding (Hutloff et al. 1999). However, in the tissue microenvironment, ICOS 
expressing T cell (activated and memory) interacts with iDC ICOSL in the context of weak 
CD28-B7 signalling. This promotes stimulation of T cell, as well as the acquisition of T cell 
helper functions in T cell effector / differentiation phase via ICOS:ICOSL costimulation (Coyle 
et al. 2000; Mak et al. 2003; Shilling et al. 2009). The kinetic changes of ICOSL expression by 
DC that are related to the maturation state of the DC reflect the correlation between the level of 
ICOSL expression and the stage of immune response. 
In the course of studying ICOS:ICOSL role in T cell functions, the effect of blocking the 
ICOS:ICOSL pathway on T cell function was assessed in MLR with and without anti-ICOSL 
blocking Ab. T cell proliferation was assessed by [
3
H]-thymidine incorporation and the cytokine 
concentration levels were analysed by ELISA. It was demonstrated that T cell proliferation was 
reduced by ~20-60 % following blocking of ICOS:ICOSL pathway. In previous reports, the use 
of ICOSL Ig fusion protein promoted in vitro T cell proliferation through engagement of T cell 
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ICOS, whereas the addition of anti-ICOSL Ig fusion protein Ab inhibited in vitro T cell 
proliferation by blocking ICOS signalling (Yoshinaga et al. 1999; Aicher et al. 2000).  
ICOS:ICOSL role in the development of T cell effector functions was also shown, where the 
secretion of IL-4 by T cells decreased by 75 % following blocking of the ICOS:ICOSL pathway. 
IL-4 secretion levels were higher in MLRs where iDCs were stimulators compared to mDCs. 
This difference could be related to the difference in ICOSL expression level between iDCs and 
mDCs. Meanwhile, in MLRs where CHO ICOSL cells were used as stimulators, IL-4 secretion 
levels were below detection levels. In the light of this in vitro study, it could be suggested that 
ICOS:ICOSL signalling may not be the initiator for IL-4 secretion, nevertheless ICOS:ICOSL 
engagement is pivotal for IL-4 upregulation. As the T cell received only ICOS:ICOSL signal 
from CHO ICOSL missing other essential co-stimulatory signals as CD28-B7 signal, this 
suggests that CD28-B7 could be the inducer in IL-4 secretion while ICOS:ICOSL is the 
upregulator. Our results are in line with recent in vivo study conducted on CD28
-/-
 mice that 
show ICOS can be expressed on T cells in the absence of CD28. However, Th2 induced airway 
inflammation could not be induced independent of CD28 (Shilling et al. 2009). In the same 
study, CD28 could not solely augment Th2–mediated airway inflammation in ICOS-/- mice. 
These results therefore demonstrated the role of ICOS:ICOSL signalling in IL-4 secretion by 
activated T cells. 
In transplantation setting, although Th1 response dominates acute allograft rejection; the role of 
Th2 in the graft rejection cannot be ignored. A study demonstrated that cardiac allograft was 
acutely rejected in severe combined immunodeficiency (SCID) mice model following 
transfusion with donor-specific Th2 polarized cells (VanBuskirk et al. 1996). Histological 
examination of the graft revealed cellular infiltration with IL-4 producing lymphocytes which 
confirmed the role of Th2 in promoting graft rejection (VanBuskirk et al. 1996). This 
demonstrated the importance of targeting ICOS:ICOSL pathway as an approach to promote graft 
acceptance.  
Meanwhile, the contribution of ICOS:ICOSL pathway in regulating IFN-γ was not significant, as 
no changes in IFN-γ secretion levels were detected with anti-ICOSL blocking Ab. These data 
suggest that ICOS signalling may not contribute to Th1 functions which agrees which previous 
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studies showing that blocking ICOS:ICOSL pathway does not affect IFN-γ secretion (Akbari et 
al. 2002; Sandner et al. 2005). As regards ICOS:ICOSL role in regulation of IL-10 secretion, 
although reduction in IL-10 secretion levels were detected following ICOS:ICOSL pathway 
blocking, it was not statistically significant. A recent in vivo study that minimal reduction in IL-
10 secretion levels were detected by stimulated T cells in ICOS 
-/-
 mice as compared to WT mice 
(Mahajan et al. 2007). However, other studies demonstrated showed significant reduction in IL-
10 concentration levels following blocking of the ICOS:ICOSL interaction (Witsch et al. 2002; 
Harada et al. 2003). This data discrepancy could be explained in the light of study conducted by 
Lohning et al. as they reported that effector T cells expressing high levels of ICOS represents 
about 50% of all IL-10 secreting cells (Lohning et al. 2003). This implied that ICOS signaling 
was not the only signal that regulates IL-10 secretion. Furthermore, an in vitro study showed that 
high doses of anti-CD3 mAb were needed to activate T cells prior to induction of an increase in 
IL-10 concentration levels by ICOSL Ig stimulation (Wang et al. 2000). Thus ICOS:ICOSL role 
in IL-10 secretion is established, however, the differences reported in the effect of ICOS:ICOSL 
interaction blocking on  IL-10 secretion could be related to the protocol used to stimulate T cells.   
The role of activated T cells to regulate ICOSL surface expression by DCs and CHO ICOSL 
cells was studied. It was shown that ICOSL expression was down-regulated by DCs or CHO 
ICOSL cells cocultured with activated T cells. In addition coculturing of iDCs, mDCs or CHO 
ICOSL cells with activated T cells in the presence of anti-ICOSL blocking Ab restored ICOSL 
expression and inhibited its down-regulation as compared to isotype control. These data showed 
that ICOSL down regulation was mediated through a dependent cell to cell contact pathway 
following binding of ICOSL to ICOS on T cells. Further study showed also that ICOSL down-
regulation could be mediated in an independent cell to cell contact manner, following culturing 
of iDCs or CHO ICOSL cells with SN from activated T cells. This demonstrated that regulation 
of ICOSL could be mediated in absence of ICOS:ICOSL engagement.  
The data in this study could suggest a hierarchy of T cell costimulation in vivo, where on initial 
interaction of T cells with APC, CD28/B7 engagement induces activation of T cells with the up-
regulation of ICOS expression. Following T cells activation, CTLA4 is up-regulated and 
terminates the interaction of CD28 with its ligands. In this second phase of immune response, 
ICOS:ICOSL pathway continues to costimulate T cells and regulates the pattern of the secreted 
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cytokines and T cells effector functions. ICOS then induces ICOSL down-regulation on APCs to 
avoid the continuous T cells stimulation through ICOS:ICOSL pathway. Thus ICOSL down-
regulation is mediated via a negative feedback loop to maintain peripheral tolerance and prevent 
pathological immune responses. 
In the course of studying the possible mechanisms of ICOSL regulation, the results in this study 
suggested that ectodomain shedding could be a possible mechanism of ICOSL regulation on 
human DCs surface. The generated data showed that protease inhibitors cocktails inhibited 
ICOSL down-regulation by iDCs and CHO ICOSL cells cocultured with activated T cells. 
Consistent with this study data, an in vivo study detected sICOSL in the serum of WT mice but 
not in ICOS 
-/-
 mice (Logue et al. 2006). The generated data showed also that there were no 
significant changes in ICOSL mRNA following incubation of DCs with SN from activated T 
cells. This suggested that ICOSL down regulation is mainly mediated at the posttranscriptional 
level. ICOSL down-regulation by DC cultured in SN from activated T cells was probably 
resulted from maturation of DC induced by cytokines secreted by T cells. This DC maturation 
stage was detected by the up-regulation of CD86 which was accompanied by ICOSL down-
regulation. Unexpectedly ICOSL mRNA was down regulated in CHO ICOSL cells cocultured 
with activated T cells. The differences between DC and CHO ICOSL response could be 
explained by the differences in ICOSL transcribing promoter in both cells, as in DCs the ICOSL 
gene is transcribed by endogenous ICOSL promoter, while in CHO ICOSL cells the ICOSL gene 
is transcribed by pCMV promoter. Published studies reported that IFN-γ and TNF-α inhibited 
transgene expression by the CMV promoter (Harms and Splitter 1995; Qin, Ding et al. 1997). 
Therefore, the down-regulation of ICOSL mRNA detected in CHO ICOSL cells was probably 
induced by the cytokines produced by activated T cells. Hence, the decrease in ICOSL mRNA in 
CHO ICOSL cells was a non specific result.  
As the study showed that ectodomain shedding could be a possible ICOSL regulatory 
mechanism, it was decided to investigate the possibility to identify ICOSL cleavage products. 
The expression of ICOSL protein in DCs and CHO ICOSL cells lysates following coculture with 
activated T cells was analysed by western blotting. The generated data showed the expression of 
two bands: a heavy sized band which corresponded to ICOSL full length and another smaller 
sized band which could correspond to the remaining extracellular domain after ICOSL cleavage. 
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This suggested that ICOSL cleavage site could be in the Ig C-like domain. However, a cleavage 
site in the stalk could not be rule out. Probing the cell lysates with antibody against ICOSL 
cytoplasmic domain could help in identifying if there are other cleavage products. Further 
investigations are required to identify the protease enzyme that regulate ICOSL shedding and its 
cleavage site.  Confirmation of the exact nature of the detected smaller band could be obtained 
by analysis of the SN of cell cocultures for sICOSL by western blotting or mass spectrometry.  
As demonstrated by the results in this study, activated T cell ICOS dependent ICOSL down 
regulation could be a novel regulatory mechanism in human DCs. ICOSL surface down- 
regulation is controlled most probably at the posttranscriptional level and was partly mediated 
via ectodomain shedding. This study could help in understanding the regulatory mechanisms that 
function to maintain peripheral tolerance and prevent continuous T cell stimulation.  
7.3 Alternative strategies of gene therapy in transplantation 
Research in transplantation field has advanced significantly with the advent of effective 
immunosuppressive strategies that can be the key to successful organ transplantation. The 
currently used immunosuppression regimens have reduced the incidence of acute allograft 
rejection with improvement of short term (<1 year) and long term (>10years) graft survival for 
most of solid organ transplantation (Arias et al. 2009). However, the risk of graft rejection 
following the first year post transplant has not improved significantly.  
 
Over years, the continuous improvement in gene delivery vector design with the advances in 
transplantation immunobiology to identify targets for gene manipulation allowed the progression 
in gene therapy in transplantation. Several strategies have been used to induce transplantation 
tolerance using gene therapy either through graft modification to escape host alloimmune 
response or through manipulating host immune system to accept the graft (Laurence et al. 2009). 
Graft modification can be achieved by several approaches as the modification of the 
costimulatory signals such as blocking of CD28-B7 pathway by CTLA4 Ig prolonged allograft 
survival in a rat model of corneal transplantation (Comer et al. 2002). Graft modification can be 
also achieved by the modification of cytokine expression such as the induction of IL-10 
expression which improved cardiac allograft survival by inhibiting donor specific immune 
response in a murine model of cardiac transplantation (DeBruyne et al. 1998) and donor cornea 
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transfected with cDNA encoding IL-10 exhibited prolonged graft survival in a sheep model of 
corneal allograft (Klebe et al. 2001). Immunomodualtory enzymes as IDO have been used to 
modify the graft prior to transplantation. IDO overexpression in a murine donor cornea 
transduced with IDO construct significantly prolonged the survival of IDO transduced corneal 
allografts (Beutelspacher et al. 2006). An alternative approach addressed the modulation of 
leukocyte trafficking and adhesion molecules as knocking down the expression of the 
intercellular adhesion molecule 1 (ICAM -1) using anti-sense oligonucleotides in rat cardiac 
allograft (Feeley et al. 2000). This strategy interrupted the interaction of ICAM-1 with its ligand 
leukocyte function-associated antigen-1 (LFA-1) on neutrophils and prevented neutrophils 
binding adhesion. Blocking of ICAM-1 minimized the harsh effects of ischemic-reperfusion 
injury and improved the graft function (Feeley et al. 2000). An alternative approach tried the 
induction of apoptosis in graft infiltrating alloimmune lymphocyte. Ex vivo gene transfer using 
adenoviral vector encoding human IL-10 in liver grafts induced apoptosis of graft infiltrating 
lymphocytes via Fas/Fas-L pathway and promoted liver graft survival in a rat transplantation 
model (Li et al. 2010). Other gene therapy strategies to induce transplantation tolerance aimed to 
tolerate the recipient to donor alloantigen, thus the host immune system will not reject the 
allograft. Modification of donor APCs to be tolerogenic with reduced capacity of allostimulation 
was used in transplantation settings. Donor DCs transduced with adenoviral expressing SOCS1 
gene, suppressor of cytokine signalling, were resistant to maturation and induced allogenic T 
cells hyporesponsivenes in vitro and promoted cardiac graft survival in murine transplantation 
model (Fu et al. 2009).  
Recent reports have described several organ transplant human recipients in whom allograft have 
maintained good function for upto five years without immunosuppressive treatment. In these 
clinical trials, human bone marrow was administered simultaneously or shortly after solid organ 
transplantation (Kawai et al. 2008; Scandling et al. 2008). The authors attributed the successful 
outcome to the co-transplantation of donor-derived haematopoietic stem cells generating a state 
of mixed chimerism in the recipients. 
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7.4 Clinical Application 
Given the strength of the indirect pathway after transplantation, recipient derived DC will be the 
target for genetic modification in our strategy approach. Most of studies to induce transplant 
tolerance use donor derived DCs and only a few were conducted with recipient DCs (Nouri-
Shirazi and Thomson 2006). However, the objectives of using recipient derived DCs for 
transfection with the bicistronic constructs are related to the role of recipient DCs in the 
regulation of indirect allorecognition pathway. The role of direct allorecognition fades with time 
after transplantation, whereas the indirect allorecognition establishes dominance in the chronic 
phase of allograft rejection (Lechler et al. 2003). Hence, manipulating recipient DCs would 
promote targeting indirect pathway with the potential to induce long term transplantation 
tolerance and ameliorate chronic rejection. Furthermore, protocols that modify donor-derived 
DCs require preparation of DC several days before transplantation, which is not applicable to 
organ transplantation from deceased donors. However, recipient derived DCs could be generated 
and manipulated in vitro, which make it practically more feasible at any time.   
 
Therefore, a clinically feasible application for the negative-vaccination would entail the ex vivo 
modification of recipient derived DC to generate tolerogenic DC expressing donor derived 
allopeptide. This will then be followed by administration of the tolerogenic DC prior to the 
induction of chronic phase of allograft rejection. The construction of the negative vaccine would 
be composed of two main parts; the first would be a method for delivering a tolerogenic signal to 
induce tolerance in the responding cells using ICOS-KDEL strategy. The second would provide 
the alloantigen that can be recognized by the T cells via the indirect pathway of alloresponse 
using Ii-peptide fusion gene strategy. It is anticipated that this strategy would be convenient to 
induce tolerance to the indirect allorecognition pathway and improve graft survival. As it has 
been shown in in vivo studies that blocking of costimulatory signalling could enhance graft 
survival, however rejection of the graft cannot be completely prevented using single therapeutic 
approach (Ozkaynak et al. 2001; Nanji et al. 2004; Zhang et al. 2008), in addition to the role of 
direct allorecognition after transplantion, combination of low doses of immunosuppression 
agents e.g rapamycin or CsA could control the acute phase of alloimmune response. This is 
expected to reduce the frequency of alloreactive T cell with direct allospecifity prior to 
administration of the DNA negative vaccine in the later phase of alloimmune response.  
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One main limitation to the practical application of the DNA negative vaccine in the 
transplantation setting is the identification of donor MHC peptides recognized by indirect 
allorecognition pathway. However, much of these peptides have already been identified, thus 
with the use of the available identified peptides proof - of - principle could be possible. 
The current knowledge of the immune system and its complexity is in large part due to studying 
transplantation. When Medawar‟s experiments were performed in the 1950s, little was known 
about the immune system, the induction and maintenance of tolerance. However, their study 
showed that tolerance was achievable in animal model. Although the mechanisms of donor-
specific tolerance are still being investigated, studies have shown that with the use of an effective 
strategy, donor-specific tolerance in humans can be induced and the need for toxic immuno-
suppressives can be avoided.  
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